State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# Filing at a Glance

Company: MVP Health Plan, Inc. Product Name: VT Small Group 2024

State: VermontGMCB

TOI: H16G Group Health - Major Medical Sub-TOI: H16G.003G Small Group Only - Other

Filing Type: GMCB Rate
Date Submitted: 05/09/2023

SERFF Tr Num: MVPH-133660956

SERFF Status: Assigned

State Tr Num: State Status: Co Tr Num:

Effective 01/01/2024

Date Requested:

Author(s): Christopher Pontiff, Julia Dorr

Reviewer(s): Geoffrey Battista (primary), David Dillon, Jacqueline Lee, Michael Barber, Laura Beliveau,

Jennifer DaPolito

Disposition Date:
Disposition Status:
Effective Date:

State Filing Description:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

**General Information** 

Project Name: Status of Filing in Domicile:
Project Number: Date Approved in Domicile:
Requested Filing Mode: Review & Approval Domicile Status Comments:

Explanation for Combination/Other: Market Type: Group

Submission Type: New Submission Group Market Size: Small

Group Market Type: Employer, Other Explanation for Other Group Market Type: Small Group

Overall Rate Impact: 12.5% Filing Status Changed: 05/10/2023

State Status Changed:

Deemer Date: Created By: Julia Dorr

Submitted By: Julia Dorr Corresponding Filing Tracking Number:

PPACA: Non-Grandfathered Immed Mkt Reforms

PPACA Notes: null

Exchange Intentions: Plans are proposed to be sold on the state of Vermont's

exchange.

Filing Description:

These rates are for Small Group members purchasing coverage through the VT Exchange (or ACA-compliant plans directly from MVP) effective January 1, 2024.

# **Company and Contact**

# **Filing Contact Information**

Christopher Pontiff, CPontiff@mvphealthcare.com

625 State Street 518-386-7696 [Phone]

Schenectady, NY 12305

# **Filing Company Information**

MVP Health Plan, Inc.CoCode: 95521State of Domicile: New York625 State StreetGroup Code: 1198Company Type: HealthSchenectady, NY 12305Group Name:Maintenance Organization

(518) 388-2469 ext. [Phone] FEIN Number: 14-1640868 State ID Number:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# **Filing Fees**

# **State Fees**

Fee Required? No Retaliatory? No

Fee Explanation:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# Post Submission Update Request Processed On 05/10/2023

Status: Allowed

Created By: Julia Dorr

Processed By: Geoffrey Battista

Comments:

# **Company Rate Information:**

Company Name: MVP Health Plan, Inc.

Field NameRequested ChangePrior ValueWritten Premium for this Program\$132401862\$148953216

Product: NEW

Product Name VT Small Group HMO

HIOS Product ID 77566VT005

Number of Covered Lives 16262

SERFF Tracking #: MVPH-133660956 State Tracking #: Company Tracking #: Company Tracking #:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# **Rate Information**

Rate data applies to filing.

Filing Method: SERFF

Rate Change Type: Increase

Overall Percentage of Last Rate Revision: 18.250%

Effective Date of Last Rate Revision: 01/01/2023

Filing Method of Last Filing: SERFF

SERFF Tracking Number of Last Filing: MVPH-133238198

# **Company Rate Information**

Company Name:	Company Rate Change:	Overall % Indicated Change:	Overall % Rate Impact:	Written Premium Change for this Program:	Number of Policy Holders Affected for this Program:	Premium for	Maximum % Change (where req'd):	Minimum % Change (where req'd):
MVP Health Plan, Inc.	Increase	12.500%	12.500%	\$16,551,353	1,273	\$132,401,862	15.230%	8.400%

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# **Rate Review Detail**

**COMPANY:** 

Company Name: MVP Health Plan, Inc.

HHS Issuer Id: 77566

# **PRODUCTS:**

Product Name	HIOS Product ID	HIOS Submission ID	Number of Covered Lives
VT Small Group HMO	77566VT005		16262

Trend Factors:

**FORMS:** 

New Policy Forms: Affected Forms:

Other Affected Forms: VT EXCHANGE COC

# **REQUESTED RATE CHANGE INFORMATION:**

Change Period: Annual
Member Months: 249,323
Benefit Change: Increase

Percent Change Requested: Min: 8.4 Max: 15.23 Avg: 12.5

**PRIOR RATE:** 

Total Earned Premium: 132,401,862.00 Total Incurred Claims: 123,202,115.00

Annual \$: Min: 575.27 Max: 970.41 Avg: 678.48

**REQUESTED RATE:** 

Projected Earned Premium: 148,953,216.00 Projected Incurred Claims: 135,636,113.00

Annual \$: Min: 637.14 Max: 1,104.16 Avg: 763.30

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# **URRT**

**State Determination** 

Review Status: Incomplete

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# **URRT Items**

Item Name	Attachment(s)
Unified Rate Review Template	Unified-Rate-Review-VT-Small-2024_20230508103749.xml
Actuarial Memorandum	2024-Federal-Act-Memo-Vermont-Exchange-Small.pdf
Actuarial Memorandum - Redacted	2024-Federal-Act-Memo-Vermont-Exchange-Small-Redacted.pdf
Consumer Justification Narrative	Consumer-Disclosure-Form-2024-VT-Exchange-Small.pdf
Other Supporting Documents	Unified-Rate-Review-VT-Small-2024.pdf

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number:

Attachment Unified-Rate-Review-VT-Small-2024\_20230508103749.xml is not a PDF document and cannot be reproduced here.



# **Contact Information**

**Company Identifying** 

**Information** 

Company Legal Name: MVP Health Plan, Inc.

HIOS Issuer ID: 77566 NAIC Number: 95521

**Primary Contact Information** 

Contact Name: Christopher Pontiff, FSA, MAAA

Senior Director, Commercial Pricing, Network & Trend

Contact Title: Actuary

Primary Contact Phone #: 1-800-777-4793, ext. 17696

Primary Contact Address: 625 State Street

Schenectady, NY 12301-2207

Primary Contact E-mail: Cpontiff@mvphealthcare.com

## **ACTUARIAL MEMORANDUM**

#### 2024 Vermont Small Group Exchange Filing

#### **General Information**

This memorandum details the methods and assumptions underlying the proposed 2024 premium rates for the State of Vermont's small group ACA compliant market. These products will be issued by MVP Health Plan, Inc. (MVP), a non-profit subsidiary of MVP Health Care, Inc. The rate filing has been prepared to satisfy the requirements of 8 V.S.A §5104 as well as the requirements of the Federal ACA including 45 CFR Part 156, §156.80. The premium rates are effective between 1/1/2024 and 12/31/2024. There are no benefit plans being retired, nor are there any new benefit plans being added. MVP modified several of the benefits being offered, and the updated forms have been submitted in a separate SERFF filing. The proposed average rate increase (MVP's revenue increase) is 12.5%, with increases ranging from 8.4% to 15.2%.

#### **Drivers of Rate Increase**

The proposed premium rates reflect an increase over the prior rates due to single risk pool experience which is more adverse than assumed in the current rates, medical and pharmacy cost and utilization inflation, and an increase to contribution to reserve assumptions. Premium rate increases are varying by plan due to benefit modifications of several benefits being offered as well as the impact of fixed PMPM non-claim costs on premiums that vary based on benefit level.

#### Market/Benefits

All benefit plans included in this rate filing are available to small employer groups. All Essential Health Benefits (EHBs) are covered. Only one EHB substitution was made as required by the Department of VHA, a substitution for the \$2,000 annual Private Duty Nursing benefit limit in the benchmark plan. MVP contracted Milliman to determine an actuarially equivalent visit limit, and the experience period data reflects this actuarially equivalent limit.

The non-standard plans proposed by MVP and included in this rate filing contain two benefits in excess of the EHBs: a wellness benefit and an acupuncture allowance of \$500. The wellness benefit and acupuncture allowance are included in all non-standard products and the wellness benefit is filed as a mandatory rider, form: FRVT366.

To inform consumers of the availability and details of the products included in this filing, MVP will provide community outreach support as well as offer web and print product content and other printed product materials for VT plans. MVP will also have a mass media presence to further educate health care customers in Vermont.

The book of business affected by this rate filing is 1,273 policyholders, 10,032 subscribers and 16,262 members based on February 2023 membership.

# **Experience Period Premium and Claims (Worksheet 1, Section 1 of Unified Rate Review Template)**

Worksheet 1, Section 1 of the Unified Rate Review Template contains MVP Health Plan, Inc. small group data for Vermont members over the time period 1/1/2022 - 12/31/2022, completed through 3/31/2023.

MVP does not project to rebate consumers for 2022 dates of service, and therefore no adjustments were made to the earned premium amount reflected on Worksheet 1, Section 1 of the Unified Rate Review Template. The earned premium shown reflects the amount of premium MVP collected from groups over the experience period.

Allowed claim data includes claims from our fee for service (FFS) claim warehouses (medical and pharmacy) along with additional medical expenses not captured in the claim warehouse such as: payments associated with medical home, physician incentive payments, FFS write-offs and net reinsurance expenses.

An allowance for incurred but not reported paid claims (IBNR) was added to the experience period fee-for-service (FFS) medical claims. IBNR files were supplied directly from MVP's reserving actuary. MVP uses a combination PMPM and completion factor method to develop IBNR estimates, and Vermont specific data for the experience period was used to develop the factors. The fee-for-service experience period claims were reconciled with the IBNR lag triangles to ensure accuracy.

The Risk adjustment reflected in the experience period is for the merged market and includes High Cost Risk Pool recoveries per the URRT instructions.

A summary of experience period claims processed through MVP's claim system, experience period costs not processed through MVP's claims system, as well as an estimate of IBNR are summarized below for the claims shown in Worksheet I, Section I of the URRT.

	Allowed	Incurred
Claims Processed Through Claim System	\$160,123,453	\$132,363,962
Experience Period Costs Not Processed Through Claims System	\$3,666,723	\$3,666,723
IBNR	\$2,466,829	\$2,032,442
Total	\$166,257,005	\$138,063,128

# Benefit Categories (Worksheet 1, Section 2 of Unified Rate Review Template)

MVP determines benefit category based on the type of claim form submitted in conjunction with the code and type of code attached to the claim form (i.e. ICD-9, ICD-10, Diagnosis Code, or HCPCS). The "Other Medical" category includes pediatric dental claims. The "Capitation" category includes capitated payments as well as all other claims not processed through MVP's claim warehouses.

#### **Medical Trend Factors**

The assumed unit cost trends reflect known and assumed price increases from MVP's provider network, weighted by benefit category. The Capitation unit cost trend reflects the expected change between the capitated and non-FFS claim expense between the experience period and the projection period.

MVP analyzed historical utilization patterns for the ACA-compliant business to determine whether there has been a utilization trend pattern in the recent past. Because of the rapid membership growth in this block in the past several years and COVID-19, the utilization trends produced by the model were not considered reliable. However, the regulatory actuary in the 2020 rate filing performed an analysis that found that "a reasonable range for market wide utilization trend to be 1% to 4%". MVP has maintained this same trend in the filing each year. Because MVP believes that their data still lacks necessary stability and L&E's view of utilization trend encompasses the entire market, MVP has built in a 1% annual utilization trend for this filing.

#### **Rx Trend Factors**

Annual allowed Rx trend factors split by generic, brand, and specialty drugs are provided by MVP's PBM and were determined using MVP specific data over the experience period by drug class. The forecast provided by MVP's PBM accounts for drugs coming off patent, changes in average wholesale price, new drugs being released to the market, and price competitiveness amongst generic and brand drug manufacturers.

# <u>Credibility Manual Rate Development (Worksheet 1, Section 2 of Unified Rate Review Template)</u>

MVP is assuming that the small group market risk pool membership base of 249,323 member months in the experience period is fully credible for rating purposes. Therefore, the applied credibility percentage is 100.00% (0.00% weight on credibility manual).

#### Projection Factors (Worksheet 1, Section 2 of Unified Rate Review Template)

## Morbidity Adjustment- Impact of COVID Testing

MVP is assuming a 10% reduction in Covid testing costs in the projection period due to a utilization decrease. We expect demand for testing to decrease once cost sharing is reinstituted. This factor is decreasing the experience period allowed claim cost by 0.06%.

#### Morbidity Adjustment-Impact of COVID Vaccines

It is expected commercial payers will have to pay the full ingredient cost of Covid vaccines by 2024. MVP is taking 2022 experience and increasing it by \$130/\$40, the expected ingredient cost in 2024 over what we pay currently<sup>1</sup>. The factor is increasing the experience period allowed claim cost by 0.3%.

#### Plan Design Changes- Impact of Hearing Aids as EHB

Hearing aids have been added as an essential health benefit in 2024. MVP analyzed historical experience in its New York population and determined this mandate would increase the experience period allowed claim cost by 0.05%.

#### Other- Impact of Leap Year

Because the rating period is a leap year and the experience period is not a leap year, the rating period will have one more day than the experience period. Assuming claims are uniformly distributed among all days in the year, MVP is adjusting the experience period claim expense upward by 0.27% (366 days / 365 days).

# Reinsurance (Worksheet 1, Section 2)

MVP is reflecting \$0.00 PMPM in reinsurance recoveries during the projection period.

# Federal Risk Adjustment Program (Worksheet 1, Section 2)

Based on the Interim Risk Transfer results for 2022 provided by CMS, MVP is expected to pay \$9,579,344 into the small group market transfer pool for 2022. This is \$38.42 on a PMPM basis or 6.9% of experience period claims prior to market-wide adjustments.

The URRT instructions state that the projected risk adjustment PMPM on Worksheet 1 is to be calculated on an allowed basis. Therefore, MVP has taken the projected risk adjustment PMPM on a net basis and divided by the projection period paid to allowed ratio to come up with the value shown (\$55.29 PMPM).

#### **Exchange User Fees (Worksheet 1, Section 2)**

Vermont's Exchange is not a Federally-Facilitated Exchange, therefore 0.00% of premium is built in to account for user fees during the projection period.

#### Market-Wide Adjusted Index Rate

The experience period index rate of 666.83 is equal to the small group market allowed claim data for the time period, 1/1/2022 - 12/31/2022, completed through 3/31/2023.

The actual market adjusted index rate for the projection period equals \$843.93. However, due to the rounding of factors present in the URRT, the value in the file reflects \$844.90. This value was computed by adjusting the projection period index rate for the federal risk adjustment program, reinsurance and marketplace user fees. Please see above for details on the computation of the projected value of the risk adjustment program. Note that this is a true expectation of allowed costs and is not equivalent to the adjusted claim cost for pricing on Exhibit 7 of the rate filing.

 $<sup>^{1}\</sup> https://www.kff.org/coronavirus-covid-19/issue-brief/how-much-could-covid-19-vaccines-cost-the-u-s-after-commercialization/$ 

#### **Actuarial Values and Cost Sharing Design of Plan (Worksheet 2, Section 3)**

The AV Metal Level for each plan was determined using the Federally prescribed Actuarial Value Calculator. Adjustments for aggregate deductibles, the VT Rx OOPM, and safe harbor prescription Rx benefits were made to the calculator results for the non-standard Gold 3 and non-Standard Silver 2 plans. The actuarial certification of these adjustments has been included.

The Benefit Actuarial Value for each plan was determined using MVP's in-house benefit pricing tools. The pricing tools value the expected net paid claim cost associated with unique benefit plan designs from a starting single risk pool allowed amount. The AV is the ratio of the expected paid to allowed amount for each plan design. MVP did not reflect any induced utilization in the projection of the net paid amounts for each unique benefit plan.

The induced utilization factors used to set premium rates and compute the average in-force induced utilization factor are the HHS prescribed induced utilization factors of 1.00 for Bronze, 1.03 for Silver, 1.08 for Gold, and 1.15 for Platinum.

The actual paid to allowed ratio during the experience period and the assumed paid to allowed ratio used for pricing differ. The actual paid to allowed ratio (including assumed payments for cost sharing reductions) for the experience period is different than the pricing paid to allowed ratio produced by MVP's internal benefit relativity model. Because MVP prices using net claim expense instead of allowed claims, the allowed claims in the URRT need to be adjusted for the difference in the paid to allowed ratios to develop an equivalent Plan Adjusted Index Rate. The total of this adjustment is 1.0%.

The total adjustment made is the product of the three values (AV, induced demand, and difference in paid to allowed ratio).

#### Provider Network Adjustment (Worksheet 2, Section 3)

MVP only offers one provider network for its Vermont plans; therefore, no plan-level adjustment is necessary.

#### Benefits in Addition to EHB (Worksheet 2, Section 3)

Members purchasing a non-standard plan will receive MVP's Member Wellness Incentive (Form: FRVT366) and a \$500 acupuncture allowance. The wellness benefit provides subscribers with up to \$600 in wellness rewards per year, subject to certain guidelines. The cost of these benefits is included in the experience period claims as well as the plan AVs so an adjustment is not required.

#### **Non-Claim Expense Plan Level Adjustments**

Non claim expenses include both percent of premium loads and PMPM loads. The loads do not vary by plan. Each Standard and Non-Standard plan is being loaded with the same PMPM and Percent of Premium loads. The loads are outlined below:

#### Federal Taxes PMPM based

A total of \$0.44 PMPM is added for fees MVP must pay to the Federal Government per ACA regulations on a PMPM basis. This is comprised of \$0.19 PMPM for the risk adjustment user fee levied by the Department of Health and Human Services and \$0.25 PMPM for the Patient Centered Outcome Research Fee.

#### State Taxes PMPM Based

\$2.37 PMPM is added for fees MVP must pay to the State of Vermont to help fund expenses incurred by state agencies and other non-profit organizations on MVP's behalf, including the Green Mountain Care Board, the Vermont Program for Quality in Health Care, Inc., and the Office of the Health Care Advocate. This is found by using the best available information about the market-wide cost of each of the programs and then accounting for MVP's growth in market share from 2022 to 2024.

#### State Taxes Premium based – VT Vaccine Assessment

Based on information provided by the Vermont Vaccine Purchasing Program (VVPP), MVP's rates are \$13.54 per covered child and \$2.74 per covered adult for 2024, followed by an estimate of \$15.05 per covered child and \$3.00 per covered adult for 2025. Based on a blend of MVP's child and adult membership in the projection period, the total PMPM costs were determined for each year and given an equal weight, resulting in \$4.42 PMPM. This blended PMPM was then compared to the projection period premium PMPM before the assessment load to convert the assessment to a percent of premium load of 0.58%.

# Federal Fees Premium based- National High Cost Reinsurance Pool (HCRP) Charge

In the 2024 Notice of Benefit and Payment Parameters issued by HHS, carriers will be compensated 60% for members' paid claims above \$1 million in a given plan year. The total reinsurance received across all states will be aggregated and compared to the national average premium PMPM to determine a percentage of premium charged to each issuer to fund the program.

Based on a national study performed by Wakely Consulting Group, the estimate of the load charged to small group market issuers in 2024 will be 0.69%.

# General Administrative Expense Load (Including QI component)

The total administrative expense load included as a plan level adjustment equals \$44.62 PMPM and is used to cover SG&A expenses as well as Quality Improvement/Cost Containment Programs (QI). Based on an analysis of MVP's historical Supplemental Health Care Exhibit (SHCE) expenses, approximately 7% of MVP's total administrative expense was spent on QI. Therefore, \$3.12 PMPM of the \$44.62 PMPM administrative expense is attributable to QI.

The following table summarizes the administrative expenses for small group and individual lines of business from the 2019, 2020, and 2021 SHCEs compared to the available admin expense built into the rates for the same time period.

Combined VT AR42 and AR44	Year	Exchange Available Admin PMPM	SHCE Admin PMPM*
Individual	2020	N/A	\$35.40
Small Group	2020	N/A	\$33.65
Combined	2020	\$42.00	\$34.40
Individual	2021	N/A	\$51.71
Small Group	2021	N/A	\$44.49
Combined	2021	\$43.75	\$47.44
Individual	2022	\$47.10	\$48.26
Small Group	2022	\$38.75	\$39.63
Combined	2022	\$42.20	\$43.07

<sup>\*</sup>Reflects lines 1.07, 6.6, 8.3, 10.1, and 10.4 of SHCE, Part 1

#### Contribution to Reserves/Risk Charge

MVP is building a 1.5% contribution to reserves/risk charge into the VT Exchange premium rates for 2024. This charge is added to premium rates to meet statutory reserve requirements for MVP's VT block of business and protect against adverse experience relative to pricing assumptions.

#### Bad Debt Expense

A plan level adjustment equal to 0.10% of premium was added to account for non-payment of premium risk.

# Age/Geographic/Tobacco Calibration (Worksheet 2, Section 3)

Per Vermont stating rating rules, variation in rates due to tobacco and age are not allowed. Therefore, all calibration factors are 1. Additionally, there is only 1 rating region in Vermont, so the geography calibration is also 1.

#### **Consumer Adjusted Premium Rates**

The Calibrated Plan Adjusted Index Rate PMPMs are converted to per contract premium rates using the computed single conversion factor and the prescribed standard load ratios. Please note that due to the rounding present in the URRT template, actual Plan Adjusted Index Rate PMPMs may vary from the URRT to the actual rates as filed.

The single conversion factor (SCF) was calculated using subscriber and member data by contract type for the eligible population enrolled with MVP as of February 2023. The SCF = weighted average contract size / weighted average load ratio.

# **Projection Period Membership**

MVP's projection period membership equals the February 2023 enrollment of the population eligible to purchase these products, or 16,262 members. On Worksheet 2 of the URRT, members are mapped based on their February 2023 benefit to the same benefits for 2024.

MVP is aware that the Medicaid continuous enrollment provision will not continue in 2024. We have decided not to assume a membership or morbidity change for this. We expect the impact to be the same as the overall market wide morbidity impact which we do not have data to support.

#### **Loss Ratio Information**

The traditional target loss ratio (claims cost / premium) for the rates proposed in this rate filing is 91.1%. After adjusting for taxes/assessments and expenses associated with quality improvements, the Federal target loss ratio for the rates proposed in this filing is 93.0%. Please see the following table for a calculation of these loss ratios based on MVP's projected starting claim cost in 2024:

Target Loss Ratio for 2024 VT Exchang											
	i										
A) Claims Expense	\$711.56										
B) Taxes/Assessments	\$12.74										
C) Quality Improvement	\$3.12										
D) Premium	\$781.42										
E) Traditional Loss Ratio	91.1%										
= A) / D)											
F) Federal Loss Ratio = [A) + C)] / [D) - B)]	93.0%										

#### **Actuarial Certification**

I, Christopher Pontiff, am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. The projected Index Rate and Adjusted Paid Amount used in the development of these proposed premium rates is in compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80(d)(1)) and developed in compliance with the applicable Actuarial Standards of Practice. I have examined the assumptions and methods used in determining MVP's requested rates. Based on my review and examination, it is my opinion that the proposed premium rates are reasonable in relation to the benefits provided and that they are not excessive, nor inadequate, nor unfairly discriminatory. They are developed using only the permitted rating classifications. The Adjusted Paid Amount and only the allowable modifiers as described in 45 CFR 156.80(d)(1) and 45 CFR 156.80(d)(2) were used to generate plan level rates. The Standard AV Calculator was used to determine the Metal AV Value to be shown in Worksheet 2 of the Part I Unified Rate Review template for all the plans. The EHB portion of premium reflected in Worksheet 2, Sections 3 and 4 was calculated in accordance with actuarial standards of practice.

The URRT does not demonstrate the process that was used to develop premium rates. Rather it represents information required by Federal regulation to be provided in support of the review of rate increases and for certification that the Index rate is developed in accordance with Federal regulation and used consistently and only adjusted by the allowable modifiers.

I certify that I am knowledgeable as to the Vermont laws and regulations that apply to this filing and that, to the best of my knowledge and belief, this filing is in compliance with such laws and regulations and provides all required benefits.

I am of the opinion that this filing is in compliance with the applicable Federal and State Laws and Regulations concerning the PPACA and the HCERA of 2010.

I certify that each rate filing has been prepared in accordance with the following Actuarial Standards of Practice; ASOP #5, ASOP#8, ASOP #12, ASOP #23, ASOP #25, ASOP#41, ASOP#45, and ASOP#50.

05/09/2023

Christopher Pontiff, FSA, MAAA

(Mu Vart

Date

Senior Director, Commercial Pricing, Network & Trend Actuary

MVP Health Care, Inc.



# **Contact Information**

**Company Identifying** 

**Information** 

Company Legal Name: MVP Health Plan, Inc.

HIOS Issuer ID: 77566 NAIC Number: 95521

**Primary Contact Information** 

Contact Name: Christopher Pontiff, FSA, MAAA

Senior Director, Commercial Pricing, Network & Trend

Contact Title: Actuary

Primary Contact Phone #: 1-800-777-4793, ext. 17696

Primary Contact Address: 625 State Street

Schenectady, NY 12301-2207

Primary Contact E-mail: Cpontiff@mvphealthcare.com

#### **ACTUARIAL MEMORANDUM**

#### 2024 Vermont Small Group Exchange Filing

#### **General Information**

This memorandum details the methods and assumptions underlying the proposed 2024 premium rates for the State of Vermont's small group ACA compliant market. These products will be issued by MVP Health Plan, Inc. (MVP), a non-profit subsidiary of MVP Health Care, Inc. The rate filing has been prepared to satisfy the requirements of 8 V.S.A §5104 as well as the requirements of the Federal ACA including 45 CFR Part 156, §156.80. The premium rates are effective between 1/1/2024 and 12/31/2024. There are no benefit plans being retired, nor are there any new benefit plans being added. MVP modified several of the benefits being offered, and the updated forms have been submitted in a separate SERFF filing. The proposed average rate increase (MVP's revenue increase) is 12.5%, with increases ranging from 8.4% to 15.2%.

#### **Drivers of Rate Increase**

The proposed premium rates reflect an increase over the prior rates due to single risk pool experience which is more adverse than assumed in the current rates, medical and pharmacy cost and utilization inflation, and an increase to contribution to reserve assumptions. Premium rate increases are varying by plan due to benefit modifications of several benefits being offered as well as the impact of fixed PMPM non-claim costs on premiums that vary based on benefit level.

#### Market/Benefits

All benefit plans included in this rate filing are available to small employer groups. All Essential Health Benefits (EHBs) are covered. Only one EHB substitution was made as required by the Department of VHA, a substitution for the \$2,000 annual Private Duty Nursing benefit limit in the benchmark plan. MVP contracted Milliman to determine an actuarially equivalent visit limit, and the experience period data reflects this actuarially equivalent limit.

The non-standard plans proposed by MVP and included in this rate filing contain two benefits in excess of the EHBs: a wellness benefit and an acupuncture allowance of \$500. The wellness benefit and acupuncture allowance are included in all non-standard products and the wellness benefit is filed as a mandatory rider, form: FRVT366.

To inform consumers of the availability and details of the products included in this filing, MVP will provide community outreach support as well as offer web and print product content and other printed product materials for VT plans. MVP will also have a mass media presence to further educate health care customers in Vermont.

The book of business affected by this rate filing is 1,273 policyholders, 10,032 subscribers and 16,262 members based on February 2023 membership.

# Experience Period Premium and Claims (Worksheet 1, Section 1 of Unified Rate Review Template)

Worksheet 1, Section 1 of the Unified Rate Review Template contains MVP Health Plan, Inc. small group data for Vermont members over the time period 1/1/2022 - 12/31/2022, completed through 3/31/2023.

MVP does not project to rebate consumers for 2022 dates of service, and therefore no adjustments were made to the earned premium amount reflected on Worksheet 1, Section 1 of the Unified Rate Review Template. The earned premium shown reflects the amount of premium MVP collected from groups over the experience period.

Allowed claim data includes claims from our fee for service (FFS) claim warehouses (medical and pharmacy) along with additional medical expenses not captured in the claim warehouse such as: payments associated with medical home, physician incentive payments, FFS write-offs and net reinsurance expenses.

An allowance for incurred but not reported paid claims (IBNR) was added to the experience period fee-for-service (FFS) medical claims. IBNR files were supplied directly from MVP's reserving actuary. MVP uses a combination PMPM and completion factor method to develop IBNR estimates, and Vermont specific data for the experience period was used to develop the factors. The fee-for-service experience period claims were reconciled with the IBNR lag triangles to ensure accuracy.

The Risk adjustment reflected in the experience period is for the merged market and includes High Cost Risk Pool recoveries per the URRT instructions.

A summary of experience period claims processed through MVP's claim system, experience period costs not processed through MVP's claims system, as well as an estimate of IBNR are summarized below for the claims shown in Worksheet I, Section I of the URRT.

	Allowed	Incurred
Claims Processed Through Claim System	\$160,123,453	\$132,363,962
Experience Period Costs Not Processed Through Claims System	\$3,666,723	\$3,666,723
IBNR	\$2,466,829	\$2,032,442
Total	\$166,257,005	\$138,063,128

# Benefit Categories (Worksheet 1, Section 2 of Unified Rate Review Template)

MVP determines benefit category based on the type of claim form submitted in conjunction with the code and type of code attached to the claim form (i.e. ICD-9, ICD-10, Diagnosis Code, or HCPCS). The "Other Medical" category includes pediatric dental claims. The "Capitation" category includes capitated payments as well as all other claims not processed through MVP's claim warehouses.

#### **Medical Trend Factors**

The assumed unit cost trends reflect known and assumed price increases from MVP's provider network, weighted by benefit category. The Capitation unit cost trend reflects the expected change between the capitated and non-FFS claim expense between the experience period and the projection period.

MVP analyzed historical utilization patterns for the ACA-compliant business to determine whether there has been a utilization trend pattern in the recent past. Because of the rapid membership growth in this block in the past several years and COVID-19, the utilization trends produced by the model were not considered reliable. However, the regulatory actuary in the 2020 rate filing performed an analysis that found that "a reasonable range for market wide utilization trend to be 1% to 4%". MVP has maintained this same trend in the filing each year. Because MVP believes that their data still lacks necessary stability and L&E's view of utilization trend encompasses the entire market, MVP has built in a 1% annual utilization trend for this filing.

#### **Rx Trend Factors**

Annual allowed Rx trend factors split by generic, brand, and specialty drugs are provided by MVP's PBM and were determined using MVP specific data over the experience period by drug class. The forecast provided by MVP's PBM accounts for drugs coming off patent, changes in average wholesale price, new drugs being released to the market, and price competitiveness amongst generic and brand drug manufacturers.

# <u>Credibility Manual Rate Development (Worksheet 1, Section 2 of Unified Rate Review Template)</u>

MVP is assuming that the small group market risk pool membership base of 249,323 member months in the experience period is fully credible for rating purposes. Therefore, the applied credibility percentage is 100.00% (0.00% weight on credibility manual).

#### Projection Factors (Worksheet 1, Section 2 of Unified Rate Review Template)

## Morbidity Adjustment- Impact of COVID Testing

MVP is assuming a 10% reduction in Covid testing costs in the projection period due to a utilization decrease. We expect demand for testing to decrease once cost sharing is reinstituted. This factor is decreasing the experience period allowed claim cost by 0.06%.

#### Morbidity Adjustment-Impact of COVID Vaccines

It is expected commercial payers will have to pay the full ingredient cost of Covid vaccines by 2024. MVP is taking 2022 experience and increasing it by \$130/\$40, the expected ingredient cost in 2024 over what we pay currently<sup>1</sup>. The factor is increasing the experience period allowed claim cost by 0.3%.

#### Plan Design Changes- Impact of Hearing Aids as EHB

Hearing aids have been added as an essential health benefit in 2024. MVP analyzed historical experience in its New York population and determined this mandate would increase the experience period allowed claim cost by 0.05%.

#### Other- Impact of Leap Year

Because the rating period is a leap year and the experience period is not a leap year, the rating period will have one more day than the experience period. Assuming claims are uniformly distributed among all days in the year, MVP is adjusting the experience period claim expense upward by 0.27% (366 days / 365 days).

# Reinsurance (Worksheet 1, Section 2)

MVP is reflecting \$0.00 PMPM in reinsurance recoveries during the projection period.

# Federal Risk Adjustment Program (Worksheet 1, Section 2)

Based on the Interim Risk Transfer results for 2022 provided by CMS, MVP is expected to pay \$9,579,344 into the small group market transfer pool for 2022. This is \$38.42 on a PMPM basis or 6.9% of experience period claims prior to market-wide adjustments.

The URRT instructions state that the projected risk adjustment PMPM on Worksheet 1 is to be calculated on an allowed basis. Therefore, MVP has taken the projected risk adjustment PMPM on a net basis and divided by the projection period paid to allowed ratio to come up with the value shown (\$55.29 PMPM).

#### **Exchange User Fees (Worksheet 1, Section 2)**

Vermont's Exchange is not a Federally-Facilitated Exchange, therefore 0.00% of premium is built in to account for user fees during the projection period.

#### Market-Wide Adjusted Index Rate

The experience period index rate of 666.83 is equal to the small group market allowed claim data for the time period, 1/1/2022 - 12/31/2022, completed through 3/31/2023.

The actual market adjusted index rate for the projection period equals \$843.93. However, due to the rounding of factors present in the URRT, the value in the file reflects \$844.90. This value was computed by adjusting the projection period index rate for the federal risk adjustment program, reinsurance and marketplace user fees. Please see above for details on the computation of the projected value of the risk adjustment program. Note that this is a true expectation of allowed costs and is not equivalent to the adjusted claim cost for pricing on Exhibit 7 of the rate filing.

 $<sup>^{1}\</sup> https://www.kff.org/coronavirus-covid-19/issue-brief/how-much-could-covid-19-vaccines-cost-the-u-s-after-commercialization/$ 

#### **Actuarial Values and Cost Sharing Design of Plan (Worksheet 2, Section 3)**

The AV Metal Level for each plan was determined using the Federally prescribed Actuarial Value Calculator. Adjustments for aggregate deductibles, the VT Rx OOPM, and safe harbor prescription Rx benefits were made to the calculator results for the non-standard Gold 3 and non-Standard Silver 2 plans. The actuarial certification of these adjustments has been included.

The Benefit Actuarial Value for each plan was determined using MVP's in-house benefit pricing tools. The pricing tools value the expected net paid claim cost associated with unique benefit plan designs from a starting single risk pool allowed amount. The AV is the ratio of the expected paid to allowed amount for each plan design. MVP did not reflect any induced utilization in the projection of the net paid amounts for each unique benefit plan.

The induced utilization factors used to set premium rates and compute the average in-force induced utilization factor are the HHS prescribed induced utilization factors of 1.00 for Bronze, 1.03 for Silver, 1.08 for Gold, and 1.15 for Platinum.

The actual paid to allowed ratio during the experience period and the assumed paid to allowed ratio used for pricing differ. The actual paid to allowed ratio (including assumed payments for cost sharing reductions) for the experience period is different than the pricing paid to allowed ratio produced by MVP's internal benefit relativity model. Because MVP prices using net claim expense instead of allowed claims, the allowed claims in the URRT need to be adjusted for the difference in the paid to allowed ratios to develop an equivalent Plan Adjusted Index Rate. The total of this adjustment is 1.0%.

The total adjustment made is the product of the three values (AV, induced demand, and difference in paid to allowed ratio).

#### Provider Network Adjustment (Worksheet 2, Section 3)

MVP only offers one provider network for its Vermont plans; therefore, no plan-level adjustment is necessary.

#### Benefits in Addition to EHB (Worksheet 2, Section 3)

Members purchasing a non-standard plan will receive MVP's Member Wellness Incentive (Form: FRVT366) and a \$500 acupuncture allowance. The wellness benefit provides subscribers with up to \$600 in wellness rewards per year, subject to certain guidelines. The cost of these benefits is included in the experience period claims as well as the plan AVs so an adjustment is not required.

#### **Non-Claim Expense Plan Level Adjustments**

Non claim expenses include both percent of premium loads and PMPM loads. The loads do not vary by plan. Each Standard and Non-Standard plan is being loaded with the same PMPM and Percent of Premium loads. The loads are outlined below:

#### Federal Taxes PMPM based

A total of \$0.44 PMPM is added for fees MVP must pay to the Federal Government per ACA regulations on a PMPM basis. This is comprised of \$0.19 PMPM for the risk adjustment user fee levied by the Department of Health and Human Services and \$0.25 PMPM for the Patient Centered Outcome Research Fee.

#### State Taxes PMPM Based

\$2.37 PMPM is added for fees MVP must pay to the State of Vermont to help fund expenses incurred by state agencies and other non-profit organizations on MVP's behalf, including the Green Mountain Care Board, the Vermont Program for Quality in Health Care, Inc., and the Office of the Health Care Advocate. This is found by using the best available information about the market-wide cost of each of the programs and then accounting for MVP's growth in market share from 2022 to 2024.

#### State Taxes Premium based – VT Vaccine Assessment

Based on information provided by the Vermont Vaccine Purchasing Program (VVPP), MVP's rates are \$13.54 per covered child and \$2.74 per covered adult for 2024, followed by an estimate of \$15.05 per covered child and \$3.00 per covered adult for 2025. Based on a blend of MVP's child and adult membership in the projection period, the total PMPM costs were determined for each year and given an equal weight, resulting in \$4.42 PMPM. This blended PMPM was then compared to the projection period premium PMPM before the assessment load to convert the assessment to a percent of premium load of 0.58%.

# Federal Fees Premium based- National High Cost Reinsurance Pool (HCRP) Charge

In the 2024 Notice of Benefit and Payment Parameters issued by HHS, carriers will be compensated 60% for members' paid claims above \$1 million in a given plan year. The total reinsurance received across all states will be aggregated and compared to the national average premium PMPM to determine a percentage of premium charged to each issuer to fund the program.

Based on a national study performed by Wakely Consulting Group, the estimate of the load charged to small group market issuers in 2024 will be 0.69%.

# General Administrative Expense Load (Including QI component)

The total administrative expense load included as a plan level adjustment equals \$44.62 PMPM and is used to cover SG&A expenses as well as Quality Improvement/Cost Containment Programs (QI). Based on an analysis of MVP's historical Supplemental Health Care Exhibit (SHCE) expenses, approximately 7% of MVP's total administrative expense was spent on QI. Therefore, \$3.12 PMPM of the \$44.62 PMPM administrative expense is attributable to QI.

The following table summarizes the administrative expenses for small group and individual lines of business from the 2019, 2020, and 2021 SHCEs compared to the available admin expense built into the rates for the same time period.

Combined VT AR42 and AR44	Year	Exchange Available Admin PMPM	SHCE Admin PMPM*
Individual	2020	N/A	\$35.40
Small Group	2020	N/A	\$33.65
Combined	2020	\$42.00	\$34.40
Individual	2021	N/A	\$51.71
Small Group	2021	N/A	\$44.49
Combined	2021	\$43.75	\$47.44
Individual	2022	\$47.10	\$48.26
Small Group	2022	\$38.75	\$39.63
Combined	2022	\$42.20	\$43.07

<sup>\*</sup>Reflects lines 1.07, 6.6, 8.3, 10.1, and 10.4 of SHCE, Part 1

#### Contribution to Reserves/Risk Charge

MVP is building a 1.5% contribution to reserves/risk charge into the VT Exchange premium rates for 2024. This charge is added to premium rates to meet statutory reserve requirements for MVP's VT block of business and protect against adverse experience relative to pricing assumptions.

#### Bad Debt Expense

A plan level adjustment equal to 0.10% of premium was added to account for non-payment of premium risk.

# Age/Geographic/Tobacco Calibration (Worksheet 2, Section 3)

Per Vermont stating rating rules, variation in rates due to tobacco and age are not allowed. Therefore, all calibration factors are 1. Additionally, there is only 1 rating region in Vermont, so the geography calibration is also 1.

#### **Consumer Adjusted Premium Rates**

The Calibrated Plan Adjusted Index Rate PMPMs are converted to per contract premium rates using the computed single conversion factor and the prescribed standard load ratios. Please note that due to the rounding present in the URRT template, actual Plan Adjusted Index Rate PMPMs may vary from the URRT to the actual rates as filed.

The single conversion factor (SCF) was calculated using subscriber and member data by contract type for the eligible population enrolled with MVP as of February 2023. The SCF = weighted average contract size / weighted average load ratio.

# **Projection Period Membership**

MVP's projection period membership equals the February 2023 enrollment of the population eligible to purchase these products, or 16,262 members. On Worksheet 2 of the URRT, members are mapped based on their February 2023 benefit to the same benefits for 2024.

MVP is aware that the Medicaid continuous enrollment provision will not continue in 2024. We have decided not to assume a membership or morbidity change for this. We expect the impact to be the same as the overall market wide morbidity impact which we do not have data to support.

#### **Loss Ratio Information**

The traditional target loss ratio (claims cost / premium) for the rates proposed in this rate filing is 91.1%. After adjusting for taxes/assessments and expenses associated with quality improvements, the Federal target loss ratio for the rates proposed in this filing is 93.0%. Please see the following table for a calculation of these loss ratios based on MVP's projected starting claim cost in 2024:

Target Loss Ratio for 2024 VT Exchang											
	i										
A) Claims Expense	\$711.56										
B) Taxes/Assessments	\$12.74										
C) Quality Improvement	\$3.12										
D) Premium	\$781.42										
E) Traditional Loss Ratio	91.1%										
= A) / D)											
F) Federal Loss Ratio = [A) + C)] / [D) - B)]	93.0%										

#### **Actuarial Certification**

I, Christopher Pontiff, am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. The projected Index Rate and Adjusted Paid Amount used in the development of these proposed premium rates is in compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80(d)(1)) and developed in compliance with the applicable Actuarial Standards of Practice. I have examined the assumptions and methods used in determining MVP's requested rates. Based on my review and examination, it is my opinion that the proposed premium rates are reasonable in relation to the benefits provided and that they are not excessive, nor inadequate, nor unfairly discriminatory. They are developed using only the permitted rating classifications. The Adjusted Paid Amount and only the allowable modifiers as described in 45 CFR 156.80(d)(1) and 45 CFR 156.80(d)(2) were used to generate plan level rates. The Standard AV Calculator was used to determine the Metal AV Value to be shown in Worksheet 2 of the Part I Unified Rate Review template for all the plans. The EHB portion of premium reflected in Worksheet 2, Sections 3 and 4 was calculated in accordance with actuarial standards of practice.

The URRT does not demonstrate the process that was used to develop premium rates. Rather it represents information required by Federal regulation to be provided in support of the review of rate increases and for certification that the Index rate is developed in accordance with Federal regulation and used consistently and only adjusted by the allowable modifiers.

I certify that I am knowledgeable as to the Vermont laws and regulations that apply to this filing and that, to the best of my knowledge and belief, this filing is in compliance with such laws and regulations and provides all required benefits.

I am of the opinion that this filing is in compliance with the applicable Federal and State Laws and Regulations concerning the PPACA and the HCERA of 2010.

I certify that each rate filing has been prepared in accordance with the following Actuarial Standards of Practice; ASOP #5, ASOP#8, ASOP #12, ASOP #23, ASOP #25, ASOP#41, ASOP#45, and ASOP#50.

05/09/2023

Christopher Pontiff, FSA, MAAA

(Mu Vart

Date

Senior Director, Commercial Pricing, Network & Trend Actuary

MVP Health Care, Inc.



# Consumer Disclosure about Proposed Health Insurance Rate Increase VT 2024 ACA Small Group Exchange Rate Filing

#### **About Us**

MVP Health Plan, Inc. is a non-profit health care payer operating in Vermont and New York. MVP's mission is to provide high quality and affordable health care with a focus on wellness to our members.

# **Why We Are Changing Our Premiums**

MVP must obtain approval from the Green Mountain Care Board for the health insurance premium rates charged. MVP files annual premium rates for the Exchange which are guaranteed for 12 months. This rate filing seeks approval of MVP's 2024 Small Group Exchange rates for effective dates of coverage between January 1, 2024 and December 31, 2024. The premium rates filed reflect MVP's current estimate of the cost to provide health insurance for that coverage period. The filed premium rates may be higher or lower than the previously filed premium rates, however, premium rates generally increase over time. Changes in the filed premium rates (relative to previously approved rates) are driven by many factors, including:

- -Increases in base period experience. Premium rates are increasing by 1.7% because our estimate of 2023 claims are higher than expected compared to the previous year.
- -Increases in cost and utilization of services. The cost and utilization of medical and pharmacy services generally increase over time. Premium rates are increasing by **7.5**% because of this estimated trend in 2024.
- -Impact of the Federal Risk Adjustment Program. The federal risk adjustment program seeks to "level the playing field" among insurers. MVP has enrolled a population of lower-risk members, so it is required to pay into the program. MVP's small group payment has become more, increasing premium rates by approximately 1.4%.
- -Changes in the cost of doing business. As the cost of doing business rises over time, MVP must collect a portion of the premium revenue to protect consumers by ensuring its solvency. MVP aligned its administrative costs with the expected cost of the small group market. These changes are worth approximately 1.2% of a premium increase.
- -Impact of the Leap Year. MVP is increasing rates by approximately **0.3%** to account for 2024 being a leap year (and having an additional day).

#### Conclusion

The proposed rates reflect an average rate adjustment to prior rates of 12.5%, ranging from 8.4% to 15.2%. There are 1,273 policyholders, 10,032 subscribers and 16,262 members impacted by this rate filing.

Vermonters can provide public comment on the proposed rate increases during the public comment period beginning on May 9<sup>th</sup>. For information about providing public comment, please visit https://ratereview.vermont.gov/public-comment

Т	A B	С	D		E	F		G	Н	1	1	J	$\overline{}$	К	L	М	N	0		Р	Q R		S T	_
1	Unified Rate Review v6.0		•					•					То		uct to W		•	_			uct button o	Ctrl + Sh	ft + P.	_
																					tton or Ctrl +			
3	Company Legal Name:	MVP Health Plan, Inc.												validate, se								,		
4	HIOS Issuer ID:	77566	State:	VT										finalize, sel										
5		1/1/2024	Market:		all Group									, manze, ser	cct tire i	manze bat		err - Singe -						
6	Effective Bate of Nate change(s).	-, -,	Worker.			_																		
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22																								
8	Market Level Calculations (Same for a	all Plans)																						
9																								
10																								
11	Section I: Experience Period Data																							
12	Experience Period:			1/1/2022	to	12/31/2022																		
14	Allowed Claims				Total \$166,257,004.8	PMPM	\$666.83	1																
15	Reinsurance				\$100,237,004.6		\$0.00																	
16	Incurred Claims in Experience Period				\$138,063,127.6		\$553.75																	
17	Risk Adjustment				-\$9,579,344.1		-\$38.42																	
18	Experience Period Premium				\$143,456,180.0	00	\$575.38																	
19	Experience Period Member Months				249,32	13		]																
20																								
21	Section II: Projections		1	Year 1 Tre	ond.	1	Voor 1	2 Trend	1															
22		Experience Period Index		Tear 1 In	ena		rear 2	2 Trend	Trended EHB Allowed Claims															
23	Benefit Category	Rate PMPM	Cost		Utilization	Cost		Utilization	PMPM															
24	Inpatient Hospital	\$91.9	7	1.114	1.01	.0	1.060	1.010	\$110.78															
25	Outpatient Hospital	\$302.8		1.119	1.01		1.053		\$363.99															
26	Professional	\$164.7		1.066	1.01		1.031		\$184.67															
27	Other Medical	\$2.1		1.000	1.01		1.000		\$2.18															
28	Capitation Prescription Drug	\$14.7 \$90.4		1.031	1.00		1.031		\$15.64 <u>\$106.84</u>															
30	Total	\$666.8		1.037	1.02	.0	1.057	1.028	\$784.11															
31		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							***															
32	Morbidity Adjustment						1.003	7																
33	Demographic Shift						1.000																	
34	Plan Design Changes						1.001																	
35	Other	211211		4 /4 /2024			1.003																	
36	Adjusted Trended EHB Allowed Claims	S PMPM TOP		1/1/2024			\$789.61	.1																
38	Manual EHB Allowed Claims PMPM						\$0.00	1																
39	Applied Credibility %						100.00%																	
40						'		-																
41								Projected Period Totals	_															
42	Projected Index Rate for			1/1/2024			\$789.61																	
43	Reinsurance						\$0.00																	
44	Risk Adjustment Payment/Charge Exchange User Fees						-\$55.29 0.00%	-\$10,789,511.76 \$0.00																
46	Market Adjusted Index Rate						\$844.90																	
47						1	y5-1-1.50	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1															
48	Projected Member Months						195,144																	
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49					<del></del>																			
	Information Not Releasable to the Pu	ublic Unless Authorized by La	aw: This information has no	t been public	ally disclosed and may be privi				t be disseminated, distributed, or c	pied to pe	ersons not	authorize	ed to i	eceive the	informat	ion. Unaut	thorized	disclosure	may resu	ılt in prosec	ution			
50							to the full of	extent of the law.																

#### Product-Plan Data Collection

MVP Health Plan, Inc. Company Legal Name:

HIOS Issuer ID: Effective Date of Rate Change(s): 77566 1/1/2024 State: Market: VT Small Group To add a product to Worksheet 2 - Plan Product Info, select the Add Product button or Ctrl + Shift + P.

To add a plan to Worksheet 2 - Plan Product Info, select the Add Plan button or Ctrl + Shift + L.

To validate, select the Validate button or Ctrl + Shift + I.

To disables, selected the Finalish exhance could not  $(II + 3)q^2 + I$ .

To finalise, selected the Finalish bottom or  $(III + 3)q^2 + I$ .

To remove a princher, nowigate to the corresponding Product Name/Product ID field and select the Remove Product button or  $(III + 5)q^2 + Q$ .

To remove a plan, involvable to the corresponding Plan Name/Plan ID field and select the Remove Plan Button or  $(III + 5)q^2 + Q$ .

To remove a plan, involvable to the corresponding Plan Name/Plan ID field and select the Remove Plan Button or  $(III + 5)q^2 + Q$ .

Field # Section I: General Product and Plan Information																	
1.1 Product Name									Small Group								
1.2 Product ID		77566VT00S															
1.3 Plan Name	S (2024)	001-S (2024)	002-N (2024)	003-N (2024)	S (2024)	004-S (2024)	002-N (2024)	N (2024)	II (2024)	S II (2024)	N II (2024)	II (2024)	S (2024)	003-S (2024)	S (2024)	N (2024)	N (2024)
1.4 Plan ID (Standard Component ID)	77566VT0050001	77566VT0050002	77566VT0050004	77566VT0050023	77566VT0050005	77566VT0050006	77566VT0050024	77566VT0050007	77566VT0050030	77566VT0050031	77566VT0050029	77566VT0050028	77566VT0050009	77566VT0050010	77566VT0050025	77566VT0050026	77566VT0050011
1.5 Metal	Platinum	Gold	Gold	Gold	Silver	Bronze	Bronze	Bronze	Bronze	Bronze							
1.6 AV Metal Value	0.901	0.813	0.815	0.803	0.707	0.713	0.720	0.717	0.707	0.713	0.719	0.717	0.620	0.630	0.648	0.631	0.635
1.7 Plan Category	Renewing																
1.8 Plan Type	нмо	нмо	нмо	HMO	HMO	нмо	НМО	нмо	HMO	HMO	нмо	НМО	HMO	HMO	НМО	HMC	HMO
1.9 Exchange Plan?	Yes	No	No	No	No	Yes	Yes	Yes	Yes	Yes							
1.10 Effective Date of Proposed Rates	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024	1/1/2024
1.11 Cumulative Rate Change % (over 12 mos prior)	13.78%	14.76%	12.81%	15.23%	8.40%	8.74%	9.24%	9.28%	8.40%	8.74%	9.28%	9.30%	10.46%	10.33%	9.06%	10.82%	11.64%
1.12 Product Rate Increase %									12.50%	•							
1.13 Submission Level Rate Increase %									12.50%								

Worksheet 1 Totals	Section II: Experience Period and Current Plan Level	I Information																	
	2.1 Plan ID (Standard Component ID)	Total	77566VT0050001	77566VT0050002	77566VT0050004	77566VT0050023	77566VT0050005	77566VT0050006	77566VT0050024	77566VT0050007	77566VT0050030	77566VT0050031	77566VT0050029	77566VT0050028	77566VT0050009	77566VT0050010	77566VT0050025	77566VT0050026	77566VT0050011
\$166,257,005	2.2 Allowed Claims	\$166,257,005	\$34,943,047	\$28,633,184	\$4,167,658	\$52,982,889	\$0	\$93,215	\$0	\$304,424	\$7,677,890	\$8,365,441	\$4,407,565	\$8,343,225	\$5,323,391	\$9,038,277	\$526,064	\$695,010	\$755,725
\$0	2.3 Reinsurance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
	2.4 Member Cost Sharing	\$28,193,877	\$2,357,530	\$4,302,123	\$461,530	\$8,560,507	\$0	\$36,312	\$0	\$52,090	\$2,012,743	\$2,206,837	\$911,959	\$1,853,441	\$1,699,426	\$3,204,472	\$139,611	\$164,405	\$230,892
	2.5 Cost Sharing Reduction	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
\$138,063,128	2.6 Incurred Claims	\$138,063,128	\$32,585,517	\$24,331,062	\$3,706,128	\$44,422,382	\$0	\$56,903	\$0	\$252,335	\$5,665,147	\$6,158,604		\$6,489,783	\$3,623,966	\$5,833,806	\$386,453	\$530,605	\$524,833
-\$9,579,344	2.7 Risk Adjustment Transfer Amount	-\$9,579,344	\$3,802,531	-\$1,402,260	-\$333,606	\$3,625,976	\$0	-\$69,374	\$0	-\$238,209	-\$2,922,121	-\$3,458,801	-\$1,082,683	-\$2,310,182	-\$1,397,030	-\$2,811,081	-\$193,114	-\$344,098	-\$445,292
\$143,456,180	2.8 Premium	\$143,456,180	\$27,947,959	\$25,351,555	\$3,160,145	\$37,790,593	\$0	\$170,579	\$0	\$361,162	\$9,266,669	\$8,910,249	\$3,855,411	\$8,953,633	\$4,944,775	\$10,511,389	\$548,104	\$665,081	\$1,018,876
249,323	2.9 Experience Period Member Months	249,323	39,081	43,140	4,999	63,984	0	306	0	652	16,793	17,495	7,415	16,759	10,431	23,527	1,129	1,361	2,251
	2.10 Current Enrollment	16,262	2,648	3,006	379	2,749	1	37	0	49	1,306	1,222	695	1,299	659	1,833	95	130	154
	2.11 Current Premium PMPM	\$678.48	\$859.93	\$714.39	\$765.80	\$726.55	\$669.71	\$676.13	\$0.00		\$613.74	\$592.16	\$617.66	\$621.32	\$543.87	\$514.50	\$550.76	\$541.35	\$522.11
	2.12 Loss Ratio	103.13%	102.63%	101.59%	131.12%	107.26%	#DIV/0!	56.23%	#DIV/0!	205.23%	89.29%	112.97%	126.07%	97.69%	102.15%	75.76%	108.86%	165.31%	91.50%
	Per Member Per Month																		
	2.13 Allowed Claims	\$666.83	\$894.12	\$663.73	\$833.70	\$828.06	#DIV/0!	\$304.62	#DIV/0!	\$466.91	\$457.21	\$478.16	\$594.41	\$497.84	\$510.34	\$384.17	\$465.96	\$510.66	\$335.73
	2.14 Reinsurance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	#DIV/0!	\$0.00	#DIV/0!	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
	2.15 Member Cost Sharing	\$113.08	\$60.32	\$99.72	\$92.32	\$133.79	#DIV/0!	\$118.67	#DIV/0!	\$79.89		\$126.14	\$122.99	\$110.59	\$162.92	\$136.20	\$123.66	\$120.80	\$102.57
	2.16 Cost Sharing Reduction	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	#DIV/0!	\$0.00	#DIV/0!	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
	2.17 Incurred Claims	\$553.75	\$833.79	\$564.00	\$741.37	\$694.27	#DIV/0!	\$185.96	#DIV/0!	\$387.02	\$337.35	\$352.02	\$471.42	\$387.24	\$347.42	\$247.96	\$342.30	\$389.86	\$233.16
	2.18 Risk Adjustment Transfer Amount	-\$38.42	\$97.30	-\$32.50	-\$66.73	\$56.67	#DIV/0!	-\$226.71	#DIV/0!	-\$365.35	-\$174.01	-\$197.70	-\$146.01	-\$137.85	-\$133.93	-\$119.48	-\$171.05	-\$252.83	-\$197.82
	2.19 Premium	\$575.38	\$715.13	\$587.66	\$632.16	\$590.63	#DIV/0!	\$557.45	#DIV/0!	\$553.93	\$551.82	\$509.30	\$519.95	\$534.26	\$474.05	\$446.78	\$485.48	\$488.67	\$452.63

Section III: Plan Adjustment Factors																		
3.1 Plan ID (Standard Component ID)		77566VT0050001	77566VT0050002	77566VT0050004	77566VT0050023	77566VT0050005	77566VT0050006	77566VT0050024	77566VT0050007	77566VT0050030	77566VT0050031	77566VT0050029	77566VT0050028	77566VT0050009	77566VT0050010	77566VT0050025	77566VT0050026	77566VT0050011
3.2 Market Adjusted Index Rate										\$844.90								
3.3 AV and Cost Sharing Design of Plan		1.0799	0.8904	0.9235	0.9277	0.6908	0.7057	0.7141	0.6908	0.6908	0.7057	0.7133	0.6908	0.5994	0.6091	0.6214	0.6056	0.6046
3.4 Provider Network Adjustment		1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000 1.0000
3.5 Benefits in Addition to EHB		1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000
Administrative Costs																		
3.6 Administrative Expense		4.52%	5.42%	5.24%	5.22%	6.87%	6.74%	6.67%	6.87%	6.87%	6.74%	6.67%	6.87%	7.83%	7.72%	7.58%	7.76%	7.77%
3.7 Taxes and Fees		1.56%	1.61%	1.60%	1.60%	1.70%	1.70%	1.69%	1.70%	1.70%	1.70%	1.69%	1.70%	1.76%	1.76%	1.75%	1.76%	1.76%
3.8 Profit & Risk Load		1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%	1.60%
3.9 Catastrophic Adjustment		1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000	1.0000
3.10 Plan Adjusted Index Rate		\$988.31	\$823.35	\$852.19	\$855.88	\$649.73	\$662.79	\$670.08	\$649.73	\$649.73	\$662.79	\$669.33	\$649.73	\$570.24	\$578.75	\$589.45	\$575.69	\$574.80
						•			_									
3.11 Age Calibration Factor	1.0000									1.0000								
3.12 Geographic Calibration Factor	1.0000									1.0000								
3.13 Tobacco Calibration Factor	1.0000									1.0000								
3.14 Calibrated Plan Adjusted Index Rate		\$988.31	\$823.35	\$852.19	\$855.88	\$649.73	\$662.79	\$670.08	\$649.73	\$649.73	\$662.79	\$669.33	\$649.73	\$570.24	\$578.75	\$589.45	\$575.69	\$574.80

Section IV: Projected Plan Level Information																		
4.1 Plan ID (Standard Component ID)	Total	77566VT0050001	77566VT0050002	77566VT0050004	77566VT0050023	77566VT0050005	77566VT0050006	77566VT0050024	77566VT0050007	77566VT0050030	77566VT0050031	77566VT0050029	77566VT0050028	77566VT0050009	77566VT0050010	77566VT0050025	77566VT0050026	77566VT005
4.2 Allowed Claims	\$165,315,998	\$29,119,316	\$31,044,029	\$3,914,068	\$28,389,899	\$9,849	\$364,422	\$0	\$482,613	\$12,863,103	\$12,035,767	\$6,845,220	\$12,794,159	\$6,301,599	\$17,527,817	\$908,425	\$1,243,108	\$1,4
4.3 Reinsurance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	
4.4 Member Cost Sharing	\$38,445,373	\$2,038,352	\$5,696,579	\$599,635	\$4,238,612	\$3,307	\$117,162	\$0	\$162,061	\$4,319,430	\$3,869,499	\$2,150,768	\$4,296,278	\$2,560,970	\$6,955,038	\$349,380	\$497,492	\$5
4.5 Cost Sharing Reduction	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	
4.6 Incurred Claims	\$126,870,625	\$27,080,964	\$25,347,450	\$3,314,432	\$24,151,287	\$6,542	\$247,260	\$0	\$320,551	\$8,543,673	\$8,166,268	\$4,694,452	\$8,497,880	\$3,740,629	\$10,572,779	\$559,045	\$745,616	\$8
4.7 Risk Adjustment Transfer Amount	-\$8,802,766	-\$1,878,980	-\$1,758,702	-\$229,968	-\$1,675,708	-\$454	-\$17,156	\$0	-\$22,241	-\$592,793	-\$566,607	-\$325,719	-\$589,615	-\$259,539	-\$733,580	-\$38,789	-\$51,734	-9
4.8 Premium	\$149,212,624	\$31,367,515	\$29,668,753	\$3,871,244	\$28,201,185	\$7,789	\$293,913	\$0	\$381,638	\$10,171,812	\$9,707,068	\$5,575,812	\$10,117,292	\$4,504,573	\$12,714,670	\$671,173	\$897,096	\$1,0
4.9 Projected Member Months	195,144	31,776	36,072	4,548	32,988	12	444	0	588	15,672	14,664	8,340	15,588	7,908	21,996	1,140	1,560	
4.10 Loss Ratio	90.36%	91.84%	90.82%	91.02%	91.05%	89.19%	89.34%	#DIV/0!	89.19%	89.19%	89.34%	89.42%	89.19%	88.12%	88.25%	88.40%	88.20%	
Per Member Per Month																		
4.11 Allowed Claims	\$847.15	\$916.39	\$860.61	\$860.61	\$860.61	\$820.77	\$820.77	#DIV/0!	\$820.77	\$820.77	\$820.77	\$820.77	\$820.77	\$796.86	\$796.86	\$796.86	\$796.86	9
4.12 Reinsurance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	#DIV/0!	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	
4.13 Member Cost Sharing	\$197.01	\$64.15	\$157.92	\$131.85	\$128.49	\$275.61	\$263.88	#DIV/0!	\$275.61	\$275.61	\$263.88	\$257.89	\$275.61	\$323.85	\$316.20	\$306.47	\$318.90	
4.14 Cost Sharing Reduction	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	#DIV/0!	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	
4.15 Incurred Claims	\$650.14	\$852.25	\$702.69	\$728.77	\$732.12	\$545.16	\$556.89	#DIV/0!	\$545.16	\$545.16	\$556.89	\$562.88	\$545.16	\$473.02	\$480.67	\$490.39	\$477.96	
4.16 Risk Adjustment Transfer Amount	-\$45.11	-\$59.13	-\$48.76	-\$50.56	-\$50.80	-\$37.83	-\$38.64	#DIV/0!	-\$37.82	-\$37.82	-\$38.64	-\$39.06	-\$37.82	-\$32.82	-\$33.35	-\$34.03	-\$33.16	
4.17 Premium	\$764.63	\$987.14	\$822.49	\$851.20	\$854.89	\$649.04	\$661.97	#DIV/0!	\$649.04	\$649.04	\$661.97	\$668.56	\$649.04	\$569.62	\$578.04	\$588.75	\$575.06	5

#### **Rating Area Data Collection**

 $Specify \ the \ total \ number \ of \ Rating \ Areas \ in \ your \ State \ by \ selecting \ the \ Create \ Rating \ Areas \ button \ or \ Ctrl + Shift + R.$ Select only the Rating Areas you are offering plans within and add a factor for each area. To validate, select the Validate button or  $\operatorname{Ctrl} + \operatorname{Shift} + \operatorname{I}$ .

To finalize, select the Finalize button or Ctrl + Shift + F.

Rating Area **Rating Factor** Rating Area 1

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

Product Name: VT Small Group 2024

Project Name/Number: /

# **Supporting Document Schedules**

Satisfied - Item:	Actuarial Memorandum and Certifications
Comments:	
Attachment(s):	2024 Actuarial Memorandum Vermont Exchange Small.pdf Actuarial Memo Dataset 2024 SMALL_SERFF.pdf Actuarial Memo Dataset 2024 SMALL_SERFF.xlsx Federal AVC Actuarial Certification for Non-standard Plans 2024.pdf Non-Standard AVC Screenshots 2024 VT.pdf Consumer-Disclosure-Form-2024-VT-Exchange-Small.pdf Wakely - VT Standard Plan Designs - AV Certification_2023-03-30.pdf Rate Increase Exhibit 2023-2024 SMALL_SERFF.pdf Rate Increase Exhibit 2023-2024 SMALL_SERFF.xlsx VT 2024 Exchange Rate Filing SMALL_SERFF.xlsx Unified-Rate-Review-VT-Small-2024.xlsm VT Rx Data 2024 SMALL_SERFF.pdf VT Rx Data 2024 SMALL_SERFF.xlsx
Item Status:	
Status Date:	
Satisfied - Item:	Civil Union Rating Requirements
Comments:	MVP's rating rules satisfy 8 V.S.A. § 4724.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Filing Compliance Certification
Comments:	
Attachment(s):	Certification of Compliance - 2024 VT.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Third Party Filing Authorization
Bypass Reason:	N/A
Attachment(s):	
Item Status:	
Status Date:	

SERFF Tracking #: MVPH-133660956 State Tracking #: Company Tracking #: Company Tracking #:

State: VermontGMCB Filing Company: MVP Health Plan, Inc.

TOI/Sub-TOI: H16G Group Health - Major Medical/H16G.003G Small Group Only - Other

**Product Name:** VT Small Group 2024

Project Name/Number:

Attachment Actuarial Memo Dataset 2024 SMALL\_SERFF.xlsx is not a PDF document and cannot be reproduced here.

Attachment Rate Increase Exhibit 2023-2024 SMALL\_SERFF.xlsx is not a PDF document and cannot be reproduced here.

Attachment VT 2024 Exchange Rate Filing SMALL\_SERFF.xlsx is not a PDF document and cannot be reproduced here.

Attachment Unified-Rate-Review-VT-Small-2024.xlsm is not a PDF document and cannot be reproduced here.

Attachment VT Rx Data 2024 SMALL\_SERFF.xlsx is not a PDF document and cannot be reproduced here.



# **Contact Information**

**Company Information** 

Company Legal Name: MVP Health Plan, Inc.

HIOS Issuer ID: 77566 NAIC Number: 95521

**Primary Contact Information** 

Contact Name: Christopher Pontiff, FSA, MAAA

Senior Director, Commercial Pricing, Network & Trend

Contact Title: Actuary

Primary Contact Phone #: 1-800-777-4793, ext. 17696

Primary Contact Address: 625 State Street

Schenectady, NY 12301-2207

Primary Contact E-mail: Cpontiff@mvphealthcare.com

# ACTUARIAL MEMORANDUM 2024 Vermont Small Group Exchange Filing

# **Purpose and Scope of Filing**

This memorandum details the methods and assumptions underlying the proposed 2024 premium rates for the State of Vermont's small group ACA compliant market. These products will be issued by MVP Health Plan, Inc. (MVP), a non-profit subsidiary of MVP Health Care, Inc. The rate filing has been prepared to satisfy the requirements of 8 V.S.A §5104 as well as the requirements of the Federal ACA including 45 CFR Part 156, §156.80. The premium rates are effective between 1/1/2024 and 12/31/2024. There are no benefit plans being retired, nor are there any new benefit plans being added. MVP modified several of the benefits being offered, and the updated forms have been submitted in a separate SERFF filing. The proposed average rate increase (MVP's revenue increase) is 12.5%, with increases ranging from 8.4% to 15.2%.

# Market/Benefits

All benefit plans included in this rate filing are available to small employer groups.

A description of benefits is included in Exhibit 1 of the rate filing. As in 2023, MVP has filed Silver plans to be sold off exchange known as "reflective" Silver plans. These plans are equivalent to the corresponding on exchange plan with the exception of a \$5 copay or 5% coinsurance change to the ambulance benefit or a modification to the deductible/maximum out of pocket for the plan which has no cost sharing after the deductible.

Exhibit 1A of the filing provides an overview of benefit changes for renewing plans from 2023 to 2024. As noted in the rate filing document, design changes from the previous year's plan design are shaded in gray.

All Essential Health Benefits (EHBs) are covered. Only one EHB substitution was made as required by the DVHA, a substitution for the \$2,000 annual Private Duty Nursing benefit limit in the benchmark plan. MVP previously contracted Milliman to determine an actuarially equivalent visit limit, and the claim data in the experience period represents this actuarially equivalent limit.

The non-standard plans proposed by MVP and included in this rate filing contain two benefits in excess of the EHBs: a wellness benefit and an acupuncture allowance of \$500. The wellness benefit and acupuncture allowance are included in all non-standard products and the wellness benefit is filed as a mandatory rider, form: FRVT366.

To inform consumers of the availability and details of the products included in this filing, MVP will provide community outreach support as well as offer web and print product content and other printed product materials for VT plans. MVP will also have a mass media presence to further educate health care customers in Vermont.

The book of business affected by this rate filing is 1,273 policyholders, 10,032 subscribers and 16,262 members based on February 2023 membership.

## **Experience Period Claims**

MVP historical claim data was the basis of the premium rate development. All ACA compliant small group data is included in the experience period data set. The claim data is assumed to be fully credible.

The experience period for the historical claims is incurred dates of service between 1/1/22 and 12/31/22, paid through 2/28/23. MVP has restated its incurred medical claim estimates to complete the claims through 3/31/23.

Please see Exhibit 3 for a summary of MVP's experience period claims, market-wide adjustments to experience period claims, and the development of the paid Index rate PMPM. Details of the market-wide adjustments and trend projections being made to MVP's experience period data are discussed below.

Line 1 of Exhibit 3 provides the member months for the experience period for the rating pool.

Line 2 of Exhibit 3 provides the experience period fee for service medical claim expense on a "per member per month" (PMPM basis). This includes all claims for medical services paid by MVP for the rating pool during the experience period.

Line 3 of Exhibit 3 provides the FFS claims paid by MVP for pediatric dental services provided to members in the rating pool during the experience period.

Line 4 reflects the assumption for claims Incurred but not Reported (IBNR) as of the latest date the claims data was paid through. We have completed the claims using an IBNR factor of 1.8% which is our best estimate of ultimate liabilities as of 3/31/23. MVP uses a combined trended PMPM and completion factor method to value its ultimate claim liabilities. Note that the model used to calculate IBNR for this block of business includes all Vermont business, so the paid and incurred claims below will not match the paid and incurred claims in the filing. Please see the following table comparing incurred and paid claim amounts by month for the experience period.

1	1	I	
		Incurred	
Incurred Month	Paid Claims	Claims	IBNR Factor
202212	\$18,211,516	\$19,193,037	1.054
202211	\$16,714,473	\$17,322,906	1.036
202210	\$18,629,912	\$19,962,840	1.072
202209	\$15,745,369	\$15,922,114	1.011
202208	\$17,689,240	\$17,868,631	1.010
202207	\$17,196,684	\$17,476,872	1.016
202206	\$17,427,673	\$17,467,389	1.002
202205	\$17,299,783	\$17,342,327	1.002
202204	\$17,055,835	\$17,078,435	1.001
202203	\$17,459,308	\$17,462,993	1.000
202202	\$14,493,506	\$14,482,313	0.999
202201	\$15,014,176	\$15,010,911	1.000
Total	\$202,937,477	\$206,590,768	1.018

Line 5 reflects medical plus dental fee-for-service (FFS) claims, completed with IBNR. The formula is line 2 multiplied by line 4, then adding line 3. MVP is assuming that dental claims are fully complete with two months of run-out, and therefore IBNR is not applied to these claims.

Line 6 provides the experience period incurred pharmacy claims for the rating pool. Pharmacy claims include any claims which are paid through the pharmacy portion of the member's benefits.

Experience period Rx rebates are reflected in line 7 of Exhibit 3.

Line 8 of Exhibit 3 reflects MVP's ultimate liability for pharmacy claims during the experience period, which nets manufacturer rebates from the incurred claims paid by MVP.

Line 9 of Exhibit 3 reflects expenses for services such as capitations and other non-FFS medical expenses which come from MVP's General Ledger and are not processed through MVP's claims system. Please see the table below for detail on the items that comprise the capitation and non-FFS expenses reflected in MVP's experience period claims.

# Summary of Experience Period Non-FFS and Capitation Amounts

Other Medical Expenses not in claim warehouse	\$3.66
Net Reinsurance Expense	\$1.09
Medical Home and PCP Incentive	\$3.76
<b>Total Non-FFS and Capitation Amounts</b>	\$8.51

<sup>\*</sup>Note: VT Paid Claim Surcharge (0.999% of paid claims) and NY HCRA Surcharge (0.15% of paid claims) are not reflected in figures above. Line 9 of Exhibit 3 = (line 5 of Exhibit 3 + line 8 of Exhibit 3) \* 1.149% + the applicable value shown above.

Line 10 of Exhibit 3 represents MVP's best estimate of the costs incurred to cover members in the rating pool during the experience period after making the adjustments described above. It is calculated by summing the medical and dental FFS incurred claims completed with IBNR (line 5 of Exhibit 3), the pharmacy incurred claims net of rebates (line 8 of Exhibit 3), and the capitation and non-FFS medical expenses (line 9 of Exhibit 3).

# **Market-Wide Adjustments to Experience Period Claims**

Several adjustments to the experience period incurred claim costs were necessary to adjust for items not captured in the experience period. The adjustments are explained below.

#### Line 11- Adjustment for Waived Cost Share Due to COVID-19

MVP is removing \$2.02 PMPM to account for cost sharing related to the COVID-19 pandemic including treatment, visits, and testing that was waived during the experience period. Cost sharing will shift back to the members in 2024 with the unwinding of the public health emergency.

#### Line 12- Adjustment for COVID Testing

MVP is assuming a 10% reduction in Covid testing costs in the projection period due to a utilization decrease, resulting in the removal of \$0.41 PMPM. We expect demand for testing to decrease once cost sharing is reinstituted.

# Line 13- Adjustment for COVID Vaccines

It is expected commercial payers will have to pay the full ingredient cost of Covid vaccines by 2024. MVP is taking 2022 experience and increasing it by \$130/\$40, the expected ingredient cost in 2024 over what we pay currently<sup>1</sup>. This results in an additional \$2.32 PMPM.

#### Line 14- Adjustment for Hearing Aids as EHB

Hearing aids have been added as an essential health benefit in 2024. MVP analyzed historical experience in its New York population and determined this mandate would result in an additional \$0.34 PMPM.

#### Line 15- Adjustment for Abortions Covered in Full

Vermont has mandated coverage of abortions without cost sharing except before the deductible on HDHPs. MVP analyzed its historical VT experience and determined this is worth \$0.03 PMPM.

#### Line 16- Adjustment for Telemedicine Benefit Expansion

Telemedicine is now covered in full on all plans. The Consolidation Appropriations Act of 2023 allowed the extension of safe harbor before the deductible for all telehealth, even for HDHPs. Our benefit relativity model accounts for this so the expansion of telemedicine for all HDHPs is reflected in the AV of the plan. Based on the cost share MVP took in 2022, this benefit is an additional \$0.04 PMPM on the rate.

 $<sup>^{1}\</sup> https://www.kff.org/coronavirus-covid-19/issue-brief/how-much-could-covid-19-vaccines-cost-the-u-s-after-commercialization/$ 

#### Line 17- Adjustment for Leap Year

Because the rating period is a leap year and the experience period is not a leap year, the rating period will have one more day than the experience period. Assuming claims are uniformly distributed among all days in the year, MVP is adjusting the experience period claim expense upward by 0.27% (366 days / 365 days), or \$1.52 PMPM.

#### **Medical Trend Factors**

The development of annual medical paid claim trend factors for 2023 and 2024 is illustrated in Exhibit 2a.

For VT providers whose contractual reimbursement changes are governed by the GMCB, MVP is reflecting the GMCB's most recently approved budgeted changes as the unit cost trend for 2023. Due to the unusually large increases in hospital budgets last year, we are using approved 2022 increases as the best estimate of future budgeted changes for 2024. For VT providers not governed by the GMCB and non-VT providers, MVP is reflecting its best estimate of unit cost changes. Total allowed unit cost trend is 10.4% for 2023 and 4.9% for 2024.

MVP analyzed historical medical utilization trends for its VT block of business and determined that the data has been too volatile in recent years to use for medical utilization trend purposes. MVP attributes this volatility to the significant membership growth for this block of business and COVID-19. During the 2020 filing, "L&E [Lewis & Ellis Actuaries and Consultants] performed a series of independent trend calculations using market wide utilization data from 2015 to 2018" and found that "After assessing all the market wide results, L&E believes that a reasonable range for market wide utilization trend to be 1% to 4%" (L&E Actuarial Memo, SERFF # MVPH-131934219, page 7). MVP has maintained this same trend in the filing each year. Because MVP believes that their data still lacks necessary stability and L&E's view of utilization trend encompasses the entire market, MVP has built in a 1% annual utilization trend for this filing.

In addition to the medical cost inflation rate assumed from the historical experience period to the rating period, an adjustment is needed to reflect the impact of cost share leveraging on the carrier's share of the medical cost. Leveraging is a result of the fixed nature of deductibles and copays in health benefit plans. When there are fixed member deductibles and copays, the carrier bears a greater portion of the cost of medical inflation. Therefore, an additional factor adjustment is made to the trend assumption to capture this cost.

The trend applied to the deductible portion of the experience period was derived using the distribution of claims for MVP's entire book of business (consistent with the data in MVP's benefit relativity model). Claims below the average deductible amount over the experience period were trended at the applicable allowed trend rate while claims greater than the deductible were held flat.

The average annual allowed trend factor applied to FFS medical claims in this filing is 8.7%. The annual paid leveraging factor is 0.9% which results in an average annual paid FFS medical trend of 9.7%. This can be found on line 19 of Exhibit 3.

## **Rx Trend Factors**

Annual allowed Rx trend factors split by generic, brand, and specialty drugs are illustrated in Exhibit 2a. The trend forecast provided by MVP's PBM was determined using MVP's Vermont commercial data by drug class. The forecasts provided by MVP's PBM account for drugs coming off patent, changes in average wholesale price, new drugs being released to the market, and price competitiveness amongst generic and brand drug manufacturers. In addition to the market trend data provided by the PBM, MVP is also reflecting its best estimate of known contract changes for 2023 and 2024. Those contract changes are reflected in the unit cost trends shown on Exhibit 2a.

Supporting documentation illustrating how the Rx trends shown on Exhibit 2a were converted to paid trends for 2023 and 2024 can be found in Exhibit 2b.

To project rebates, MVP has taken the experience period rebates as a percentage of the experience period allowed claims (30.8%) and applied that percentage to the rating period allowed claims. This represents MVP's best estimate of future rebates that will be shared between the PBM and MVP.

The average annual allowed Rx trend in this filing is 8.6%, and the average annual paid Rx trend net of Rx rebates is 9.2% which can be found in line 20 of Exhibit 3.

The Annual FFS Claim Trend Projection factor shown in line 21 of Exhibit 3 represents the blended FFS annual trend projection. To arrive at the blended trend projection shown in line 21, the following calculation is performed: [line 5 \* line 19 + line 8 \* line 20] / [line 5 + line 8]. The annual trend is then applied for 24 months to move the experience period data from the experience period to the rating period, and the rating period FFS claim expense on a PMPM basis is reflected in line 23 of Exhibit 3.

# Paid Claim Surcharges, Capitation, and Non-FFS PMPM Projection

The paid claim surcharges, capitation, and non-FFS expenses shown in lines 24 and 25 of Exhibit 3 represent MVP's best estimate of these costs in the projection period. A summary of the expenses driving the capitation and non-FFS expenses in line 25 can be found below. Expenses captured in the "Other Medical Expense not in warehouse" line include student out of area charges, a surcharge levied by the state of Massachusetts, and manual checks.

Summary of Rating Period Non-FFS and Capitation Amounts					
Other Medical Expenses not in claim warehouse	\$3.66				
Net Reinsurance Expense	\$0.75				
Medical Home and PCP Incentive	\$3.76				
Total Non-FFS and Capitation Amounts	\$8.17				

MVP is assuming that the VT paid claim surcharge will remain unchanged in 2024 and equal 0.999%. The NYS HCRA surcharge of 0.15% is also unchanged.

# Federal Risk Adjustment Program

Based on the Interim Risk Transfer results for 2022 provided by CMS, MVP is expected to pay \$9,579,344 into the small group market transfer pool for 2022. This is \$38.42 on a PMPM basis or 6.9% of experience period claims prior to market-wide adjustments. To calculate line 27 of Exhibit 3, MVP applied this risk adjustment payment as a percentage of claim expense to line 26 of Exhibit 3, which the best estimate of the rating period claim expense. This results in an estimated payment of \$46.17 PMPM or \$11,510,596 using experience period membership.

# Plan Level Adjustments / Plan Specific Net and Gross Index PMPM rates

Line 28 of Exhibit 3 represents MVP's projected paid index rate after adjustments for 2024. This is the starting net claim cost that will be used to set 2024 premium rates. Gross Index rates and contract tier rates are calculated in Exhibit 7. The plan specific net claim cost for each plan is computed as follows on Exhibit 7:

Adjusted Claim Cost For Pricing (see Exhibit 7)	=	Projected Paid Index Rate After Adjustments PMPM (line 28 of Exhibit 3)  [ Avg Inforce Actuarial Value * Induced Utilization Factor ]
Plan Specific Net Claim Cost PMPM (see Exhibit 7)	=	Adjusted Claim Cost for Pricing * Benefit Actuarial Value * Plan Induced Utilization Factor

The Plan Specific Gross Claim Cost PMPM for each plan is derived by adjusting the Plan Specific Net Claim Cost PMPM which account for Benefits in Excess of EHBs, PMPM non-claim expense loads, and percent of premium non-claim expense loads.

# **Actuarial Values and Induced Utilization Factors**

The AV Metal Level for each plan was determined using the Federally prescribed Actuarial Value Calculator. Adjustments for aggregate deductibles, the VT Rx OOPM, and safe harbor prescription Rx benefits were made to the calculator results for the non-standard plans. The actuarial certification of these adjustments has been included as an attachment to this filing in SERFF.

The Benefit Actuarial Value for each plan was determined using MVP's in-house benefit relativity model. The pricing tools value the expected net paid claim cost associated with unique benefit plan designs from a starting single risk pool allowed amount. The AV is the ratio of the expected paid to allowed amount for each plan design.

The induced utilization factors used to set premium rates and compute the average in-force induced utilization factor are the HHS prescribed induced utilization factors of 1.00 for Bronze, 1.03 for Silver, 1.08 for Gold, and 1.15 for Platinum. The experience period actuarial value times induced demand factor (0.8350) can be found in Exhibit 7.

# **Non-Claim Expense Plan Level Adjustments**

Non claim expenses include both percent of premium loads and PMPM loads. The loads do not vary by plan. Each Standard and Non-Standard plan is being loaded with the same PMPM and Percent of Premium loads. The loads are outlined below and summarized in Exhibit 5.

# Federal Taxes PMPM based

A total of \$0.44 PMPM is added for fees MVP must pay to the Federal Government per ACA regulations on a PMPM basis. This is comprised of \$0.19 PMPM for the risk adjustment user fee levied by the Department of Health and Human Services and \$0.25 PMPM for the Patient Centered Outcome Research Fee.

# State Taxes PMPM Based

\$2.37 PMPM is added for fees MVP must pay to the State of Vermont to help fund expenses incurred by state agencies and other non-profit organizations on MVP's behalf, including the Green Mountain Care Board, the Vermont Program for Quality in Health Care, Inc., and the Office of the Health Care Advocate. This is found by using the best available information about the market-wide cost of each of the programs and then accounting for MVP's growth in market share from 2022 to 2024.

# State Taxes Premium based – VT Vaccine Assessment

Based on information provided by the Vermont Vaccine Purchasing Program (VVPP), MVP's rates are \$13.54 per covered child and \$2.74 per covered adult for 2024, followed by an estimate of \$15.05 per covered child and \$3.00 per covered adult for 2025. Based on a blend of MVP's child and adult membership in the projection period, the total PMPM costs were determined for each year and given an equal weight, resulting in \$4.42 PMPM. This blended PMPM was then compared to the projection period premium PMPM before the assessment load to convert the assessment to a percent of premium load of 0.58%.

# Federal Fees Premium based – National High Cost Reinsurance Pool (HCRP) Charge

In the 2024 Notice of Benefit and Payment Parameters issued by HHS, carriers will be compensated 60% for members' paid claims above \$1 million in a given plan year. The total reinsurance received across all states will be aggregated and compared to the national average premium PMPM to determine a percentage of premium charged to each issuer to fund the program.

Based on a national study performed by Wakely Consulting Group, the estimate of the load charged to small group market issuers in 2024 will be 0.69%.

# General Administrative Expense Load (Including QI component)

The total administrative expense load included as a plan level adjustment equals \$44.62 PMPM and is used to cover SG&A expenses as well as Quality Improvement/Cost Containment Programs (QI). Based on an analysis of MVP's historical Supplemental Health Care Exhibit (SHCE) expenses, approximately 7% of MVP's total administrative expense was spent on QI. Therefore, \$3.12 PMPM of the \$44.62 PMPM administrative expense is attributable to QI.

The following table summarizes the administrative expenses for small group and individual lines of business from the 2019, 2020, and 2021 SHCEs compared to the available admin expense built into the rates for the same time period.

Combined VT AR42 and AR44	Year	Exchange Available Admin PMPM	SHCE Admin PMPM*
Individual	2020	N/A	\$35.40
Small Group	2020	N/A	\$33.65
Combined	2020	\$42.00	\$34.40
Individual	2021	N/A	\$51.71
Small Group	2021	N/A	\$44.49
Combined	2021	\$43.75	\$47.44
Individual	2022	\$47.10	\$48.26
Small Group	2022	\$38.75	\$39.63
Combined	2022	\$42.20	\$43.07

\*Reflects lines 1.07, 6.6, 8.3, 10.1, and 10.4 of SHCE, Part 1

# Contribution to Reserves/Risk Charge

MVP is building a 1.5% contribution to reserves/risk charge into the VT Exchange premium rates for 2024. This charge is added to premium rates to meet statutory reserve requirements for MVP's VT block of business and protect against adverse experience relative to pricing assumptions.

# Bad Debt Expense

A plan level adjustment equal to 0.10% of premium was added to account for non-payment of premium risk.

# Rider FRVT366 (Wellness Benefit in Addition to EHBs)

Members purchasing a non-standard plan will receive MVP's Member Wellness Incentive (Form: FRVT366). This is an enhancement to the current wellness benefit whereby primary subscribers can earn up to \$600 in reimbursements for wellness-related activities. The cost of this benefit is included in the experience period claims as well as the plan AVs so an adjustment is not required on Exhibit 7.

# Acupuncture Allowance (Benefit in Addition to EHBs)

MVP is including a \$500 acupuncture allowance in its benefits in 2024. The cost of this benefit is included in the experience period claims as well as the plan AVs so an adjustment is not required on Exhibit 7.

# **Per Contract Premium Rates**

The Plan Specific Gross Claim Cost PMPMs computed in Exhibit 7 are converted to per contract premium rates using the computed single conversion factor and the prescribed standard load ratios. The single conversion factor (SCF) was calculated using subscriber and member data by contract type for the eligible population enrolled with MVP as of

February 2023. The SCF = weighted average contract size / weighted average load ratio. Please see Exhibit 4 for the derivation of the SCF.

# **Loss Ratio Information**

The traditional target loss ratio (claims cost / premium) for the rates proposed in this rate filing is 91.1%. After adjusting for taxes/assessments and expenses associated with quality improvements, the Federal target loss ratio for the rates proposed in this filing is 93.0%. Please see the following table for a calculation of these loss ratios based on MVP's projected starting claim cost in 2024:

Target Loss Ratio for 2024 VT Exchange						
	Ī					
A) Claims Expense	\$711.56					
B) Taxes/Assessments	\$12.74					
C) Quality Improvement	\$3.12					
D) Premium	\$781.42					
E) Traditional Loss Ratio	91.1%					
= A) / D)						
F) Federal Loss Ratio = [A) + C)] / [D) - B)]	93.0%					

MVP does not anticipate having to rebate members for 2022 per the ACA minimum MLR requirements.

# Actuarial Dataset, Rate Increase Exhibit, URRT, and Federal Memorandum

Also included with this rate filing are L&E's Actuarial Dataset, a projection of rate increases for ACA compliant subscribers as of February 2023, the Federal URRT, and the Federal Actuarial Memorandum.

# Projection Period Enrollment

MVP's projection period membership equals the February 2023 enrollment of the population eligible to purchase these products, or 16,262 members. On Worksheet 2 of the URRT, members are mapped based on their February 2023 benefit to the same benefits for 2024.

MVP is aware that the Medicaid continuous enrollment provision will not continue in 2024. We have decided not to assume a membership or morbidity change for this. We expect the impact to be the same as the overall market wide morbidity impact which we do not have data to project or support.

# **Actuarial Certification**

I, Christopher Pontiff, am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries. The projected Index Rate and Adjusted Paid Amount used in the development of these proposed premium rates is in compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80(d)(1)) and developed in compliance with the applicable Actuarial Standards of Practice. I have examined the assumptions and methods used in determining MVP's requested rates. Based on my review and examination, it is my opinion that the proposed premium rates are reasonable in relation to the benefits provided and that they are not excessive, nor inadequate, nor unfairly discriminatory. They are developed using only the permitted rating classifications. The Adjusted Paid Amount and only the allowable modifiers as described in 45 CFR 156.80(d)(1) and 45 CFR 156.80(d)(2) were used to generate plan level rates. The Standard AV Calculator was used to determine the Metal AV Value to be shown in Worksheet 2 of the Part I Unified Rate Review template for all the plans.

I certify that I am knowledgeable as to the Vermont laws and regulations that apply to this filing and that, to the best of my knowledge and belief, this filing is in compliance with such laws and regulations and provides all required benefits.

I am of the opinion that this filing is in compliance with the applicable Federal and State Laws and Regulations concerning the PPACA and the HCERA of 2010. The proposed premium rates were developed based on currently approved State and Federal regulations and statutes. If modifications are made to State or Federal regulations or statutes for the 2024 plan year after this filing is submitted, including but not limited to changes to the enforcement of the individual mandate, changes to rules around selling across state lines or association groups, the proposed premium rates may not be reasonable relative to the benefits being offered and could result in inadequate premium rates. If such modifications are made, MVP will pursue an adjustment to the proposed premium rates to reflect the regulations and statutes that will be in place for the 2024 plan year.

I certify that each rate filing has been prepared in accordance with the following Actuarial Standards of Practice; ASOP #5, ASOP#8, ASOP #12, ASOP #23, ASOP #25, ASOP #26, ASOP#41, ASOP#42, ASOP#45, and ASOP#50.

05/09/2023

Christopher Pontiff, FSA, MAAA

Date

Senior Director, Commercial Pricing, Network & Trend Actuary

MVP Health Care, Inc.

# Actuarial Memorandum Dataset Supplement - Plan Year 2024

Please provide Company specific inputs for any cells shaded in blue.

# Purpose, Scope, and Reason for Rate Increase

Insurance Company Name HIOS ID SERFF Filing Number Date of Submission Proposed Effective Date

The sauce must complete the Assardal Memorandum Dissest Supplement and submit with the filling.

\*Enter data for all the studence disto construct enter the first sector \$4 in \$4 the student delivers construct enter the first sector \$4 in \$4 the student delivers construct.

\*This includes colls where the generalcheet contains sample input feet entries are just proxy values that help fillustrate what found due providedly.

\*In the student is submitted to the student enter the supplement of the student fillustrate that the student the Supporting Documentation Tab in the FormState filling.

\*Please submitted Exact Sommat under the Supporting Documentation Tab in the FormState filling.

\*Pleasements to so coll to the right: These is domination requested the though Column N.

Amount in SERFF's Rate Explanation for differences

		Review Detail Section	
Proposed Overall Rate Change	12.50%	12.50%	N/A
Proposed Minimum Rate Change	8.40%	8.40%	N/A
Proposed Maximum Rate Change	15.23%	15.23%	N/A

If the difference between the maximum and minimum rate increase is greater than 10%, Provide a statement and clear delineation of contributing factors explaining why certain individual will receive a rate decrease as low as the minimum while others will face rate increases as high as the maximum

Relationship of Proposed Rate Scale to Current Rate Scale:

Provide a detailed breakdown of the average rate change from the previous approved filing by using the chart below to itemize the
citiess of the average rate change. The table should include the previous assumption, current assumption, and the resulting

Source of Change	Previous filing	Current Filing	Relativity	
	Assumption	Assumption	Current Filing / Previous filing	
Base Period Experience	1.000	1.073	1.073	e.g. previous filing experience period index rate compared to the current filing experience index rate
Large Claim Adjustment	0.994	1.000	1.006	
Adjustment for Insulin Cap	1.000	1.000	1.000	
Adjustment for High Cost Claimant in 2021 At		1.000	1.005	
Adjustment for COVID Services	0.991	1.000	1.009	
Adjustment for Waived Cost Share Due to CC		0.996	1.006	
Adjustment for COVID Testing	1.000	0.999	0.999	
Adjustment for COVID Vaccines	1.000	1.004	1.004	
Adjustment for Hearing Aids as EHB	1.000	1.001	1.001	
Adjustment for Abortions Covered in Full	1.000	1.000	1.000	
Adjustment for Telemedicine Benefit Expansion		1.000	1.000	
Adjustment for Leap Year	1.000	1.003	1.003	
Pricing Trend	1.217	1.198	0.984	The change in this factor is based on the change the trend assumption in previous filing and current filing (e.g. 1.075^2 / 1.08^2)
Risk Adjustment Recoveries	1.055	1.069	1.014	The change in this factor is based on the change in the risk adjustment recoveries assumptions between previous filing and current filing
Experience Period Benefit and AV Change	0.993	1.000	1.007	
SG&A	1.057	1.052	0.996	
Total PMPM Taxes/Assessments	1.002	1.003	1.001	
Total % of Premium Taxes/Assessments	1.009	1.013	1.004	
Margin	1.000	1.016	1.017	
Single Conversion Factor	1.127	1.119	0.993	
			1.000	
			1.000	
			1.000	
			1.000	
Total Rate Change			1.125	
If applicable, Provide an explanation for different average rate change in cell B18	ence between the Calculate	d Rate change and the	1.125	

Annual Rate Change Distribution Reduction of 15.00% or more Reduction of 10.01% to 14.99%, Reduction of 5.01% to 10.00% Reduction of 5.01% to 10.00% No Change Increase of 0.01% to 5.00% Increase of 0.01% to 5.00% Increase of 10.01% to 10.00% Increase of 15.00% or more Total

	History of Rate Changes		
F . W		Average Annual Proposed	Average Annual Approved
	For Year	Rate Change	Rate Change
	2020	8.45%	10.08%
	2021	7.30%	2.70%
	2022	4.97%	0.83%

Rev. 4/30/2019

				Proposed Change in	Proposed Change in
	PMPM in effect during the	PMPM from Most Recent	Proposed PMPM for	PMPM Compared to	PMPM Compared to Most
	experience period	Approved Rate Filing	Effective Date	Prior 12 months	Recently Approved Filing
Dates	1/1/2022 - 12/31/2022	1/1/2023 - 12/31/2023	1/1/2024 - 12/31/2024		
Commissions & Brokers Fees	\$0.00	\$0.00	\$0.00		
Taxes, Licenses & Fees	\$5.02	\$4.78	\$12.51	149.35%	161.82%
Exchange Fee	\$0.00	\$0.00	\$0.00		
Reinsurance	\$0.00	\$0.00	\$0.00		
All Other Admin Expense	\$38.75	\$43.56	\$44.62	15.15%	2.42%
Profit/Risk Margin	\$6.32	-\$0.34	\$12.21	93.09%	-3676.00%
Total	\$50.09	\$48.00	\$69.34	38.43%	44.46%
Variable	\$25.33	\$18.80	\$34.83	37.50%	85.30%
Non-Variable	\$24.76	\$29.20	\$34.51	39.38%	18.18%
Total	\$50.09	\$48.00	\$69.34	38.43%	44.46%
Charak	TRUE	TDLIE	TDLIC		

		As % of Premium from		Proposed Change in %	Proposed Change in % of Premium Compared to
	As % of Premium during the experience period	Most Recent Approved Rate Filing	Proposed As % of Premium for Effective Date		
Commissions & Brokers Fees	0.00%		0.00%		
Taxes, Licenses & Fees	0.87%	0.70%	1.64%	87.83%	134.29%
Exchange Fee	0.00%	0.00%	0.00%		
Reinsurance	0.00%	0.00%	0.00%		
All Other Admin Expense	6.74%	6.38%	5.85%	-13.26%	-8.35%
Profit/Risk Margin	1,10%	-0.05%	1.60%	45.45%	-3300.00%
Total	8.71%	7.03%	9.08%	4.28%	29.27%
Variable	4.41%		4.56%	3.58%	65.81%
Non-Variable	4.31%	4.28%	4.52%	4.99%	5.75%
Total	8.71%	7.03%	9.08%	4.28%	29.27%
Check	TRUE	TRUE	TRUE		

Trend & Projection Assumptions

Incurred or Allowed	Inquired	(1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed").
Basis? <sup>(1)</sup> :		

	Historical Experience (ACA Only):	Basis r											
Monthly Trend Analysis Based on			Monthly Incurred Claims S		Annualized Rolling 6 Mo	Annualized Rolling 3 Mo		Average Age/Gender		Normalized Monthly	Normalized Rolling 12 Mo	Normalized Annualized	Normalized Annualized
Experience Data Time Period	Month	Member Months	PMPM*	Rolling 12 Mo Trend	Trend	Trend	Average Benefit Factor	Factor	Other Factor	Incurred Claims \$ PMPM	* Trend	Rolling 6 Mo Trend	Rolling 3 Mo Trend
Used for Rate Development (ACA Onl	() Jan-2020	20,828	\$329.17				1.00	1.00	1.00	\$329.17			
	Feb-2020	20,833	\$329.76				1.00	1.00	1.00	\$329.57			
	Mar-2020	20,768	\$315.61				1.00	1.00	1.00	\$314.86			
	Apr-2020	20,641	\$256.59				1.00	1.00	1.00	\$255.88			
	May-2020	20,565	\$331.12				1.00	1.00	1.00	\$329.73			
	Jun-2020	20,653	\$393.86			2.91%	1.00	1.00	1.00	\$391.75			1.55%
	Jul-2020	20,531	\$465.34			202.70%	1.00	1.00	1.00	\$462.48			198.46%
	Aug-2020	20,510	\$419.04			300.74%	1.00	1.00	1.00	\$415.95			295.69%
	Sep-2020	20,523	\$442.06			233.46%	1.00	1.01	1.00	\$438.26			229.38%
	Oct-2020	20,579	\$460.40			52.01%	1.00	1.01	1.00	\$456.37			50.24%
	Nov-2020	20,696	\$421.06			14.96%	1.00	1.01	1.00	\$417.60			13.94%
	Dec-2020	20,620	\$460.63		86.09%	4.76%	1.00	1.01	1.00	\$455.91		84.01%	4.02%
	Jan-2021	21,795	\$373.71		51.44%	-19.22%	1.00	1.01	1.00	\$372.00		50.16%	-19.07%
	Feb-2021		\$409.94		38.22%	-22.48%	1.00	1.01	1.00	\$408.23		37.52%	-21.84%
	Mar-2021	21,817	\$484.73		27.80%	-20.19%	1.00	1.01	1.00	\$482.16		27.58%	-18.77%
	Apr-2021		\$478.47		9.49%	44.21%	1.00	1.01	1.00	\$475.57		9.58%	45.72%
	May-2021	21,667	\$466.61		5.58%	75.81%	1.00	1.01	1.00	\$462.78		5.78%	75.78%
	Jun-2021	21,722	\$516.58		4.64%	76.35%	1.00	1.01	1.00	\$512.11		5.05%	74.28%
	Jul-2021	21,773	\$473.38		20.86%	26.67%	1.00	1.01	1.00	\$469.45		21.15%	25.06%
	Aug-2021	21,797	\$470.17		27.08%	8.71%	1.00	1.01	1.00	\$466.46		27.11%	7.93%
	Sep-2021	21,751	\$656.81		37.82%	43.63%	1.00	1.01	1.00	\$651.10		37.51%	43.23%
	Oct-2021	21,720	\$537.42		41.03%	70.42%	1.00	1.01	1.00	\$532.62		40.45%	70.32%
	Nov-2021	21,622	\$596.52		47.86%	126.34%	1.00	1.01	1.00	\$591.30		47.24%	125.90%
	Dec-2021	21,513	\$568.06	30.46%	46.31%	27.95%	1.00	1.01	1.00	\$563.17	30.24%	45.64%	27.74%
	Jan-2022	20,922	\$431.61	30.54%	33.09%	-14.72%	0.99	1.01	1.00	\$429.30	30.35%	32.74%	-14.46%
	Feb-2022	20,903	\$414.05	28.48%	23.57%	-60.86%	0.99	1.01	1.00	\$411.66	28.31%	23.44%	-60.55%
	Mar-2022	20,868	\$525.71	24.80%	1.09%	-57.85%	0.99	1.01	1.00	\$522.16	24.64%	1.19%	-57.39%
	Apr-2022	20,893	\$507.39	19.99%	-4.62%	-32.98%	0.99	1.01	1.00	\$503.29	19.84%	-4.41%	-32.74%
	May-2022	20,802	\$501.34	17.62%	-17.62%	37.72%	1.00	1.01	1.00	\$497.45	17.50%	-17.38%	37.32%
	Jun-2022	20,773	\$561.77	15.74%	-20.64%	72.02%	1.00	1.01	1.00	\$557.61	15.68%	-20.38%	70.82%
	Jul-2022	20,757	\$533.31	16.68%	-13.09%	48.11%	0.99	1.01	1.00	\$529.78	16.65%	-12.90%	47.92%
	Aug-2022	20,799	\$616.42	18.29%	2.08%	54.80%	1.00	1.01	1.00	\$612.83	18.29%	2.27%	55.38%
	Sep-2022	20,775	\$515.64	11.22%	10.46%	26.51%	1.00	1.01	1.00	\$511.67	11.24%	10.54%	27.06%
	Oct-2022	20,662	\$647.09	11.61%	22.61%	54.19%	1.00	1.01	1.00	\$642.20	11.64%	22.68%	54.35%
	Nov-2022	20,613	\$593.80	8.26%	38.15%	10.82%	1.00	1.01	1.00	\$588.98	8.31%	38.14%	10.29%
Last Month in Evastiance Period	Dec-2022	20.556	\$827.48	7 32%	44 20%	58 40%	1.00	1.01	1.00	\$621.77	7 36%	44 1396	57 30%

Last Month in Experience Period Dec-2022

Add more rows if needed.

If applicable, please provide an explanation for the Other normalization factor.

Please provide additional trend exhibits, in excel with working formulas, that are similar to the aggregate information provided above. These exhibits should provide the data by Service Category, Metal Tier, etc. that are used by the Company in the trend development. Please state where in the filing it is footied.

Please see the tabs "Med Trends by Category" and "Rx Trend by Category" for the historical incurred claims by Med category (IP/OP/PHY) and Rx category (Generic/Brand/Specialty).

### Solvency

,	Most Recent Quarterly Financial Statement	Most Recent Annual Financial Statement
Total Adjusted Capital	413.454.802	413.454.802
Authorized Control Level	111.961.115	111.961.115
RBC Ratio	369.28%	369.28%

# Loss Ratio

					Earned	Loss
Time Period	Period Beginning Date	Period Ending Date	Member Months	Incurred Claims	Premium	Ratio
Historical Year -4	1/1/2018	12/31/2018	172,746	74,840,641	82,151,955	91.1%
Historical Year -3	1/1/2019	12/31/2019	190,666	87,826,336	93,565,302	93.9%
Historical Year -2	1/1/2020	12/31/2020	247,747	114,541,370	135,778,843	84.4%
Historical Year -1	1/1/2021	12/31/2021	260,789	149,383,070	148,056,238	100.9%
Historical Year 0	1/1/2022	12/31/2022	249,323	147,642,472	143,456,179	102.9%
Historical Totals			1,121,271	574,233,888	603,008,518	95.2%

Interim Time Period	1/1/2023	2/28/2023	32,686	17,730,179	22,184,702	79.9%
Future Year 1	1/1/2024	12/31/2024	195,144	135,636,113	148,953,216	91.1%

72.364.454	103.4%
84,687,557	103.7%
121,132,986	94.6%
134,663,356	110.9%
131,043,915	112.7%
543,892,268	105.6%

135,636,113 100.0%

Quality Improvement	Adjustments	Adi Medical
	to Earned Premium	
Expenses		Loss Ratio
658,162	1,292,740	93.4%
758,851	202,106	94.9%
624,322	2,285,762	86.3%
676,904	1,030,321	102.1%
579,676	1,251,423	104.2%
3,297,915	6,062,353	96.7%
85,436	155,559	80.9%
609,507	2,441,290	93.0%

Anticipated Pricing Loss Ratio (no adjustments)	91.1%
Anticipated LR using Federally-prescribed MLR methodology	93.0%

Intal Retinuous Automatics

Note:

The historical time periods should represent calendar years since the inception date of the plan type through the most recent date available allowing for the appropriate amount of run-out.

The interint time period the time periods available in the current year.

The future year should represent the 12 months immediately following the rate effective date.

Consumer Adjusted Premium Rate Development
Section is all VRS2 of the URR1 (requires that the issuer provide the Actuarial Value and cost-sharing design of the plan. Provide the breakdown of this value between Cost Sharing Only and Induced Utilization for every plan in the URR1. (Add additional columns as reeded to include all plans shown on the URR1)
Provide the breakdown of this value between Cost Sharing Only and Induced Utilization for every plan in the URR1. (Add additional columns as reeded to include all plans shown on the URR1)
Provide the breakdown of this value between Cost Sharing Only and Induced Utilization for every plan in the URR1. (Add additional columns as reeded to include all plans shown on the URR1)
Provide the breakdown of this value between Cost Sharing Only and Induced Utilization for every plan in the URR1. (Add additional columns as reeded to include all plans shown on the URR1)

Actuarial value and Cost-Sharing Design of the Plan (add additional columns as needed to include all plans shown in Section III of WS2 of the URRT)

Plan ID (Standard Component ID)	77566VT0050001	77566VT0050002	77566VT0050004	77566VT0050023	77566VT0050005	775663/T0050006	77566VT0050024	77566VT0050007	77566VT0050030	77566VT0050034	77566VT0050029	77566VT0050028	77566VT0050009	77566VT0050010	77566VT0050025	77566VT0050026	77566VT0050011
(From Line 3.1 of the URRT)	11000410000001	7700077000000	11000110000004	1100011000025	11000410000000	11000410000000	11000110000024	11000110000001	1100011000000	11000410000001	11000110000025	1100011000020	11000110000000	11000410000010	7700047000025	11000110000020	77500476055077
AV and Cost-Sharing Design of Plan	1.080	0.890	0.023	0.928	0.601	0.708	0.714	0.601	0.601	0.708	0.713	0.601	0.500	0.600	0.621	0.606	0.605
(From Line 3.3 of the URRT)	1.080	0.000	0.923	0.928	0.081	0.700	0.714	0.091	0.091	0.700	0.713	0.091	0.000	0.009	0.021	0.000	0.005
Paid/Allowed Ratio (Cost-Sharing only)	0.930	0.817	0.847	0.851	0.664	0.679	0.687	0.664	0.664	0.679	0.686	0.664	0.594	0.603	0.615	0.600	0.599
Used Induced utilization factors	1.150	1.080	1.080	1.080	1.030	1.030	1.030	1.030	1.030	1.030	1.030	1.030	1.000	1.000	1.000	1.000	1.000
Calculated	1.070	0.882	0.915	0.919	0.684	0.699	0.707	0.684	0.684	0.699	0.706	0.684	0.594	0.603	0.615	0.600	0.599

# In the text box, please state where in the filing it is located.

Please see the columns "Benefit Actuarid Value" and "Induced Utilization Factor" on Enhibit 7 of the rate filing. The "Calculated" value above does not tie out to the "AV and Cost Sharing Design" line item of WS2 of the URST Decases this includes the paid-to-dioxed inormalization factor, as ordered.

# Risk Adjustment

				Proposed Change in	Proposed Change in
	Actual Risk Adjustment	Assumed in Most Recent	Assumed in Current Rate	PMPM Compared to	PMPM Compared to Most
	Received	Approved Rate Filing	Filing	Prior 12 months	Recently Approved Filing
Time Period	1/1/2022	1/1/2023	1/1/2024		
Total Risk adjustment (Dollar amount)	(\$9,579,344)	(\$8,379,424)	(\$9,009,292)		
Membership Member Months	249,323	250,800	195,144	-21.73%	-22.19%
PMPM	(\$38.42)	(\$33.41)	(\$46.17)	20.16%	38.18%
Premium	\$143,456,179	\$171,307,065	\$148,953,216	3.83%	-13.05%
As a % of Premium	-7%	-5%	-6%	-9.42%	23.65%

If the actual risk adjustment payable/receivable was more than 20% different than what was estimated in the previous filing, please provide details on how the current risk adjustment estimate has addressed prior results.

	Enrollment (member months) During the Experience Period	Emerging Enrollment (member months) in Most Recent Approved Rate Filing	Projected Enrollment (member months) Assumed in Current Rate Filing
Time Period	01/01/2022-12/31/2022	01/01/2023-02/28/2023	01/01/2024-12/31/2024
94% AV Variant	0	0	0
87% AV Variant	0	0	0
77% AV Variant (if applicable)	0	0	0
73% AV Variant	0	0	0
70% AV Variant	958	87	1,044

# Trend & Projection Assumptions For Inpatient Claims

Historical Experience (ACA Only): weed Basis? (1): Incurred (1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed").

										Normalized	Normaliz	Normalize	
			Monthly				Averag	Average		Monthly	ed	d	Normalized
			Incurred		Annualized	Annualized	e	Age/Gen		Incurred	Rolling	Annualize	Annualized
		Member	Claims \$	Rolling 12 Mo	Rolling 6 Mo	Rolling 3 Mo	Benefit	der	Other	Claims \$	12 Mo	d Rolling 6	Rolling 3 Mo
Monthly Trend Analysis Based on Experience Data Time Period	Month	Months	PMPM*	Trend	Trend	Trend	Factor	Factor	Factor	PMPM*		Mo Trend	Trend
used for Rate Development (ACA Only)	Jan-2020	20,828	\$61.09				1.00	1.00	1.00	\$61.09			
	Feb-2020	20,833	\$69.69				1.00	1.00	1.00	\$69.65			$\overline{}$
Ī	Mar-2020	20,768	\$55.06				1.00	1.00	1.00	\$54.93			
	Apr-2020	20,641	\$45.98				1.00	1.00	1.00	\$45.86			
	May-2020	20,565	\$61.80				1.00	1.00	1.00	\$61.54			
	Jun-2020	20,653	\$52.25			-45.08%	1.00	1.00	1.00	\$51.97			-45.79%
	Jul-2020	20,531	\$116.59			231.22%	1.00	1.00	1.00	\$115.88			226.34%
	Aug-2020	20,510	\$93.23			569.00%	1.00	1.00	1.00	\$92.54			560.31%
	Sep-2020	20,523	\$73.46			882.92%	1.00	1.01	1.00	\$72.83			871.03%
	Oct-2020	20,579	\$69.05			9.40%	1.00	1.01	1.00	\$68.44			8.22%
	Nov-2020	20,696	\$68.21			-58.08%	1.00	1.01	1.00	\$67.65			-58.44%
	Dec-2020	20,620	\$59.61		92.43%	-76.68%	1.00	1.01	1.00	\$59.00		90.31%	-76.85%
	Jan-2021	21,795	\$80.43		22.69%	-38.34%	1.00	1.01	1.00	\$80.07		21.73%	-38.14%
	Feb-2021	21,855	\$96.82		12.00%	62.73%	1.00	1.01	1.00	\$96.41		11.58%	64.53%
	Mar-2021	21,817	\$77.15		4.52%	178.93%	1.00	1.01	1.00	\$76.74		4.44%	183.89%
	Apr-2021	21,757	\$97.26		6.56%	184.34%	1.00	1.01	1.00	\$96.67		6.71%	186.82%
	May-2021	21,667	\$81.11		9.13%	32.91%	1.00	1.01	1.00	\$80.44		9.40%	32.52%
	Jun-2021	21,722	\$113.99		29.77%	74.47%	1.00	1.01	1.00	\$113.00		30.21%	72.36%
	Jul-2021	21,773	\$97.38		61.01%	35.31%	1.00	1.01	1.00	\$96.57		61.30%	33.55%
	Aug-2021	21,797	\$76.19		46.13%	60.27%	1.00	1.01	1.00	\$75.58		46.00%	59.09%
	Sep-2021	21,751	\$217.84		127.95%	220.57%	1.00	1.01	1.00	\$215.95		127.20%	219.56%
	Oct-2021	21,720	\$88.61		96.86%	192.60%	1.00	1.01	1.00	\$87.81		95.90%	192.39%
	Nov-2021	21,622	\$124.06		111.56%	403.72%	1.00	1.01	1.00	\$122.97		110.53%	402.86%
	Dec-2021	21,513	\$85.00	49.71%	58.94%	-66.49%	1.00	1.01	1.00	\$84.27	49.42%	58.20%	-66.53%
	Jan-2022	20,922	\$78.99	46.11%	42.17%	-67.59%	0.99	1.01	1.00	\$78.57	45.86%	41.77%	-67.48%
	Feb-2022	20,903	\$67.83	38.17%	50.18%	-91.57%	0.99	1.01	1.00	\$67.44	37.94%	50.01%	-91.50%
	Mar-2022	20,868	\$85.90	35.82%	-39.58%	-62.65%	0.99	1.01	1.00	\$85.32	35.60%	-39.52%	-62.24%
	Apr-2022	20,893	\$101.26	28.85%	-35.08%	-39.12%	0.99	1.01	1.00	\$100.44	28.64%	-34.94%	-38.93%
	May-2022	20,802	\$67.25	25.01%	-54.11%	44.65%	1.00	1.01	1.00	\$66.72	24.85%	-53.97%	44.15%
	Jun-2022	20,773	\$90.41	15.19%	-49.13%	53.37%	1.00	1.01	1.00	\$89.74	15.09%	-48.96%	52.28%
	Jul-2022	20,757	\$85.42	16.07%	-45.09%	-17.46%	0.99	1.01	1.00	\$84.85	16.01%	-44.96%	-17.52%
	Aug-2022	20,799	\$123.15	22.80%	-30.84%	90.59%	1.00	1.01	1.00	\$122.43	22.76%	-30.69%	91.38%
	Sep-2022	20,775	\$48.28	-8.07%	-5.80%	-3.18%	1.00	1.01	1.00	\$47.91	-8.06%	-5.71%	-2.67%
	Oct-2022	20,662	\$129.72	-6.03%	0.00%	135.29%	1.00	1.01	1.00	\$128.74	-6.00%	0.08%	135.63%
	Nov-2022	20,613	\$93.89	-12.85%	37.68%	-31.87%	1.00	1.01	1.00	\$93.13	-12.80%	37.69%	-32.21%
Last Month in Experience Period	Dec-2022	20,556	\$69.11	-15.76%	24.98%	68.96%	1.00	1.01	1.00	\$68.48	-15.72%	24.88%	67.84%

# Trend & Projection Assumptions For Outpatient Claims

Historical Experience (ACA Only): weed Basis? [1]: Incurred [1] Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed").

			Monthly				Averag	Average		Normalized Monthly	Normaliz ed	Normalize	Normalized
			Incurred		Annualized	Annualized	c	Age/Gen		Incurred		Annualize	
		Member	Claims \$	Rolling 12 Mo	Rolling 6 Mo	Rolling 3 Mo	Benefit	der	Other	Claims \$			Rolling 3 Mo
Monthly Trend Analysis Based on Experience Data Time Period	Month	Months	PMPM*	Trend	Trend	Trend	Factor	Factor	Factor	PMPM*	Trend	Mo Trend	Trend
used for Rate Development (ACA Only)	Jan-2020	20,828	\$160.55				1.00	1.00	1.00	\$160.55	П		
	Feb-2020	20,833	\$138.55				1.00	1.00	1.00	\$138.47			
	Mar-2020	20,768	\$125.28				1.00	1.00	1.00	\$124.98			
	Apr-2020	20,641	\$87.90				1.00	1.00	1.00	\$87.65			
	May-2020	20,565	\$131.65				1.00	1.00	1.00	\$131.10			
	Jun-2020	20,653	\$177.62			-23.30%	1.00	1.00	1.00	\$176.67			-24.37%
	Jul-2020	20,531	\$180.37			274.60%	1.00	1.00	1.00	\$179.26			269.27%
	Aug-2020	20,510	\$152.46			380.39%	1.00	1.00	1.00	\$151.34			374.51%
	Sep-2020	20,523	\$189.87			199.95%	1.00	1.01	1.00	\$188.24			196.36%
	Oct-2020	20,579	\$200.68			51.30%	1.00	1.01	1.00	\$198.92			49.51%
	Nov-2020	20,696	\$175.86			51.45%	1.00	1.01	1.00	\$174.42			50.06%
	Dec-2020	20,620	\$195.41		77.47%	43.27%	1.00	1.01	1.00	\$193.41		75.45%	42.29%
	Jan-2021	21,795	\$163.30		63.87%	-6.71%	1.00	1.01	1.00	\$162.55		62.49%	-6.52%
	Feb-2021	21,855	\$165.34		62.05%	-27.33%	1.00	1.01	1.00	\$164.65		61.23%	-26.73%
	Mar-2021	21,817	\$217.61		47.64%	-16.76%	1.00	1.01	1.00	\$216.46		47.40%	-15.29%
	Apr-2021	21,757	\$194.10		15.85%	36.59%	1.00	1.01	1.00	\$192.92		15.96%	38.00%
	May-2021	21,667	\$207.34		12.59%	96.51%	1.00	1.01	1.00	\$205.64		12.81%	96.49%
	Jun-2021	21,722	\$214.74		12.71%	61.89%	1.00	1.01	1.00	\$212.88		13.16%	59.99%
	Jul-2021	21,773	\$194.76		22.92%	30.59%	1.00	1.01	1.00	\$193.15		23.21%	28.94%
	Aug-2021	21,797	\$205.09		28.48%	-2.89%	1.00	1.01	1.00	\$203.47		28.51%	-3.58%
	Sep-2021	21,751	\$238.87		26.12%	15.45%	1.00	1.01	1.00	\$236.79		25.84%	15.15%
	Oct-2021	21,720	\$234.65		35.83%	46.46%	1.00	1.01	1.00	\$232.56		35.27%	46.38%
	Nov-2021	21,622	\$252.98		37.69%	95.22%	1.00	1.01	1.00	\$250.77		37.12%	94.83%
	Dec-2021	21,513	\$259.77	32.99%	42.13%	87.40%	1.00	1.01	1.00	\$257.53	32.76%	41.48%	87.08%
	Jan-2022	20,922	\$211.26	35.30%	38.14%	30.25%	0.99	1.01	1.00	\$210.13	35.12%	37.79%	30.67%
	Feb-2022	20,903	\$196.01	35.06%	27.93%	-28.46%	0.99	1.01	1.00	\$194.87	34.90%	27.82%	-27.87%
	Mar-2022	20,868	\$250.79	30.38%	25.68%	-39.89%	0.99	1.01	1.00	\$249.10	30.23%	25.81%	-39.22%
	Apr-2022	20,893	\$225.83	25.45%	16.47%	-25.89%	0.99	1.01	1.00	\$224.00	25.30%	16.74%	-25.65%
	May-2022	20,802	\$249.22	23.07%	8.02%	39.27%	1.00	1.01	1.00	\$247.29	22.95%	8.32%	38.85%
	Jun-2022	20,773	\$265.03	23.21%	1.77%	59.94%	1.00	1.01	1.00	\$263.07	23.15%	2.11%	58.83%
	Jul-2022	20,757	\$253.71	25.06%	5.38%	69.97%	0.99	1.01	1.00	\$252.03	25.03%	5.60%	69.74%
	Aug-2022	20,799	\$276.07	25.36%	18.74%	43.83%	1.00	1.01	1.00	\$274.46	25.37%	18.93%	44.36%
	Sep-2022	20,775	\$263.08	23.77%	18.72%	31.83%	1.00	1.01	1.00	\$261.06	23.79%	18.79%	32.38%
	Oct-2022	20,662	\$274.38	23.65%	27.95%	25.93%	1.00	1.01	1.00	\$272.31	23.69%	28.01%	26.05%
	Nov-2022	20,613	\$263.43	20.28%	31.12%	3.08%	1.00	1.01	1.00	\$261.29	20.33%	31.10%	2.59%
Last Month in Experience Period	Dec-2022	20,556	\$310.25	19.24%	37.76%	30.82%	1.00	1.01	1.00	\$307.43	19.27%	37.59%	29.98%

# Trend & Projection Assumptions For Physician Claims

Historical Experience (ACA Only): wed Basis? [10]: Incurred (1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allowed").

Monthly Trend Analysis Based on Experience Data Time Period	Month	Member Months	Monthly Incurred Claims \$ PMPM*	Rolling 12 Mo Trend	Annualized Rolling 6 Mo Trend	Annualized Rolling 3 Mo Trend	Averag e Benefit Factor	Average Age/Gen der Factor	Other Factor	Normalized Monthly Incurred Claims \$ PMPM*	ed Rolling	Normalize d Annualize d Rolling 6 Mo Trend	Normalized Annualized Rolling 3 Mo Trend
used for Rate Development (ACA Only)	Jan-2020	20,828	\$75.39				1.00	1.00	1.00	\$75.39			
	Feb-2020	20,833	\$75.33				1.00	1.00	1.00	\$75.29			
	Mar-2020	20,768	\$72.27				1.00	1.00	1.00	\$72.09			
	Apr-2020	20,641	\$55.90				1.00	1.00	1.00	\$55.74			
	May-2020	20,565	\$80.19				1.00	1.00	1.00	\$79.86			
	Jun-2020	20,653	\$94.42			14.19%	1.00	1.00	1.00	\$93.92			12.66%
	Jul-2020	20,531	\$100.64			234.15%	1.00	1.00	1.00	\$100.03			229.51%
	Aug-2020	20,510	\$104.33			326.29%	1.00	1.00	1.00	\$103.56			320.94%
	Sep-2020	20,523	\$115.26			272.44%	1.00	1.01	1.00	\$114.27			267.81%
	Oct-2020	20,579	\$121.35			135.42%	1.00	1.01	1.00	\$120.29			132.63%
	Nov-2020	20,696	\$107.37			74.24%	1.00	1.01	1.00	\$106.49			72.70%
	Dec-2020	20,620	\$118.95		116.95%	38.88%	1.00	1.01	1.00	\$117.73		114.51%	37.94%
	Jan-2021	21,795	\$98.52		93.12%	-18.16%	1.00	1.01	1.00	\$98.07		91.49%	-18.01%
	Feb-2021	21,855	\$94.91		66.50%	-32.68%	1.00	1.01	1.00	\$94.51		65.66%	-32.13%
	Mar-2021	21,817	\$123.55		45.36%	-30.88%	1.00	1.01	1.00	\$122.89		45.12%	-29.65%
	Apr-2021	21,757	\$127.69		18.52%	29.71%	1.00	1.01	1.00	\$126.92		18.63%	31.03%
	May-2021	21,667	\$117.81		12.07%	96.96%	1.00	1.01	1.00	\$116.84		12.29%	97.00%
	Jun-2021	21,722	\$123.38		5.41%	83.47%	1.00	1.01	1.00	\$122.32		5.84%	81.36%
	Jul-2021	21,773	\$110.15		9.96%	6.20%	1.00	1.01	1.00	\$109.24		10.23%	4.87%
	Aug-2021	21,797	\$117.61		20.96%	-18.07%	1.00	1.01	1.00	\$116.68		21.00%	-18.67%
	Sep-2021	21,751	\$125.98		18.53%	-15.46%	1.00	1.01	1.00	\$124.89		18.29%	-15.70%
	Oct-2021	21,720	\$137.90		19.35%	38.97%	1.00	1.01	1.00	\$136.67		18.88%	38.90%
	Nov-2021	21,622	\$142.26		23.60%	78.93%	1.00	1.01	1.00	\$141.02		23.09%	78.57%
	Dec-2021	21,513	\$140.09	30.22%	27.31%	99.20%	1.00	1.01	1.00	\$138.88	30.03%	26.73%	98.85%
	Jan-2022	20,922	\$96.42	27.45%	19.12%	-1.85%	0.99	1.01	1.00	\$95.91	27.29%	18.80%	-1.58%
	Feb-2022	20,903	\$92.94	25.24%	4.85%	-56.23%	0.99	1.01	1.00	\$92.41	25.09%	4.73%	-55.89%
	Mar-2022	20,868	\$114.66	19.14%	1.00%	-72.62%	0.99	1.01	1.00	\$113.89	19.00%	1.07%	-72.31%
	Apr-2022	20,893	\$106.49	10.85%	-10.19%	-53.18%	0.99	1.01	1.00	\$105.63	10.71%	-10.00%	-53.00%
	May-2022	20,802	\$111.28	7.26%	-23.39%	2.57%	1.00	1.01	1.00	\$110.42	7.16%	-23.17%	2.31%
	Jun-2022	20,773	\$126.26	5.17%	-29.88%	63.91%	1.00	1.01	1.00	\$125.33	5.10%	-29.65%	62.77%
	Jul-2022	20,757	\$114.87	4.84%	-23.35%	58.49%	0.99	1.01	1.00	\$114.11	4.81%	-23.18%	58.27%
	Aug-2022	20,799	\$127.12	4.54%	-9.74%	50.62%	1.00	1.01	1.00	\$126.38	4.53%	-9.58%	51.17%
	Sep-2022	20,775	\$119.71	3.25%	-5.58%	22.27%	1.00	1.01	1.00	\$118.78	3.25%	-5.50%	22.78%
	Oct-2022	20,662	\$158.43	3.38%	18.97%	74.66%	1.00	1.01	1.00	\$157.24	3.40%	19.04%	74.80%
	Nov-2022	20,613	\$141.42	0.77%	41.23%	68.28%	1.00	1.01	1.00	\$140.27	0.81%	41.22%	67.49%
Last Month in Experience Period	Dec-2022	20,556	\$148.17	-0.18%	56.06%	135.41%	1.00	1.01	1.00	\$146.82	-0.16%	55.87%	133.95%

## Trend & Projection Assumptions For RX Generic Claims

Historical Experience (ACA Only): I Basis? [1]: Incurred (1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allow

										Normaliz			
										ed	Normaliz		
			Monthly					Average		Monthly	ed	Normalized	
			Incurred			Annualize		Age/Gen		Incurred	Rolling	Annualized	
		Member	Claims \$			d Rolling 3		der	Other	Claims \$	12 Mo	Rolling 6	Rolling 3
Monthly Trend Analysis Based on Experience Data Time Period	Month	Months	PMPM*	Trend	Mo Trend	Mo Trend	Factor	Factor	Factor	PMPM*	Trend	Mo Trend	Mo Trend
used for Rate Development (ACA Only)	Jan-2020	20,828	\$5.45				1.00	1.00	1.00	\$5.45			
	Feb-2020	20,833	\$5.71				1.00	1.00	1.00	\$5.70			
	Mar-2020	20,768	\$7.98				1.00	1.00	1.00	\$7.96			
	Apr-2020	20,641	\$9.13				1.00	1.00	1.00	\$9.10			
	May-2020	20,565	\$10.45				1.00	1.00	1.00	\$10.40			
	Jun-2020	20,653	\$12.01			642.39%	1.00	1.00	1.00	\$11.94			633.36%
	Jul-2020	20,531	\$12.45			449.41%	1.00	1.00	1.00	\$12.37			442.38%
	Aug-2020	20,510	\$12.37			219.47%	1.00	1.00	1.00	\$12.28			215.50%
	Sep-2020	20,523	\$12.21			88.97%	1.00	1.01	1.00	\$12.11			86.59%
	Oct-2020	20,579	\$13.35			39.50%	1.00	1.01	1.00	\$13.24			37.85%
	Nov-2020	20,696	\$12.35			12.41%	1.00	1.01	1.00	\$12.25			11.40%
	Dec-2020	20,620	\$14.85		134.56%	43.76%	1.00	1.01	1.00	\$14.70		132.10%	42.74%
	Jan-2021	21,795	\$8.05		60.09%	-27.12%	1.00	1.01	1.00	\$8.02		58.74%	-27.11%
	Feb-2021	21,855	\$7.79		12.35%	-58.48%	1.00	1.01	1.00	\$7.76		11.69%	-58.25%
	Mar-2021	21,817	\$9.12		-10.02%	-85.64%	1.00	1.01	1.00	\$9.07		-10.29%	-85.38%
	Apr-2021	21,757	\$9.17		-29.94%	-69.36%	1.00	1.01	1.00	\$9.11		-29.96%	-69.00%
	May-2021	21,667	\$10.31		-37.64%	-22.05%	1.00	1.01	1.00	\$10.23		-37.57%	-21.88%
	Jun-2021	21,722	\$9.91		-50.95%	92.09%	1.00	1.01	1.00	\$9.82		-50.75%	89.81%
	Jul-2021	21,773	\$11.04		-38.24%	106,68%	1.00	1.01	1.00	\$10.95		-38.08%	104.07%
	Aug-2021	21,797	\$11.35		-20.27%	62,73%	1.00	1.01	1.00	\$11.26		-20.21%	61.63%
	Sep-2021	21,751	\$10.93		-7.13%	65.20%	1.00	1.01	1.00	\$10.83		-7.25%	64.79%
	Oct-2021	21,720	\$11.77		14.75%	40.48%	1.00	1.01	1.00	\$11.66		14.40%	40.41%
	Nov-2021	21,622	\$11.86		28,30%	30.98%	1.00	1.01	1.00	\$11.76		27.86%	30.70%
	Dec-2021	21,513	\$13.39	-2.76%	67.44%	52.27%	1.00	1.01	1.00	\$13.27	-2.89%	66,69%	51.99%
	Jan-2022	20,922	\$7.98	-4.59%	38,07%	-8.17%	0.99	1.01	1.00	\$7.94	-4.72%	37.72%	-7.94%
	Feb-2022	20,903	\$8.14	-5.65%	11.23%	-46.11%	0.99	1.01	1.00	\$8.09	-5.77%	11.12%	-45.72%
	Mar-2022	20,868	\$9.86	-5.80%	1.46%	-75.76%	0.99	1.01	1.00	\$9.79	-5.91%	1.53%	-75.49%
	Apr-2022	20.893	\$10.80	-4.52%	-9.39%	-44.23%	0.99	1.01	1.00	\$10.72	-4.63%	-9.21%	-44.02%
	May-2022	20,802	\$11.74	-3.35%	-14.03%	43.39%	1.00	1.01	1.00	\$11.65	-3.42%	-13.81%	43.04%
	Jun-2022	20,773	\$11.67	-0.46%	-26.79%	201.12%	1.00	1.01	1.00	\$11.58	-0.50%	-26.57%	199.03%
	Jul-2022	20,757	\$12.86	1.94%	-6.80%	151.48%	0.99	1.01	1.00	\$12,77	1.94%	-6.59%	151.22%
	Aug-2022	20,799	\$14.00	4.70%	21.90%	100.02%	1.00	1.01	1.00	\$13.92	4.73%	22.13%	100.82%
	Sep-2022	20,775	\$14.19	8.24%	41.89%	107.21%	1.00	1.01	1.00	\$14.08	8.27%	42.03%	108.07%
	Oct-2022	20,662	\$16.34	13.05%	68,83%	127.21%	1.00	1.01	1.00	\$16.22	13.10%	68.94%	127.37%
	Nov-2022	20,613	\$14.61	15.57%	82.13%	88.46%	1.00	1.01	1.00	\$14.50	15.63%	82.15%	87.54%
Last Month in Experience Period		20,556	\$14.46	17.55%	106.46%	49.97%	1.00	1.01	1.00	\$14.33	17.58%	106.24%	49.07%

## Trend & Projection Assumptions For RX Brand Claims

Historical Experience (ACA Only): I Basis? [1]: Incurred [1] Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allow

Normaliz ed Normaliz | Monthly | ed | Normalized | Normalized | Normalized | Annualized | A Rolling Annualize Annualize Average Age/Gen 12 Mo d Rolling 6 d Rolling 3 Benefit der Incurred Member Claims \$ Months PMPM\* 12 Mo d Rolling 6 d Rolling 3 Benefit der Trend Mo Trend Mo Trend Factor Factor Monthly Trend Analysis Based on Experience Data Time Period Month used for Rate Development (ACA Only) 20.828 \$16.99 1.00 \$16.99 Jan-2020 Feb-2020 Mar-2020 1.00 \$19.24 1.00 \$26.25 20,641 \$21.73 Apr-2020 1.00 \$21.67 20,565 \$22,72 20,653 \$23,63 20,531 \$25,67 20,510 \$27,47 20,523 \$25,40 20,579 \$26,42 20,696 \$25,55 1.00 \$22.62 May-2020 Jun-2020 40.54% 1.00 \$23.50 1.00 \$25.52 38.88% Jul-2020 31.23% 38.33% 29.52% 36.52% Aug-2020 Sep-2020 1.00 \$25.18 74.94% 1.00 \$26.19 Oct-2020 47.01% 45.28% Nov-2020 3.23% 1.00 \$25.34 2.33% Dec-2020 55.83% 33.54% 1.00 1.00 \$32.14 54.09% 32.58% Jan-2021 26.43% -9.55% 1.00 \$19.57 25.30% -9.50% 6.82% -11.01% 12.59% -48.65% 1.00 \$23.32 6.21% -10.39% 12.31% -47.72% Feb-2021 1.00 \$28.25 Mar-2021 1.00 Apr-2021 7.89% 13.29% 1.00 \$27.80 7.93% 14.60% May-2021 7.14% 58.51% 1.00 \$27.72 7.31% 58.70% -6.81% 108.66% 1.00 \$29.72 -6.44% 106.21% Jun-2021 16.41% 56.29% 34.96% 46.77% 34.83% 47.66% 38.45% 32.52% 41.20% 18.18% \$31.26 \$31.56 1.00 \$31.00 1.00 \$31.31 16.71% 54.31% 35.02% 45.73% Jul-2021 Aug-2021 
 351.51
 35.02%
 45.73%

 351.60
 34.57%
 47.28%

 331.98
 37.94%
 32.46%

 332.34
 40.66%
 17.94%

 336.17
 20.18%
 54.52%
 31.00%

 526.61
 21.66%
 28.41%
 1.55%

 237.83
 21.57%
 12.84%
 -19.78%

 336.57
 23.42%
 14.38%
 -32.74%
 Sep-2021 1.00 S31.60 Oct-2021 Nov-2021 \$36.49 20.40% \$5.21% \$31.24% 1.00 \$26.75 21.84% 28.74% 1.25% 0.99 \$27.99 21.74% 12.93% 2-20.42% 0.99 \$36.82 23.57% 14.26% -33.47% 0.99 Dec-2021 Jan-2022 Feb-2022 Mar-2022 \$27.83 \$36.57 Apr-2022 \$32.28 22.46% 9.02% 4.55% \$34.97 22.65% 6.23% 68.10% \$37.99 22.67% 0.72% 74.58% 1.00 \$34.70 22.54% 6.52% 67.63% May-2022 Jun-2022 1.00 \$37.70 22.61% 1.05% 73.39% Jul-2022 \$37.56 22.45% 17.21% 67.91% 1.00 \$37.31 22.43% 17.46% 67.69% 1.00 \$39.92 23.50% 36.50% 53.30% Aug-2022 16 23.48% 36.28% 52.75% \$41.99 24.12% 35.71% 67.46% 1.00 \$41.67 24.15% 35.79% 68.14% 1.00 \$41.45 24.84% 47.45% 58.15% 1.00 \$44.49 25.87% 56.27% 51.91% Oct-2022 \$41.76 24.79% 47.39% 58.02% 1.00 1.01 25.81% 56.29% 52.65% 1.00 Nov-2022 Last Month in Experience Period 20,556 \$49.90 28.11% 69.48% 69.06% 1.00 1.01 1.00 \$49.44 28.14% 69.27% 68.00%

Last Month in Experience Period

Historical Experience (ACA Only): 1 Basis? [1]: Incurred (1) Choose the option based on how pricing is developed (i.e., if allowed trends are used in projections, select "Allow

Normaliz ed Normaliz Monthly Incurred Rolling Annualize Annualize Average Age/Gen Monthly ed Normalized Normalized Incurred Rolling Annualized Annualized Member Claims \$ 12 Mo d Rolling 6 d Rolling 3 Benefit
Months PMPM\* Trend Mo Trend Mo Trend Factor der Other Claims \$ 12 Mo Rolling 6 Rolling 3 Monthly Trend Analysis Based on Experience Data Time Period Month Factor PMPM\* Factor Trend Mo Trend Mo Trend used for Rate Development (ACA Only) Jan-2020 20 828 \$29 68 1.00 \$29.68 Feb-2020 \$41.35 1.00 1.00 1.00 \$41.33 20,768 \$49,22 20,641 \$56.80 20,565 \$45.08 20,653 \$53.69 20,531 \$49.38 20,510 \$49.06 20,523 \$46.05 1.00 \$49.10 1.00 1.00 Mar-2020 Apr-2020 1.00 1.00 \$56.65 1.00 \$44.89 May-2020 Jun-2020 180.56% \$53.40 \$49.08 2.36% 2.77% -25.64% -9.51% -12.52% Jul-2020 1.04% \$48.70 \$45.65 Aug-2020 Sep-2020 Oct-2020 Nov-2020 1.45% -26.62% -10.58% -13.31% 20.71% 49.30% \$49.40 \$51.68 \$58.92 \$48.97 \$51.25 50.38% 1.00 1.00 \$58.32 Dec-2020 \$35.26 \$53.17 -3.91% 1.69% -4.78% 1.74% Feb-2021 -6.04% -0.88% 1.00 \$52.95 -6.58% -0.12% 5.63% -25.30% 1.00 \$59.98 5.35% -23.96% Mar-2021 .00 \$53.25 .00 \$52.87 Apr-2021 14.05% 75.61% 14.10% 77.69% May-2021 10.20% 68.22% 10.39% 68.32% Jun-2021 4.48% 42.62% \$55.19 4.91% 40.95% 34.62% 4.74% 35.54% 20.03% 1.00 \$59.51 34.99% 3.40% 35.58% 19.16% Jul-2021 1.00 \$58.86 Aug-2021 Sep-2021 24.89% 57.51% 28.42% 44.18% 1.00 \$62.22 24.62% 57.09% 27.91% 44.10% \$62.53 Oct-2021 34.63% 37.60% \$63.14 34.09% 37.32% Dec-2021 Jan-2022 \$63.54 17.84% 43.14% 19.33% 1.00 \$63.00 7.62% 42.48% 19.11% \$49.87 19.40% 16.45% -15.82% 0.99 1.00 \$49.60 19.20% 16.14% -15.56% Feb-2022 \$ \$60.80 18.26% 13.21% -28.41% 0.99 \$ \$67.23 17.11% 14.25% -23.71% 0.99 1.00 \$60.45 18.08% 13.11% -27.81% 1.00 \$66.78 16.95% 14.37% -22.87% Mar-2022 
 1.00
 \$66.78
 16.95%
 14.37%
 -22.87%

 1.00
 \$86.92
 20.26%
 12.25%
 \$5.46

 1.00
 \$86.74
 20.75%
 7.57%
 84.51%

 1.00
 \$86.75
 21.87%
 23.15%
 11.59%

 1.00
 \$873.99
 22.30%
 30.50%
 19.13%

 1.00
 \$873.42
 20.01%
 23.15%
 11.5%

 1.00
 \$673.42
 20.01%
 27.74%
 9.92

 1.00
 \$65.06
 17.98%
 20.32%
 8.36%

 1.00
 \$73.30
 18.15%
 22.00%
 5.09%
 \$70.19 20.41% 12.31% 55.93% Apr-2022 May-2022 Jun-2022 Jul-2022 Aug-2022 Sep-2022 Oct-2022 Nov-2022



# ACTUARIAL CERTIFICATION FEDERAL ACTUARIAL VALUE ADJUSTMENT VERMONT EXCHANGE Gold 3 HDHP Plus Silver 2 HDHP Plus Silver 2 HDHP Plus II

MVP Health Plan, Inc., a fully owned subsidiary of MVP Health Care, offers a range of products on the Vermont Exchange as well as Silver metal plans off the Exchange. One standard plan is offered at the Platinum and Catastrophic metal levels, while standard and non-standard plans are offered at the remaining levels. Standard plans are prescribed by the State of Vermont and are separately certified where necessary. Non-standard plans are filed at the discretion of MVP. MVP offers three non-standard benefit plans, Gold 3 HDHP Plus, Silver 2 HDHP Plus, and Silver 2 HDHP Plus II, with benefit features that don't fit into the parameters of the Federal Actuarial Value Calculator and therefore are being certified herein. The purpose of this memorandum is to document the actuarial analysis and adjusted actuarial values output from the 2024 Federal Actuarial Value calculator exhibiting compliance with the metal level requirements outlined in 45 CFR 156.140(b).

MVP's benefit pricing model is populated with allowed claim utilization from approximately 190,000 covered MVP commercial members. The data reflects claims paid for 2021 incurred dates, paid as of December 31st, 2022. MVP combines data from all its commercial products and states to increase the credibility in the data set. This data set is considered fully credible and appropriate for use as a benefit pricing tool for MVP's fully insured commercial members. The underlying data is appropriate relative to the Vermont Essential Health Benefit Package.

The model uses traditional continuance table logic to value plan deductibles and OOP maximums as well as average utilization per 1,000 and average unit cost per service data for all the significant services that drive member cost sharing. Specific factor adjustments are included in the methodology to account for family deductible and OOP limits, aggregate deductible types, and the State of Vermont maximum Rx OOP regulation. While reduced copays for 90-day supplies of mail order prescriptions also does not fit into the Federal Actuarial Value calculator, the impact on the Actuarial Value is negligible for all plans and is not reflected in the factors presented. The factor adjustments were derived based on modeling the Net Plan liabilities from this subscriber/member based historical allowed claim data set both with and without these benefit features.

The methodology of MVP's benefit pricing tool is consistent with the methodology underlying the Federal calculator with regard to the following factors: continuance tables that reflect membership enrolled for a full 12 months, out of network costs are not considered in the actuarial values, and the model reflects the anticipated utilization of the standard population buying products at these metal levels without consideration for induced demand.

Pursuant to 45 CFR 156.135(b) one of two permitted alternative methods must be used to determine any final adjusted Federal AV. MVP used the AV Calculator to determine the Federal AV for the plan provisions that fit within the calculator parameters and then calculated an actuarial adjustment factor to apply to the calculator produced AV to account for the plan features that materially deviate from the calculator parameters. The product of the Federal Calculator produced AV times the actuarial adjustment factor is the final Federal AV for the benefit plan. I certify that the adjustments made are appropriate and in accordance with generally accepted actuarial principles and methodologies.

The following 3 benefit features for the Gold 3 HDHP Plus were determined to not fit the Federal Calculator:

VT secondary Rx OOP max

Aggregate Family Deductible

Safe harbor prescription drug benefits excluded from the plan deductible

The following 2 benefit features for the Silver 2 HDHP Plus and Silver 2 HDHP II Plus were determined to not fit the Federal Calculator:

VT secondary Rx OOP max

Safe harbor prescription drug benefits excluded from the plan deductible

The following 2 benefit features for the Silver 2 HDHP Plus 73%, 77%, and 87% cost-sharing reduction plans were determined to not fit the Federal Calculator:

VT secondary Rx OOP max

Safe harbor prescription drug benefits excluded from the plan deductible

The following benefit feature for the Silver 2 HDHP Plus 94% cost-sharing reduction plan was determined to not fit the Federal Calculator:

Safe harbor prescription drug benefits excluded from the plan deductible

To determine the adjustment factors, I used MVP's proprietary benefit pricing tool to value the AV for these plans first excluding the above features that don't fit the calculator and a second time with the above benefit changes. The ratio of the two AVs is the actuarial adjustment factor used to modify the Federal Calculator computed AV.

Plan Description	MVP determined AV	Federal AV before/after
Gold 3 HDHP Plus with no secondary Rx OOP max, with embedded single deductibles and with no safe harbor drug benefit	83.88%	adjustment 80.89%
Gold 3 HDHP Plus including the secondary Rx OOP max, the aggregate family deductible and the safe harbor drug benefit	83.24%	80.27%
	50.150/	
Silver 2 HDHP Plus with no secondary Rx OOP max and with no safe harbor drug benefit	69.16%	70.12%
Silver 2 HDHP Plus including the secondary Rx OOP max and the safe harbor drug benefit	71.01%	72.00%
CT - 2 HPHP PL - 72W CCP - TH P - OOP	74.520/	72.520/
Silver 2 HDHP Plus 73% CSR with no secondary Rx OOP max and with no safe harbor drug benefit	71.53%	72.53%
Silver 2 HDHP Plus 73% CSR including the secondary Rx OOP max and the safe harbor drug benefit	72.86%	73.88%
		1
Silver 2 HDHP Plus 77% CSR with no secondary Rx OOP	76.04%	77.16%
max and with no safe harbor drug benefit Silver 2 HDHP Plus 77% CSR including the secondary Rx	76.76%	77.89%
OOP max and the safe harbor drug benefit	70.70%	77.83%
Silver 2 HDHP Plus 87% CSR with no secondary Rx OOP	84.72%	87.65%
max and with no safe harbor drug benefit	04.750/	07.000/
Silver 2 HDHP Plus 87% CSR including the secondary Rx OOP max and the safe harbor drug benefit	84.75%	87.68%
Silver 2 HDHP Plus 94% CSR with no safe harbor drug benefit	90.83%	94.15%
Silver 2 HDHP Plus 94% CSR including the safe harbor drug	90.84%	94.16%
benefit		
Silver 2 HDHD Blue II with no secondary By COD may and	60.07%	70.05%
Silver 2 HDHP Plus II with no secondary Rx OOP max and with no safe harbor drug benefit	69.07%	70.05%
Silver 2 HDHP Plus II including the secondary Rx OOP max	70.93%	71.94%
and the safe harbor drug benefit		

Actuarial Adjustment factor for Gold 3 Plan: 0.9924 = 83.24% / 83.88% Final Federal AV for Gold 3 Plan:  $80.89\% \times 0.9924 = 80.27\%$ 

Actuarial Adjustment factor for Silver 2 Plan: 1.0267 = 71.01% / 69.16%

Final Federal AV for Silver 2 Plan: 70.12% x 1.0267 = 72.00%

Actuarial Adjustment factor for Silver 2 73% Plan: 1.0186 = 72.86% / 71.53%

Final Federal AV for Silver 2 73% Plan: 72.53% x 1.0186 = 73.88%

Actuarial Adjustment factor for Silver 2 77% Plan: 1.0095 = 76.76% / 76.04% Final Federal AV for Silver 2 77% Plan:  $77.16\% \times 1.0095 = 77.89\%$ 

Actuarial Adjustment factor for Silver 2 87% Plan: 1.0004 = 84.75% / 84.72% Final Federal AV for Silver 2 87% Plan: 87.65% x 1.0004 = 87.68%

Actuarial Adjustment factor for Silver 2 94% Plan: 1.0001 = 90.84% / 90.83% Final Federal AV for Silver 2 94% Plan: 94.15% x 1.0001 = 94.16%

Actuarial Adjustment factor for Silver 2 II Plan: 1.0269 = 70.93% / 69.07% Final Federal AV for Silver 2 II Plan:  $70.05\% \times 1.0269 = 71.94\%$ 

# CERTIFICATION

I, Christopher Pontiff, Senior Director, Actuarial Services for MVP Health Care, am a member of the Academy of Actuaries and a Fellow of the Society of Actuaries, and I meet its qualification standards to provide this certification. I have used the 2024 Actuarial Value Calculator to determine the actuarial value for the plan provisions that fit within the calculator and have determined the actuarially appropriate adjustment factors to apply where necessary for the identified plan features that, in my opinion, deviates substantially from the allowable inputs of the Federal calculator. The development of the actuarial value adjustment factor was determined in accordance with generally accepted actuarial principles and practices and conforms with the exception methodology outlined in 45 CFR 156.135 (b)(3).

The final actuarial values reported for each of these benefit plans, those from the Federal Calculator alone, and the adjusted plans, meet the required actuarial values for each respective metal level as outlined in 45 CFR 156.140(b).

Christopher Pontiff, FSA, MAAA

Senior Director, Commercial Pricing, Network & Trend Actuary

**MVP Health Care** 

3/9/2023

Date

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s _	Tie	ered Network O	ption_			
Apply Inpatient Copay per Day?		HSA/HRA Emp	loyer Contribution	3	Tiere	d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:		1st	Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	V	Annual Contri	button Amount.		2nd	Tier Utilization:	į.			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier	Bronze ▼									
Desired Wetal Hel		r 1 Plan Benefit De	esign	Ī	Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$7,250.00	\$700.00	Compilied		Medical	2.08	Companie			
Coinsurance (%, Insurer's Cost Share)	50.00%	40.00%								
MOOP(\$)		00.00	0.	•	is .					
MOOP if Separate (\$)		100000	f-	-		,				
		1	-		0	<del>50</del>	•			
Click Here for Important Instructions		Tie	er 1			Ti	ier 2		Tier 1	Tier 2
4.0.00	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	C	
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		y after deductible?
Medical	V AII	- All			V AII	V AII			All	□ All
Emergency Room Services										
All Inpatient Hospital Services (inc. MH/SUD)					- ✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	<b>&gt;</b>			440.00	✓	<b>▽</b>			V	
rays)		_		\$40.00	N=2				Va	
Specialist Visit	~			\$100.00	~	~			~	
Mental/Behavioral Health and Substance Use Disorder Outpatient	•			440.00	✓	✓			•	П
Services				\$40.00		~			120-02	_
Imaging (CT/PET Scans, MRIs)	Common of the Co				Second :					
Speech Therapy	· · · · · · · · · · · · · · · · · · ·				V	✓				
	>			¢50.00	✓	✓			✓	
Occupational and Physical Therapy				\$50.00		-				
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services					<b>V</b>					
X-rays and Diagnostic Imaging					<b>V</b>	<b>∨ ∨</b>			_	
Skilled Nursing Facility	<u> </u>				<u> </u>	~				
Outpotient Facility Foo (o.g. Ambulatory Surgary Contar)	>				✓	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)		П			<b>~</b>	<b>~</b>				
Outpatient Surgery Physician/Surgical Services	All	All			▼ All	▼ All			All	
Drugs	- All				V A⊪	▼ AII			All	A
Generics				\$19.50	· ·	₹			<b>V</b>	H
Preferred Brand Drugs	7	<u> </u>		\$100.00	<u> </u>	<u>~</u>				H
Non-Preferred Brand Drugs	<u> </u>				~	<u> </u>				
Specialty Drugs (i.e. high-cost)					35-50	<u>.</u>				
Options for Additional Benefit Design Limits:	-Π	T .	•	: [MVP VT Plus] B						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMO-SB-0	001-N					
Specialty Rx Coinsurance Maximum:		-	Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):		1	AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	_									
Begin Primary Care Deductible/Coinsurance After a Set Number of	_			4==						
Copays?			Generic:	\$25						
# Copays (1-10):		1	VBID:	\$3						
Outpu* Calculate										
Status/Error Messages:	Expanded Bronze	Standard (58% to	65%), Calculation	Successful.						
	63.54%									
	Bronze									
		re services are no	t subject to the de	ductible and have	no copav. Anv	service with this	cost-sharing struct	ure is covered	at 100% by the pla	n in the deductible
							ng outpatient inpu			

Calculation Time: 0.1562 seconds

User Inputs for Plan Parameters	•									
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s 🗆	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	?	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:		1st	Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	7	Annual Contri	bution Amount.		2nd	Tier Utilization:	b .			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier	Bronze ▼									
	Tie	r 1 Plan Benefit De	esign		Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$9,450.00							
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$9,450.00	ū.						
MOOP if Separate (\$)							1			
Click Here for Important Instructions		Tie	er 1				ier 2		Tier 1	Tier 2
Click Here for important instructions	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coirsurance?	different	separate	Deductible?	Coin rance?	different	separate	Copay applies only	after deductible?
Medical					~	<u>~</u>				=
Emergency Room Services	<u> </u>					<u>~</u>			I	$\overline{\Box}$
All Inpatient Hospital Services (inc. MH/SUD)										
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	~	V			✓	✓				
rays)	<b>Y</b>	~			~	~				
Specialist Visit		_								_
Mental/Behavioral Health and Substance Use Disorder Outpatient Services	•	•			<b>V</b>	<u>v</u>				
Imaging (CT/PET Scans, MRIs)						₹				
Speech Therapy	<b></b>	<u> </u>				▼				
	V	~			<b>~</b>	<b>~</b>				
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization	~		100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	· · · · · · · · · · · · · · · · · · ·	¥	Seekantas			✓ ✓	SSININI	in and the state of the state o		
X-rays and Diagnostic Imaging	<b>V</b>					<u>~</u>				П
Skilled Nursing Facility	<u> </u>	<u> </u>			· · · · · · · · · · · · · · · · · · ·	······································				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	V	<b>~</b>			V	✓				
Outsetient Surgery Physician / Surgical Services	<u> </u>	<u> </u>			_ 💌	✓			D	
Outpatient Surgery Physician/Surgical Services	✓ All	✓ All			✓ All	✓ All			All	All
Drugs Generics				\$27.00		<u>~</u>				
Preferred Brand Drugs	<u> </u>	<b>_</b>	vanuanananananana	\$27.00		<b>~</b>				
Non-Preferred Brand Drugs					<b>Z</b>	<u>~</u>			<u> </u>	
Specialty Drugs (i.e. high-cost)	~	<b>Y</b>			V					
Options for Additional Benefit Design Limits:			Plan Description	: [MVP VT Plus] B	ronze 5					
Set a Maximum on Specialty Rx Coinsurance Payments?		Ī	Name:	FRVT-HMO-SB-0						
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?		Ť	Issuer HIOS ID:							
# Days (1-10):	~		AVC Version:	2024 1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	<u>V</u>	İ		—						
# Visits (1-10):	_ 3	22								
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):										
Outpu <sup>r</sup> Calculate										
Status/Error Messages:	Expanded Bronze	Standard (58% to	65%), Calculation	Successful.						
	63.12%									
	Bronze									
		re services are not	subject to the de	ductible and have	no copay. Any s	ervice with this	cost-sharing struct	ure is covered	d at 100% by the plan	in the deductible
	range.			3.10 1.040					, are plan	
Additional Motes.										
Calculation Time:	0.332 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option:	s	Tie	ered Network O	otion			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	? 🗌	Tiere	d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contril	bution Amount:			Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?		Almadi Contin	oution / tinounti		2nd	Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				-i						
	The second secon	r 1 Plan Benefit De				2 Plan Benefit I	T			
Deductible (\$)	\$850.00	\$350.00	Combined	-	Medical	Drug	Combined			
Coinsurance (%, Insurer's Cost Share)	80.00%	50.00%								
MOOP (\$)		30.00%	100							
MOOP if Separate (\$)		\$1,500.00	4	-8						
Moor in separate (4)	\$0,000.00	\$1,500.00	1,				1			
Click Here for Important Instructions		Tie	er 1			Т	er 2		Tier 1	Tier 2
Tallian Walliam	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only	after deductible?
Medical	✓ All	☐ All			✓ All	✓ All			☐ All	☐ All
Emergency Room Services	~			\$250.00	✓	✓			~	
All Inpatient Hospital Services (inc. MH/SUD)	✓	V			✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-		П		\$20.00	✓					
rays)				#619/2000/0000	Second :	-				
Specialist Visit				\$45.00	✓	₹				
Mental/Behavioral Health and Substance Use Disorder Outpatient				\$20.00	V	✓				
Services										
Imaging (CT/PET Scans, MRIs)	₹			\$400.00	<b>Z</b>	~			V	
Speech Therapy	✓			\$45.00	<b>∠</b>	✓			Y	
Once the second of Physical Theorem				\$25.00	✓	✓				
Occupational and Physical Therapy Preventive Care/Screening/Immunization		П	100%		1		100%	\$0.00		
Laboratory Outpatient and Professional Services	~		100%	\$45.00	V	✓	100%	\$0.00	V	
X-rays and Diagnostic Imaging	V			\$80.00	✓	✓			V	
Skilled Nursing Facility	V	<u> </u>		\$80.00	. ✓	✓				H
Skilled Rd13llig Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	V	V			✓	✓				
Outpatient Surgery Physician/Surgical Services	<b>v</b>	~			✓	✓				
Drugs	✓ All	☐ All			✓ All	✓ All			☐ All	☐ All
Generics				\$14.00	~	✓				
Preferred Brand Drugs	•			\$40.00	<b>V</b>	✓			>	
Non-Preferred Brand Drugs	~	<b>Y</b>			✓	✓				
Specialty Drugs (i.e. high-cost)	✓.	~			~	~				
Options for Additional Benefit Design Limits:		т		: [MVP VT Plus] Go						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMO-G-00	02-N					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?	Ш		Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits? #Visits (1-10):	Ш									
Begin Primary Care Deductible/Coinsurance After a Set Number of	П									
Copays?										
# Copays (1-10):										
Output		1								
Calculate										
	Calculation Succes	sful.								
	81.53%									
Metal Tier:	Gold									
	NOTE: One or mo	re services are not	subject to the dec	ductible and have	no copay. Any	service with this	cost-sharing struct	ure is covered	at 100% by the plan	in the deductible
Additional Notes:	range.									
Calculation Time:	0.1289 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	<b>V</b>		HSA/HRA Option		Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	? L		Network Plan				
Apply Skilled Nursing Facility Copay per Day?		Annual Contril	bution Amount:		1st	Tier Utilization	:			
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	oution Amount.		2nd	Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier										
		1 Plan Benefit De	sign	Ĩ	Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$3,000.00	_						
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$3,000.00	U.						
MOOP if Separate (\$)	1			<del></del> t-		"				
			•			<del>?</del>	•			
Click Here for Important Instructions		Tie	er 1			Ť	ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay applies only	after deductible?
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		
Medical	✓ All	☐ All			✓ All	✓ All			☐ All	All
Emergency Room Services	~	~			✓	✓				
All Inpatient Hospital Services (inc. MH/SUD)	<b>V</b>	✓			✓.	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•	~			V	✓				
rays)										
Specialist Visit	~	~			~	~				
Mental/Behavioral Health and Substance Use Disorder Outpatient	•	<b>V</b>			<b>✓</b>	✓				
Services	97.57.				3 1				20 - 200 	
Imaging (CT/PET Scans, MRIs)	~	~			_ ✓	✓				
Speech Therapy	<b>Y</b>	<b>Y</b>			✓	✓				
Occupational and Physical Therapy	✓	•			<b>▽</b>	✓				
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	~	~	100%		~	~	100%	30.00		
X-rays and Diagnostic Imaging	<b>V</b>	V			<u></u>	✓				
Skilled Nursing Facility	V	<b>y</b>			✓	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	V	V			✓	✓				
Outpatient racinty ree (e.g., Ambulatory Surgery Center)					<b>~</b>					
Outpatient Surgery Physician/Surgical Services		<u> </u>			0.000	<u> </u>				
Drugs	✓ All	□ All			✓ All	✓ All			All	All
Generics	~			\$10.00	~	~			V	Ш
Preferred Brand Drugs	V			\$15.00	✓	✓			<b>V</b>	
Non-Preferred Brand Drugs	V	V	95%		<u>~</u>	✓				
Specialty Drugs (i.e. high-cost)	~	~	95%		~	~				Ш
Options for Additional Benefit Design Limits:			Plan Description	: [MVP VT Plus] G						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMOH-SG	6-003					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):										
Output Calculate										
Status/Error Messages:	Calculation Succes	sful.								
Actuarial Value:	80.89% 0.9922	24 80.27%								
Metal Tier:		lj AV Final								
			subject to the de	ductible and have	no copay. Any s	ervice with this	cost-sharing struct	ture is covered	at 100% by the plan	in the deductible
Additional Notes:	range.		A PARTY OF THE PAR				The same of the sa			
Calculation Time:	0.203 seconds									

Hamiltonia for Plan Personature	-									
User Inputs for Plan Parameters  Use Integrated Medical and Drug Deductible	, 🖺		HSA/HRA Option	s 🗇	Tie	red Network O	ntion			
Apply Inpatient Copay per Days			oyer Contribution			Network Plan				
Apply Skilled Nursing Facility Copay per Days		5 3 3				Tier Utilization				
Use Separate MOOP for Medical and Drug Spending		Annual Contrib	oution Amount:			Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard										
Desired Metal Tier										
	·	r 1 Plan Benefit De	sign		Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$	\$2,500.00	\$850.00								
Coinsurance (%, Insurer's Cost Share	50.00%	50.00%								
MOOP (\$	)				3					
MOOP if Separate (\$	\$7,500.00	\$1,500.00					1			
		;	5				2.000			
Click Here for Important Instructions	4	Tie					ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to	Subject to	Coinsurance, if	Copay, if	Copay applies only	y after deductible?
	Dç≓ugtible?	Coir unance?	different	separate	Ded ctible?	Coin rance?	different	separate	All	☐ All
Medical	~			Value of the control	~	✓			~	
Emergency Room Services	7	<b>V</b>		\$400.00	<b>V</b>	✓				
All Inpatient Hospital Services (inc. MH/SUD)		<del></del>								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	<b>V</b>			\$30.00	•	<b>▽</b>			•	
rays)	~			Mathematical Conference	~	✓			<b>v</b>	
Specialist Visit				\$60.00						••••••••••••••••••••••••
Mental/Behavioral Health and Substance Use Disorder Outpatient	•			\$30.00	<b>V</b>	<b>∠</b>			¥	
Services	<u> </u>				<b>.</b>	✓			<u> </u>	
Imaging (CT/PET Scans, MRIs)	<b>v</b>			\$1,400.00	<b>V</b>	✓			<b>v</b>	
Speech Therapy	<b>V</b>			\$60.00	- V	✓			v	
20 Yo. 20 GG 1993	•	Ш		\$45.00	•	~			_	
Occupational and Physical Therapy				Ç+3.00						
Preventive Care/Screening/Immunization	<b>V</b>		100%		~	✓	100%	\$0.00	<b>V</b>	
Laboratory Outpatient and Professional Services	<b>v</b>			\$60.00	<b>v</b>	✓			7	
X-rays and Diagnostic Imaging	<b>v</b>	✓		\$150.00	<b>~</b>	✓				
Skilled Nursing Facility	<b>V</b>				₹	<b>▽</b>				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	November 1			\$1,400.00	•	<u>~</u>			V	
	7				<b>V</b>	✓			7	
Outpatient Surgery Physician/Surgical Services	✓ All	✓ All		\$300.00	✓ All	✓ All			All	All
Drugs	~				~	✓			<b>v</b>	
Generics	<b>V</b>	₹		\$4.00	V	✓				
Preferred Brand Drugs	V	✓			V	✓				
Non-Preferred Brand Drugs	~	~			✓	✓				
Specialty Drugs (i.e. high-cost)										
Options for Additional Benefit Design Limits:		т		: [MVP VT Plus] S						
Set a Maximum on Specialty Rx Coinsurance Payments			Name:	FRVT-HMO-SS-0	01-N					
Specialty Rx Coinsurance Maximum	$\overline{}$		Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copays			Issuer HIOS ID:	10000						
# Days (1-10)			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits				4-						
# Visits (1-10)			Generic:	\$5						
Begin Primary Care Deductible/Coinsurance After a Set Number o			VBID:	\$1						
Copaysi 41 10										
# Copays (1-10)	: 3	1								
Outpu Calculate										
Status/Error Messages:	Calculation Succes	ssful.								
Actuarial Value:	71.67%									
Metal Tier:	Silver									
	NOTE: One or mo	re services are not	subject to the de	ductible and have	no copay. Any s	ervice with this	cost-sharing struc	ure is covered	at 100% by the pla	n in the deductible
Additional Notes:							ng outpatient inpu			

Calculation Time:
Draft 2024 AV Calculator

0.125 seconds

Hear Innute for Dan Parameters										
User Inputs for Plan Parameters  Use Integrated Medical and Drug Deductible?			HSA/HRA Option		Ti	ered Network O	Intion			
Apply Inpatient Copay per Day?			over Contribution			d Network Plan				
Apply Skilled Nursing Facility Copay per Day?						t Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?	~	Annual Contri	bution Amount:			Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier	Sliver									
	Tie	er 1 Plan Benefit De	esign		Tie	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$1,750.00	\$650.00								
Coinsurance (%, Insurer's Cost Share)	50.00%	50.00%								
MOOP(\$)						16				
MOOP if Separate (\$)	\$6,500.00	\$1,500.00	1							
Click Here for Important Instructions		Tie	er 1			1	Tier 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coipsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only	y after deductible?
Medical					V //	▼ All			V	H.
Emergency Room Services	V			\$350.00		· ·				
All Inpatient Hospital Services (inc. MH/SUD)	<b>Y</b>	Ψ	~~~~~~~~~~~~~~~~~	~~~~~~~~~~~~						
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•			\$30.00	•	✓			~	
rays)	~			\$30.00	~	~			~	
Specialist Visit		Ч		\$60.00	•					
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓			\$30.00	✓	✓			~	
Services					. V	✓			<b>V</b>	
Imaging (CT/PET Scans, MRIs)				\$1,400.00		<u>-</u>			<u> </u>	
Speech Therapy	ellellellellellellellellellellellellell			\$60.00						
	V			\$45.00	✓	✓			~	
Occupational and Physical Therapy				82,					,,,	
Preventive Care/Screening/Immunization	~		100%	400.00	~	~	100%	\$0.00	~	
Laboratory Outpatient and Professional Services	<b>V</b>			\$60.00	<b>V</b>	✓			<b>V</b>	
X-rays and Diagnostic Imaging Skilled Nursing Facility	<b>V</b>	<b>V</b>		\$150.00		✓			»———————	
Skilled Nursing Facility	~				<b>7</b>	<b>7</b>			<b>V</b>	
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)		_		\$1,400.00						
Outpatient Surgery Physician/Surgical Services	<b>V</b>			\$300.00	. <b>(</b>	✓			<u> </u>	
Drugs	✓ All	— All		\$300.00	✓ All	<u> </u>			- All	
Generics	~			\$4.00	~				~	
Preferred Brand Drugs	<b>V</b>	<u> </u>		<u> </u>		<u>~</u>				
Non-Preferred Brand Drugs	<b>V</b>				- V	₹				
Specialty Drugs (i.e. high-cost)	~	<b>V</b>								
Options for Additional Benefit Design Limits:			Plan Description	: [MVP VT Plus] Si	ilver 1 CSR 73					
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMO-S1-0	001-N					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):		_								
Begin Primary Care Deductible/Coinsurance After a Set Number of			120							
Copays?			Generic:	\$5						
# Copays (1-10): Output Calculate	3		VBID:	\$1						
Calculate										
Status/Error Messages:		(200-250% FPL), Ca	Ilculation Successf	ul.						
Actuarial Value:	73.88%									
Metal Tier:	Silver									
									d at 100% by the plan	n in the deductible
Additional Notes:	range. NOTE: Se	rvice-specific cost-s	haring is applying	tor service(s) with	n tac/prot comp	onents, overridi	ing outpatient inpu	ts for those se	ervice(s).	

Calculation Time: 0.2188 seconds

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	· —	Tie	ered Network O	ntion—			
Apply Inpatient Copay per Day?			over Contribution			d Network Plan				
Apply Skilled Nursing Facility Copay per Day?			362			t Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?	•	Annual Contri	bution Amount:			Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	· ·	,•								
Desired Metal Tier	Silver									
	Tie	r 1 Plan Benefit De	esign	Ī	Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$900.00	\$450.00								
Coinsurance (%, Insurer's Cost Share)	70.00%	60.00%								
MOOP (\$)			10				39			
MOOP if Separate (\$)	\$6,000.00	\$1,500.00	Ţ			k S	1 "			
Click Here for Important Instructions		Tie	er 1			Т	ier 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	C	
Type of Benefit	Deductible?	Coir-urance?	different	separate	Ded uctible?	Coingrance?	different	separate	Copay applies only	after deductible?
Medical	7				<b>V</b>	¥			\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
Emergency Room Services	7	<b>V</b>		\$150.00	<b>~</b>	~			I	$\overline{\Box}$
All Inpatient Hospital Services (inc. MH/SUD)										_
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	~			\$15.00	✓	7			~	
rays)	~	П		\$15.00	~	~			~	
Specialist Visit	_			\$40.00						_
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓			\$15.00	<b>▽</b>	~			•	
Services		П		\$15.00	<b>.</b>	<b>V</b>			V	П
Imaging (CT/PET Scans, MRIs)	<u> </u>			\$500.00		7			7	Ä
Speech Therapy				\$40.00	Sec. 1					
	V			\$19.00	✓	<b>~</b>			V	
Occupational and Physical Therapy				\$15.00						
Preventive Care/Screening/Immunization			100%		<u>~</u>	<u>~</u>	100%	\$0.00	✓	
Laboratory Outpatient and Professional Services	<b>V</b>			\$40.00		<b>V</b>			7	ā
X-rays and Diagnostic Imaging	7	<u></u>		\$100.00		<u>~</u>				F I
Skilled Nursing Facility										_
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~			\$800.00	V	<u>~</u>			V	
Outpatient racinty ree (e.g., Ambulatory Surgery Center)	✓			J000.00	. 🔽	<b>v</b>			<b>V</b>	
Outpatient Surgery Physician/Surgical Services	✓ All	All		\$200.00	✓ All	✓ All			All	All
Drugs	<b>Y</b>				<u>~</u>	~			<b>V</b>	
Generics		<u></u>		\$4.00		<b>V</b>				
Preferred Brand Drugs	<b>V</b>	<b>V</b>				<u>~</u>				
Non-Preferred Brand Drugs	~	✓_			✓	<u>~</u>				
Specialty Drugs (i.e. high-cost)										
Options for Additional Benefit Design Limits:		т.		: [MVP VT Plus] Si						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMO-S1-0	04-N					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	10000						
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?				4-						
# Visits (1-10):	~		Generic	\$5						
Begin Primary Care Deductible/Coinsurance After a Set Number of			VBID	\$1						
Copays?	3									
# Copays (1-10): Outpu' Calculate	3	1								
Calculate										
		itside of [0, +1] per	rcent de minimis v	rariation for CSRs.						
	77.73%									
Metal Tier:										
									d at 100% by the plar	in the deductible
Additional Notes:	range. NOTE: Ser	vice-specific cost-s	haring is applying	for service(s) with	fac/prof compo	onents, overridi	ng outpatient inpu	ts for those se	ervice(s).	

Calculation Time: 0.0781 seconds

User Inputs for Plan Parameters	_									
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	s	Tie	ered Network Op	otion			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	,	Tiere	d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:			Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	•	Annuar contri	batton Amount.		2nc	Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	<b>V</b>									
Desired Metal Tier	Gold			-						
		1 Plan Benefit De				2 Plan Benefit D				
21 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$300.00	\$300.00								
Coinsurance (%, Insurer's Cost Share)	90.00%	60.00%		_	ē.					
MOOP(\$)	40.000.00	4750.00				T T				
MOOP if Separate (\$)	\$2,800.00	\$750.00	1				I			
Click Here for Important Instructions		Tie	er 1			Ti	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only a	ter deductible?
Medical	All	☐ All	unicient	Separate	✓ All	✓ All	unicicit	зеринис	☐ All	□ All
Emergency Room Services	~			\$50.00	✓	✓			<b>V</b>	
All Inpatient Hospital Services (inc. MH/SUD)	<b>V</b>	<b>V</b>		<b>V30.00</b>	- ✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-										
rays)	✓			\$5.00	V	✓			✓	
Specialist Visit	~			\$30.00	~	~			✓	
Mental/Behavioral Health and Substance Use Disorder Outpatient	~				<b>V</b>	☑			V	
Services	10-0			\$5.00					10-50	
Imaging (CT/PET Scans, MRIs)	<b>Y</b>			\$100.00	~	✓			¥	
Speech Therapy	Y			\$30.00	~	✓			<b>Y</b>	
	•			\$7.00	✓	✓			▼	
Occupational and Physical Therapy				\$7.00						
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	<b>Y</b>	Ц		\$30.00	~	~			~	L
X-rays and Diagnostic Imaging	Y			\$30.00	~	<u> </u>			V	
Skilled Nursing Facility	Y	V			Z.	~				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	•			\$200.00	₹.	₹.			₹	
Outpatient Surgery Physician/Surgical Services	<b>V</b>			\$100.00	<b>V</b>	✓				
Drugs	✓ All	All		\$100.00	✓ All	✓ All			All	☐ All
Generics	~			\$4.00	~	✓			<b>V</b>	
Preferred Brand Drugs	~	•	80%	<u> </u>	✓	✓				
Non-Preferred Brand Drugs	~	~			✓	✓				
Specialty Drugs (i.e. high-cost)	~	~			~	~				
Options for Additional Benefit Design Limits:			Plan Description	: [MVP VT Plus] Si	ilver 1 CSR 87					
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMO-S1-0	002-N					
Specialty Rx Coinsurance Maximum:	1999		Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			<b>AVC Version:</b>	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of	<b>⊻</b>									
Copays?			Generic:	\$5						
# Copays (1-10):	3		VBID:	\$1	-8					
Output Calculate										
Status/Error Messages:	CSR Level of 87% (	150-200% FPL), Ca	Iculation Successf	ul.						
	87.35%									
	Gold									
	NOTE: One or mor	re services are not	subject to the dec	ductible and have	no copay. Any	service with this	cost-sharing struct	ure is covered	at 100% by the plan in	the deductible
	range. NOTE: Serv									

Calculation Time: 0.207 seconds

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	ä		HSA/HRA Options		Tie	ered Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution	?	Tiere	d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?	~	Annual Contri	bution Amount:			Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?	~	/imaar contin			2nc	Tier Utilization				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?  Desired Metal Tier	Platinum 🔻									
besited Wetal Hel	Tie	r 1 Plan Benefit De	sign	Ĭ	Tier	2 Plan Benefit I	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$0.00	\$0.00								
Coinsurance (%, Insurer's Cost Share)	95.00%	95.00%								
MOOP (\$)			16		3					
MOOP if Separate (\$)	\$1,800.00	\$700.00		<del>-</del> 16						
		8					=&			
Click Here for Important Instructions		Tie					ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay applies only	after deductible?
	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		
Medical					~	✓				
Emergency Room Services		<b>v</b>		\$30.00	<b>v</b>	✓				
All Inpatient Hospital Services (inc. MH/SUD)										
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-				\$5.00	~	✓				
rays)				\$600000000	~	✓				
Specialist Visit				\$10.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient				\$5.00	~	✓				
Services						✓				
Imaging (CT/PET Scans, MRIs)				\$25.00		✓				
Speech Therapy				\$10.00	<b>7</b>	✓				
2 2 3 3 3 3				\$7.00	•	•				
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization			100%		~	✓	100%	\$0.00		
Laboratory Outpatient and Professional Services				\$10.00	<b>V</b>	✓				
X-rays and Diagnostic Imaging				\$10.00	<b>v</b>	✓				
Skilled Nursing Facility					<b>V</b>	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)				\$50.00						
Outpatient Surgery Physician/Surgical Services		2 2		\$25.00		<u>~</u>				
Drugs	- All	— All		ĢE3.00	✓ All	✓ All				All
Generics				\$4.00						
Preferred Brand Drugs						<u>~</u>				
Non-Preferred Brand Drugs		<u> </u>				<u>.</u>				
Specialty Drugs (i.e. high-cost)		<b>V</b>			~	~				
Options for Additional Benefit Design Limits:			Plan Description:	[MVP VT Plus] Si	ilver 1 CSR 94					
Set a Maximum on Specialty Rx Coinsurance Payments?		Ī	Name:	FRVT-HMO-S1-C						
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			<b>AVC Version:</b>	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?			Generic:	\$5	•					
# Copays (1-10):			VBID:	\$1						
Outpu' Calculate		500								
Status/Error Messages:	CSR Level of 94%	(100-150% FPL), Ca	Iculation Successfu	uL						
	94.83%	(100-130/0 11 L), Cd	iculation successit	ui.						
	Platinum									
		ocific cost-sharing i	s anniving for con-	vice(s) with factor	of components	overriding outs	atient inputs for th	nce cervicals)		
Additional Notes:	no ic. service-spe	come cost-stiatifig i	a abbiting for serv	iω(s) with rat/pr	or components,	over name outh	adent inputs for th	ose sei vice(S).		
0.1.1.5	0.2400									
Calculation Time:	0.2188 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	5	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Empl	loyer Contribution	? 🗆		d Network Plan				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:			Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?	<u>~</u>				2nd	Tier Utilization	3			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Silver ▼									
Desired Metal Tier		1 Plan Benefit De		Ť	Tion	2 Dian Danafit	Desim			
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Medical		Combined	-	Medical	2 Plan Benefit Drug	Combined			
Deductible (\$)	\$2,500.00	\$850.00	Combined		Medical	Drug	Combined			
Coinsurance (%, Insurer's Cost Share)	50.00%	50.00%								
MOOP (\$)	30.0070	30.0070	0.				9			
MOOP if Separate (\$)	\$7,500.00	\$1,500.00		-		ľ	1			
to de representado de constator de la constato			1/8			4	-			
Click Here for Important Instructions		Tie	er 1			Т	ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Consu applies only	y after deductible?
Type of Bellefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	copay applies offi	y arter deductible:
Medical	<b>✓</b> All	☐ All			✓ All	<b>✓</b> All			☐ All	☐ All
Emergency Room Services	₹			\$400.00	V	<b>~</b>			<b>V</b>	
All Inpatient Hospital Services (inc. MH/SUD)	✓	₹			V	<b>₹</b>				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•			\$30.00	<b>V</b>	✓			V	
rays)				(#000001000001						
Specialist Visit	V			\$60.00	V	<b>V</b>			•	
Mental/Behavioral Health and Substance Use Disorder Outpatient	•			\$30.00	V	V			•	
Services										
Imaging (CT/PET Scans, MRIs)	<u> </u>			\$1,400.00	2	~			<b>V</b>	_
Speech Therapy	<b>v</b>			\$60.00	V	V			✓	
Occupational and Physical Therapy	~			\$45.00	~	✓			•	
Preventive Care/Screening/Immunization		П	100%	0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	~		100%	\$60.00	~	V	100%	30.00	V	
X-rays and Diagnostic Imaging	V			\$150.00	V	<u>.</u>			₹	
Skilled Nursing Facility	₹	<u></u>		<b>Q150.00</b>	7	<u>~</u>			П	$\overline{\Box}$
				5						· · · · · · · · · · · · · · · · · · ·
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~			\$1,400.00	<b>V</b>	✓			✓	
Outpatient Surgery Physician/Surgical Services	✓			\$300.00	V	<b>~</b>			•	
Drugs	✓ All	<b>✓</b> All			✓ All	✓ All			☐ All	☐ All
Generics	~			\$4.00	~	✓			~	
Preferred Brand Drugs	✓	✓			•	<b>∀</b>				
Non-Preferred Brand Drugs	<b>Y</b>	~			•	✓				
Specialty Drugs (i.e. high-cost)	✓.	✓			~	✓				
Options for Additional Benefit Design Limits:				: [MVP VT Plus] Re						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMO-SS-00	01-N II					
Specialty Rx Coinsurance Maximum:	_		Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?				45						
#Visits (1-10):  Begin Primary Care Deductible/Coinsurance After a Set Number of			Generic: VBID:	\$5 \$1						
Copays?	•		VBID.	\$1						
# Copays (1-10):	3									
Output # Copays (1-10).	J									
Calculate										
	Calculation Succes	sful.								
	71.67%									
	Silver									
		e services are not	t subject to the dea	ductible and have r	no copay. Any	service with this	cost-sharing struct	ure is covered	at 100% by the plan	n in the deductible
Additional Notes:	range. NOTE: Serv	ice-specific cost-s	haring is applying	for service(s) with	fac/prof compo	onents, overridi	ng outpatient input	s for those se	rvice(s).	

0.0781 seconds

Calculation Time:
Draft 2024 AV Calculator

User Inputs for Plan Parameters	lia l									
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	s 🖂	Tie	ered Network Op	otion			
Apply Inpatient Copay per Day?	· 🖁	HSA/HRA Empl	oyer Contribution	?	Tiere	d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:		1st	t Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	'	Annual Contin	button Amount.		2nc	Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Silver									
Desired Metal Tier			120	Ť		Total all as t				
		r 1 Plan Benefit De		_		2 Plan Benefit D				
2 1 111 (4)	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$5,725.00							
Coinsurance (%, Insurer's Cost Share) MOOP (\$)			100.00% \$5,725.00	-						
MOOP if Separate (\$)			\$3,723.00			<u>'</u>				
moor in separate (2)			4,				L			
Click Here for Important Instructions		Tie	er 1			Ti	er 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Conay applies only	y after deductible?
	Dç; uctible?	Coir urance?	different	separate	Ded ; ctible?	Coin rance?	different	separate	All	All All
Medical	~	V			✓	✓				
Emergency Room Services	<u> </u>				. ✓	✓				
All Inpatient Hospital Services (inc. MH/SUD)					✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	☑	<b>₽</b>			~	~				
rays)	~	<b>V</b>			~					
Specialist Visit  Mental/Behavioral Health and Substance Use Disorder Outpatient	V	<b>2</b>			-	₩				П
Services										
Imaging (CT/PET Scans, MRIs)		<u> </u>				<u>~</u>				
Speech Therapy	<u> </u>	<b>Y</b>				₹				
	•	7			<b>∠</b>	<b>∠</b>				
Occupational and Physical Therapy		П				П				
Preventive Care/Screening/Immunization		<u> </u>	100%		<u>~</u>		100%	\$0.00		
Laboratory Outpatient and Professional Services	<u> </u>					7			I	<u> </u>
X-rays and Diagnostic Imaging	<b>V</b>	<b>V</b>			<b>~</b>	<b>~</b>				
Skilled Nursing Facility	<b>V</b>	✓			V	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	▼ ▼	▼			<b>∨</b>	∨				
Outpatient Surgery Physician/Surgical Services	✓ All	V All				✓ All				
Drugs	V	V AII			V All	V All			All	All
Generics	7	~			V	<u> </u>				H
Preferred Brand Drugs	7	<u> </u>								
Non-Preferred Brand Drugs	7				<u> </u>	<del>-</del> -				
Specialty Drugs (i.e. high-cost)					: Cial	Charles (				. <u> </u>
Options for Additional Benefit Design Limits:			Plan Description	: [MVP VT Plus] Si						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMOH-S-0	002-N					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10): Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):										
Outpur Calculate		1								
Calculate										
Status/Error Messages:	Calculation Succes	ssful.								
Actuarial Value:	70.12% 1.0267	72.00%								
Metal Tier:		AV Final								
		re services are not	subject to the dec	ductible and have	no copay. Any	service with this	cost-sharing struc	ture is covered	d at 100% by the plan	n in the deductible
Additional Notes:	range.									
Calculation Time:	0.1953 seconds									

User Inputs for Plan Parameters	=			_						
Use Integrated Medical and Drug Deductible?	HSA/HRA Options			S .	Tie	ered Network O				
Apply Inpatient Copay per Day?						d Network Plan				
Apply Skilled Nursing Facility Copay per Day?		5. 31 30		310	1s	t Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	ibution Amount:		2nd	d Tier Utilization	:			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				_			-			
		r 1 Plan Benefit De				2 Plan Benefit I	The state of the s			
212 222	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$4,900.00							
Coinsurance (%, Insurer's Cost Share)			100.00%			L	1			
MOOP (\$)  MOOP if Separate (\$)			\$4,900.00			ľ				
WOOF II Separate (3)			_,		67	v :	L.			
Click Here for Important Instructions		Tie	er 1			Т	ier 2		Tier 1	Tier 2
Type of Benefit	Striggt to Deductible?	Subject to Coirpurance?	Coinsurance, if different	Copay, if separate	Subject to Deductible?	Sultipotito Coincirance?	Coinsurance, if different	Copay, if separate	Copay piles on	ly after dalactible?
Medical	~				V	7				
Emergency Room Services					× ***					
All Inpatient Hospital Services (inc. MH/SUD)	V	V			V	V				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X- rays)	•	•			~	✓				
Specialist Visit	~	~			~	~				
Mental/Behavioral Health and Substance Use Disorder Outpatient	~	<b>V</b>			<b>V</b>	<b>~</b>				
Services	7					<u> </u>				
Imaging (CT/PET Scans, MRIs)	~	<b>V</b>			<b>~</b>	[ <b>~</b> ]			<u> </u>	
Speech Therapy		U								<u> </u>
0 1 10 1 17										
Occupational and Physical Therapy	<b>.</b>	V	1000/		_ ☑	<b>~</b>	1000/	¢0.00		
Preventive Care/Screening/Immunization  Laboratory Outpatient and Professional Services	~	<u> </u>	100%		~	~	100%	\$0.00		
X-rays and Diagnostic Imaging	<u> </u>	<u> </u>			<b>.</b>	<u>v</u>				
Skilled Nursing Facility	~	✓			✓	<b>v</b>				
	V	V			<b>V</b>	<b>▽</b>				П
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	▼ All	V AIL			▼ All	▼ All				All
Outpatient Surgery Physician/Surgical Services	<b>V</b>	<b>V</b>			Ž	7				
Drugs	V	V			, i	Ÿ			H	
Generics	7	<u> </u>			<b>V</b>	7			l i	
Preferred Brand Drugs	v	<b>V</b>				<u> </u>				
Non-Preferred Brand Drugs								***************************************		
Specialty Drugs (i.e. high-cost)	L <sub>D</sub>									
Options for Additional Benefit Design Limits:	9 90 91	т		: [MVP VT Plus] S						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMOH-S2	!-001-N					
Specialty Rx Coinsurance Maximum: Set a Maximum Number of Days for Charging an IP Copay?		-	Plan HIOS ID: Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?			Ave version.	2024_16						
# Visits (1-10):	Ш									
Begin Primary Care Deductible/Coinsurance After a Set Number of		1								
Copays?										
Calculate # Copays (1-10):										
Output										
			rcent de minimis v	ariation for CSRs.						
	72.53% 1.0186 7									
Metal Tier:	AV Adj A		+ au bio at + a + b	dustible and b	. no conou A	comico with this	and the aring of	turo la pous	l a+ 1000/ bu +bl-	on in the deductible
Addistract Nation		re services are no	it subject to the de	uuciibie and nave	no copay. Any	service with this	cost-snaring struc	ture is covered	a at 100% by the big	an in the deductible
Additional Notes:	range.									
Calculation Time:	0.168 seconds									

Calculation Time:

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	~		HSA/HRA Option	s	Tie	ered Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emp	loyer Contribution	?	Tiere	d Network Plan	?			
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	ibution Amount:		1st	t Tier Utilization	1:			
Use Separate MOOP for Medical and Drug Spending?	. 153	Alliuai Collui	button Amount.		2nd	Tier Utilization	0			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Silver ▼									
Desired Metal Tier			. 020	<b>-</b>						
		r 1 Plan Benefit De		_		2 Plan Benefit				
Deductible (\$)	Medical	Drug	\$3,550.00		Medical	Drug	Combined			
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$3,550.00	+			-12			
MOOP if Separate (\$)			\$3,530.00	-		ľ	-			
						b)	<del>-</del>			
Click Here for Important Instructions		Tie	er 1			T	ier 2		Tier 1	Tier 2
Time of Danielle	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Canavanulias aul	y after deductible?
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		
Medical	✓ All	V All			✓ All	✓ All			All	[] All
Emergency Room Services	<u> </u>	<u> </u>			· ·	<b>∨</b> <b>∨</b>				
All Inpatient Hospital Services (inc. MH/SUD)	Y	<b>V</b>			•	•				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	✓	•			~	✓				
rays)	~	<b>V</b>			V	~				
Specialist Visit										
Mental/Behavioral Health and Substance Use Disorder Outpatient Services	~	<b>Y</b>			~	✓				
Imaging (CT/PET Scans, MRIs)	V	<b>V</b>			<b>'</b>	<b>~</b>				
Speech Therapy	<b>V</b>	<b>Y</b>			~	<b>~</b>				
	•	<b>~</b>			•	✓				
Occupational and Physical Therapy					,					
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	<b>V</b>	V			<b>V</b>	<b>y</b>				
X-rays and Diagnostic Imaging	<u>v</u>	<u>~</u>			<u>v</u>	<u>∨</u> ✓				
Skilled Nursing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	•	•			<b>V</b>	▼ _				
Outpatient Surgery Physician/Surgical Services	V	<b>V</b>				<b>~</b>				
Drugs	✓ All	▼ All			✓ All	✓ All			All	All
Generics	<b>Y</b>	V			<b>y y</b>	<b>y</b>				
Preferred Brand Drugs	<u>v</u>	<u> </u>			- V	<u>~</u>				
Non-Preferred Brand Drugs	<u> </u>	<u> </u>			~	<u>-</u>			<del></del>	
Specialty Drugs (i.e. high-cost)			n! n '	SAMPLE DI LO	(Second)	10000011				(
Options for Additional Benefit Design Limits:  Set a Maximum on Specialty Rx Coinsurance Payments?		T	Name:	: [MVP VT Plus] S FRVT-HMOH-S2		( //				
Specialty Rx Coinsurance Payments:  Specialty Rx Coinsurance Maximum:			Plan HIOS ID:	FRVT-HIVIOH-32	:-004-IN					
Set a Maximum Number of Days for Charging an IP Copay?		-	Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024 1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?			7110 10130111	2021_10						
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):										
Output Calculate										
Status/Error Messages:	Error: Result is ou	tside of [-2, +2] pe	ercent de minimis	variation.						
	77.16% 1.0095	77.89%								
Metal Tier:	AV Adj									
		re services are no	t subject to the de	ductible and have	no copay. Any	service with this	cost-sharing struc	ure is covered	d at 100% by the pla	n in the deductible
Additional Notes:	range.									
Calculation Time:	0.2188 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	~		HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Empl	oyer Contribution			d Network Plan				
Apply Skilled Nursing Facility Copay per Day?		Annual Cantui	bution Amount:		1st	Tier Utilization				
Use Separate MOOP for Medical and Drug Spending?	~	Annual Contri	oution Amount.		2nd	Tier Utilization	b .			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Gold ▼									
Desired Metal Tier			No.	_		17.52.0 EAV. 0.52.0				
		r 1 Plan Benefit De	T	_		2 Plan Benefit I				
Dedicable (A)	Medical	Drug	Combined	_	Medical	Drug	Combined			
Deductible (\$)			\$1,600.00 100.00%							
Coinsurance (%, Insurer's Cost Share) MOOP (\$)			\$1,600.00	-						
MOOP if Separate (\$)			\$1,000.00			ľ				
WOOT II Separate (5)			4,				La Company			
Click Here for Important Instructions		Tie	er 1			т	ier 2		Tier 1	Tier 2
W 111 200	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if		
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	Copay applies only	
Medical	V All								All	- All
Emergency Room Services										
All Inpatient Hospital Services (inc. MH/SUD)	<b>V</b>	<b>V</b>		~~~~~~~~~~~~	- ✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	✓	•			✓	✓				
rays)	<u> </u>	<u> </u>			~					
Specialist Visit	<b>Y</b>	<u> </u>			<b>Y</b> .	•				L-
Mental/Behavioral Health and Substance Use Disorder Outpatient	~	•			✓	✓				
Services	<b>V</b>				- <b>~</b>	✓			П	
Imaging (CT/PET Scans, MRIs)	<u> </u>	<u> </u>			7	7			· — —	
Speech Therapy	<b>V</b>	~			~	~				
Occupational and Physical Therapy	•	•								
Preventive Care/Screening/Immunization			100%				100%	\$0.00		
Laboratory Outpatient and Professional Services	~	~	10070		~	~	10070	50.00		
X-rays and Diagnostic Imaging					. ✓	₹				
Skilled Nursing Facility	<b>V</b>	<b></b>			✓	<b>▽</b>				
	V	<b>V</b>			✓	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	<b>V</b>	<b>~</b>			. V					П
Outpatient Surgery Physician/Surgical Services	V All	▼ All			✓ All	✓ All			All	
Drugs	V	V A			V A⊪	V AII				L All
Generics	<u>v</u>	<u>~</u>			· •	<b>∀</b>			<u> </u>	
Preferred Brand Drugs	<b>V</b>	<u> </u>			<b>\</b>	₹				
Non-Preferred Brand Drugs	· ·	<u>.</u>	001/01/01/01/01/01/01/01/01/01/01/01/01/		- <del>-</del>	<del>`</del>				
Specialty Drugs (i.e. high-cost)					=	<del>200</del> 2)				
Options for Additional Benefit Design Limits:		Т		: [MVP VT Plus] Si		87				
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMOH-S2-	-002-N					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:							
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):  Begin Primary Care Deductible/Coinsurance After a Set Number of		-								
Copays?										
# Copays (1-10):										
Output		1								
Calculate										
Status/Error Messages:	CSR Level of 87%	150-200% FPL), Ca	Iculation Successf	ul.						
Actuarial Value:	87.65% 1.0004									
Metal Tier:	Gold AV Adj	AV Final								
	NOTE: One or mo	re services are not	subject to the de	ductible and have	no copay. Any	service with this	cost-sharing struct	ure is covered	d at 100% by the plan	in the deductible
Additional Notes:	range.									
Calculation Time:	0.3242 seconds									

User Inputs for Plan Parameters	V									
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	,	Tie	ered Network O	otion			
Apply Inpatient Copay per Day?			oyer Contribution			d Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		5 37 30 30	bution Amount:		1st	Tier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	~	Annual Contin	oution Amount.		2nc	Tier Utilization:				
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Platinum 🔻									
Desired Metal Tier			120	Ť						
		r 1 Plan Benefit De				2 Plan Benefit [				
Deductible (\$)	Medical	Drug	\$600.00		Medical	Drug	Combined			
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP(\$)			\$600.00	Q .		<u> </u>				
MOOP if Separate (\$)	*		Ç000100			1				
and representation of the constraint of the cons		1	-			b	5			
Click Here for Important Instructions		Tie	r 1			Ti	er 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Conav annlies on	ly after deductible?
	De uttible?	Coil Lurance?	different	separate	Ded≚ctible?	Coin Zrance?	different	separate		
Medical	<b>V</b>	<b>V</b>			V	~				
Emergency Room Services	V	<b>V</b>			✓	<u>~</u>				Ш
All Inpatient Hospital Services (inc. MH/SUD)	<b>V</b>				. ✓	✓				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	✓	•			V	₩				
rays) Specialist Visit	7777.71	N-0				72007				
Mental/Behavioral Health and Substance Use Disorder Outpatient	<b>V</b>	<b>V</b>			- ✓	✓				
Services	•	~			✓	✓				
Imaging (CT/PET Scans, MRIs)	7	<b>~</b>			✓	<b>∀</b>				
Speech Therapy	<b>V</b>	V			✓	✓				П
		82.27				<u> </u>				
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization	~	✓	100%		✓	<b>⊻</b>	100%	\$0.00		
Laboratory Outpatient and Professional Services	<u> </u>	V				<u> </u>				
X-rays and Diagnostic Imaging	V	Z			☑	₹				
Skilled Nursing Facility	<b>V</b>	<u>v</u>			✓	✓				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~	•			✓	✓				
Outpatient Surgery Physician/Surgical Services	<b>☑</b> All	✓ All			✓ All	✓ All			☐ All	☐ All
Drugs	<b>v</b>	<b>V</b>			✓	✓				
Generics	<b>v</b>	~			✓	✓		-		
Preferred Brand Drugs	V	V		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	✓	✓				
Non-Preferred Brand Drugs	✓	V			✓	✓				
Specialty Drugs (i.e. high-cost)									0	
Options for Additional Benefit Design Limits:		т.	Plan Description	: [MVP VT Plus] Si						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	FRVT-HMOH-S2-	-003-N					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024 4						
# Days (1-10):  Begin Primary Care Cost-Sharing After a Set Number of Visits?			AVC Version:	2024_1e						
#Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of	_									
Copays?										
# Copays (1-10):										
Output Calculate		•								
Status/Error Messages:	CCD Lovel of Day /	100 1500/ 501) 6-	lculation Cusssf	od.						
Actuarial Value:		100-150% FPL), Ca 94.16%	iculation successi	ui.						
Metal Tier:										
The contract of the contract o	Platinum AV Adj	re services are not	subject to the dec	ductible and have	no copav. Anv	service with this	cost-sharing struct	ure is covered	at 100% by the nla	an in the deductible
Additional Notes:	range.								, and pi	
The state of the s	×									
Calculation Time:	0.3086 seconds									

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible			HSA/HRA Options	s ¬	Tie	ered Network O	ption			
Apply Inpatient Copay per Day		HSA/HRA Emp	loyer Contribution			d Network Plan				
Apply Skilled Nursing Facility Copay per Days	·	Annual Cantui	ibution Amount:		1st	Tier Utilization	:			
Use Separate MOOP for Medical and Drug Spending	'	Annual Contri	bution Amount:		2nd	Tier Utilization	3			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard	Silver ▼									
Desired Metal Tier		r 1 Plan Benefit De	neian		Tier	2 Plan Benefit	Dosign			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$		Diug	\$5,750.00		Wedicar	Diug	Combined			
Coinsurance (%, Insurer's Cost Share			100.00%							
MOOP (\$			\$5,750.00	- u	7	1	0			
MOOP if Separate (\$						i'				
			<del>-</del> ,		<del>-</del>		-			
Click Here for Important Instructions		Tie	er 1			Т	ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay applies only	after deductible?
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate		All All
Medical	V				~					
Emergency Room Services	- <del>-</del>				_ ~	~				Ä
All Inpatient Hospital Services (inc. MH/SUD)										
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	•	•			<b>∨</b>	Y				
rays)	~	~			~	~				
Specialist Visit										
Mental/Behavioral Health and Substance Use Disorder Outpatient	~	✓			✓	~				
Services	<b>V</b>	<b></b>			✓	<b>~</b>				
Imaging (CT/PET Scans, MRIs)	<u> </u>	<b>V</b>				<u> </u>				
Speech Therapy	<b>v</b>	~			₩.	<b> </b> ₹				· · · · · · · · · · · · · · · · · · ·
Opening the selection of the selection o										
Occupational and Physical Therapy Preventive Care/Screening/Immunization			100%				1,000/	\$0.00		
Laboratory Outpatient and Professional Services	~	~	100%		~	~	100%	\$0.00		
X-rays and Diagnostic Imaging	<b>V</b>				· ·	<u>~</u>				
Skilled Nursing Facility	<u> </u>				✓	✓				
	•	V			✓	<b>~</b>				
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	<b>~</b>					~			П	П
Outpatient Surgery Physician/Surgical Services	V AII	V AII			✓ All	V All				
Drugs		▼ AII			V AII	700 A STAN			-	AII
Generics	V	V			_ v	<b>▽</b>				
Preferred Brand Drugs	<b>V</b>	V V			V	<u>v</u>				H
Non-Preferred Brand Drugs	<b>Y</b>	<u> </u>			V	<del>V</del>				
Specialty Drugs (i.e. high-cost)		·							]	
Options for Additional Benefit Design Limits:		-	Plan Description	: [MVP VT Plus] R		HDHP				
Set a Maximum on Specialty Rx Coinsurance Payments			Name:	FRVT-HMOH-S-0	002-N II					
Specialty Rx Coinsurance Maximum	<u> </u>	1	Plan HIOS ID:							
Set a Maximum Number of Days for Charging an IP Copays			Issuer HIOS ID:							
# Days (1-10)			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits										
# Visits (1-10)  Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays										
# Copays (1-10)										
Output		1								
Calculate										
Status/Error Messages:	Calculation Succe	ssful.								
Actuarial Value:	70.05% 1.0269									
Metal Tier:	Silver AV Adj									
			t subject to the dea	ductible and have	no copay. Any	service with this	cost-sharing struc	ture is covere	d at 100% by the plan	in the deductible
Additional Notes:	range.		and a second							
Calculation Time:	0.2031 seconds									

User Inputs for Plan Parameters	✓							
Use Integrated Medical and Drug Deductible?			HSA/HRA Options	П	Tie	ered Network O	ption	
Apply Inpatient Copay per Day?		HSA/HRA Emplo	oyer Contribution?	_	Tiere	d Network Plan?		
Apply Skilled Nursing Facility Copay per Day?		Annual Contrib	ution Amount:		1st	Tier Utilization:		
Use Separate MOOP for Medical and Drug Spending?		Allitual Collette	oution Amount.		2nd	Tier Utilization:	:	
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	Bronze ▼							
Desired Metal Tier								
	Tie	r 1 Plan Benefit De	sign		Tier	2 Plan Benefit I	Design	
	Medical	Drug	Combined		Medical	Drug	Combined	
Deductible (\$)			\$9,450.00					
Coinsurance (%, Insurer's Cost Share)			100.00%					
MOOP (\$)			\$9,450.00					
MOOP if Separate (\$)								
Click Here for Important Instructions		Tie	r 1			Ti	ier 2	
	Subject to	Tie Subject to	r 1 Coinsurance, if	Copay, if	Subject to	Subject to	ier 2 Coinsurance, if	Copay, if
Type of Benefit	Subject to DÇügtible?			Copay, if separate	Subject to Ded_ctible?			Copay, if separate
		Subject to	Coinsurance, if			Subject to	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services	Dr√ugtible?	Subject to Coipugance?	Coinsurance, if		Ded ctible?	Subject to Coingrance?	Coinsurance, if	
Type of Benefit  Medical	Devugtible?	Subject to Coirugance?	Coinsurance, if		Ded ctible?	Subject to Cointyrance?	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services	Dqõgtible?	Subject to Coipugance?	Coinsurance, if		Ded ctible?	Subject to Coingrance?	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services All Inpatient Hospital Services (inc. MH/SUD)	Devugtible?	Subject to Coirugance?	Coinsurance, if		Ded ctible?	Subject to Cointyrance?	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services All Inpatient Hospital Services (inc. MH/SUD)  Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-	Derugible?	Subject to Colivugance?	Coinsurance, if		Degockible?	Subject to Coincrance?	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services All Inpatient Hospital Services (inc. MH/SUD) Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-rays)	Drugtible?	Subject to Coipugance?	Coinsurance, if		Der chible?	Subject to Coingrance?	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services All Inpatient Hospital Services (Inc. MH/SUD)  Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-rays) Specialist Visit	Derugible?	Subject to Colivugance?	Coinsurance, if		Degockible?	Subject to Coincrance?	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services All Inpatient Hospital Services (inc. MH/SUD) Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-rays) Specialist Visit Mental/Behavioral Health and Substance Use Disorder Outpatient	Dç ygtible?	Subject to Coipygance?  V  V  V	Coinsurance, if		Ded Stripple?	Subject to Coin rance?  V  V  V	Coinsurance, if	
Type of Benefit  Medical  Emergency Room Services All Inpatient Hospital Services (Inc. MH/SUD)  Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and X-rays)  Specialist Visit  Mental/Behavioral Health and Substance Use Disorder Outpatient  Services	Drugtible?	Subject to Coliguegance?  V  V  V	Coinsurance, if		Ded Stripple?	Subject to Cointyrance?  V  V  V  V	Coinsurance, if	

<u>-</u>

V

V

✓ □ All

V

			V
Outpatient	R		
Outpatient	Surgery Physician/Surgical Service	S	V All
	Drugs		V
Generics			₽
Preferred B	rand Drugs		V
Non-Prefer	red Brand Drugs		✓
Specialty D	rugs (i.e. high-cost)		
Options for	Additional Benefit Design Limits:		
	Set a Maximum on Specialty	Rx Coinsurance Payments?	
	Specialty	y Rx Coinsurance Maximum:	
	Set a Maximum Number of Day	ys for Charging an IP Copay?	
		# Days (1-10):	
	Begin Primary Care Cost-Sharing A	fter a Set Number of Visits?	
		# Visits (1-10):	✓
Begi	n Primary Care Deductible/Coinsu	rance After a Set Number of	
		Copays?	
		# Copays (1-10):	3
Outpu	Calculate		

Plan Description: MVP VT Secure
Name: MVP VT Secure
Plan HIOS ID:
Issuer HIOS ID:
AVC Version: 2024\_1e

Tier 1

П 

-0-

8

-0-

#

\$0.00

Copay applies only after deductible?

Tier 2

Status/Error Messages: Actuarial Value: Metal Tier:

Occupational and Physical Therapy Preventive Care/Screening/Immunization Laboratory Outpatient and Professional Services X-rays and Diagnostic Imaging Skilled Nursing Facility

Error: Result is outside of [-2, +2] percent de minimis variation. 62.76%

V

V

**V** 

0.2656 seconds

Calculation Time: Final 2024 AV Calculator



# Consumer Disclosure about Proposed Health Insurance Rate Increase VT 2024 ACA Small Group Exchange Rate Filing

# **About Us**

MVP Health Plan, Inc. is a non-profit health care payer operating in Vermont and New York. MVP's mission is to provide high quality and affordable health care with a focus on wellness to our members.

# **Why We Are Changing Our Premiums**

MVP must obtain approval from the Green Mountain Care Board for the health insurance premium rates charged. MVP files annual premium rates for the Exchange which are guaranteed for 12 months. This rate filing seeks approval of MVP's 2024 Small Group Exchange rates for effective dates of coverage between January 1, 2024 and December 31, 2024. The premium rates filed reflect MVP's current estimate of the cost to provide health insurance for that coverage period. The filed premium rates may be higher or lower than the previously filed premium rates, however, premium rates generally increase over time. Changes in the filed premium rates (relative to previously approved rates) are driven by many factors, including:

- -Increases in base period experience. Premium rates are increasing by 1.7% because our estimate of 2023 claims are higher than expected compared to the previous year.
- -Increases in cost and utilization of services. The cost and utilization of medical and pharmacy services generally increase over time. Premium rates are increasing by **7.5**% because of this estimated trend in 2024.
- -Impact of the Federal Risk Adjustment Program. The federal risk adjustment program seeks to "level the playing field" among insurers. MVP has enrolled a population of lower-risk members, so it is required to pay into the program. MVP's small group payment has become more, increasing premium rates by approximately 1.4%.
- -Changes in the cost of doing business. As the cost of doing business rises over time, MVP must collect a portion of the premium revenue to protect consumers by ensuring its solvency. MVP aligned its administrative costs with the expected cost of the small group market. These changes are worth approximately 1.2% of a premium increase.
- -Impact of the Leap Year. MVP is increasing rates by approximately **0.3%** to account for 2024 being a leap year (and having an additional day).

# Conclusion

The proposed rates reflect an average rate adjustment to prior rates of 12.5%, ranging from 8.4% to 15.2%. There are 1,273 policyholders, 10,032 subscribers and 16,262 members impacted by this rate filing.

Vermonters can provide public comment on the proposed rate increases during the public comment period beginning on May 9<sup>th</sup>. For information about providing public comment, please visit https://ratereview.vermont.gov/public-comment



# State of Vermont

Actuarial Value Certification for 2024 Standard Plan Designs

March 30, 2023

Prepared by:

**Wakely Consulting Group, LLC** 

**Darren Johnson, ASA, MAAA**Consulting Actuary II

Alex Jarocki, ASA, MAAA Associate Actuary

Julie Peper, FSA, MAAA Principal



# **Table of Contents**

Executive Summary	1
Regulatory Background	2
CSR Loading	3
Chiropractic and Physical Therapy Copays	4
Limiting Out-of-Pocket Expenses for Insulin	4
Addition of Hearing Aid Coverage to EHBs	5
Actuarial Value Considerations	5
Methodology	9
Vermont-Specific Adjustment Model	9
Adjusted AV Calculations	11
Mental Health/Substance Abuse Office Limits with \$0 Cost Sharing	13
Insulin Out-of-Pocket Limit	14
Disclosures and Limitations	15
Appendix A: Actuarial Certification	18
Appendix B: Summary of Plan Design Changes from 2023 Designs	20
Appendix C: On and Off-Exchange Reflective Silver Standard Plan Designs	21
Appendix D: Comments Relative to Applicable ASOPs	22
Appendix E: Standard Plan Designs	26
Appendix F: Summary of Adjustments Considered and Final Adjusted AVs	30
Appendix G: Screen Shots and AV Development	31



# **Executive Summary**

The Affordable Care Act (ACA) requires that health care coverage provided by issuers to non-grandfathered individual and small groups must cover all Essential Health Benefits (EHBs) and have plan designs that have Actuarial Values (AVs) that fall under the Platinum (90% AV), Gold (80% AV), Silver (70% AV), or Bronze (60% AV) tiers.

The State of Vermont (State) is standardizing several plan designs that all issuers offering plans in the Exchange, Vermont Health Connect, must offer. Issuers must offer the standard plan designs in the individual and small group markets. In 2023, there was one Platinum, one Gold, two Silver, and three Bronze standard plan designs for Vermont Health Connect. There is a traditional deductible plan at each of the Platinum, Gold, and Silver metal levels, with two at the Bronze level, and a High Deductible Health Plan (HDHP) at each of the Silver and Bronze levels. The 2023 standard plan designs are all continuing in 2024.

For each of the Silver standard plan designs, the cost-sharing reduction plan designs are also standard. Cost sharing reduction (CSR) plan designs were developed at each of the 73% (Federal), 77% (Vermont specific), 87% (Federal), and 94% (Federal) AV levels. There is uncertainty on whether the Vermont-specific CSR plans will be offered in 2024.

The State contracted with Wakely Consulting Group, LLC, an HMA Company (Wakely), to assist in the development of the 2024 standard plan designs and to provide an actuarial certification of the actuarial values of the state's standard plan designs that do not fit within the parameters of the Federal calculator and require adjustment. This memo documents the approved 2024 standard plan designs as well as the process for developing the corresponding actuarial values. The actuarial certification is provided in Appendix A.

The 2024 Notice of Benefit and Payment Parameters (NBPP) and Federal Actuarial Value Calculator (AVC) Model are still in draft form. Should there be changes between the draft and final versions, the plan designs reflected here may require changes. In addition, the IRS limits for HDHPs have not been released yet for 2024. Additional changes may be required to the Silver and Bronze HDHPs, should the plan designs presented here not comply with federal or state requirements.

A detailed list of the changes from the 2023 standard plan designs is in Appendix B. At a high level the changes for each base standard plan are:

 Platinum – The medical deductible and medical Maximum Out of Pocket (MOOP) were increased.



- Gold The pharmacy Maximum Out of Pocket (MOOP) was increased. The specialist, physical therapist/chiropractor, urgent care, ambulance, generic drug and preferred brand drug copays were all increased.
- Silver Deductible The combined medical/pharmacy MOOP and pharmacy only MOOP were increased.
- Bronze Deductible with Pharmacy Limit The combined medical/pharmacy MOOP and pharmacy only MOOP were increased.
- Bronze Deductible without Pharmacy Limit The combined deductible and combined MOOP were increased.
- Silver HDHP The embedded individual combined medical/pharmacy MOOP was increased. In addition, all medical coinsurances were increased 5%.
- Bronze HDHP The combined medical/pharmacy MOOP and the embedded individual combined medical/pharmacy MOOP were increased.

In addition to the standard plans, the State of Vermont requests that issuers offer a Gold plan where the deductible and MOOP are set at the same amount. This means that once the deductible is met, the plan pays 100% of all services. Unlike the standard plans, it is not required that issuers offer this plan, but it is highly recommended. The issuer may determine the amount at which to set the deductible and MOOP, as long as they are equal and the resulting plan falls in the Gold tier. Since the amounts are to be determined by the issuers, these plans are not included within this memo.

# Regulatory Background

The ACA allows for a de minimis range around the target AVs for each metal level. The 2024 draft NBPP proposed a range of -2% to +2% for most plans. For example, any plan design that has an AV from 78% to 82% is considered a Gold plan. Consistent with the final 2023 NBPP, the 2024 draft NBPP proposed a smaller range for On-Exchange Silver plans of 0% to +2% (or an AV between 70% and 72%). Off-Exchange Silver plans would continue to be subject to the -2% to +2% range. The plan designs presented here comply with the proposed AV ranges. Bronze plan designs meeting certain criteria are eligible for an expanded range of +5% on the higher end, allowing an AV up to 65% compared to a high end at 62%. Plans that meet these criteria include HDHPs and plans that cover at least one major service, other than preventive, prior to the deductible. All three Bronze standard plans qualify for the expanded range.



The Center for Consumer Information and Insurance Oversight (CCIIO) released the draft 2024 Actuarial Value Calculator (AVC)¹ that issuers must use to determine the AV of a plan. The 2024 plan designs presented in this report are compliant with the draft 2024 AVC. However, should there be changes between the draft and final versions, changes may be required to be in compliance with the de minimis AV ranges. Changes to the plan designs will be dependent on the magnitude and direction of changes between the draft and final versions of the AVC.

The Annual Limitation on Cost Sharing was released in a separate guidance letter and has been finalized for 2024. The limitation will be \$9,450 for 2024, an increase of \$350 from the \$9,100 limit in 2023T

While CCIIO anticipates that most plans will be able to use the AVC without modification, some plan designs have features which are not supported by the AVC. In these instances, an actuary can either modify the inputs to most closely represent the plan design or an actuary can modify the results of the AVC to account for the features not supported by the AVC. An actuarial certification documenting the development of the AV for these designs is required.

The federal HDHP minimum deductible and MOOP limits are not yet released for 2024. The 2023 minimum deductible and MOOP were \$1,500 and \$7,500, respectively. The 2023 increases were significantly higher than the historical averages, where the deductible had increased \$50 every two to three years and the MOOP has increased around \$100 a year. We do not anticipate increases in the deductible for 2024 but should the minimum deductible differ when the limits are released, changes may be required to both HDHPs (and corresponding Silver CSR HDHPs). Since the HDHP MOOPs are below the 2023 maximum, it is not likely that any changes would be needed for any IRS changes to the 2024 MOOP limit.

# **CSR Loading**

As of 2020, Act No. 88 (Bill S.19) requires the premiums of the Silver on-Exchange plans to reflect the cost of funding for CSR subsidies, following the announcement that federal funding would cease. This resulted in a "CSR load" to these plans such that the Silver premiums are higher than they would have been without the CSR load. For individuals who are not eligible for premium subsidies (and are therefore not protected from the CSR load), issuers offer "reflective" off-Exchange Silver plans whose premiums have not been increased for the CSR load and have only a minor difference in plan design compared to their on-Exchange counterparts. These plans will continue in 2024.

\_

<sup>&</sup>lt;sup>1</sup> http://www.cms.gov/CCIIO/Resources/Regulations-and-guidance/index.html



The Off-Exchange "reflective" plans will have a \$5 copay or 5% coinsurance increase on ambulance services compared to the on-Exchange plans. These differentials apply to both standard and non-standard Silver plans. A comparison of the standard Silver on and off-Exchange plan designs are shown in Appendix C. As ambulance services are not explicitly included in the AVC and the differences in cost sharing are minimal, there is no difference in the calculation of the federal AV for these plans. Unless otherwise noted, in the Appendices the cost sharing for ambulance services represents the on-Exchange plan design.

In the event there is a Silver plan approved with 100% coinsurance, the off-Exchange "reflective" plan will have a \$25 deductible and MOOP increase compared to the on-Exchange plan. Unlike the ambulance cost sharing above, this difference will impact the AV. The issuer submitting such a plan will need to ensure that both the on and off-Exchange plan designs fit within the AV requirements. Since this is for non-standard plans only, these plans are not included within this memo.

# **Chiropractic and Physical Therapy Copays**

Act No. 7<sup>2</sup> requires that the copay for chiropractic and physical therapy services for Silver and Bronze metal level plans be between 125% and 150% of the copay applicable to services provided by a primary care provider (PCP). All of the Silver and Bronze Deductible plans are in compliance. HDHPs are exempt from the requirement since they are deductible and coinsurance based.

# **Limiting Out-of-Pocket Expenses for Insulin**

Bill S.296³, an act relating to limiting out-of-pocket expenses for prescription insulin drugs, was introduced and passed by the senate in 2020. This act limits a member's total out-of-pocket responsibility to \$100 per 30-day supply for insulin prescriptions, regardless of the amount, type, or number of insulin medications prescribed for the beneficiary. This change cannot be accommodated by the Federal AVC as it does not allow for separate cost-sharing inputs for insulin drugs. These prescriptions would be included with non-insulin prescriptions in the data underlying the AVC. Therefore, we reviewed utilization, costs, and member cost sharing for insulin prescriptions for issuers in Vermont Health Connect to determine the impact of this limit. We have not adjusted the AVs reflected here for this change. However, we did confirm that all plan designs will continue to be within the required de minimis range for 2024. Additional information on the methodology used to determine the impact on AV is included in the Methodology section below.

<sup>&</sup>lt;sup>2</sup> https://legislature.vermont.gov/Documents/2018.1/Docs/ACTS/ACT007/ACT007%20As%20Enacted.pdf

<sup>&</sup>lt;sup>3</sup> https://legislature.vermont.gov/bill/status/2020/S.296



# Addition of Hearing Aid Coverage to EHBs

The Vermont EHBs were expanded for the 2024 year to include one set of prescription hearing aids every three years as well as annual hearing exams.<sup>4</sup> The cost sharing for these benefits is to be standardized such that the hearing aids are covered with the same cost sharing as durable medical equipment (DME), and the annual exam is covered the same as a specialist office visit. This was determined to not impact actuarial values sufficiently to warrant an adjustment, but we recommend issuers add an explicit line for DME (which aligns with Outpatient Coinsurance) to assist in transparency.

## **Actuarial Value Considerations**

A summary of Vermont's standard plan designs is in Appendix E. Five of the standard plan designs (and the cost-sharing reduction plan designs) have features not supported by the AVC and thus an actuarial certification is required. The remaining standard plan designs have features that may warrant an AV adjustment but no explicit adjustment or actuarial certification has been done for these plans. In developing these standard plan designs and the resulting actuarial certification, Wakely also followed applicable Actuarial Standards of Practice (ASOP) as detailed in Appendix D and including:

- ASOP No. 23 Data Quality;
- ASOP No. 25 Credibility Procedures;
- ASOP No. 41 Actuarial Communications;
- ASOP No. 50 Determining Minimum Value and Actuarial Value under the Affordable Care Act; and
- ASOP No. 56 Modeling.

Both Silver plans and all three Bronze plans have design features that are both significant and not supported by the AVC. The Silver cost-sharing reduction plan designs have similar features. While most plans have some subtleties in their design that are not supported by the AVC, CCIIO has stated and regulations dictate that modifications should be made only for substantial differences. The five potential substantial differences that Wakely considered include:

<sup>&</sup>lt;sup>4</sup>https://governor.vermont.gov/press-release/federal-government-approves-expanded-coverage-vermont%E2%80%99s-essential-health-benefits



- Family deductible and MOOPs. There are two common types of applications for deductibles and MOOPs, commonly referred to in Vermont as stacked and aggregate. The data supporting the AVC is only at the member level, and thus most closely resembles the stacked application of deductibles and MOOPs, although the family stacked AV will be higher in most instances. Most HDHPs use the aggregate application of deductible and MOOPs, which can significantly lower the AV since a family of two would need to accumulate to a deductible that is twice that of a single contract. Note that if the family MOOP is more than the 2024 single limit of \$9,450, the MOOP must either be stacked or there must be an embedded individual MOOP of \$9,450. Wakely developed a model to account for aggregate family deductibles and has modified this model to account for stacked and embedded MOOPs for HDHPs. Thus, a specific adjustment has been made to the appropriate AVs for HDHPs.
- Vermont implemented a statute (H.559 Sec. 32. 8 V.S.A. § 4089) for prescription drug deductibles and MOOPs. The requirement mandates, in part, that the MOOP for prescription drug costs in any plan design shall not exceed the minimum deductible amount for HDHPs per Section 223(c)(2)(A)(i) of the Internal Revenue Code of 1986 (\$1,500 and \$3,000 for individual and family coverage in 2023, 2024 amounts not yet known). The requirement also states that for HDHPs the cost sharing benefit for prescription drugs must start after the minimum deductible amount for HDHPs (same \$1,500 and \$3,000 for individual and family coverage in 2023) is met, but the amount may be met with either medical or prescription drug claims. This means that for all HDHPs, for purposes of prescription drug coverage, the deductible is considered met when accumulated medical and drug claims reach \$1,500 for individual or \$3,000 for family, regardless of what the medical deductible amount is. Similarly, the MOOP for only drug claims (including amounts used to accumulate to the deductible) is \$1,500 or \$3,000, regardless of the amount of the overall MOOP which will include both drug and medical claims.

Since for an integrated deductible and MOOP, only one amount is able to be input in the AVC, the value of the lower drug deductible and MOOP cannot be modeled in the AVC. This statute has a significant impact on AV, particularly at the lower AV tiers where the difference between the medical and prescription drug deductible and MOOP is greater.

<sup>&</sup>lt;sup>5</sup> Stacked deductibles and MOOPs are typical in traditional deductible plans where the individual deductible and MOOP apply to each member of a contract and the family deductible and MOOP is used as a protection for contracts where multiple members have claims. For example, if the family MOOP is two times the individual MOOP but three members of a contract all would have reached their individual MOOP, it limits the family's liability to two times the individual MOOP.

Aggregate deductible and MOOPs are typical in HDHPs where all claims for all members of a non-single contract accumulate to the family deductible and MOOP. For two person or family contracts where only one member has significant claims, the member still must reach the higher deductible and MOOP amounts which makes the average member liability higher under an aggregate deductible.



Wakely has developed a model to account for Vermont's prescription drug regulation and thus, where appropriate, a specific adjustment has been made to the AVs using this model.

- The 2024 plan designs for all plans except the HDHPs and the Bronze Deductible plan with Pharmacy Limit include three free PCP or MH/SA office visits prior to application of member cost sharing. The AVC allows an input to begin primary care cost sharing after a set number of visits. However, the plan designs for 2024 include a combination of PCP and/or MH/SA office visits to ensure compliance with the requirements of the Mental Health Parity and Addiction Equity Act (MHPAEA). Since the AVC does not allow input for a number of free MH/SA visits, an adjustment to the output of the calculator is necessary. Therefore, we reviewed utilization of PCP and MH/SA office visits to determine the impact of the free visits. This review found that the impact was negligible for Platinum and Gold plans, as well as the CSR 87% and 95% plans, and therefore no adjustment was made for these plans. The impact to the Silver and Bronze without pharmacy limit plans and was worth up to 0.1%. Therefore, a specific adjustment has been made to the AVs for those plans.
- In the current market, most Vermont HDHPs waive the deductible for preventive prescription drugs. This is another plan feature not currently supported by the AVC. Wakely has not analyzed the exact portion of drugs this represents, and this may vary by issuer. The impact to AV would only apply to drug costs that would normally be incurred prior to the member reaching the deductible. Any costs after the deductible and MOOP are met would be similar to the AVC. It is possible that this design feature could have a significant impact on the AV. Based on high-level estimates, Wakely believes the impact to AV for this design feature is likely around 0.5%. Since Wakely did not quantify the exact adjustment of the preventive drug difference for HDHPs, Wakely did not make a specific adjustment but did make sure that any AVs developed for HDHPs were at least 0.5% below the high end of the de minimis range in order to account for this increased benefit. It is expected that the impact for these drugs would be highest for the Bronze plan where the deductible is highest and the impact would decrease as deductibles decrease (and AVs increase).

Given the issuers now have credible data on the portion of claims that are preventive prescription drugs, we requested that they review the appropriateness of this adjustment for the 2024 plan designs. Both issuers indicated that 0.5% was adequate and appropriate. Wakely is relying on the issuer's assessment and continues to make sure that any AVs developed for HDHPs are at least 0.5% below the high end of the de minimis range in order to account for this increased benefit.

 Bill S.296, an act relating to limiting out-of-pocket expenses for prescription insulin drugs. This act limits a member's total out-of-pocket responsibility to \$100 per 30-day supply for insulin prescriptions, regardless of the amount, type, or number of insulin medications prescribed for the beneficiary. This change cannot be accommodated by



the Federal AVC as it does not allow for separate cost sharing inputs for insulin drugs. These prescriptions would be included with non-insulin prescriptions in the data underlying the AVC. Therefore, we reviewed utilization, costs, and member cost sharing for insulin prescriptions for issuers in Vermont Health Connect to determine the impact of this limit. This review found that the impact was negligible for Platinum, Gold, and Silver plans and was worth up to 0.1% for Bronze plans.

Wakely did not make a specific adjustment for this requirement but did make sure that any AVs developed for Bronze plans were at least 0.1% below the high end of the de minimis range in order to account for this increased benefit. No adjustments were made to the de minimis range for the other metal levels. Additional information on the methodology used to determine the impact on AV is included in the Methodology section below.

There are other potential design features for which adjustments could be made. However, given the expectation that adjustments be made for only the most substantive deviations, Wakely does not believe additional adjustments are warranted. It is also important to note that the bucketing of claims and the methodology used to calculate the AVC are not always clearly defined. Thus, at times it is difficult to ascertain whether an adjustment is warranted and how that adjustment would be estimated.

As stated, Wakely made explicit adjustments to account for the stacked and aggregate family deductible/MOOP, the three free PCP and MH/SA office visits, and Vermont's prescription drug regulation. These adjustments are described in detail in the Methodology section. For the preventive prescription drug benefits, Wakely did not make an explicit adjustment but did allow cushion in the AV such that an increase of up to 0.5% would not result in the AV falling outside of the required range. For the insulin limitations on cost sharing, Wakely did not make an explicit adjustment but did allow cushion in the Bronze AVs such that an increase of up to an additional 0.1% would not result in the AV falling outside of the required range. The table below shows the acceptable range for each standard plan design after accounting for this cushion where an explicit adjustment was not made.

Table 1: Adjusted Acceptable Federal Actuarial Values

	Plan	Acceptable Range <sup>1</sup>	Final Adjusted AV
	Platinum	88.0%-92.0%	90.1%
	Gold	78.0%-82.0%	81.3%
Deductible Plans	Silver	70.0%-72.0%	70.7%
	Bronze (with drug limit)	58.0%-64.9%	62.0%
	Bronze (without drug limit)	58.0%-64.9%	64.8%
HDHD-	Silver - Embedded OOPM	70.0%-71.5%	71.3%
HDHPs	Bronze - Embedded OOPM	58.0%-64.4%	63.0%
	250-300% FPL (73% AV)	73.0%-74.0%	73.7%



Cost Sharing Reduction Plan Designs - Deductible Plans	200-250% FPL (77% AV)	77.0%-78.0%	77.3%
	150-200% FPL (87% AV)	87.0%-88.0%	88.0%
	133-150% FPL (94% AV)	94.0%-95.0%	94.9%
Cost Sharing Reduction Plan Designs - HDHPs	250-300% FPL (73% AV) 200-250% FPL (77% AV) 150-200% FPL (87% AV) 133-150% FPL (94% AV)	73.0%-73.5% 77.0%-77.5% 87.0%-87.5% 94.0%-94.5%	73.5% 77.5% 87.5% 94.3%

<sup>1</sup> Based on revised de minimis ranges in the draft 2024 NBPP

The table in Appendix F shows all plan designs for which adjustments were made, the adjustments considered, the original AV from the AVC, and the final adjusted AV.

# Methodology

Since several of the standard plan designs have features not supported by the AVC, Wakely developed a model to capture the impact of these features on the AV. It was anticipated that the AVC would not accommodate all of the Vermont plan design features.

If a plan has substantive differences from what the AVC allows, there are two allowed approaches defined in the federal regulations. The first allows the actuary to adjust the inputs of the plan design to "fit" it into the AVC. The second allows the actuary to put in as many of the design features as possible into the AVC and then adjust the resulting AV to account for the unique design features. Wakely determined the second approach was most appropriate for the Vermont plan design differences. Thus for the plan designs where adjustments were made, Wakely first input as much of the plan design as possible into the AVC and then modified the resulting AV to account for the unique features.

The following discusses the model that Wakely developed and the process used to adjust the actuarial values from the AVC.

# **Vermont-Specific Adjustment Model**

Anticipating the need to quantify some of Vermont's unique plan design features, Wakely developed a model that would account for both aggregate deductibles and MOOPs as well as quantify the impact of Vermont's prescription drug regulation. This model is updated every few years to capture recent Vermont-specific data. The current model was updated for the 2024 plan designs and includes Vermont-specific ACA data incurred in 2019. While 2020 data was available at the time of the update, given the COVID impact on claims for that year, it was decided that 2019 data would be a better dataset to use.

In developing the model, Wakely was provided with membership and medical and pharmacy claims data extracts from the Vermont Healthcare Claims Uniform Reporting and Evaluation



System (VHCURES). Filters were then applied to the data to target the most appropriate population for the model and reduce the number of records included. The data used included:

- Small group and individual ACA markets
- Allowed medical and prescription drug data that was incurred in 2019
- Product types HMO (non-Medicare risk), PPO, POS and EPO
- Excluded claims marked as denied, out-of-state, and duplicates

The methodology developed for the model does not use the traditional approach of continuance tables. When determining the paid claims and resulting actuarial value of the plan designs where the prescription drug regulation is a factor, the order in which the claims occur is important. Continuance tables fail to recognize the impact of the order of the claims on actuarial values. Thus, the model re-prices the claims based on the inputs provided in the model rather than rely on continuance tables.

The model allows a user to enter the following:

- Medical and Prescription drug deductible amounts for both individual and family contracts. These amounts can differ but the model assumes the amounts are always integrated, or that both medical and drug claims will accumulate to both deductibles, even if different amounts.
- Medical and prescription drug maximum out of pocket amounts for both individual and family contracts. These amounts can differ and the model allows for different treatment of the MOOPs as noted below.
- Medical and prescription drug coinsurance amounts. If the plan design includes copays, an effective coinsurance needs to be input.
- The structure of the deductibles and MOOPs. As can be seen in the table below, the model can distinguish between aggregate and stacked deductibles and MOOPs. It also allows for different accumulations of claims to the medical and prescription drug MOOPs. There are six structural selections available in the model, described in the table below. Option 5 is most closely aligned to the federal AVC. Option 6 represents the design of the Vermont HDHPs.



**Table 2: Model Structures** 

	Costs that Accumulate						
Options	Deductible	Maximum Out-of	-Pocket (MOOP)	Deductible / MOOP Type			
		Medical	Rx				
1	Medical & Rx	Medical & Rx	Rx Only	Aggregate			
2	Medical & Rx	Medical & Rx	Rx Only	Stacked			
3	Medical & Rx	Medical Only	Rx Only	Aggregate			
4	Medical & Rx	Medical Only	Rx Only	Stacked			
5	Medical & Rx	Medical & Rx	Medical & Rx	Stacked			
6	Medical & Rx	Medical & Rx	Rx Only	Aggregate Deductible /Aggregate MOOP with Embedded Ind MOOP (can also be used for Stacked MOOP)			

# **Adjusted AV Calculations**

Using the federal AV calculator and the model as outlined above, the following methodology was used to develop the adjusted AV calculations for the HDHPs:

- 1. The plan designs were entered into the AVC ignoring the separate prescription drug deductible and MOOP thresholds. The resulting AV is the unadjusted value, which does not account for the prescription drug regulations or the aggregate family deductible and MOOP levels.
- 2. The model was used to determine the revised AV.
- 3. The same plan design input into the AVC was input into the model. The model only allows for coinsurance. Since the HDHP designs include copays and/or different coinsurance amounts, an effective coinsurance was developed for each plan design. The effective coinsurance amounts were developed separately for medical and prescription drug services using the allowed weights and average cost per service from the federal AVC continuance tables for the relevant metal tier.
- 4. The model was normalized to the AVC for each plan design. This means the same plan design, ignoring the prescription drug thresholds and assuming a stacked family deductible and MOOP, was input into the model and the underlying data was adjusted to arrive at the same AV as the AVC. This was done to ensure the same starting AV in both models and to try to mirror the induced utilization in the AVC. The normalization factors were reviewed for reasonability and deemed reasonable given they are accounting for trend, regional differences in cost and utilization and induced utilization.



- 5. The plan design in the model was adjusted to lower the prescription drug deductible and MOOP inputs (if applicable) to the appropriate plan design amounts and also to adjust the prescription drug MOOP to only consider prescription drug claims (the medical MOOP amount continues to use both medical and prescription drug claims). The application of deductible and MOOP was also changed to use an aggregate family deductible and family MOOP with an embedded individual MOOP equal to \$9,450.
- The resulting AV from the model is used as the final AV for tier placement.

The model was intended only for HDHPs where medical and drug claims both accumulate to the deductible. The Bronze plan with the pharmacy limit<sup>6</sup> and Silver deductible plans (and associated CSR plans) need to be adjusted to account for the lower prescription drug MOOP, but the deductible plan has separate medical and drug deductibles. Thus, the model was used but with a slight variation in methodology. The following highlight the differences in methodology used only for the Bronze and Silver Deductible plans.

- 1. Same as for HDHPs, as much of the plan design as possible was entered into the AVC. This is the unadjusted AV. The Bronze and Silver Deductible plans then need to be adjusted for the lower and separate prescription drug MOOP.
- 2. The model was used to develop the AV adjustments in a slightly different process than for the HDHPs.
  - a. Instead of normalizing the model to the AVC, the normalization factor for the Bronze or Silver HDHP was used.
  - b. The model cannot accommodate plan designs where both medical and drug claims do not accumulate to the deductible. Thus, the same plan design was entered into the model as in the AVC but the model selection indicated that both medical and drug claims accumulated to the deductible amounts.
  - c. The model was then re-run with the lower drug MOOP and to adjust the prescription drug MOOP to only consider prescription drug claims (the medical MOOP amount continues to use both medical and prescription drug claims). The model continued to use a stacked application for deductible and MOOP since it is a traditional deductible plan.
- 3. The final AV is the ratio of the AV from 2c and 2b applied to the AV from the AVC in 1.

\_

<sup>&</sup>lt;sup>6</sup> Only the Bronze plan with the pharmacy limit needs to be adjusted. The Bronze plan without the pharmacy limit is not subject to the lower prescription drug MOOP and as such does not require an explicit adjustment to the AVC results.



# Mental Health/Substance Abuse Office Limits with \$0 Cost Sharing

The 2024 plan designs for all plans except the Bronze Deductible plan with Pharmacy Limit and HDHPs include three free PCP or MH/SA office visits prior to application of member cost sharing. The AVC allows an input to begin primary care cost sharing after a set number of visits. However, the plan designs for 2024 include a combination of PCP and/or MH/SA office visits to ensure compliance with the requirements of the Mental Health Parity and Addiction Equity Act (MHPAEA). Since the AVC does not allow input for a number of free MH/SA visits, an adjustment to the output of the calculator is necessary. The table below reflects the adjustment made to each of the standard plan designs.

Table 3: Estimated Impact of 3 Free PCP and/or MH/SA Visits

Metal	Increase to AV
Silver Deductible	1.001
Bronze Deductible w/o Pharmacy Limit	1.001
Silver Deductible CSR – 73%	1.001
Silver Deductible CSR – 77%	1.001

The impact was also calculated for the Platinum, Gold, 87% Silver CSR, and 94% Silver CSR plans but given the lower copays, the impact the determined to be negligible. The following methodology was used to develop the impacts.

- Wakely developed a continuance table based on the number of office visits a member incurred in the year. Wakely utilized similar VHCURES data as described above, except the data reflects claims incurred in the 2018 calendar year. The same filters were applied as described above and the summary reflects the experience of almost 900,000 member months.
- 2. Wakely identified PCP and MH/SA office visits based primarily on a list of CPT codes. It was assumed that only the PCP and MH/SA office visit payments would be subject to the first 3 free visits. Specifically, we assumed that for any other services that may have the same cost sharing as PCP and MH/SA office visits, the reduced cost sharing would not apply (i.e., no changes for cost sharing for these services). Consistent with the AV Calculator, we also did not include other services that may happen in conjunction with an office visit (e.g. lab work) in our AV adjustment. It is our understanding that only the office visit copay would be waved and any copays for additional services incurred at the same time may still apply (e.g. copay stacking) based on the carrier's adjudication practices.



- 3. Two separate continuance tables were developed. The first reflects only claims identified as a PCP office visit and is consistent with the methodology of the AVC. The second is a combination of both PCP and MH/SA visits.
- 4. Based on the continuance tables, the cost share and paid claim amounts were calculated, assuming no member cost sharing applies for the first 3 visits. The difference between the paid amounts calculated utilizing the PCP only continuance table and PCP and MH/SA combined tables reflects the adjustment made to the AVC outputs.
- 5. Two AVs were calculated. The first was based on the unadjusted high level allowed and paid costs of the VHCURES data. This was done in total including both medical and pharmacy claims. The second, adjusted AV, added the additional paid costs from step 2 to the high level total paid claim amounts. The ratio of the two AVs is the increase applied to the federal AV. This was done separately for each standard plan design.

Appendix G includes screen shots from the AVC and the model for each plan design with an adjusted actuarial value. Also included is a summary of the AVs and in the instance of the Bronze and Silver Deductible plans, a calculation of the adjustment.

#### **Insulin Out-of-Pocket Limit**

As mentioned above, a bill has been introduced that would limit a member's total out-of-pocket responsibility to \$100 per 30-day supply for insulin prescriptions. The AVs reflected here have not been adjusted for this requirement. However, we did review the impact of the requirement and determined that all plan designs presented here would continue to meet the de minimis requirements.

Since insulin drugs only represent a portion of the claims in a given drug tier and only one input can be made in the AVC for each drug tier, the value of the cost sharing limit cannot be modeled in the AVC. This statute has a larger impact on AV at the lower AV tiers where the drug deductibles are higher. The estimated impact by metal tier is shown in the table below.

Table 4: Estimated Impact of Insulin Out-of-Pocket Limit

Metal	Increase to AV
Bronze	0.1%
Silver	0.0%
Gold	0.0%
Platinum	0.0%



The following methodology was used to develop the impacts:

- Both carriers, BCBS VT and MVP, provided claim-level data for insulin prescriptions based on their individual and small group experience in Vermont in 2019 and 2020. The data included metal tier, allowed and paid costs, days' supply, and member cost sharing. Each carrier also provided high-level market information for 2019 and 2020, including metal tier, member months, and total allowed and paid costs for medical and pharmacy.
- 2. Based on the claim-level data, the cost share and paid claim amounts were recalculated, assuming a limit of \$100 per prescription for a 30-day supply. The difference between the cost sharing in the experience data and the new cost sharing incorporating the limit was added to the paid claim costs.
- 3. Two AVs were calculated. The first based on the unadjusted high level allowed and paid costs. This was done in total including both medical and pharmacy claims. The second, adjusted AV, added the additional paid costs from step 2 to the high level total paid claim amounts. The difference in AV between these two is the increase to AV. This was done separately for each metal level.

Based on this analysis, the impact on all metal levels except Bronze is negligible. For the Bronze plans, all plan designs presented here are more than 0.1% below the high end of the de minimis range, therefore, will continue to be within the range.

# **Disclosures and Limitations**

**Responsible Actuary**. Julie Peper and Darren Johnson are the actuaries responsible for this communication. Julie is a Member of the American Academy of Actuaries and a Fellow of the Society of Actuaries. Darren is a Members of the American Academy of Actuaries and a Fellow of the Society of Actuaries. Both meet the Qualification Standards of the American Academy of Actuaries to issue this report. Alex Jarocki also contributed significantly to this report.

**Intended Users.** This information has been prepared for the sole use of the State of Vermont and issuers within that state that will be submitting standard plan designs. Distribution to such parties should be made in its entirety. This report cannot be distributed to or relied on by any third party without the prior written permission of Wakely.

**Risks and Uncertainties.** The assumptions and resulting estimates included in this report and produced by the model are inherently uncertain. Users of the results should be qualified to use it and understand the results and the inherent uncertainty. Actual results may vary, potentially materially, from our estimates. Wakely does not warrant or guarantee that actual experience will tie to the AV estimated for the placement of plan designs into tiers. The developed actuarial values are for the purposes of classifying plan designs of similar value and do not represent the expected



actuarial value of a plan or pricing AV used to determine premium rates. Actual AVs will vary based on a plan's specific population, utilization, unit cost, and other variables.

Conflict of Interest. Wakely provides actuarial services to a variety of clients throughout the health industry. Our clients include commercial, Medicare, and Medicaid health plans, the federal government and state governments, medical providers, and other entities that operate in the domestic and international health insurance markets. Wakely has implemented various internal practices to reduce or eliminate conflict of interest risk in serving our various clients. Except as noted here, the responsible actuaries are financially independent and free from conflict concerning all matters related to performing the actuarial services underlying this analysis. In addition, Wakely is organizationally and financially independent to the state of Vermont.

**Data and Reliance.** We have relied on others for data and information used in the actuarial value adjustments. We have reviewed the data for reasonableness, but have not performed any independent audit or otherwise verified the accuracy of the data/information. If the underlying information is incomplete or inaccurate, our estimates may be impacted, potentially significantly. Below is a list of data and assumptions provided by others and assumptions required by law.

- The draft 2024 Federal AVC Model was relied on for the original AV. While reasonability tests have shown there are some assumptions and methodologies that are not consistent with expectations, the AVC was developed for plan classification and not pricing. Thus, the model is being used as such and we make no warranties for the accuracy of the AVs that result from the AVC.
- VHCURES data supplied by the state was used in the development of the HDHP model.
- Adjustment to the high-end of the de minimis AV range for HDHPs to account for prescription drugs for which the deductible is waived. This was reviewed by both issuers, BCBS VT and MVP, based on their internal experience and claims data.
- Insulin prescription claim experience. This was provided by both issuers, BCBS VT and MVP, based on their internal experience and claims data.

**Subsequent Events.** There are no known relevant events subsequent to the date of information received that would impact the results of this report, other than those discussed in the report and below.

• The federal HDHP minimum deductible and Maximum Out of Pocket (MOOP) limits are not yet released for 2024. The 2023 minimum deductible and MOOP are \$1,500 and \$7,500, respectively. The 2023 increases were significantly higher than the historical averages, where the deductible had increased \$50 every two to three years and the MOOP has increased around \$100 a year. We do not anticipate increases to the minimum deductible in 2024, but should the minimum deductible differ when the limits



are released, changes may be required to both HDHPs (and corresponding Silver CSR HDHPs).

- The 2024 Notice of Benefits and Payment Parameters (NBPP) is still in draft form. The
  plan designs presented are compliant with the 2024 draft NBPP and may need to
  change if there are differences between the draft and final versions.
- The 2024 Federal AVC Model is also still in draft form. The plan designs presented are compliant with the 2024 draft Federal AVC and may need to change if there are changes to the final model from the draft version.
- The Vermont Legislature is considering not offering the 77% AV CSR Variant plans in 2024.
- Other changes to regulations passed subsequent to this report.

**Contents of Actuarial Report.** This document and the supporting exhibits constitute the entirety of actuarial report and supersede any previous communications on the project.

**Deviations from ASOPS.** Wakely completed the analysis using sound actuarial practice. To the best of my knowledge, the report and methods used in the analysis are in compliance with the appropriate Actuarial Standards of Practice (ASOP) with no known deviations. A summary of ASOP compliance is listed in Exhibit D.

Exhibit A contains the formal actuarial certification. If you have any questions regarding this letter or the certification, please contact us.



# Appendix A: Actuarial Certification

# Actuarial Certification State of Vermont Actuarial Value of Standard Plan Designs Effective January 1, 2024

I, Darren Johnson, am associated with the firm of Wakely Consulting Group, LLC (Wakely), an HMA company, am an Associate of the Society of Actuaries and a member of the American Academy of Actuaries and meet its Qualification Standards for Statements of Actuarial Opinion. Wakely was retained by the State of Vermont to provide a certification of the actuarial value of the state's standard plan designs that are effective January 1, 2024 on Vermont Health Connect. This certification may not be appropriate for other purposes.

To the best of my information, knowledge and belief, the actuarial values provided with this certification are considered actuarially sound for purposes of § 156.135(b), according to the following criteria:

- The 2024 federal Actuarial Value Calculator was used to determine the AV for the plan provisions that fit within the calculator parameters;
- Appropriate adjustments were calculated, to the AV identified by the calculator, for plan design features that deviate substantially from the parameters of the AV calculator;
- The actuarial values have been developed in accordance with generally accepted actuarial principles and practices; and
- The actuarial values meet the requirements of § 156.135(b).

The assumptions and methodology used to develop the actuarial values have been documented in my correspondence with the State of Vermont. The actuarial values associated with this certification are for standard plan designs (Silver HDHP, Bronze HDHP, Bronze Deductible with Pharmacy Limit, Bronze Deductible without Pharmacy Limit, Silver Deductible, Silver HDHP CSR 73%, Silver HDHP CSR 77%, Silver HDHP CSR 87%, Silver HDHP CSR 94%, Silver Deductible CSR 73%, Silver Deductible CSR 77%, Silver Deductible CSR 87%, and Silver Deductible CSR 94%) that will be effective as of January 1, 2024 for individual and group coverage sold on Vermont Health Connect.

The developed actuarial values are for the purposes of classifying plan designs of similar value and do not represent the expected actuarial value of a plan. Actual AVs will vary based on a plan's specific population, utilization, unit cost and other variables.



In developing the actuarial values, I have relied upon the federal Actuarial Value calculator and data from the Vermont Healthcare Claims Uniform Reporting and Evaluation System (VHCURES). I did not audit the data provided; however, I did review the data for reasonableness and consistency.

Actuarial methods, considerations, and analyses used in forming my opinion conform to the appropriate Standards of Practice as promulgated from time-to-time by the Actuarial Standards Board, whose standards form the basis of this Statement of Opinion.

\_\_\_\_\_

Darren Johnson

Darren Johnson, FSA, MAAA March 30, 2023



# Appendix B: Summary of Plan Design Changes from 2023 Designs

	Deductible Plans				
Plan	Platinum	Gold			
	Increase medical deductible from \$425 to \$450	Increase pharmacy MOOP from \$1,400 to \$1,500			
	Increase pharmacy OOPM from \$1,400 to	Increase specialist office visit copay from \$50 to			
Changes	\$1,500	\$55			
		Increase PT/chiro copays from \$30 to \$35			
		Increase urgent care copay from \$60 to \$65			
		Increase ambulance copay from \$70 to \$75			
		Increase generic Rx copay from \$12 to \$15			
		Increase preferred brand Rx copay from \$55 to			
		\$60			

	Deductible Plans			
Plan	Silver	Bronze w/ Rx Limit		
Changes	Increase combined OOPM from \$9,100 to \$9,300	Increase medical OOPM from \$9,100 to \$9,450		
		Increase pharmacy MOOP from \$1,400 to \$1,500		
		Increase generic Rx copay from \$15 to \$20		

	Deductible Plans
Plan	Bronze w/o Rx Limit
	Increase medical deductible from \$9,000 to \$9,400
Changes	Increase combined OOPM from \$9,000 to \$9,400

	HDHPs				
Plan	Silver - Embedded MOOP	Bronze - Embedded MOOP			
	•	Increase combined OOPM from \$7,100 to \$7,200			
Changes	·	Increase embedded single OOPM from \$9,100 to \$9,450			
	Increase embedded single OOPM from \$9,100 to \$9,450				



# Appendix C: On and Off-Exchange Reflective Silver Standard Plan Designs

	2024 Plan De Deductik	signs - Silver ble Plans	2024 Plan Designs - Silver HDHP Plans		
Deductible/OOP	On-	Off-	On Evolungo	Off Evolution	
Max	Exchange	Exchange	On-Exchange	Off- Exchange	
Type of Plan	Deductible	Deductible	HSA Q/HDHP	HSA Q/HDHP	
Medical Ded	\$4,000	\$4,000	\$2,100	\$2,100	
Rx Ded	\$500	\$500	\$1,500	\$1,500	
Integrated Ded	No	No	Yes	Yes	
Medical MOOP	\$9,300	\$9,300	\$7,050	\$7,050	
Rx MOOP	\$1,500	\$1,500	\$1,500	\$1,500	
Later and a LMOOD	Rx -No,	Rx -No,			
Integrated MOOP	Medical - Yes	Medical - Yes	Yes	Yes	
Formily Dodynatible	Charlend Ov		Aggregate with Combined	Aggregate with Combined	
Family Deductible	Stacked, 2x	Stacked, 2x	Medical/Rx embedded	Medical/Rx embedded	
/ OOP	Individual	Individual	\$9,450 Single OOPM; 2x	\$9,450 Single OOPM; 2x	
Mar Paral			Individual	Individual	
Medical	Prev, OV,	Prev, OV,	Duningstine	Danisantissa	
Deductible waived for:	UC, Amb	UC, Amb	Preventive	Preventive	
Drug Deductible	Generic	Generic	Wellness scripts	Wellness scripts	
waived for:	scripts	scripts		т	
Service	Copay /	Copay /	Copay / Coinsurance	Copay / Coinsurance	
Category	Coinsurance	Coinsurance			
Inpatient	50%	50%	35%	35%	
Outpatient	50%	50%	35%	35%	
ER	\$500	\$500	35%	35%	
Radiology (MRI, CT, PET)	50%	50%	35%	35%	
Preventive	\$0	\$0	0%	0%	
DOD 04" 1" "	First 3 Visits	First 3 Visits	450/	450/	
PCP Office Visit	\$0, Then \$40	\$0, Then \$40	15%	15%	
MH/SA Office	First 3 Visits	First 3 Visits	15%	15%	
Visit	\$0, Then \$40	\$0, Then \$40	1376	1576	
Specialist Office Visit	\$90	\$90	35%	35%	
Chiropractic	\$50	\$50	35%	35%	
Physical Therapy	\$50	\$50	35%	35%	
Urgent Care	\$100	\$100	35%	35%	
Ambulance	\$100	\$10 <b>5</b>	35%	40%	
Rx Generic	\$20	\$20	\$10	\$10	
Rx Preferred					
Brand	\$70	\$70	\$40	\$40	
Rx Non-Preferred	50%	50%	50%	50%	
Brand					
Rx Specialty	50%	50%	50%	50%	
Actuarial Value					
2024 Federal	<b>-0</b> -c'	<b></b>	<b>2</b> 4 207	<b>-</b> 4 -50	
AVC, Adjusted if Necessary	70.7%	70.7%	71.3%	71.3%	



# Appendix D: Comments Relative to Applicable ASOPs

This appendix includes comments relative to the following applicable Actuarial Standards of Practice (ASOP).

- ASOP No. 23, Data Quality;
- ASOP No. 25, Credibility Procedures;
- ASOP No. 41, Actuarial Communications; and
- ASOP No. 50 Determining Minimum Value and Actuarial Value under the Affordable Care Act.
- ASOP No. 56 Modeling

#### **ASOP 23: DATA QUALITY**

- <u>3.1 Overview</u> VHCURES data was used as the basis for the HDHP model and Vermont-specific insulin prescription data was used as the basis for the insulin limit impact. This data source was deemed reasonable for the analysis discussed in the management report.
- <u>3.2 Selection of Data</u> The data was considered reasonable for our analysis subject to the following considerations
  - a. The data sources contained all material data elements.
  - b. The following considerations were reviewed as part of our analysis:
    - 1. Data was appropriate and sufficiently current.
    - 2. Data was reasonable and comprehensive of the necessary data elements.
    - 3. There were no known, material limitations of the data.
    - 4. No alternative data sets were reasonably available. The reliability of the data underlying our analysis did not require support from alternative data sets.
    - 5. Alternative data sets were not deemed necessary to complete the analysis.
    - 6. Sampling methods were not required.



- 3.3 Reliance on Data Supplied by Others Reliance is discussed in the management report to which this appendix is attached.
- 3.4 Reliance on Other Information Relevant to the Use of Data We relied on information contained in the report. We did not detect any material errors in the data provided and relied upon the data as part of our analysis.
- <u>3.5 Review of Data</u> We reviewed the data. Data definitions were included as part of the VHCURES data. Ultimately the data was reasonable with the adjustments discussed in our management report.
- 3.6 Limitation of the Actuary's Responsibility We did not audit the data.
- <u>3.7 Use of Data</u>– Use and adjustments to the data are discussed in this management report. In addition:
- a. We deem that the data are of sufficient quality to perform the analysis;
- b. The data did not require enhancement before the analysis could be performed
- c. The data was reasonable for the analysis and did not require adjustment beyond that discussed in the management report;
- d. We did not detect any material defects in any data source;
- e. The data were adequate to perform our analysis.

#### **ASOP 25: CREDIBILITY PROCEDURES**

The HDHP model uses data as its starting point. The experience used is fully credible and therefore no credibility blending or adjustments were necessary.

#### **ASOP 41: ACTUARIAL COMMUNICATIONS**

This report and the actuarial memorandum submitted are consistent with the guidance in ASOP 41.

#### 3.1 General Requirements for Actuarial Communications

3.1.1 Principal and Scope of Engagement – These results were developed to comply with § 156.135(b) and should not be used for any other purpose. The distribution of this report to other users is limited to the State of Vermont.



- <u>3.1.2 Form and Content</u> The State of Vermont was the principal for this engagement and the scope of the engagement included developing and certifying the actuarial values for the standard plan designs as discussed in the management report.
- <u>3.1.3 Timing of Communication</u> This report is provided in conjunction with the actuarial certification of the submitted actuarial values.
- <u>3.1.4 Identification of Responsible Actuary</u> The responsible actuary is identified in the attestation and this management report.
- <u>3.2 Actuarial Report</u> This management report is an Actuarial Report as defined in this ASOP. Correspondence between Wakely and the State of Vermont as part of this engagement should also be considered part of the Actuarial Report.
- <u>3.3 Specific Circumstances</u> No constraints apply beyond any discussed in the attachment management report.
- <u>3.4 Disclosures Within an Actuarial Report</u> all relevant disclosures have been made in the management report. Consistent with this ASOP, we make specific mention to the following items here:
  - <u>3.4.1 Uncertainty or Risk</u> Uncertainty is discussed in the management report.
  - <u>3.4.2 Conflict of Interest</u> Wakely is financially, organizationally, and otherwise independent from the State of Vermont and any reliant parties.
  - <u>3.4.3 Reliance on Other Sources for Data and Other Information</u> Reliance regarding data and assumptions are discussed in this management report.
  - <u>3.4.4 Responsibility for Assumptions and Methods</u> Assumptions and methods are discussed in the management report and the parties associated with the assumptions and methods have been delineated. Therefore, pursuant to this ASOP, no additional disclosure is necessary.
  - <u>3.4.5 Information Date of Report</u> -The management report lists the applicable dates for the analysis and correspondence.
  - <u>3.4.6 Subsequent Events</u> Subsequent events are listed in the Limitations and Disclosures section.
- <u>3.5 Explanation of Material Differences</u> Wakely has issued no other report regarding the development of these actuarial values. No comparison to prior results is necessary.
- <u>3.6 Oral Communications</u> No oral communication is considered part of this actuarial report. Any material assumptions or methods discussed in oral communications have been documented in written form as well.
- 3.7 Responsibility to Other Users Intended users of this report have been specifically noted in the document.



# ASOP 50: DETERMINING MINIMUM VALUE AND ACTUARIAL VALUE UNDER THE AFFORDABLE CARE ACT

- 3.1 Use of AVC or MVC The federal AVC was used.
- 3.2 Exceptions to the AVC The federal AV was determined by making adjustments to the results of the federal AVC based on provisions that could not be appropriate modeled in the AVC.
- 3.3 Exceptions to the MVC Not applicable.
- <u>3.4 Evaluating Non-Standard Plan Designs</u> The HDHP model was normalized to the federal AVC.
- <u>3.5 Reasonableness of Assumptions for Non-Standard Plan Designs</u> The assumptions used to modify the federal AVs were reviewed for reasonability.
- 3.6 Unreasonable Results Not applicable.
- <u>3.7 Documentation</u> See ASOP 41 documentation above.



# Appendix E: Standard Plan Designs

**Deductible Plan Designs** 

Deductible/OOP Max	Platinum	Gold	Silver	Bronze w/ Rx Limit	Bronze w/o Rx Limit
Type of Plan	Deductible	Deductible	Deductible	Deductible	Deductible
Medical Ded	\$450	\$1,400	\$4,000	\$6,450	\$9,400
Rx Ded	\$0	\$200	\$500	\$1,100	N/A
Integrated Ded	No	No	No	No	Yes
Medical MOOP	\$1,500	\$5,600	\$9,300	\$9,450	\$9,400
Rx MOOP	\$1,500	\$1,500	\$1,500	\$1,500	N/A
Integrated MOOP	No	No	Rx -No, Medical - Yes	Rx -No, Medical - Yes	Yes
Family Deductible / OOP	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual
Medical Deductible waived for:	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Preventive	Preventive, OV
Drug Deductible waived for:	N/A	Generic scripts	Generic scripts	Generic Scripts	Generic Scripts
Service Category	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance
Inpatient	10%	30%	50%	50%	0%
Outpatient	10%	30%	50%	50%	0%
ER	\$100	\$150	\$500	50%	0%
Radiology (MRI, CT, PET)	10%	30%	50%	50%	0%
Preventive	\$0	\$0	\$0	\$0	0%
PCP Office Visit	First 3 Visits \$0, Then \$15	First 3 Visits \$0, Then \$20	First 3 Visits \$0, Then \$40	\$35	First 3 Visits \$0, Then \$40
MH/SA Office Visit	First 3 Visits \$0, Then \$15	First 3 Visits \$0, Then \$20	First 3 Visits \$0, Then \$40	\$35	First 3 Visits \$0, Then \$40
Specialist Office Visit	\$40	\$55	\$90	\$90	\$100
Chiropractic	\$20	\$35	\$50	\$45	\$50
Physical Therapy	\$20	\$35	\$50	\$45	\$50
Urgent Care	\$50	\$65	\$100	\$100	0%
Ambulance	\$60	\$75	\$100	\$100	0%
Rx Generic	\$10	\$15	\$20	\$20	\$30
Rx Preferred Brand	\$50	\$60	\$70	\$85	0%
Rx Non-Preferred Brand	50%	50%	50%	60%	0%
Rx Specialty	50%	50%	50%	60%	0%
Actuarial Value					
2024 Federal AVC, Adjusted if Necessary	90.1%	81.3%	70.7%	62.0%	64.8%



**Deductible Plan Designs – Cost Sharing Reduction Plans** 

		esigns – Cost Sna 250-300% FPL	200-250% FPL	150-200% FPL	133-150% FPL
Deductible/OOP Max	70% AV Silver	(73% AV)	(77% AV)	(87% AV)	(94% AV)
Type of Plan	Deductible	Deductible	Deductible	Deductible	Deductible
Medical Ded	\$4,000	\$3,000	\$2,900	\$1,250	\$250
Rx Ded	\$500	\$450	\$350	\$250	\$0
Integrated Ded	No	No	No	No	No
Medical MOOP	\$9,300	\$6,700	\$6,300	\$2,450	\$1,000
Rx MOOP	\$1,500	\$1,300	\$1,200	\$450	\$200
Integrated MOOP	Rx -No, Medical - Yes	Rx -No, Medical - Yes	Rx -No, Medical - Yes	Rx -No, Medical - Yes	Rx -No, Medical - Yes
Family Deductible / OOP	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual	Stacked, 2x Individual
Medical Deductible waived for:	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb	Prev, OV, UC, Amb
Drug Deductible waived for:	Generic scripts	Generic scripts	Generic scripts	Generic scripts	N/A
Service Category	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance
Inpatient	50%	50%	50%	40%	10%
Outpatient	50%	50%	50%	40%	10%
ER	\$500	\$500	\$350	\$250	\$75
Radiology (MRI, CT, PET)	50%	50%	50%	40%	10%
Preventive	\$0	\$0	\$0	\$0	\$0
PCP Office Visit	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$30	First 3 Visits \$0, Then \$10	First 3 Visits \$0, Then \$5
MH/SA Office Visit	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$40	First 3 Visits \$0, Then \$30	First 3 Visits \$0, Then \$10	First 3 Visits \$0, Then \$5
Specialist Office Visit	\$90	\$90	\$60	\$30	\$15
Chiropractic	\$50	\$50	\$35	\$12	\$6
Physical Therapy	\$50	\$50	\$35	\$12	\$6
Urgent Care	\$100	\$100	\$70	\$40	\$25
Ambulance	\$100	\$100	\$100	\$100	\$50
Rx Generic	\$20	\$20	\$15	\$10	\$5
Rx Preferred Brand	\$70	\$70	\$60	\$50	\$20
Rx Non-Preferred Brand	50%	50%	50%	50%	30%
Rx Specialty	50%	50%	50%	50%	30%
Actuarial Value					
2024 Federal AVC, Adjusted if Necessary	70.7%	73.7%	77.3%	88.0%	94.9%



**HDHP Plan Designs** 

ndhr Fiail Designs										
Deductible/OOP Max	Silver	Bronze								
Type of Plan	HSA Q/HDHP	HSA Q/HDHP								
Medical Ded	\$2,100	\$5,800								
Rx Ded	\$1,500	\$1,500								
Integrated Ded	Yes	Yes								
Medical MOOP	\$7,050	\$7,200								
Rx MOOP	\$1,500	\$1,500								
Integrated MOOP	Yes	Rx -No, Medical - Yes								
Family Deductible / OOP	Aggregate with Combined Medical/Rx embedded \$9,450 Single OOPM; 2x Individual	Aggregate with Combined Medical/Rx embedded \$9,450 Single OOPM; 2x Individual								
Medical Deductible waived for:	Preventive	Preventive								
Drug Deductible waived for:	Wellness scripts	Wellness scripts								
Service Category	Copay / Coinsurance	Copay / Coinsurance								
Inpatient	35%	50%								
Outpatient	35%	50%								
ER	35%	50%								
Radiology (MRI, CT, PET)	35%	50%								
Preventive	0%	0%								
PCP Office Visit	15%	50%								
MH/SA Office Visit	15%	50%								
Specialist Office Visit	35%	50%								
Chiropractic	35%	50%								
Physical Therapy	35%	50%								
Urgent Care	35%	50%								
Ambulance	35%	50%								
Rx Generic	\$10	\$12								
Rx Preferred Brand	\$40	40%								
Rx Non-Preferred Brand	50%	60%								
Rx Specialty	50%	60%								
Actuarial Value										
2024 Federal AVC, Adjusted if Necessary	71.3%	63.0%								



**HDHP Plan Designs - Cost Sharing Reduction Plans** 

	HDHP Plan Designs – Cost Snaring Reduction Plans											
Deductible/OOP Max	70% AV Silver	liver 250-300% FPL 200-250% FPL (73% AV) (77% AV)		150-200% FPL (87% AV)	133-150% FPL (94% AV)							
Type of Plan	HSA Q/HDHP	HSA Q/HDHP	HSA Q/HDHP	HSA Q/HDHP	Deductible (NOT HSAQ)							
Medical Ded	\$2,100	\$2,000	\$1,750	\$1,550	\$550							
Rx Ded	\$1,500	\$1,500	\$1,500	N/A	N/A							
Integrated Ded	Yes	Yes	Yes	Yes	Yes							
Medical MOOP	\$7,050	\$5,800	\$4,650	\$1,550	\$550							
Rx MOOP	\$1,500	\$1,500	\$1,500	N/A	N/A							
Integrated MOOP	Yes	Rx -No, Medical - Yes	Rx -No, Medical - Yes	Yes	Yes							
Family Deductible / OOP	Aggregate with Combined Medical/Rx embedded \$9,450 Single OOPM; 2x Individual	Aggregate with Combined Medical/Rx embedded \$9,450 Single OOPM; 2x Individual	Aggregate, 2x Individual	Aggregate, 2x Individual	Aggregate, 2x Individual							
Medical Deductible waived for:	Preventive	Preventive	Preventive	Preventive	Preventive							
Drug Deductible waived for:	Wellness scripts	Wellness scripts	Wellness scripts	Wellness scripts	Wellness scripts							
Service Category	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance	Copay / Coinsurance							
Inpatient	35%	30%	30%	0%	0%							
Outpatient	35%	30%	30%	0%	0%							
ER	35%	30%	30%	0%	0%							
Radiology (MRI, CT, PET)	35%	30%	30%	0%	0%							
Preventive	0%	0%	0%	0%	0%							
PCP Office Visit	15%	10%	10%	0%	0%							
MH/SA Office Visit	15%	10%	10%	0%	0%							
Specialist Office Visit	35%	30%	30%	0%	0%							
Chiropractic	35%	30%	30%	0%	0%							
Physical Therapy	35%	30%	30%	0%	0%							
Urgent Care	35%	30%	30%	0%	0%							
Ambulance	35%	30%	30%	0%	0%							
Rx Generic	\$10	\$10	\$10	\$0	\$0							
Rx Preferred Brand	\$40	\$40	\$40	\$0	\$0							
Rx Non-Preferred Brand	50%	50%	50%	0%	0%							
Rx Specialty	50%	50%	50%	0%	0%							
Actuarial Value												
2024 Federal AVC, Adjusted if Necessary	71.3%	73.5%	77.5%	87.5%	94.3%							



# Appendix F: Summary of Adjustments Considered and Final Adjusted AVs

Adjustments Considered	Aggreg ate Ded	Aggre gate MOOP, Embed ded \$9,450	Stac ked MO OP	Drug Regul ation	Preve ntive Drugs	insul in Cost Shari ng Limit	\$0 Cost Share on PCP/M HSA Visits	AV from AVC	Final Adjusted AV
Bronze Deductible (without pharmacy limit)	No	No	No	No	No	Yes	Yes	64.8%	64.8%
Silver HDHP	Yes	Yes	No	Yes	Yes	No	No	73.6%	71.3%
Bronze HDHP	Yes	Yes	No	Yes	Yes	Yes	No	64.9%	63.0%
Silver Deductible	No	No	No	Yes	No	No	Yes	69.8%	70.7%
Bronze Deductible (with pharmacy limit)	No	No	Yes	Yes	No	Yes	No	61.3%	62.0%
Silver HDHP - CSR 73%	Yes	Yes	No	Yes	Yes	No	No	75.7%	73.5%
Silver HDHP - CSR 77%	Yes	No	No	Yes	Yes	No	No	79.6%	77.5%
Silver HDHP - CSR 87%	Yes	No	No	No	Yes	No	No	87.9%	87.5%
Silver HDHP - CSR 94%	Yes	No	No	No	Yes	No	No	94.6%	94.3%
Silver Deductible CSR – 73%	No	No	Yes	Yes	No	No	Yes	73.1%	73.7%
Silver Deductible CSR – 77%	No	No	Yes	Yes	No	No	Yes	76.8%	77.3%
Silver Deductible CSR – 87%	No	No	Yes	Yes	No	No	Yes	87.8%	88.0%
Silver Deductible CSR – 94%	No	No	Yes	Yes	No	No	Yes	94.8%	94.9%



# Appendix G: Screen Shots and AV Development

- 1. Bronze Deductible Plan (without pharmacy limit)
- 2. Silver HDHP Embedded MOOP
- 3. Bronze HDHP Embedded MOOP
- 4. Silver Deductible Plan
- 5. Bronze Deductible Plan (with pharmacy limit)
- 6. Silver HDHP Embedded MOOP CSR 73%
- 7. Silver HDHP Embedded MOOP CSR 77%
- 8. Silver HDHP Embedded MOOP CSR 87%
- 9. Silver HDHP Embedded MOOP CSR 94%
- 10. Silver Deductible CSR 73%
- 11. Silver Deductible CSR 77%
- 12. Silver Deductible CSR 87%
- 13. Silver Deductible CSR 94%



# BRONZE DEDUCTIBLE (WITHOUT PHARMACY LIMIT)

AV from AVC = 64.8%

Adjusted AV = 64.8% \* 1.001(MH/SA Copay Adj) = <math>64.8%

#### **AVC Screen Shot:**

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	<b>&gt;</b>		HSA/HRA Options			red Network C				
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution?	· 🗆		Network Plan				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:	\$0.00	1st 7	Tier Utilization	: 100%			
Use Separate MOOP for Medical and Drug Spending?		Allitual Colletti	button Amount.	Ş0.00	2nd 1	Tier Utilization	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				-						
		1 Plan Benefit De				2 Plan Benefit				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$9,400.00							
Coinsurance (%, Insurer's Cost Share)			100.00%	4						
MOOP (\$)			\$9,400.00							
MOOP if Separate (\$)			I							
Click Here for Important Instructions		Tie	er 1			Т	ier 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance, if	Copay, if	Copay applie	s only after
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	different	separate	deduc	tible?
Medical	☐ All	☐ All			All	All			☐ All	☐ All
Emergency Room Services	v	V								
All Inpatient Hospital Services (inc. MH/SUD)	V	✓								Ö
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$40.00	П					П
X-rays)	_								Ц	_
Specialist Visit				\$100.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient				\$40.00						
Services				ψ 10.00	_					_
Imaging (CT/PET Scans, MRIs)	D	V								
Speech Therapy	~	✓								
Occupational and Physical Therapy				\$50.00						
Preventive Care/Screening/Immunization	П		100%	\$0.00	П	П	100%	\$0.00		
Laboratory Outpatient and Professional Services		V	100%	30.00	H		100%	30.00	П	
X-rays and Diagnostic Imaging	Ū	V			Ö	– H			- i	Ä
Skilled Nursing Facility	V	V			H	Ä			Ö	
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	V	✓								
Outpatient Surgery Physician/Surgical Services	V	V								
Drugs	□ All	□ All			All	All			☐ All	All
Generics				\$30.00						
Preferred Brand Drugs	V	V								
Non-Preferred Brand Drugs	V									
Specialty Drugs (i.e. high-cost)	V	☑								
Options for Additional Benefit Design Limits:			Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2024 Bronze No						
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2024 Bronze No	RX Limit Optio	in 3				
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024						
# Days (1-10):	0		AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays? #Copays (1-10):	0									
Output	- 0									
Calculate										
Status/Error Messages:	Expanded Bronze	Standard (58% +	n 65%) Calculatio	in Successful						
Actuarial Value:	64.76%	Standard (SO/) (	o obzej, carculatio	Juccessiui.						
Metal Tier:	Bronze									
mean ner	NOTE: Office-visi	t-snecific cost-sh	aring is anniving	to x-rays in office	settings					
Additional Notes:		c specific cost-sii	og is applying	Con rays in office	Jecuings.					
Additional Notes:										
Calculation Times	0.4453 seconds									
Calculation Time: Draft 2024 AV Calculator	u.4453 seconds									
Drait 2024 AV Calculator										



## SILVER HDHP - EMBEDDED MOOP

AV from AVC = 73.6%

Adjusted AV = 71.3%

## AVC Screen Shot:

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗌	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:	\$0.00	1st 7	Fier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contin	batton Amount.	\$0.00	2nd 1	Fier Utilization:	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				_						
		1 Plan Benefit D				2 Plan Benefit				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$2,100.00				\$6,500.00			
Coinsurance (%, Insurer's Cost Share)			65.00%				60.00%			
MOOP (\$)			\$7,050.00				\$8,700.00			
MOOP if Separate (\$)										
Click Here for Important Instructions		Ti.	er 1			т.	ier 2		Tier 1	Tier 2
Click here for important instructions	Subject to	Subject to	Coinsurance. if	Copay, if	Subject to	Subject to	Coinsurance,	Copay, if	Copay applies	
Type of Benefit	Deductible?	Coinsurance?	different	separate		Coinsurance?		separate	deducti	
Medical	☐ All	□ All	unierent	зерагасе	All	All	ii dillerent	separate	□ All	□ All
Emergency Room Services	<b>V</b>	<u> </u>								
All Inpatient Hospital Services (inc. MH/SUD)	V	V								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and										
X-rays)	~	✓	85%							
Specialist Visit	V	✓								
Mental/Behavioral Health and Substance Use Disorder Outpatient	v	✓	85%							
Services			8376		_					_
Imaging (CT/PET Scans, MRIs)	V	V								
Speech Therapy	V	✓								
	✓	✓								
Occupational and Physical Therapy	1									
Preventive Care/Screening/Immunization			100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	Z.	V								
X-rays and Diagnostic Imaging	V C	V								
Skilled Nursing Facility	V	<u>v</u>								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~	✓								
Outpatient Surgery Physician/Surgical Services	7	<b>7</b>								
Drugs	☐ All	□ All			All	☐ All			☐ All	All
Generics	~			\$10.00					✓	
Preferred Brand Drugs	V			\$40.00					✓	
Non-Preferred Brand Drugs	V	✓	50%							
Specialty Drugs (i.e. high-cost)	V	✓	50%							
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2024 Silver HDH	IP Option 1					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2024 Silver HDH	IP Option 1					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024						
# Days (1-10):	0		AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
#Copays (1-10):	0									
Output										
Calculate	5 B It '									
Status/Error Messages:	Error: Result is or	Itside of [-2, +2]	percent de minim	iis variation.						
Actuarial Value:	73.60%									
Metal Tier:	NOTE: Office			** · · · · · · · · · · · · · · · · · ·						
A ddikional Nakon	NOTE: Office-vis	ı-specific cost-sh	iaring is applying	to x-rays in office	sectings.					
Additional Notes:										
Calculation Time:	0.1953 seconds									
Draft 2024 AV Calculator										



# Silver HDHP – Embedded MOOP, Continued

#### HDHP Model – Normalization:

Note that t	the model run-tim	ne will vary base	d on the comput	ers processing s	oeed.	
A message	box will appear t	o indicate that t	the calculations o	re done.		
			_			
		Medical	Rx			
Individual Deductible			2,100			
F	amily Deductible	4,200	4,200			
Individu	al Out-of-Pocket	7,050	7,050			
	ly Out-of-Pocket		14,100			
	,		2.,200			
Coinsura	nce (50% or Less)	32%	25%			
		Co	osts that Accumu	late		
			C	OOP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
		Calcula	ate			
Results						
Nesuits						
		Medical	Rx	Total		
	Allowed PMPM					
	Plan PMPM					
	Actuarial Value			73.60%		



# Silver HDHP – Embedded MOOP, Continued

HDHP Model – Adjusted Actuarial Value:

	the blue cells be te' anvtime an ii		vn selection is ch			
	•		d on the comput	-	peed.	
		•	he calculations a			
		Medical	Rx			
Individ	dual Deductible	2,100	1,500			
Far	mily Deductible		3,000			
	,		,			
Individua	l Out-of-Pocket	7,050	1,500			
Family	y Out-of-Pocket	14,100	3,000			
Coinsuran	ce (50% or Less)	32%	25%			
		Co	sts that Accumu	late		
			C	ОР	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Aggregate Plus	6
Results						
		Medical	Rx	Total		
	Allowed PMPM		110	1000		
	Plan PMPM					
	Actuarial Value			71.28%		



## **BRONZE HDHP - EMBEDDED MOOP**

AV from AVC = 64.9%

Adjusted AV = 63.0%

## AVC Screen Shot:

User Inputs for Plan Parameters		-								
Use Integrated Medical and Drug Deductible?	~		HSA/HRA Option	s		red Network C				
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗆		Network Plan				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:	\$0.00		Fier Utilization				
Use Separate MOOP for Medical and Drug Spending?					2nd 1	Fier Utilization	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?  Desired Metal Tier										
Desired Metal Her		1 Plan Benefit D	acian	1	Tier	2 Plan Benefit	Decign			
	Medical	Drug	Combined	-	Medical	Drug	Combined			
Deductible (\$)	cureur	Diag	\$5,800.00		Wicarear	Diug	combined			
Coinsurance (%, Insurer's Cost Share)			50.00%							
MOOP (\$)			\$7,200.00							
MOOP if Separate (\$)				_						
Challenge Control of the Control of							*		<b></b>	T 2
Click Here for Important Instructions	Subject to	Subject to	er 1 Coinsurance, if	Copay, if	Subject to		ier 2 Coinsurance, if	Copay, if	Tier 1 Copay applie	Tier 2
Type of Benefit	Deductible?	Coinsurance?	different	separate		Coinsurance?		separate	deduct	
Medical	□ All	□ All	different	separate	All	All	umerent	separate	☐ All	All
Emergency Room Services	<u> </u>	<u> </u>								
All Inpatient Hospital Services (inc. MH/SUD)	V	<u> </u>								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	1									П
X-rays)	V	✓								
Specialist Visit	V	V								
Mental/Behavioral Health and Substance Use Disorder Outpatient	~	~								
Services	2	V								
Imaging (CT/PET Scans, MRIs)										
Speech Therapy	<u> </u>	V								
Occupational and Physical Therapy	~	~								
Preventive Care/Screening/Immunization	П	П	100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	V	V								
X-rays and Diagnostic Imaging	V	V								
Skilled Nursing Facility	হ	V								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	•								
Outpatient Surgery Physician/Surgical Services	7	<b>V</b>								П
Drugs	□ All	□ All			☐ All	□ All			□ All	□ All
Generics	~			\$12.00					<b>V</b>	
Preferred Brand Drugs	V	~	60%							
Non-Preferred Brand Drugs	V	✓	40%							
Specialty Drugs (i.e. high-cost)	V	✓	40%							
Options for Additional Benefit Design Limits:		,	Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2024 Bronze HD						
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID: Issuer HIOS ID:	2024 Bronze HD 2024	OHP Option 2					
Set a Maximum Number of Days for Charging an IP Copay? # Days (1-10):	0		AVC Version:	2024 2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?		-	AVC VEISIOII.	2024_16						
#Visits (1-10):	_ 0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0	]								
Output										
Calculate Status/Error Messages:	F B II-1									
Actuarial Value:	64.91%	utside oi [-2, +2]	percent de minim	iis variation.						
Metal Tier:	04.91%									
mean ner.										
Additional Notes:										
Calculation Time:	0.3203 seconds									
Draft 2024 AV Calculator										



### **Bronze HDHP – Embedded MOOP, Continued**

### HDHP Model – Normalization:

Press 'Calculate'	' anytime an ir	put or dropdow	vn selection is ch	anged.		
Note that the i	model run-tim	e will vary base	d on the comput	ers processing sp	need.	
A message box	x will appear t	o indicate that t	he calculations o	are done.		
		Medical	Rx			
Individua	al Deductible	5,800	5,800			
Fami	ly Deductible	11,600	11,600			
Individual C	ut-of-Pocket	7,200	7,200			
Family O	ut-of-Pocket	14,400	14,400			
Coinsurance	(50% or Less)	48%	47%			
		Co	sts that Accumu	late		
			C	OOP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	5
Results						
		Medical	Rx	Total		
All	lowed PMPM	medical				
	Plan PMPM					
Δα	tuarial Value			64.92%		



## **Bronze HDHP – Embedded MOOP, Continued**

HDHP Model – Adjusted Actuarial Value:

Enter values in	the blue cells be	low, choose a se	tting option from	n the drop dow	n box, and press 'C	alculate'.
Press 'Calculo	ate' anytime an ii	nput or dropdow	n selection is ch	anged.		
Note that th	he model run-tin	ne will vary based	d on the comput	ers processing s	peed.	
A message	box will appear t	o indicate that t	he calculations a	ire done.		
		Medical	Rx			
Indivi	dual Deductible	5,800	1,500			
Fa	mily Deductible	11,600	3,000			
Individua	al Out-of-Pocket	7,200	1,500			
Famil	y Out-of-Pocket	14,400	3,000			
Coinsuran	ice (50% or Less)	48%	47%			
		Co	sts that Accumu	late		
			_	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Aggregate Plus	
Results						
		Medical	Rx	Total		
	Allowed PMPM					
	Plan PMPM					
	_					
	Actuarial Value			62.96%		



#### SILVER DEDUCTIBLE

AV from AVC = 69.8%

### Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 66.37%/65.58% = 1.012 x .698 = 70.6% \*1.001 (MH/SA Copay Adj) = 70.7%

Adjusted AV = 70.7%

### AVC Screen Shot:

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗌		Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:	\$0.00		Tier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?	_			*****	2nd 1	ier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier		1 Plan Benefit De			Ties	2 Plan Benefit [	Danier.			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)		\$500.00	Combined		ivieuicai	Diug	Combined			
Coinsurance (%, Insurer's Cost Share)	50.00%	50.00%								
MOOP (\$)		00.00								
MOOP if Separate (\$)				_						
			•				•			
Click Here for Important Instructions		Tie	er 1			Ti	er 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance,	Copay, if	Copay applie	
	Deductible?	Coinsurance?	different	separate		Coinsurance?	if different	separate	deduc	
Medical	All	All			All	All			All	All
Emergency Room Services	V			\$500.00					V	
All Inpatient Hospital Services (inc. MH/SUD)	V	V			Ш	Ш				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$40.00						П
X-rays)										
Specialist Visit	U			\$90.00		Ш				
Mental/Behavioral Health and Substance Use Disorder Outpatient Services				\$40.00						
Imaging (CT/PET Scans, MRIs)	V	✓							П	
Speech Therapy				\$90.00	ä	H				- i
Occupational and Physical Therapy				\$50.00		Ш				
Preventive Care/Screening/Immunization			100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	V	✓								
X-rays and Diagnostic Imaging	V	✓								
Skilled Nursing Facility	V	✓								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	⊻	☑				П				
					_	_				
Outpatient Surgery Physician/Surgical Services	V	V							Ш	
Drugs	All	□ All			All	All			□ All	All
Generics				\$20.00						
Preferred Brand Drugs		<u> </u>		\$70.00	H					
Non-Preferred Brand Drugs Specialty Drugs (i.e. high-cost)		<u>v</u>			H	H			H	H
Options for Additional Benefit Design Limits:	· ·	- L	Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	2024 Silver Opti	on 2					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:	2024 Silver Opti						
Set a Maximum Number of Days for Charging an IP Copay?		Ť	Issuer HIOS ID:	2024						
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	<b>V</b>	1		_						
#Visits (1-10):	3									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0	]								
Output										
Calculate										
Status/Error Messages: Actuarial Value:	Individual Marke 69.75%	t Silver QHPs mu	st meet a [U, +2] p	percent de minim	is range; Calcul	ation Successfu	и.			
			S daul. ad							
Metal Tier:		nge and Small Gro		to x-rays in office	cattings					
Additional Notes:	NOTE. OTTICE-VIS	ic-specific cost-si	armg is apprining	to A lays III office	securigs.					
Additional Notes.										
Calculation Time:	0.1953 seconds									
Draft 2024 AV Calculator										



### Silver Deductible, Continued

### HDHP Model – Without Prescription Drug Adjustments:

Enter values in	the blue cells bel	ow, choose a set	ting option from t	the drop down bo	x, and press 'Calcu	late'.
Press 'Calcula	ite' anytime an in	put or dropdown	selection is chang	ged.		
Note that th	ne model run-time	will vary based	on the computers	processing speed	d.	
A message	box will appear to	indicate that the	e calculations are	done.		
		Medical	Rx			
Individ	lual Deductible	4,000	500			
Far	mily Deductible	8,000	1,000			
Individua	I Out-of-Pocket	9,300	9,300			
Fami	ly Out-of-Pocket	18,600	18,600			
Coinsuran	ce (50% or Less)	43%	32%			
	,					
		Cos	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
	Jettings	carear a rix	careare.	III COI COI COI IX	313223	
esults						
		Medical	Rx	Total		
	Allowed PMPM					
	Plan PMPM					
	Actuarial Value			65.58%		



### Silver Deductible, Continued

## HDHP Model – With Prescription Drug Adjustments:

Enter values in the b					zii, ziia piezz carea		
	-		on the computers		ed		
		-	e calculations are				
		Medical	Rx				
Individual	Deductible	4.000	500				
Family	Deductible	8,000	1,000				
			,,,,,,				
Individual Ou	t-of-Pocket	9,300	1,500				
Family Ou	t-of-Pocket		3,000				
Coinsurance (5	0% or Less)	43%	32%				
	,						
		Co	sts that Accumu	late			
			0	OP	Deductible /		
		Deductible	Medical	Rx	OOP Type		
	Settings	Medical & Rx	Medical & Rx	Rx Only	Stacked		2
				,			
							_
Results							
tesures							_
			_			_	
		Medical	Rx	Total	ie to Normalize	100	
	wed PMPM						
	Plan PMPM						
				66.070			
Actua	arial Value			66.37%			



### **BRONZE DEDUCTIBLE (WITH PHARMACY LIMIT)**

AV from AVC = 61.3%

### Adjustments

Calculation Time:

Draft 2024 AV Calculator

 HDHP Model with drug adjustments / HDHP Model without drug adjustments = 62.34%/61.56% = 1.013 x .613 = 62.0%

Adjusted AV = 62.0%

#### **AVC Screen Shot:** User Inputs for Plan Parameters Use Integrated Medical and Drug Deductible? HSA/HRA Option Apply Inpatient Copay per Day? SA/HRA Employer Contribution? Tiered Network Plan? Apply Skilled Nursing Facility Copay per Day? Use Separate MOOP for Medical and Drug Spending? Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier Tier 1 Plan Benefit Design Tier 2 Plan Benefit Design Medical Combined Combined Drug \$1,100,00 Drug Deductible (\$) \$6,450,00 Coinsurance (%, Insurer's Cost Share) 50.00% 40.00% MOOP (\$ MOOP if Separate (\$) Tier 1 Tier 2 Subject to Type of Benefit Deductible? Coinsurance? if different Deductible deductible? Coinsurance? Medical Emergency Room Services All Inpatient Hospital Services (inc. MH/SUD) Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and \$35.00 V ✓ Specialist Visit Mental/Behavioral Health and Substance Use Disorder Outpatient \$90.00 V \$35.00 **V** Imaging (CT/PET Scans, MRIs) Speech Therapy V \$90.00 V ☑ \$45.00 Occupational and Physical Therapy Preventive Care/Screening/Immunization Laboratory Outpatient and Professional Services X-rays and Diagnostic Imaging Skilled Nursing Facility **v v** Outpatient Facility Fee (e.g., Ambulatory Surgery Center) Outpatient Surgery Physician/Surgical Services Generics \$20.00 Preferred Brand Drugs \$85.00 Non-Preferred Brand Drugs Specialty Drugs (i.e. high-cost) Set a Maximum on Specialty Rx Coinsurance Payments? 2024 Bronze RX Limit Option 4 Specialty Rx Coinsurance Maximum: Plan HIOS ID: Set a Maximum Number of Days for Charging an IP Copay? Issuer HIOS ID: 2024 Begin Primary Care Cost-Sharing After a Set Number of Visits? Begin Primary Care Deductible/Coinsurance After a Set Number of Copays? # Copays (1-10): Calculate Status/Error Messages Expanded Bronze Standard (58% to 65%), Calculation Successful. Metal Tier: Bronze NOTE: Office-visit-specific cost-sharing is applying to x-rays in office settings. Additional Notes



### Bronze Deductible (Continuing, with pharmacy limit), Continued

HDHP Model – Without Prescription Drug Adjustments:

Press 'Calculate			etting option from on selection is ch	anged.		
	•			ers processing sp	eed.	
A message bo	x will appear t	o indicate that t	he calculations o	re done.		
		Medical	Rx			
Individu	al Deductible	6,450	1,100			
Fami	ly Deductible	12,900	2,200			
	-					
Individual C	Out-of-Pocket	9,450	9,450			
Family C	Out-of-Pocket	18,900	18,900			
Ī						
Coinsurance	(50% or Less)	46%	42%			
		Co	sts that Accumu	late		
			C	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	5
esults						
		Medical	Rx	Total		
Al	lowed PMPM					
	Plan PMPM					
Δ.	tuarial Value			61.56%		



### Bronze Deductible (Continuing, with pharmacy limit), Continued

HDHP Model – With Prescription Drug Adjustments:

Press 'Calculate'	anytime an ii	nput or dropdov	wn selection is ch	anged.		
	-		d on the comput	-	peed.	
		•	the calculations o			
		Medical	Rx			
Individua	l Deductible	6,450	1,100			
Family	y Deductible	12,900	2,200			
Individual O	ut-of-Pocket	9,450	1,500			
Family O	ut-of-Pocket	18,900	3,000			
ĺ						
Coinsurance (	50% or Less)	46%	42%			
,	,					
		C	osts that Accumu	late		
			C	OOP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Stacked	
Results						
		Medical	Rx	Total		
All	owed PMPM		NA NA	Total		
Allo	Plan PMPM					
	riali rivirivi					
Act	tuarial Value			62.35%		
Acc	adrial value			02.5570		



### SILVER HDHP - EMBEDDED MOOP CSR - 73%

AV from AVC = 76.7%

Adjusted AV = 73.5%

**AVC Screen Shot:** 

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?	✓		HSA/HRA Options	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗆	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Cantri	hutian Amaunt.	\$0.00	1st	Tier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	bution Amount:	\$0.00	2nd	Tier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	✓									
Desired Metal Tier	Silver ▼									
	Tier	1 Plan Benefit D	esign		Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$2,000.00	1						
Coinsurance (%, Insurer's Cost Share)			70.00%							
MOOP (\$)			\$6,000.00	1						
MOOP if Separate (\$)				-						
Click Here for Important Instructions		Tie	er 1			Ti	er 2		Tier 1	Tier 2
Tuna of Danofit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance,	Copay, if	Copay applie	s only after
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	if different	separate	deduct	ible?
Medical	☐ All	☐ All			All	☐ All			☐ All	All
Emergency Room Services	✓	~								
All Inpatient Hospital Services (inc. MH/SUD)	~	~								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and			000/							
X-rays)	✓	•	90%							
Specialist Visit	~	~								
Mental/Behavioral Health and Substance Use Disorder Outpatient						_				
Services	✓	~	90%							
Imaging (CT/PET Scans, MRIs)	V	<b>V</b>								
Speech Therapy	V	~								
,,										
Occupational and Physical Therapy	~	•								
Preventive Care/Screening/Immunization			100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	V	<b>V</b>								
X-rays and Diagnostic Imaging	V	<b>V</b>								
Skilled Nursing Facility	<u> </u>	✓								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	•								
Outpatient Surgery Physician/Surgical Services	~	~								
Drugs	☐ All	☐ All			☐ All	☐ All			☐ All	All
Generics	~			\$10.00					•	
Preferred Brand Drugs	✓			\$40.00					V	
Non-Preferred Brand Drugs	<b>V</b>	✓	50%							
Specialty Drugs (i.e. high-cost)	V	<b>V</b>	50%							
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	2024 Silver HDH	HP 73					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2024 Silver HDH	HP 73					
Set a Maximum Number of Days for Charging an IP Copay?		1	Issuer HIOS ID:	2024						
# Days (1-10):	0		AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?		1								
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of		1								
Copays?	_									
#Copays (1-10):	0									
Output										
Calculate										
Status/Error Messages:	Error: Result is o	utside of [0, +1] n	ercent de minimi	s variation for CS	SRs.					
Actuarial Value:	75.65%									
Metal Tier:										
	NOTE: Office-vis	it-specific cost-sh	naring is applying	to x-rays in office	e settings.					
Additional Notes:	0 713									
notice and rotes.										
Calculation Time:	0.3047 seconds									



## Silver HDHP - Embedded MOOP CSR - 73%, Continued

### HDHP Model – Normalization:

e an inr	out or drondown	selection is chance	ned.		
	•			i.	
		•			
	Medical	Rx			
ctible	2,000	2,000			
ctible	4,000	4,000			
ocket	5,800	5,800			
ocket	11,600	11,600			
Less)	27%	25%			
	Cos	sts that Accumu	late		
		0	OP	Deductible /	
	Deductible	Medical	Rx	OOP Type	
ttings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
	Calcula	te			
	Calcula				
	Medical	Rx	Total		
РМРМ					
РМРМ					
	ctible ctible cocket cocket cocket	m-time will vary based pear to indicate that the Medical ctible 2,000 ctible 4,000 Pocket 5,800 Pocket 11,600 Cor.  Deductible ttings Medical & Rx  Calcula Medical PMPM	m-time will vary based on the computers pear to indicate that the calculations are    Medical   Rx	Medical Rx ctible 2,000 2,000 ctible 4,000 4,000  Pocket 5,800 5,800 Pocket 11,600 11,600  Less) 27% 25%  Costs that Accumulate OOP Deductible Medical Rx ttings Medical & Rx Medical & Rx  Calculate  Medical Rx Total PMPM	mean to indicate that the calculations are done.  Medical Rx Ctible 2,000 2,000 Ctible 4,000 4,000  Pocket 5,800 5,800 Pocket 11,600 11,600  Less) 27% 25%  Costs that Accumulate  OOP Deductible / Deductible Medical Rx OOP Type  ttings Medical & Rx Medical & Rx Stacked  Calculate  Medical Rx Total  Medical Rx Total



## Silver HDHP - Embedded MOOP CSR - 73%, Continued

### HDHP Model – Adjusted Actuarial Value:

del run-time	-,	Rx 1,500 3,000	processing spee	ed.	
Deductible Deductible t-of-Pocket	Medical 2,000 4,000 5,800	Rx 1,500 3,000		ed.	
Deductible Deductible t-of-Pocket t-of-Pocket	Medical 2,000 4,000 5,800	Rx 1,500 3,000	done.		
Deductible t-of-Pocket t-of-Pocket	2,000 4,000 5,800	1,500 3,000			
Deductible t-of-Pocket t-of-Pocket	2,000 4,000 5,800	1,500 3,000			
Deductible t-of-Pocket t-of-Pocket	4,000 5,800	3,000			
t-of-Pocket t-of-Pocket	5,800				
t-of-Pocket	-,	4.500			
t-of-Pocket	-,	4			
	11 600	1,500			
)% or Less)	11,000	3,000			
0% or Less)					
	27%	25%			
	Cos	sts that Accumu	late		
		0	OP	Deductible /	
	Deductible	Medical	Rx	OOP Type	
Settings	Medical & Rx	Medical & Rx	Rx Only	Aggregate Plus	6
	Calcula	te			
			T-1-1		
		RX	lotal		
Plan PMPM					
			73.49%		
P	wed PMPM Plan PMPM	Deductible Settings Medical & Rx  Calcula  Medical  Medical	Deductible Medical Settings Medical & Rx Medical & Rx  Calculate  Medical Rx  Medical Rx  Medical Rx  Medical Rx	Deductible Medical Rx Settings Medical & Rx Medical & Rx Only  Calculate  Medical Rx Total  Medical Rx Total  Medical Rx Total	Deductible Medical Rx OOP Type Settings Medical & Rx Medical & Rx Only Aggregate Plus  Calculate  Medical Rx Total  Medical Rx Total  Medical Rx Total  Medical Rx Total



### SILVER HDHP - EMBEDDED MOOP CSR - 77%

AV from AVC = 79.6%

Adjusted AV = 77.5%

### AVC Screen Shot:

User Inputs for Plan Parameters	_									
Use Integrated Medical and Drug Deductible?			HSA/HRA Option:	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗆	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Canta	h 0	\$0.00	1st 7	Fier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	bution Amount:	\$0.00	2nd 1	Fier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	~									
Desired Metal Tier	Gold ▼									
	Tier	1 Plan Benefit D	esign		Tier	2 Plan Benefit	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$1,750.00							
Coinsurance (%, Insurer's Cost Share)			70.00%							
MOOP (\$)			\$4,650.00							
MOOP if Separate (\$)			. ,							
moor it separate (4)			•							
Click Here for Important Instructions		Tie	er 1			Т	er 2		Tier 1	Tier 2
	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance,	Copay, if	Copay appli	
Type of Benefit	Deductible?	Coinsurance?	different	separate		•		separate	deduc	
Medical	All	All	different	Separate	All	All	ii diiiciciic	separate	□ All	All
Emergency Room Services		✓								
All Inpatient Hospital Services (inc. MH/SUD)	V	V				H			H	
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and										
	✓	✓	90%							
X-rays)	V	⊽								
Specialist Visit										
Mental/Behavioral Health and Substance Use Disorder Outpatient	✓	✓	90%							
Services	- -	<u> </u>								
Imaging (CT/PET Scans, MRIs)	***************************************									
Speech Therapy	<u> </u>	☑								
	✓	✓								
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization		H	100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	V.	V								
X-rays and Diagnostic Imaging	Ž.	Z								
Skilled Nursing Facility	V	V								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
	<u> </u>	<u> </u>								
Outpatient Surgery Physician/Surgical Services										
Drugs	☐ All	☐ All			☐ All	☐ All			☐ All	☐ All
Generics	V			\$10.00					Z	
Preferred Brand Drugs	V			\$40.00					<b>V</b>	
Non-Preferred Brand Drugs	V	<u> </u>	50%							
Specialty Drugs (i.e. high-cost)	Y	V	50%							
Options for Additional Benefit Design Limits:		,	Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2024 Silver HDH						
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:	2024 Silver HDH	P 77					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024						
# Days (1-10):			AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?	'									
# Copays (1-10):	0									
Output		='								
Calculate										
Status/Error Messages:	Error: Result is ou	utside of [0, +1] p	ercent de minimi	s variation for CS	Rs.					
Actuarial Value:	79.55%									
Metal Tier:										
	NOTE: Office-visi	t-specific cost-sh	naring is applying	to x-rays in office	settings.					
Additional Notes:					-					
Calculation Time:	0.1914 seconds									
Draft 2024 AV Calculator	5.1314 Seconds									
Digit 2027 AV Calculator										



## Silver HDHP – Embedded MOOP CSR – 77%, Continued

### HDHP Model – Normalization:

Press 'Calculate' any	time an in	put or dropdown	selection is chang	jed.		
Note that the mod					d.	
A message box wil		•				
_						
		Medical	Rx			
Individual De	eductible	1,750	1,750			
Family De	eductible	3,500	3,500			
Individual Out-	of-Pocket	4,650	4,650			
Family Out-	of-Pocket	9,300	9,300			
Coinsurance (509	6 or Less)	27%	26%			
		Co	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
		Calcula	ite			
esults						
		Medical	Rx	Total		
Allow	ed PMPM		NX.	10(8)	1	
	an PMPM					
PI	all FIVIPIVI					
A =======	ial Value			79.55%	-	
Actuar	iai vaiue			75.3370		



## Silver HDHP – Embedded MOOP CSR – 77%, Continued

### HDHP Model – Adjusted Actuarial Value:

		•			ox, and press 'Calcul	ate'.
Press 'Calculate'	•					
			on the computers		rd.	
A message box	will appear to	indicate that the	e calculations are	done.		
		Medical	Rx			
Individual	Deductible	1,750	1,500			
Family	Family Deductible		3,000			
Individual O	ut-of-Pocket	4,650	1,500			
Family O	ut-of-Pocket	9,300	3,000			
Coinsurance (	50% or Less)	27%	26%			
	•					
		Co	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Aggregate Plus	
				-		
Results						
		Medical	Rx	Total		
All	owed PMPM	Wicarcal	INA.	10(01		
A11	Plan PMPM					
	FIGIT FIVIPIVI					
Acti	Jarial Value			77.49%		
Acti	acrial value	<u> </u>		77.4370		



### SILVER HDHP - EMBEDDED MOOP CSR - 87%

AV from AVC = 87.9%

Adjusted AV = 87.5%

### AVC Screen Shot:

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option			red Network O				
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗌		Network Plan?				
Apply Skilled Nursing Facility Copay per Day?		Annual Contri	bution Amount:	\$0.00		ier Utilization:				
Use Separate MOOP for Medical and Drug Spending?	= .	7 iiiiidai Coiltii	outroit / timount.	\$0.00	2nd T	ier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				_						
		1 Plan Benefit D				2 Plan Benefit				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$1,550.00							
Coinsurance (%, Insurer's Cost Share)			100.00%							
MOOP (\$)			\$1,550.00							
MOOP if Separate (\$)							l.			
Click Here for Important Instructions		Tie	vr 1			T	er 2		Tier 1	Tier 2
CHECK HETE TOT IMPORTANT INSTRUCTIONS	Subject to	Subject to	Coinsurance. if	Copay, if	Subject to	Subject to	Coinsurance,	Copay, if	Copay applies	
Type of Benefit	Deductible?	Coinsurance?	different	separate		Coinsurance?		separate	deducti	
Medical	□ All	☐ All	unierent	separate	All	All	ii dillerent	separate	☐ All	All
Emergency Room Services		V								
All Inpatient Hospital Services (inc. MH/SUD)	N	V				Ä				
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	<b></b>				_					
X-rays)	~	✓								
Specialist Visit	V	✓								
Mental/Behavioral Health and Substance Use Disorder Outpatient										
Services	✓	✓								
Imaging (CT/PET Scans, MRIs)	v	☑								
Speech Therapy	<u> </u>	V								
	✓	~								
Occupational and Physical Therapy	l	Ŀ								
Preventive Care/Screening/Immunization			100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	☑	✓								
X-rays and Diagnostic Imaging	V	V								Ö
Skilled Nursing Facility	V	V								
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	✓	✓								
	7	<u> </u>								
Outpatient Surgery Physician/Surgical Services	□ All	□ All			□ All	□ All			□ All	☐ All
Drugs		□ All			0					
Generics Preferred Brand Drugs	V	✓								
Non-Preferred Brand Drugs	Ū	✓			H					H
Specialty Drugs (i.e. high-cost)	V	V			H					H
Options for Additional Benefit Design Limits:			Plan Description							
Set a Maximum on Specialty Rx Coinsurance Payments?	П	1	Name:	2024 Silver HDH	ID 97					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2024 Silver HDH						
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024	07					
# Days (1-10):	0		AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?				_						
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
#Copays (1-10):	0									
Output										
Calculate										
Status/Error Messages:	CSR Level of 87%	(150-200% FPL),	Calculation Succe	ssful.						
Actuarial Value:	87.94%									
Metal Tier:	Gold									
Additional Notes:										
Calculation Time:	0.293 seconds									
Draft 2024 AV Calculator										



## Silver HDHP - Embedded MOOP CSR - 87%, Continued

### HDHP Model – Normalization:

		-		•	x, and press 'Calcu	late'.
Press 'Calculo	ate' anytime an in	put or dropdown	selection is chang	ged.		
Note that t	he model run-time	e will vary based	on the computers	processing spee	d.	
A message	box will appear to	indicate that the	e calculations are	done.		
		Medical	Rx			
Individ	dual Deductible	1,550	1,550			
Fa	mily Deductible	3,100	3,100			
Individu	al Out-of-Pocket	1,550	1,550			
Fami	ly Out-of-Pocket	3,100	3,100			
Coinsuran	ce (50% or Less)	0%	0%			
		Co	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
		Calcula	ite			
Results						
		Medical	Rx	Total		
	Allowed PMPM		138	10131	1	
	Plan PMPM					
	FIGHTEWIFW					
	Actuarial Value			87.95%		



### Silver HDHP – Embedded MOOP CSR – 87%, Continued

### HDHP Model – Adjusted Actuarial Value:

ite: anvtime an in	put or dropdown	selection is chang	ned.		
				d	
	•				
	Medical	Rx			
dual Deductible	1.550	1.550			
mily Deductible	•				
,	-,	-,			
al Out-of-Pocket	1,550	1,550			
		3,100			
ce (50% or Less)	0%	0%			
,					
	Co	sts that Accumu	late		
		0	OP	Deductible /	
	Deductible	Medical	Rx	OOP Type	
Settings	Medical & Rx	Medical & Rx	Rx Only	Aggregate Plus	
	Medical	Dv	Total		
Allowed PMPM		na.	Total		
FIGHTEINEN					
1					
	dual Deductible mily Deductible al Out-of-Pocket ly Out-of-Pocket ce (50% or Less)  Settings	he model run-time will vary based box will appear to indicate that the Medical dual Deductible 1,550 mily Deductible 3,100 al Out-of-Pocket 1,550 ly Out-of-Pocket 3,100 ce (50% or Less) 0%	he model run-time will vary based on the computers box will appear to indicate that the calculations are    Medical Rx	he model run-time will vary based on the computers processing spee box will appear to indicate that the calculations are done.    Medical Rx	the model run-time will vary based on the computers processing speed.  box will appear to indicate that the calculations are done.    Medical Rx



### SILVER HDHP - EMBEDDED MOOP CSR - 94%

AV from AVC = 94.6%

Adjusted AV = 94.3%

### AVC Screen Shot:

User Inputs for Plan Parameters		_								
Use Integrated Medical and Drug Deductible?	~		HSA/HRA Option	s	Tier	red Network C	Option			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗆	Tiered	Network Plan	? 🗆			
Apply Skilled Nursing Facility Copay per Day?		Annual Control	bution Amount:	\$0.00	1st T	ier Utilization	: 100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contri	bution Amount:	\$0.00	2nd T	ier Utilization	: 0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?										
Desired Metal Tier				-						
		1 Plan Benefit De				2 Plan Benefit				
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)			\$550.00							
Coinsurance (%, Insurer's Cost Share)			100.00%	4						
MOOP (\$)			\$550.00							
MOOP if Separate (\$)										
Click Here for Important Instructions		Tie	er 1			Т	ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance,	Copay, if	Copay applies	only after
туре от венени	Deductible?	Coinsurance?	different	separate			if different	separate	deduct	
Medical	☐ All	☐ All			☐ All	☐ All			☐ All	All
Emergency Room Services	V	<b>V</b>								
All Inpatient Hospital Services (inc. MH/SUD)	V	V								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	V	✓								
X-rays)	_	_			_					
Specialist Visit	>	✓								
Mental/Behavioral Health and Substance Use Disorder Outpatient	~	✓								
Services		_				_				_
Imaging (CT/PET Scans, MRIs)	V	V								
Speech Therapy	V	<u> </u>								
O	~	✓								
Occupational and Physical Therapy										
Preventive Care/Screening/Immunization		✓	100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	v	<u>V</u>								
X-rays and Diagnostic Imaging Skilled Nursing Facility	v	<u>v</u>								
Skilled Nursing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~	✓								
Outpatient Surgery Physician/Surgical Services	V	፟፟፟፟፟								
Drugs	☐ All	☐ All			☐ All	☐ All			☐ All	☐ All
Generics	V	V								
Preferred Brand Drugs	V	✓								
Non-Preferred Brand Drugs	V	•				Ō				
Specialty Drugs (i.e. high-cost)	V	✓								
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2024 Silver HDF	HP 94					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2024 Silver HDF	HP 94					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024						
# Days (1-10):	0		AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?										
# Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
#Copays (1-10):	0									
Output  Calculate										
Status/Error Messages:	CSR Level of 04%	(100-150% EDI) (	Calculation Succe	ceful						
Actuarial Value:	94.58%	(								
Metal Tier:	Platinum									
mean near	. racinam									
Additional Notes:										
Calculation Time:	0.5 seconds									
Draft 2024 AV Calculator										



### Silver HDHP - Embedded MOOP CSR - 94%, Continued

### HDHP Model – Normalization:

Press 'Calculate	' anytime an in	put or dropdown	selection is chang	ed.		
		•	_	processing speed	d.	
		-	calculations are			
		Medical	Rx			
Individu	al Deductible	550	550			
Fami	ly Deductible	1,100	1,100			
	•					
Individual	Out-of-Pocket	550	550			
Family	Out-of-Pocket	1,100	1,100			
Coinsurance	(50% or Less)	0%	0%			
		Cos	sts that Accumul	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	5
		Calcula	te			
Results						
		Medical	Rx	Total		
A	llowed PMPM					
	Plan PMPM					
	tuarial Value			94.28%		
AC	Luariai value			34.20%		



## Silver HDHP - Embedded MOOP CSR - 94%, Continued

### HDHP Model – Adjusted Actuarial Value:

Press 'Calculate' anyt	time an in	put or dropdown	selection is chang	ged.		
Note that the mode	el run-time	e will vary based	on the computers	processing spe	ed.	
A message box will	appear to	indicate that th	e calculations are	done.		
		Medical	Rx			
Individual De	ductible	550	550			
Family De	ductible	1,100	1,100			
Individual Out-o	of-Pocket	550	550			
Family Out-o	of-Pocket	1,100	1,100			
Coinsurance (50%	or Less)	0%	0%			
		Co	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Aggregate Plus	
				,	00 0	
Results						
results						
		Medical	Rx	Total		
Allowe	ed PMPM					
Pla	an PMPM					
<u>A</u> ctuari	al Value			94.25%		



#### SILVER DEDUCTIBLE CSR - 73%

AV from AVC = 73.1%

### Adjustments

Metal Tier:

Additional Notes: Calculation Time:

Draft 2024 AV Calculator

 HDHP Model with drug adjustments / HDHP Model without drug adjustments = 70.47%/70.94% = 1.007 x 73.1% = 73.7% \* 1.001 (MH/SA Copay Adj) = 73.7%

Adjusted AV = 73.7%

#### **AVC Screen Shot:** User Inputs for Plan Parameters Use Integrated Medical and Drug Deductible? HSA/HRA Option Apply Inpatient Copay per Day? SA/HRA Employer Contribution? Tiered Network Plan? Apply Skilled Nursing Facility Copay per Day? Use Separate MOOP for Medical and Drug Spending? Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier Tier 1 Plan Benefit Design Tier 2 Plan Benefit Design Medical Combined Combined **Drug** \$450.00 Drug Deductible (\$ \$3,000,00 50.00% Coinsurance (%, Insurer's Cost Share) 50.00% MOOP (\$ MOOP if Separate (\$) Tier 2 Subject to Type of Benefit Deductible? Coinsurance? if different Deductible Coinsurance? Medical Emergency Room Services \$500.00 All Inpatient Hospital Services (inc. MH/SUD) Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and \$40.00 Specialist Visit Mental/Behavioral Health and Substance Use Disorder Outpatient \$90.00 \$40.00 Imaging (CT/PET Scans, MRIs) Speech Therapy \$90.00 П П \$50.00 Occupational and Physical Therapy Preventive Care/Screening/Immunization Laboratory Outpatient and Professional Services X-rays and Diagnostic Imaging Skilled Nursing Facility **v v** Outpatient Facility Fee (e.g., Ambulatory Surgery Center) Outpatient Surgery Physician/Surgical Service Generics \$20.00 Preferred Brand Drugs \$70.00 Non-Preferred Brand Drugs Specialty Drugs (i.e. high-cost) Set a Maximum on Specialty Rx Coinsurance Payments? 2024 Silver Deduct 73 Specialty Rx Coinsurance Maximum: Plan HIOS ID: 2024 Silver Deduct 73 Set a Maximum Number of Days for Charging an IP Copay? Issuer HIOS ID: 2024 Begin Primary Care Cost-Sharing After a Set Number of Visits? Begin Primary Care Deductible/Coinsurance After a Set Number of Copays? # Copays (1-10): Calculate Status/Error Messages CSR Level of 73% (200-250% FPL), Calculation Successful

NOTE: Office-visit-specific cost-sharing is applying to x-rays in office settings.

0.1562 seconds



### Silver Deductible CSR - 73%, Continued

### HDHP Model – Without Prescription Drug Adjustments:

Enter values in the					, and press 'Calcu	ılate'.
			selection is chang			
		-		processing speed	i.	
A message bo	x will appear to	indicate that the	calculations are	done.		
		Medical	Rx			
Individua	al Deductible	3,000	450			
Fami	ly Deductible	6,000	900			
Individual (	Out-of-Pocket	6,700	6,700			
Family (	Out-of-Pocket	13,400	13,400			
Coinsurance	(50% or Less)	43%	32%			
	,					
		Cos	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
	octtings	Wicarcar & NX	Wicarcar & Nx	Wicarcar & NX	otuckeu	_
		Calcula	te			
		Culcula				
_						
Results						
		Medical	Rx	Total	1	
A	llowed PMPM					
	Plan PMPM					
	. 10111111111					
٨٥	tuarial Value			70.94%		
AL	tuuriai value			70.5470		



## Silver Deductible CSR – 73%, Continued

### HDHP Model – With Prescription Drug Adjustments:

Enter values in the blue cells be	low, choose a set	ting option from t	the drop down bo	ox, and press 'Calcu	ılate'.
Press 'Calculate' anytime an in	nput or dropdown	selection is chang	ged.		
Note that the model run-tim	e will vary based	on the computers	processing spee	ed.	
A message box will appear t	o indicate that th	e calculations are	done.		
	Medical	Rx			
Individual Deductible	3,000	450			
Family Deductible	6,000	900			
Individual Out-of-Pocket	6,700	1,300			
Family Out-of-Pocket	13,400	2,600			
Coinsurance (50% or Less	43%	32%			
	Co	sts that Accumu	late		
		0	OP	Deductible /	
	Deductible	Medical	Rx	OOP Type	
Settings	Medical & Rx	Medical & Rx	Rx Only	Stacked	
	Calcula	ite			
Results					
	Medical	Rx	Total		
Allowed PMPN	ı				
Plan PMPM	ı				
			71.47%		



#### SILVER DEDUCTIBLE CSR - 77%

AV from AVC = 76.8%

### Adjustments

HDHP Model with drug adjustments / HDHP Model without drug adjustments =  $72.49\%/72.04\% = 1.006 \times 76.8\% = 77.2\% * 1.001 (MH/SA Copay Adj) = 77.3\%$ 

Adjusted AV = 77.3%

# **AVC Screen Shot:** User Inputs for Plan Parameters Use Integrated Medical and Drug Deductible? Apply Inpatient Copay per Day? Apply Skilled Nursing Facility Copay per Day? Use Separate MOOP for Medical and Drug Spending? HSA/HRA Options Indicate if Plan Meets CSR or Expanded Bronze AV Standard? Desired Metal Tier Tier 1 Plan Benefit Design Tier 2 Plan Benefit Design

	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)		\$350.00								
Coinsurance (%, Insurer's Cost Share)	50.00%	50.00%								
MOOP (\$)		00.00								
MOOP if Separate (\$)							Į.			
Click Here for Important Instructions		Tie					ier 2		Tier 1	Tier 2
Type of Benefit	Subject to	Subject to	Coinsurance, if		Subject to	Subject to	Coinsurance,	Copay, if		es only after
··	Deductible?	Coinsurance?	different	separate		Coinsurance?	if different	separate		ctible?
Medical	☐ All	All		4	All				□ All	All
Emergency Room Services	V	<u> </u>		\$350.00						
All Inpatient Hospital Services (inc. MH/SUD)	<u> </u>	V								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$30.00						
X-rays)				****	_					
Specialist Visit	L			\$60.00		Ш				
Mental/Behavioral Health and Substance Use Disorder Outpatient				\$30.00						
Services	v	<b>V</b>								П
Imaging (CT/PET Scans, MRIs)				ć2F 00	ä					
Speech Therapy				\$35.00						
Occupational and Physical Therapy				\$35.00						
Preventive Care/Screening/Immunization			100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	V	V	100%	30.00		Ä	100%	30.00		
X-rays and Diagnostic Imaging	Ž	<u> </u>				H				H
Skilled Nursing Facility	Ū	V			ā	Ä				Ō
	I									
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~	✓								
Outpatient Surgery Physician/Surgical Services	✓	<b>2</b>								
Drugs	☐ All	All			All	All			□ All	All
Generics				\$15.00						
Preferred Brand Drugs	V			\$60.00		Ö			V	Ē
Non-Preferred Brand Drugs	V					Ö				
Specialty Drugs (i.e. high-cost)	V	✓				Ö				
Options for Additional Benefit Design Limits:			Plan Description	n:						
Set a Maximum on Specialty Rx Coinsurance Payments?			Name:	2024 Silver Ded	uct 77					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2024 Silver Ded	uct 77					
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024						
# Days (1-10):		1	AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?	_									
# Visits (1-10):										
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?										
# Copays (1-10):	0	1								
Output										
Calculate	F B I/ 1									
Status/Error Messages:		utside of [0, +1] p	ercent de minimi	is variation for CS	KS.					
Actuarial Value:	76.76%									
Metal Tier:	NOTE: Office	it-specific cost-sh								
A APPROXIMATION OF THE PROPERTY OF THE PROPERT	NOTE: UTILE-VIS	it-specific cost-sn	iai iiig is appiying	LO A-TAYS III OTTICE	secungs.					
Additional Notes:										

Calculation Time: 0.2344 seconds Draft 2024 AV Calculator



## Silver Deductible CSR – 77%, Continued

### HDHP Model – Without Prescription Drug Adjustments:

Enter values in the blue cells bel	ow, choose a set	ting option from t	the drop down bo	k, and press 'Calcu	late'.
Press 'Calculate' anytime an in	put or dropdown	selection is chang	ged.		
Note that the model run-time	e will vary based	on the computers	processing speed	1.	
A message box will appear to	indicate that the	e calculations are	done.		
	Medical	Rx			
Individual Deductible	2,900	350			
Family Deductible	5,800	700			
Individual Out-of-Pocket	6,300	6,300			
Family Out-of-Pocket	12,600	12,600			
Coinsurance (50% or Less)	41%	29%			
	Co	sts that Accumu	late		
		C	OOP	Deductible /	
	Deductible	Medical	Rx	OOP Type	
Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
	Calcula	ite			
tesults					
	Medical	Rx	Total		
Allowed PMPM		1101			
Plan PMPM					
113.11111111					
Actuarial Value			72.04%		
Actualial value			72.0470		



## Silver Deductible CSR - 77%, Continued

### HDHP Model – With Prescription Drug Adjustments:

Enter values in	the blue cells bel	ow, choose a sett	ting option from t	he drop down box	, and press 'Calcu	late'.
Press 'Calcula	ite' anytime an in	put or dropdown	selection is chang	jed.		
Note that th	ne model run-time	e will vary based	on the computers	processing speed	f.	
A message	box will appear to	indicate that the	calculations are	done.		
		Medical	Rx			
Individ	lual Deductible	2,900	350			
Far	mily Deductible	5,800	700			
	-					
Individua	I Out-of-Pocket	6,300	1,200			
Fami	ly Out-of-Pocket	12,600	2,400			
Coinsuran	ce (50% or Less)	41%	29%			
		Cos	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Stacked	2
				,		
Results						
		Medical	Rx	Total		
	Allowed PMPM					
	Plan PMPM					
				72.50%		
			•			



### SILVER DEDUCTIBLE CSR - 87%

AV from AVC = 87.8%

### Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 84.66%/84.43% = 1.002 x 87.8%= 88.0%

Adjusted AV = 88.0%

### AVC Screen Shot:

User Inputs for Plan Parameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	ption			
Apply Inpatient Copay per Day?		HSA/HRA Emplo	yer Contribution	? 🗌	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?				****	1st 7	ier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?	· 🗆	Annual Contri	bution Amount:	\$0.00	2nd 7	ier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?	✓									
Desired Metal Tier	- Gold ▼									
	Tier	1 Plan Benefit De	esign		Tier	2 Plan Benefit [	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$1,250.00	\$250.00								
Coinsurance (%, Insurer's Cost Share)	60.00%	50.00%								
MOOP (\$)	\$2,4	50.00								
MOOP if Separate (\$)										
			=' 				-			
Click Here for Important Instructions		Tie	er 1			Ti	er 2		Tier 1	Tier 2
Town of Donofit	Subject to	Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	Coinsurance,	Copay, if	Copay appli	es only after
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	if different	separate	dedu	tible?
Medical	☐ All	☐ All			☐ All	☐ All			☐ All	All
Emergency Room Services	<b>&gt;</b>			\$300.00					V	
All Inpatient Hospital Services (inc. MH/SUD)	✓	✓								
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and	<b></b>			\$10.00						
X-rays)				\$10.00						
Specialist Visit				\$30.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient										
Services				\$10.00						
Imaging (CT/PET Scans, MRIs)	V	☑								
Speech Therapy				\$12.00						
Occupational and Physical Therapy				\$12.00						
Preventive Care/Screening/Immunization		П	100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services	V	V			Ä	Ā			П	
X-rays and Diagnostic Imaging	7	7								F
Skilled Nursing Facility	<u> </u>	<u> </u>			Ō	Ö				Ō
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~	✓								
Outpatient Surgery Physician/Surgical Services	V	V								
Drugs	☐ All	☐ All			All	All			☐ All	All
Generics				\$10.00	- i	<u> </u>				- ñ
Preferred Brand Drugs				\$50.00	Ä	Ä				Ä
Non-Preferred Brand Drugs										
Specialty Drugs (i.e. high-cost)	~	V			Ä	Ä			Ä	Ä
Options for Additional Benefit Design Limits:	_		Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	2024 Silver Dedi	urt 87					
Specialty Rx Coinsurance Maximum:			Plan HIOS ID:	2024 Silver Dedi						
Set a Maximum Number of Days for Charging an IP Copay?			Issuer HIOS ID:	2024	acc 0,					
# Days (1-10):			AVC Version:	2024 1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?			AVC VEISION.	2024_10						
#Visits (1-10):	_									
Begin Primary Care Deductible/Coinsurance After a Set Number of										
Copays?	_									
#Copays (1-10):										
Output # copays (1-10).	. 0									
Calculate										
Status/Error Messages:	CSR Level of 87%	(150-200% EDIT	Calculation Succe	ceful						
Actuarial Value:	87.76%	(130-200% FPL), I	carculation Succe	ssiul.						
Metal Tier:	67.76% Gold									
wetal her:			astanta anali te -	**						
A did the contract of the cont	INUTE: UTTICE-VIS	ı-speciiiC COST-Sh	arring is applying	to x-rays in office	setungs.					
Additional Notes:										
Calculation Time:	0.1797 seconds									
Draft 2024 AV Calculator										



## Silver Deductible CSR – 87%, Continued

### HDHP Model – Without Prescription Drug Adjustments:

		-			c, and press 'Calcu	late'.
	-		selection is chang			
			on the computers		i.	
A message bo	x will appear to	indicate that the	calculations are	done.		
		Medical	Rx			
Individu	al Deductible	1,250	250			
Fami	ly Deductible	2,500	500			
Individual	Out-of-Pocket	2,450	2,450			
Family	Out-of-Pocket	4,900	4,900			
Coinsurance	(50% or Less)	31%	26%			
		Cos	sts that Accumul	late		
				OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	
	octings	Wicarcar & NX	Wicarcar & IX	Wicarcar & NX	otuckeu	
		Calcula	te			
		Culcula				
Results						
		Medical	Rx	Total		
А	llowed PMPM					
	Plan PMPM					
Δε	tuarial Value			84.43%		
-	taariar value			01.1070		



## Silver Deductible CSR – 87%, Continued

### HDHP Model – With Prescription Drug Adjustments:

Enter values in the b		-		•	, and press 'Calcu	late'.
Press 'Calculate' an						
Note that the mo	del run-time	e will vary based	on the computers	processing speed	i.	
A message box w	ill appear to	indicate that the	calculations are	done.		
		Medical	Rx			
Individual [	Deductible	1,250	250			
Family [	Deductible	2,500	500			
Individual Out	t-of-Pocket	2,450	450			
Family Out	t-of-Pocket	4,900	900			
Coinsurance (50	% or Less)	31%	26%			
		Cos	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Stacked	
esults						
		Medical	Rx	Total	1	
Allov	wed PMPM		110			
	Plan PMPM					
				84.66%		
				01.0070		



### SILVER DEDUCTIBLE CSR - 94%

AV from AVC = 94.8%

### Adjustments

• HDHP Model with drug adjustments / HDHP Model without drug adjustments = 94.82%/94.71% = 1.001 x 94.8% = 94.9%

Adjusted AV = 94.9%

# AVC Screen Shot: User Inputs for Plan Parameters

Oser inputs for Flair raiameters										
Use Integrated Medical and Drug Deductible?			HSA/HRA Option	s	Tie	red Network O	otion			
Apply Inpatient Copay per Day?		HSA/HRA Employ	er Contribution	? 🗆	Tiered	Network Plan?				
Apply Skilled Nursing Facility Copay per Day?				40.00	1st	Fier Utilization:	100%			
Use Separate MOOP for Medical and Drug Spending?		Annual Contrib	oution Amount:	\$0.00	2nd	Fier Utilization:	0%			
Indicate if Plan Meets CSR or Expanded Bronze AV Standard?					•					
Desired Metal Tier										
besited weed the		1 Plan Benefit De	sion		Tier	2 Plan Benefit D	Design			
	Medical	Drug	Combined		Medical	Drug	Combined			
Deductible (\$)	\$250.00	\$0.00	Combined		Wedicai	Diug	Combined			
Coinsurance (%, Insurer's Cost Share)	90.00%	70.00%								
				-						
MOOP (\$)		00.00								
MOOP if Separate (\$)										
Challenge for the control of the control						_			T	T 2
Click Here for Important Instructions	Subject to	Tie Subject to	Coinsurance, if	Copay, if	Subject to	Subject to	er 2 Coinsurance,	Copay, if	Tier 1	Tier 2 es only after
Type of Benefit	Deductible?	Coinsurance?	different	separate	Deductible?	Coinsurance?	if different	separate		ctible?
Medical	□ All	□ All	uniterent	3cparate	All	All	ii dillerent	separate	☐ All	All
				\$125.00	)					
Emergency Room Services	\ \ \	<u> </u>		\$125.00					<u> </u>	
All Inpatient Hospital Services (inc. MH/SUD)		<u>v</u>							Ш	
Primary Care Visit to Treat an Injury or Illness (exc. Preventive, and				\$5.00						
X-rays)	l									-
Specialist Visit				\$15.00						
Mental/Behavioral Health and Substance Use Disorder Outpatient				ćr 00						
Services				\$5.00						
Imaging (CT/PET Scans, MRIs)	V	V								
Speech Therapy		П		\$15.00						
Occupational and Physical Therapy				\$6.00						
Preventive Care/Screening/Immunization	П	П	100%	\$0.00			100%	\$0.00		
Laboratory Outpatient and Professional Services		V	10070	30.00	H	H	100/6	30.00		
	V	<u> </u>								
X-rays and Diagnostic Imaging	<u>v</u>	☑								
Skilled Nursing Facility										
Outpatient Facility Fee (e.g., Ambulatory Surgery Center)	~	~								
Outpatient Surgery Physician/Surgical Services	V	V			J					
Drugs	☐ All	□ All			All	All			☐ All	☐ All
Generics				\$5.00						
Preferred Brand Drugs				\$20.00						
Non-Preferred Brand Drugs		✓								
Specialty Drugs (i.e. high-cost)		✓								
Options for Additional Benefit Design Limits:			Plan Description	1:						
Set a Maximum on Specialty Rx Coinsurance Payments?		1	Name:	2024 Silver Ded	uct 94					
Specialty Rx Coinsurance Maximum:	\$0		Plan HIOS ID:	2024 Silver Ded						
Set a Maximum Number of Days for Charging an IP Copay?		†	Issuer HIOS ID:	2024						
# Days (1-10):	0		AVC Version:	2024_1e						
Begin Primary Care Cost-Sharing After a Set Number of Visits?			Ave version.	2024_10						
#Visits (1-10):	0									
Begin Primary Care Deductible/Coinsurance After a Set Number of		+								
Copays?										
# Copays (1-10):	0	]								
Output										
Calculate										
Status/Error Messages:		(100-150% FPL), (	Calculation Succe	ssful.						
Actuarial Value:	94.75%									
Metal Tier:	Platinum									
	NOTE: Office-vis	it-specific cost-sh	aring is applying	to x-rays in office	settings.					
Additional Notes:					-					
Calculation Time:	0.1797 seconds									
Draft 2024 AV Calculator	0.1/3/ SECUITUS									
DIGIL 2024 AV CALCUIALOF										



## Silver Deductible CSR – 94%, Continued

### HDHP Model – Without Prescription Drug Adjustments:

Enter values in	the blue cells bel	ow, choose a sett	ting option from t	he drop down box	, and press 'Calcu	ılate'.
Press 'Calcula	ate' anytime an in	put or dropdown	selection is chang	jed.		
Note that th	he model run-time	e will vary based	on the computers	processing speed	I.	
A message	box will appear to	indicate that the	calculations are	done.		
		Medical	Rx			
Individ	dual Deductible	250	0			
Fai	mily Deductible	500	0			
Individua	al Out-of-Pocket	1,000	1,000			
Fami	ly Out-of-Pocket	2,000	2,000			
Coinsuran	ce (50% or Less)	8%	14%			
		Cos	sts that Accumul	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Medical & Rx	Stacked	5
		Calcula	te			
Results						
		Medical	Rx	Total		
	Allowed PMPM		NA NA	Total		
	Plan PMPM					
	FIGHTFIVIFIVI					
	L			94.71%		
	Actualiai value			34./1/0		



## Silver Deductible CSR – 94%, Continued

### HDHP Model – With Prescription Drug Adjustments:

Enter values in	the blue cells bel	ow, choose a set	ting option from t	he drop down box	, and press 'Calcu	late'.
Press 'Calcula	nte' anytime an in	put or dropdown	selection is chang	ged.		
Note that th	he model run-time	e will vary based	on the computers	processing speed	1.	
A message	box will appear to	indicate that the	calculations are	done.		
		Medical	Rx			
Individ	dual Deductible	250	0			
Fai	mily Deductible	500	0			
Individua	al Out-of-Pocket	1,000	200			
Fami	ly Out-of-Pocket	2,000	400			
Coinsuran	ce (50% or Less)	8%	14%			
	,					
		Cos	sts that Accumu	late		
			0	OP	Deductible /	
		Deductible	Medical	Rx	OOP Type	
	Settings	Medical & Rx	Medical & Rx	Rx Only	Stacked	2
Results						
results						
		Medical	Rx	Total		
	Allowed PMPM					
	Plan PMPM					
				94.82%		

### MVP Health Care Derivation of 2024 VT Exchange Rate Increases by Contract and Benefit Plan for ACA Compliant Members in Small Group Market as of Febuary 2023

				NON-STANDARD	PLANS								STANDARD PLAN	S				1		
	GO	LD		SILVER			BF	RONZE	PLATINUM	GOLD		SILV	'ER			BRONZE				
2024 Proposed Rates	HDHP	Non-HDHP	On Exchange Non-HDHP	Reflective Non-HDHP	On Exchange HDHP	Reflective HDHP	Non-HDHP	No RX OOP			On Exchange Non-HDHP	Reflective Non-HDHP	On Exchange HDHP	Reflective HDHP	HDHP	Non-HDHP	No RX OOP	Total Annual Premium	Average PMPM	Average Annual Premium
Single Rate	\$956.23	\$952.10	\$725.98	\$725.98	\$748.62	\$747.81	\$642.25	\$643.23	\$1,104.16	\$919.98	\$725.98	\$725.98	\$740.43	\$740.43	\$646.57	\$637.14	\$658.54			
Couple Rate	\$1,912.46	\$1,904.20	\$1,451.96	\$1,451.96	\$1,497.24	\$1,495.62	\$1,284.50	\$1,286.46	\$2,208.32	\$1,839.96	\$1,451.96	\$1,451.96	\$1.480.86	\$1,480.86	\$1,293.14	\$1,274.28	\$1,317.08			
Adult and Child(ren) Rate	\$1,845.52	\$1,837.55	\$1,401.14	\$1,401.14	\$1,444.84	\$1,443.27	\$1,239.54	\$1,241.43	\$2,131.03	\$1,775.56	\$1,401.14	\$1,401.14	\$1,429.03	\$1,429.03	\$1,247.88	\$1,229.68	\$1,270.98			
Family Rate	\$2,687.01	\$2,675.40	\$2,040.00	\$2,040.00	\$2,103.62	\$2,101.35	\$1,804.72	\$1,807.48	\$3,102.69	\$2,585.14	\$2,040.00	\$2,040.00	\$2,080.61	\$2,080.61	\$1,816.86	\$1,790.36	\$1,850.50	\$148,953,216	\$763.30	\$9,159.59
2023 Approved Rates																				
Single Rate	\$829.87	\$844.01	\$664.30	\$664.20	\$685.29	\$684.28	\$575.27	\$580.42	\$970.41	\$801.64	\$669.71	\$669.71	\$680.91	\$680.91	\$586.05	\$576.78	\$603.83			
Couple Rate	\$1,659.74	\$1,688.02	\$1,328.60	\$1,328.40	\$1,370.58	\$1,368.56	\$1,150.54	\$1,160.84	\$1,940.82	\$1,603.28	\$1,339.42	\$1,339.42	\$1,361.82	\$1,361.82	\$1,172.10	\$1,153.56	\$1,207.66			
Adult and Child(ren) Rate	\$1,601.65	\$1,628.94	\$1,282.10	\$1,281.91	\$1,322.61	\$1,320.66	\$1,110.27	\$1,120.21	\$1,872.89	\$1,547.17	\$1,292.54	\$1,292.54	\$1,314.16	\$1,314.16	\$1,131.08	\$1,113.19	\$1,165.39			
Family Rate	\$2,331.93	\$2,371.67	\$1,866.68	\$1,866.40	\$1,925.66	\$1,922.83	\$1,616.51	\$1,630.98	\$2,726.85	\$2,252.61	\$1,881.89	\$1,881.89	\$1,913.36	\$1,913.36	\$1,646.80	\$1,620.75	\$1,696.76	\$132,401,862	\$678.48	\$8,141.79
2024 Proposed Rate Increases																				
Single Rate	15.2%	12.8%	9.3%	9.3%	9.2%	9.3%	11.6%	10.8%	13.8%	14.8%	8.4%	8.4%	8.7%	8.7%	10.3%	10.5%	9.1%			
Couple Rate	15.2%	12.8%	9.3%	9.3%	9.2%	9.3%	11.6%	10.8%	13.8%	14.8%	8.4%	8.4%	8.7%	8.7%	10.3%	10.5%	9.1%			
Adult and Child(ren) Rate	15.2%	12.8%	9.3%	9.3%	9.2%	9.3%	11.6%	10.8%	13.8%	14.8%	8.4%	8.4%	8.7%	8.7%	10.3%	10.5%	9.1%			
Family Rate	15.2%	12.8%	9.3%	9.3%	9.2%	9.3%	11.6%	10.8%	13.8%	14.8%	8.4%	8.4%	8.7%	8.7%	10.3%	10.5%	9.1%	12.50%	Total Reve	ue Change
February 2023 Contracts																				
Single Rate	885	182	31	728	0	257	83	72	901	1,236	1	628	30	473	687	366	50			
Couple Rate	303	33	3	111	0	77	11	9	334	267	0	122	1	101	151	63	7			
Adult and Child(ren) Rate	77	6	1	34	0	16	2	6	68	104	0	30	1	32	52	19	3			
Family Rate	273	30	2	71	0	66	11	7	230	252	0	95	1	116	185	33	6			
Total	1,538	251	37	944	0	416	107	94	1,533	1,859	1	875	33	722	1,075	481	66	J		
February 2023 Members																		1		
Single Rate	885	182	31	728	0	257	83	72	901	1,236	1	628	30	473	687	366	50			
Couple Rate	606	66	6	222	0	154	22	18	668	534	0	244	2	202	302	126	14			
Adult and Child(ren) Rate	197	15	4	78	0	40	4	15	179	260	0	73	2	82	129	46	8			
Family Rate	1,061	116	8	271	0	244	45	25	900	976	0	361	3	465	715	121	23			
Total	2,749	379	49	1,299	0	695	154	130	2,648	3,006	1	1,306	37	1,222	1,833	659	95	]		
																		,		
2024 Proposed PMPY Revenue	\$10,046.12	\$10,366.48	\$7,920.59	\$8,149.28	#DIV/0!	\$8,100.11	\$6,994.85	\$7,199.23	\$11,741.49	\$9,838.24	\$8,711.76	\$7,983.66	\$8,822.72	\$7,727.04	\$6,811.57	\$7,209.44	\$7,207.89			
2023 Approved PMPY Revenue	\$8,718.57	\$9,189.60	\$7,247.65	\$7,455.79	#DIV/0!	\$7,411.97	\$6,265.36	\$6,496.24	\$10,319.21	\$8,572.72	\$8,036.52	\$7,364.87	\$8,113.50	\$7,105.90	\$6,173.99	\$6,526.45	\$6,609.08	_		



### MVP Health Care -- 2024 Small Group Exchange Rate Filing

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

Exhibit 1 -- Summary of Medical Coplans Offered

Exhibit 1a -- Comparison of 2023 to 2024 Benefits

Exhibit 2a -- Pricing Trend Assumptions

Exhibit 2b -- Support for Rx Trend Assumptions used in Development of Index Rate

Exhibit 3 -- Index Rate Development

Exhibit 4 -- Conversion Factor and Tier Ratios

Exhibit 5 -- Retention Loads and Paid Claim Surcharges

Exhibit 6 -- 2024 Premium Rates

#### Exhibit 1 -- Summary of Medical Coplans Offered

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

					In-Network Benefits																	
											Med						Med OOP	Med OOP	Rx OOP	Rx OOP		1
			Standard/Non-	On/Off			IP				Ded	Med Ded	Deductible		Med OOP	Rx OOP	Max	Max	Max	Max	OOP Max	
Form ID	Product Type	Metal Level	Standard	Exchange	PCP	SCP	(Med/Surg)	ER	OP Surg	Amb	Single	Family	Type	Coins.	Type	Type	Single	Family	Single	Family	Type	Pharmacy
FRVT-HMO-SP-001-S (2024)	HyHMO	Platinum	Standard	On Exchange	\$15 No DD*	\$40 No DD	10%	\$100	10%	\$60 No DD	\$450	\$900	Embedded	10%	Embedded	Embedded	\$1,500	\$3,000	\$1,500	\$3,000	Separate	\$10/\$50/50%
FRVT-HMO-SG-001-S (2024)	HyHMO	Gold	Standard	On Exchange	\$20 No DD*	\$55 No DD	30%	\$150	30%	\$75 No DD	\$1,400	\$2,800	Embedded	30%	Embedded	Embedded	\$5,600	\$11,200	\$1,500	\$3,000	Separate	\$15/\$60/50% \$200/\$400 Brand Ded
FRVT-HMO-SG-002-N (2024)	HyHMO	Gold	Non-Standard	On Exchange	\$20 No DD	\$45 No DD	20%	\$250	20%	\$50	\$850	\$1,700	Embedded	20%	Embedded	Embedded	\$6,600	\$13,200	\$1,500	\$3,000	Separate	\$15 / \$40 / 50%, \$350 / \$700 Brand Ded, VBID = \$1 #
FRVT-HMOH-SG-003-N (2024)	HDHMO	Gold	Non-Standard	On Exchange	0%	0%	0%	0%	0%	0%	\$3,000	\$6,000	Aggregate	0%	Aggregate	Aggregate	\$3,000	\$6,000	\$1,500	\$3,000	Integrated	\$10 / \$15 / 5%, Subject to Med Deductible
FRVT-HMO-SS-003-S (2024)	HyHMO	Silver	Standard	On Exchange	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$100 No DD	\$4,000	\$8,000	Embedded	50%	Embedded	Embedded	\$9,300	\$18,600	\$1,500	\$3,000	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
FRVT-HMOH-SS-004-S (2024)	HDHMO	Silver	Standard	On Exchange	15%	35%	35%	35%	35%	35%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,500	\$3,000	Integrated	\$10/\$40/50%, Subject to Med Deductible
FRVT-HMOH-SS-002-N (2024)	HDHMO	Silver	Non-Standard	On Exchange	0%	0%	0%	0%	0%	0%	\$5,725	\$11,450	Embedded	0%	Embedded	Aggregate	\$5,725	\$11,450	\$1,500	\$3,000	Integrated	0% / 0% / 0%, Subject to Med Deductible
									\$1,400 (Fac)													\$850/\$1700 Ded then \$5/50%/50%,
FRVT-HMO-SS-001-N (2024)	HyHMO	Silver	Non-Standard	On Exchange	\$30**	\$60	50%	\$400	\$300 (Phys)	\$100	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,500	\$15,000	\$1,500	\$3,000	Separate	VBID = \$1 #
VT-HMO-SS-003-S II (2024)	HyHMO	Silver	Standard	Off Exchange	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$105 No DD	\$4,000	\$8,000	Embedded	50%	Embedded	Embedded	\$9,300	\$18,600	\$1,500	\$3,000	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
VT-HMOH-SS-004-S II (2024)	HDHMO	Silver	Standard	Off Exchange	15%	35%	35%	35%	35%	40%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,500	\$3,000	Integrated	\$10/\$40/50%, Subject to Med Deductible
VT-HMOH-SS-002-N II (2024)	HDHMO	Silver	Non-Standard	Off Exchange	0%	0%	0%	0%	0%	0%	\$5,750	\$11,500	Embedded	0%	Embedded	Aggregate	\$5,750	\$11,500	\$1,500	\$3,000	Integrated	0% / 0% / 0%, Subject to Med Deductible
									\$1,400 (Fac)													\$850/\$1700 Ded then \$5/50%/50%,
VT-HMO-SS-001-N II (2024)	HyHMO	Silver	Non-Standard	Off Exchange	\$30**	\$60	50%	\$400	\$300 (Phys)	\$105	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,500	\$15,000	\$1,500	\$3,000	Separate	VBID = \$1 #
FRVT-HMO-SB-002-S (2024)	HMO	Bronze	Standard	On Exchange	\$35	\$90	50%	50%	50%	\$100	\$6,450	\$12,900	Embedded	50%	Embedded	Embedded	\$9,450	\$18,900	\$1,500	\$3,000	Integrated	\$1100/\$2200 Brand Ded then \$15/\$85/60%
FRVT-HMOH-SB-003-S (2024)	HDHMO	Bronze	Standard	On Exchange	50%	50%	50%	50%	50%	50%	\$5,800	\$11,600	Aggregate	50%	Stacked	Aggregate	\$7,200	\$14,400"	\$1,500	\$3,000	Integrated	\$12/40%/60%, Subject to Med Deductible
FRVT-HMO-SB-004-S (2024)	HMO	Bronze	Standard	On Exchange	\$40 No DD*	\$100 No DD	0%	0%	0%	0%	\$9,400	\$18,800	Embedded	0%	Embedded	Embedded	\$9,400	\$18,800	N/A	N/A	N/A	\$30 No DD/0%/0%, Subject to Med Deductible
																						\$35 No DD / \$0 / \$0, Subject to Med Deductible, VBID =
FRVT-HMO-SB-005-N (2024)	HMO	Bronze	Non-Standard	On Exchange	0%**	0%	0%	0%	0%	0%	\$9,450	\$18,900	Embedded	0%	Embedded	Embedded	\$9,450	\$18,900	N/A	N/A	N/A	\$3#
FRVT-HMO-SB-001-N (2024)	HMO	Bronze	Non-Standard	On Exchange	\$40	\$100	50%	50%	50%	\$100	\$7,250	\$14,500	Embedded	50%	Embedded	Embedded	\$8,400	\$16,800	N/A	N/A	N/A	\$25/\$100/60%, \$700/\$1400 Brand Ded, VBID = \$3 #

Services subject to deductible (DD) unless otherwise stated.
"First 3 PCP Office Visits are not subject to deductible
"First 3 PCP Office Visits are covered in full
# Ceneric Drugs are Covered in full up to age 10, after Pharmacy deductible is met
"Family structure is SQ 450 for each member up to family limit
Note: MVP's Non-Standard Plan Designs also have a Member Wellness Rider (Form: FRVT366) attached which provides up to \$598 per contract per year.

#### Exhibit 1a -- Comparison of 2023 to 2024 Benefits by Plan

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

											in-Netwo	rk Benefits									
										Med	Med OOP Med OOP Rx OOP Rx OOP										
			Standard/Non-			IP				Ded	Med Ded	Deductible		Med OOP	Rx OOP	Max	Max	Max	Max	OOP Max	
Form ID	Product Type	Metal Level	Standard	PCP	SCP	(Med/Surg)	ER	OP Surg	Amb	Single	Family	Type	Coins.	Type	Type	Single	Family	Single	Family	Type	Pharmacy
FRVT-HMO-SP-001-S (2023)	HyHMO	Platinum	Standard	\$15 No DD*	\$40 No DD	10%	\$100	10%	\$60 No DD	\$425	\$850	Embedded	10%	Embedded	Embedded	\$1,500	\$3,000	\$1,400	\$2,800	Separate	\$10/\$50/50%
FRVT-HMO-SP-001-S (2024)	HyHMO	Platinum	Standard	\$15 No DD*	\$40 No DD	10%	\$100	10%	\$60 No DD	\$450	\$900	Embedded	10%	Embedded	Embedded	\$1,500	\$3,000	\$1,500	\$3,000	Separate	\$10/\$50/50%
FRVT-HMO-SG-001-S (2023)	HyHMO	Gold	Standard	\$20 No DD*	\$50 No DD	30%	\$150	30%	\$70 No DD	\$1,400	\$2,800	Embedded	30%	Embedded	Embedded	\$5,600	\$11,200	\$1,400	\$2,800	Separate	\$12/\$55/50% \$200/\$400 Brand Ded
FRVT-HMO-SG-001-S (2024)	HyHMO	Gold	Standard	\$20 No DD*	\$55 No DD	30%	\$150	30%	\$75 No DD	\$1,400	\$2,800	Embedded	30%	Embedded	Embedded	\$5,600	\$11,200	\$1,500	\$3,000	Separate	\$15/\$60/50% \$200/\$400 Brand Ded
FRVT-HMO-SG-002-N (2023)	HyHMO	Gold	Non-Standard	\$20 No DD	\$45 No DD	20%	\$250	20%	\$50	\$850	\$1,700	Embedded	20%	Embedded	Embedded	\$6,600	\$13,200	\$1,400	\$2,800	Separate	\$15 / \$40 / 50%, \$350 / \$700 Brand Ded, VBID = \$1 #
FRVT-HMO-SG-002-N (2024)	HyHMO	Gold	Non-Standard	\$20 No DD	\$45 No DD	20%	\$250	20%	\$50	\$850	\$1,700	Embedded	20%	Embedded	Embedded	\$6,600	\$13,200	\$1,500	\$3,000	Separate	\$15 / \$40 / 50%, \$350 / \$700 Brand Ded, VBID = \$1 #
FRVT-HMOH-SG-003-N (2023)	HDHMO	Gold	Non-Standard	0%	0%	0%	0%	0%	0%	\$3,200	\$6,400	Aggregate	0%	Aggregate	Aggregate	\$3,200	\$6,400	\$1,500	\$3,000	Integrated	\$10 / \$15 / 5%, Subject to Med Deductible
FRVT-HMOH-SG-003-N (2024)	HDHMO	Gold	Non-Standard	0%	0%	0%	0%	0%	0%	\$3,000	\$6,000	Aggregate	0%	Aggregate	Aggregate	\$3,000	\$6,000	\$1,500	\$3,000	Integrated	\$10 / \$15 / 5%, Subject to Med Deductible
FRVT-HMO-SS-003-S (2023)	HyHMO	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$100 No DE	\$4,000	\$8,000	Embedded	50%	Embedded	Embedded	\$9,100	\$18,200	\$1,400	\$2,800	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
FRVT-HMO-SS-003-S (2024)	HyHMO	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$100 No DE	\$4,000	\$8,000	Embedded	50%	Embedded	Embedded	\$9,300	\$18,600	\$1,500	\$3,000	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
FRVT-HMOH-SS-004-S (2023)	HDHMO	Silver	Standard	10%	30%	30%	30%	30%	30%	\$2,100	\$4,200	Aggregate	30%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,500	\$3,000	Integrated	\$10/\$40/50%, Subject to Med Deductible
FRVT-HMOH-SS-004-S (2024)	HDHMO	Silver	Standard	15%	35%	35%	35%	35%	35%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,500	\$3,000	Integrated	\$10/\$40/50%, Subject to Med Deductible
FRVT-HMOH-SS-002-N (2023)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5,500	\$11,000	Embedded	0%	Embedded	Aggregate	\$5,500	\$11,000	\$1,500	\$3,000	Integrated	0% / 0% / 0%, Subject to Med Deductible
FRVT-HMOH-SS-002-N (2024)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5.725	\$11.450	Embedded	0%	Embedded	Aggregate	\$5,725	\$11,450	\$1,500	\$3,000	Integrated	0% / 0% / 0%, Subject to Med Deductible
								\$1,400 (Fac)							J.J. J.	11/	, , , , , ,	, ,,	1 1/1		
FRVT-HMO-SS-001-N (2023)	HvHMO	Silver	Non-Standard	\$30**	\$60	50%	\$400	\$300 (Phys)	\$100	\$2,100	\$4.200	Embedded	50%	Embedded	Embedded	\$7.000	\$14.000	\$1,400	\$2.800	Separate	\$850/\$1700 Ded then \$5/50%/50%, VBID = \$1 #
	,			***	400	99.1	7	\$1,400 (Fac)	7.00	<b>V</b> =,	<b>4</b> ., <b>2</b>					4.,	,	+ 1,100	<del></del>		**************************************
FRVT-HMO-SS-001-N (2024)	HyHMO	Silver	Non-Standard	\$30**	\$60	50%	\$400	\$300 (Phys)	\$100	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,500	\$15,000	\$1,500	\$3,000	Separate	\$850/\$1700 Ded then \$5/50%/50%, VBID = \$1 #
VT-HMO-SS-003-S II (2023)	HyHMO	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$105 No DD	\$4,000	\$8,000	Embedded	50%	Embedded	Embedded	\$9,100	\$18,200	\$1,400	\$2,800	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
VT-HMO-SS-003-S II (2024)	HyHMO	Silver	Standard	\$40 No DD*	\$90 No DD	50%	\$500	50%	\$105 No DD	\$4,000	\$8,000	Embedded	50%	Embedded	Embedded	\$9,300	\$18,600	\$1,500	\$3,000	Integrated	\$20 / \$70 / 50%, \$500/\$1,000 Brand Ded
VT-HMOH-SS-004-S II (2023)	HDHMO	Silver	Standard	10%	30%	30%	30%	30%	35%	\$2,100	\$4,200	Aggregate	30%	Stacked	Aggregate	\$7,050	\$14,100"	\$1,500	\$3,000	Integrated	\$10/\$40/50%, Subject to Med Deductible
VT-HMOH-SS-004-S II (2024)	HDHMO	Silver	Standard	15%	35%	35%	35%	35%	40%	\$2,100	\$4,200	Aggregate	35%	Stacked	Aggregate	\$7.050	\$14.100"	\$1.500	\$3.000	Integrated	\$10/\$40/50%. Subject to Med Deductible
VT-HMOH-SS-002-N II (2023)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5.525	\$11.050	Embedded	0%	Embedded	Aggregate	\$5,525	\$11.050	\$1,500	\$3.000	Integrated	0% / 0% / 0%. Subject to Med Deductible
VT-HMOH-SS-002-N II (2024)	HDHMO	Silver	Non-Standard	0%	0%	0%	0%	0%	0%	\$5,750	\$11,500	Embedded	0%	Embedded	Aggregate	\$5,750	\$11.500	\$1,500	\$3.000	Integrated	0% / 0% / 0%. Subject to Med Deductible
	-							\$1,400 (Fac)			, ,,,,,,				DD D	11,7	, ,,,,,,		7 1 / 1 1		, , , ,
VT-HMO-SS-001-N II (2023)	HvHMO	Silver	Non-Standard	\$30**	\$60	50%	\$400	\$300 (Phys)	\$105	\$2,100	\$4.200	Embedded	50%	Embedded	Embedded	\$7.000	\$14.000	\$1,400	\$2.800	Separate	\$850/\$1700 Ded then \$5/50%/50%, VBID = \$1 #
	,							\$1,400 (Fac)	,		. ,					, ,	, ,	, ,	. ,	· ·	, , , , , , , , , , , , , , , , , , , ,
VT-HMO-SS-001-N II (2024)	HyHMO	Silver	Non-Standard	\$30**	\$60	50%	\$400	\$300 (Phys)	\$105	\$2,500	\$5,000	Embedded	50%	Embedded	Embedded	\$7,500	\$15,000	\$1,500	\$3,000	Separate	\$850/\$1700 Ded then \$5/50%/50%, VBID = \$1 #
FRVT-HMO-SB-002-S (2023)	HMO	Bronze	Standard	\$35	\$90	50%	50%	50%	\$100	\$6,450	\$12,900	Embedded	50%	Embedded	Embedded	\$9,100	\$18,200	\$1,400	\$2,800	Integrated	\$1100/\$2200 Brand Ded then \$15/\$85/60%
FRVT-HMO-SB-002-S (2024)	HMO	Bronze	Standard	\$35	\$90	50%	50%	50%	\$100	\$6,450	\$12,900	Embedded	50%	Embedded	Embedded	\$9,450	\$18,900	\$1,500	\$3,000	Integrated	\$1100/\$2200 Brand Ded then \$15/\$85/60%
FRVT-HMOH-SB-003-S (2023)	HDHMO	Bronze	Standard	50%	50%	50%	50%	50%	50%	\$5,800	\$11,600	Aggregate	50%	Stacked	Aggregate	\$7,100	\$14,200"	\$1,500	\$3,000	Integrated	\$12/40%/60%, Subject to Med Deductible
FRVT-HMOH-SB-003-S (2024)	HDHMO	Bronze	Standard	50%	50%	50%	50%	50%	50%	\$5,800	\$11,600	Aggregate	50%	Stacked	Aggregate	\$7,200	\$14,400"	\$1,500	\$3,000	Integrated	\$12/40%/60%, Subject to Med Deductible
FRVT-HMO-SB-004-S (2023)	HMO	Bronze	Standard	\$40 No DD*	\$100 No DE	0%	0%	0%	0%	\$9,000	\$18,000	Embedded	0%	Embedded	Embedded	\$9,000	\$18,000	N/A	N/A	N/A	\$30 No DD/0%/0%, Subject to Med Deductible
FRVT-HMO-SB-004-S (2024)	HMO	Bronze	Standard	\$40 No DD*	\$100 No DE	0%	0%	0%	0%	\$9,400			0%	Embedded	Embedded	\$9,400	\$18,800	N/A	N/A	N/A	\$30 No DD/0%/0%. Subject to Med Deductible
FRVT-HMO-SB-005-N (2023)	HMO	Bronze	Non-Standard	0%**	0%	0%	0%	0%	0%	\$9,100	\$18,200	Embedded	0%	Embedded	Embedded	\$9,100	\$18,200	N/A	N/A	N/A	\$35 No DD / \$0 / \$0, Subject to Med Deductible, VBID = \$3 #
FRVT-HMO-SB-005-N (2024)	HMO	Bronze	Non-Standard	0%**	0%	0%	0%	0%	0%	\$9,450			0%	Embedded	Embedded	\$9,450	\$18,900	N/A	N/A	N/A	\$35 No DD / \$0 / \$0, Subject to Med Deductible, VBID = \$3 #
FRVT-HMO-SB-001-N (2023)	HMO	Bronze	Non-Standard	\$40	\$100	50%	50%	50%	\$100		\$14,500		50%	Embedded	Embedded	\$8,400	\$16,800	N/A	N/A	N/A	\$25/\$100/60%, \$700/\$1400 Brand Ded, VBID = \$3 #
FRVT-HMO-SB-001-N (2024)	HMO	Bronze	Non-Standard	\$40	\$100	50%	50%	50%	\$100			Embedded	50%	Embedded		\$8,400	\$16,800	N/A	N/A	N/A	\$25/\$100/60%, \$700/\$1400 Brand Ded, VBID = \$3 #

Changes in benefits from 2023 to 2024 are shown in gray shading.

### **Exhibit 2a -- Pricing Trend Assumptions**

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

Experience Period: January 1, 2022 - December 31, 2022 Rating Period: January 1, 2024 - December 31, 2024

	2023	2024	Total
Months of Trend	12	12	24

### **Medical Trend Summary**

		<u>202</u>	3 Annual Trend		
	C	% of Allowed Claims	Unit Cost	Utilization	Total
	IP	18.8%	11.4%	1.0%	12.5%
	OP	54.9%	11.9%	1.0%	13.0%
	PHY	26.3%	6.6%	1.0%	7.6%
1	Medical Total		10.4%	1.0%	11.5%

2024 Annual Trend										
	% of Allowed Claims	Unit Cost	Utilization	Total						
IP	19.0%	6.0%	1.0%	7.0%						
OP	55.6%	5.3%	1.0%	6.4%						
PHY	25.4%	3.1%	1.0%	4.1%						
Medical Total		4.9%	1.0%	5.9%						

Annual Allowed Medical Trend 8.7%

		Leveraging Impact - Fee-	FOI-Sei vice Medica	i Ciaiiiis	
	Allowed-COB	Coinsurance	Copay	Deductible	Paid*
Rating Period:	\$549.61	\$15.02	\$8.18	\$73.58	\$452.83
24 Months of Trend:	1.181	1.181	1.020	1.065	1.203
Projection Period:	\$649.13	\$17.74	\$8.35	\$78.33	\$544.71
Allowed Trend (Annual)	8.7%				
Paid Trend (Annual)	9.7%				
Leveraging (Annual)	0.9%				

### **Rx Trend Summary**

	2023	<u>Trend</u>	<u>2024</u>	<u>Trend</u>	Annualized Trend			
	Unit Cost	Utilization	Unit Cost	Utilization	Unit Cost	Utilization		
Generic	4.5%	2.2%	-12.7%	3.0%	-4.4%	2.6%		
Brand	3.1%	8.7%	3.4%	0.2%	3.2%	4.4%		
Specialty	2.1%	8.8%	4.4%	8.1%	3.3%	8.4%		

## Exhibit 2b -- Rx Trend Development

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

Rx Claim Information	Generic	Brand	Specialty	Total
Experience Period Scripts / 1000	13,028	897	152	14,077
Experience Period Allowed Cost per Script	\$18.70	\$556.65	\$5,437.17	\$111.53
Experience Period Deductible Per Script	\$2.63	\$20.36	\$86.16	\$4.66
Experience Period Copay Per Script	\$4.11	\$23.45	\$18.14	\$5.50
Experience Period Coinsurance Per Script	\$0.71	\$8.08	\$25.72	\$1.45
Experience Period Paid Cost Per Script	\$11.25	\$504.75	\$5,307.16	\$99.92
Experience Period Allowed PMPM	\$20.30	\$41.60	\$68.93	\$130.83
Experience Period Deductible PMPM	\$2.86	\$1.52	\$1.09	\$5.47
Experience Period Copay PMPM	\$4.46	\$1.75	\$0.23	\$6.45
Experience Period Coinsurance PMPM	\$0.77	\$0.60	\$0.33	\$1.70
Experience Period Paid PMPM Experience Period Rx Rebates PMPM	\$12.21	\$37.72	\$67.29	\$117.22 (\$40.35)
Annual Util Trend	1.026	1.044	1.084	1.028
Annual Unit Cost Trend	0.956	1.032	1.033	1.057
Annual Allowed Trend	0.980	1.078	1.120	1.086
Annual Deductible Trend	1.032	1.032	1.032	1.076
Annual Paid Trend	0.943	1.079	1.120	1.090
Annual Paid Trend Net of Rebates	n/a	n/a	n/a	1.092
Months of Trend	24	24	24	24
Projected Scripts / 1000	13,711	977	179	14,867
Projected Allowed Cost per Script	\$17.07	\$593.22	\$5,797.92	\$124.49
Projected Deductible Per Script	\$2.80	\$21.68	\$91.72	\$5.11
Projected Copay Per Script	\$4.11	\$23.45	\$18.14	\$5.55
Projected Coinsurance Per Script	\$0.65	\$8.61	\$27.43	\$1.49
Projected Paid Cost Per Script	\$9.51	\$539.48	\$5,660.63	\$112.34
Projected Allowed PMPM	\$19.50	\$48.30	\$86.43	\$154.24
Projected Deductible PMPM	\$3.20	\$1.77	\$1.37	\$6.33
Projected Copay PMPM	\$4.70	\$1.91	\$0.27	\$6.88
Projected Coinsurance PMPM	\$0.74	\$0.70	\$0.41	\$1.85
Projected Paid PMPM Projected Rx Rebates Net Projected Paid PMPM	\$10.87	\$43.93	\$84.39	\$139.18 (\$47.57) \$91.62

#### **Development of Index PMPM Claim Rate**

Experience Period Incurred DOS: 1/1/22 - 12/31/22

Completed Through: 3/31/23

	ACA Compliant Small Group
1 Member Months	249,323
2 FFS Paid Medical Claims	\$452.83
3 FFS Paid Pediatric Dental Claims	\$1.20
4 IBNR Factor	1.018
5 FFS Incurred Paid Medical Claims	\$462.18
6 FFS Incurred Rx Claims	\$117.22
7 Experience Period Rx Rebates	(\$40.35)
8 FFS Incurred Rx Claims (Net of Rebates)	\$76.87
9 Experience Period Capitation and Non-FFS Medical Costs	\$14.71
10 Adjusted Experience Period Claim Expense	\$553.75
Market-Wide Adjustments to Experience Period Claims	
11 Adjustment for Waived Cost Share Due to COVID-19	(\$2.02)
12 Adjustment for COVID Testing	(\$0.41)
13 Adjustment for COVID Vaccines	\$2.32
14 Adjustment for Hearing Aids as EHB	\$0.34
15 Adjustment for Abortions Covered in Full	\$0.03
16 Adjustment for Telemedicine Benefit Expansion	\$0.04
17 Adjustment for Leap Year	\$1.52
18 Experience Period Claim Expense After All Adjustments	\$555.57
19 Annual FFS Medical projection factor	1.097
20 Annual FFS Rx projection factor	1.092
21 Annual FFS Claim trend projection factor	1.096
22 Months of Trend	24_
23 Projection Period FFS Claim Expense PMPM Prior to Adjustment	s for Federal Programs \$649.76
24 Projection Period VT Paid Claim Surcharge + NYS HCRA	\$7.47
25 Projection Period Capitation and Non-FFS Medical Costs	\$8.17
26 Paid Index Rate PMPM Prior to Adjustments for Federal Prog	rams \$665.39
Federal Reinsurance and Risk Adjustment Programs	
27 Federal Risk Adjustment Program Impact	\$46.17
28 Paid Index Rate PMPM After Adjustments for Federal Program	ms \$711.56

## **Exhibit 4 -- Conversion Factor and Tier Ratios**

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

				Avg Contract	
Tier	Contract Type	Subscribers	Members	Size	Load Factor
4	Single	6,610	6,610	1.000	1.000
4	Double	1,593	3,186	2.000	2.000
4	Parent/Child(ren)	451	1,132	2.510	1.930
4	Family	1,378	5,334	3.871	2.810

Single Conversion Factor 1.119

# Exhibit 5 -- Retention Loads, Taxes/Assessments, and Paid Claim Surcharges

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

Broker Load 0.00% Bad Debt 0.10% Contribution to Reserves 1.50%  Total % of Premium Retention Components 1.60%  PMPM Retention Components  General Administrative Load \$44.62  **Nof Premium Taxes and Assessments*  Premium Tax 0.00% VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  **Nof Paid Claim Taxes and Assessments*  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%  PMPM Taxes and Assessments	% of Premium Retention Components									
Bad Debt 0.10% Contribution to Reserves 1.50% Total % of Premium Retention Components 1.60%  PMPM Retention Components  General Administrative Load \$44.62  **Yof Premium Taxes and Assessments**  Premium Tax 0.00% VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  **Yof Paid Claim Taxes and Assessments**  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%										
Contribution to Reserves 1.50% Total % of Premium Retention Components 1.60%  PMPM Retention Components  General Administrative Load \$44.62  % of Premium Taxes and Assessments  Premium Tax 0.00% VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  % of Paid Claim Taxes and Assessments  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%										
Total % of Premium Retention Components  PMPM Retention Components  General Administrative Load \$44.62  % of Premium Taxes and Assessments  Premium Tax 0.00% VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  % of Paid Claim Taxes and Assessments  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%	Bad Debt	0.10%								
PMPM Retention Components  General Administrative Load \$44.62  % of Premium Taxes and Assessments  Premium Tax 0.00%  VT Vaccine Pilot 0.58%  National High Cost Reinsurance Pool Charge 0.69%  Total % of Premium Taxes/Assessments 1.27%  % of Paid Claim Taxes and Assessments  Vermont Paid Claim Surcharge 0.999%  New York State HCRA Surcharge 0.150%  Total % of Paid Claim Taxes/Assessments 1.149%	•									
General Administrative Load \$44.62  **Nof Premium Taxes and Assessments*  Premium Tax 0.00% VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  **Nof Paid Claim Taxes and Assessments*  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%	Total % of Premium Retention Components	1.60%								
% of Premium Taxes and Assessments  Premium Tax 0.00% VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  % of Paid Claim Taxes and Assessments  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%	PMPM Retention Components									
Premium Tax 0.00% VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  **Of Paid Claim Taxes and Assessments*  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%	General Administrative Load	\$44.62								
VT Vaccine Pilot 0.58% National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  **Wear of Paid Claim Taxes and Assessments*  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%	% of Premium Taxes and Assessments	5								
National High Cost Reinsurance Pool Charge 0.69% Total % of Premium Taxes/Assessments 1.27%  **Mof Paid Claim Taxes and Assessments*  Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%	Premium Tax	0.00%								
Total % of Premium Taxes/Assessments 1.27%  % of Paid Claim Taxes and Assessments  Vermont Paid Claim Surcharge 0.999%  New York State HCRA Surcharge 0.150%  Total % of Paid Claim Taxes/Assessments 1.149%	VT Vaccine Pilot	0.58%								
Total % of Premium Taxes/Assessments 1.27%  % of Paid Claim Taxes and Assessments  Vermont Paid Claim Surcharge 0.999%  New York State HCRA Surcharge 0.150%  Total % of Paid Claim Taxes/Assessments 1.149%	National High Cost Reinsurance Pool Charge	0.69%								
Vermont Paid Claim Surcharge 0.999% New York State HCRA Surcharge 0.150% Total % of Paid Claim Taxes/Assessments 1.149%		1.27%								
New York State HCRA Surcharge 0.150%  Total % of Paid Claim Taxes/Assessments 1.149%	% of Paid Claim Taxes and Assessment	ts								
Total % of Paid Claim Taxes/Assessments 1.149%	Vermont Paid Claim Surcharge	0.999%								
	New York State HCRA Surcharge	0.150%								
PMPM Taxes and Assessments	Total % of Paid Claim Taxes/Assessments	1.149%								
	PMPM Taxes and Assessments									
HHC Dick Adjustment Hear Fee #0.40	LIUS Diek Adjustment Heer To-	¢0.40								
HHS Risk Adjustment User Fee \$0.19 PCORI Fee \$0.25	•									
PCORI Fee \$0.25 18 VSA 9374(h) Billback \$2.37										
Total PMPM Taxes/Assessments \$2.82	( )	<u> </u>								

#### Exhibit 6 -- 2024 Small Group Exchange Premium Rates

MVP Health Plan, Inc. 2024 Vermont Small Group Exchange Rate Filing For Effective Dates Beginning Between January 1, 2024 - December 31, 2024

2024 Adjusted Paid Claim Cost (Exhibit 3, Line 28) \$711.56

Benefit Relativity \* Induced Demand Reflected in Index Rate 0.8350

Adjusted Claim Cost for Pricing \$852.15

																		Increase	Increase		Increase
					Federal and State	Benefit	Induced			Administrative	% of Premium	PMPM Taxes						over 2023	over 2023	Increase	over 2023
	Product		Standard/Non-	On/Off	Combined	Actuarial	Utilization	<b>Net Claim Cost</b>	Bad Debt / CTR	Expense	Taxes and	and	<b>Gross Claim</b>			Parent/Child(		Single	Double	over 2023	Family
Coplan	Type	Metal Level	Standard	Exchange	Subsidy	Value	Factor*	PMPM	(% of Premium)	(PMPM)	Assessments	Assessments	Cost PMPM	Single***	Double	ren)	Family	Rate	Rate	P/C Rate	Rate
FRVT-HMO-SP-001-S (2024)	HyHMO	Platinum	Standard	On Exchange	Non-Subsidized	0.930	1.150	\$911.38	\$15.79	\$44.62	\$12.54	\$2.82	\$987.14	\$1,104.16	\$2,208.32	\$2,131.03	\$3,102.69	13.8%	13.8%	13.8%	13.8%
FRVT-HMO-SG-001-S (2024)	HyHMO	Gold	Standard	On Exchange	Non-Subsidized	0.817	1.080	\$751.45	\$13.16	\$44.62	\$10.45	\$2.82	\$822.49	\$919.98	\$1,839.96	\$1,775.56	\$2,585.14	14.8%	14.8%	14.8%	14.8%
FRVT-HMO-SG-002-N (2024)	HyHMO	Gold	Non-Standard	On Exchange	Non-Subsidized	0.847	1.080	\$779.33	\$13.62	\$44.62	\$10.81	\$2.82	\$851.20	\$952.10	\$1,904.20	\$1,837.55	\$2,675.40	12.8%	12.8%	12.8%	12.8%
FRVT-HMOH-SG-003-N (2024)	HDHMO	Gold	Non-Standard	On Exchange	Non-Subsidized	0.851	1.080	\$782.92	\$13.68	\$44.62	\$10.86	\$2.82	\$854.89	\$956.23	\$1,912.46	\$1,845.52	\$2,687.01	15.2%	15.2%	15.2%	15.2%
FRVT-HMO-SS-003-S (2024)	HyHMO	Silver	Standard	On Exchange	Non-Subsidized	0.664	1.030	\$582.98	\$10.38	\$44.62	\$8.24	\$2.82	\$649.04	\$725.98	\$1,451.96	\$1,401.14	\$2,040.00	8.4%	8.4%	8.4%	8.4%
FRVT-HMOH-SS-004-S (2024)	HDHMO	Silver	Standard	On Exchange	Non-Subsidized	0.679	1.030	\$595.53	\$10.59	\$44.62	\$8.41	\$2.82	\$661.97	\$740.43	\$1,480.86	\$1,429.03	\$2,080.61	8.7%	8.7%	8.7%	8.7%
FRVT-HMOH-SS-002-N (2024)	HDHMO	Silver	Non-Standard	On Exchange	Non-Subsidized	0.687	1.030	\$602.64	\$10.71	\$44.62	\$8.50	\$2.82	\$669.29	\$748.62	\$1,497.24	\$1,444.84	\$2,103.62	9.2%	9.2%	9.2%	9.2%
FRVT-HMO-SS-001-N (2024)	HyHMO	Silver	Non-Standard	On Exchange	Non-Subsidized	0.664	1.030	\$582.98	\$10.38	\$44.62	\$8.24	\$2.82	\$649.04	\$725.98	\$1,451.96	\$1,401.14	\$2,040.00	9.3%	9.3%	9.3%	9.3%
VT-HMO-SS-003-S II (2024)	HyHMO	Silver	Standard	Off Exchange	Non-Subsidized	0.664	1.030	\$582.98	\$10.38	\$44.62	\$8.24	\$2.82	\$649.04	\$725.98	\$1,451.96	\$1,401.14	\$2,040.00	8.4%	8.4%	8.4%	8.4%
VT-HMOH-SS-004-S II (2024)	HDHMO	Silver	Standard	Off Exchange	Non-Subsidized	0.679	1.030	\$595.53	\$10.59	\$44.62	\$8.41	\$2.82	\$661.97	\$740.43	\$1,480.86	\$1,429.03	\$2,080.61	8.7%	8.7%	8.7%	8.7%
VT-HMOH-SS-002-N II (2024)	HDHMO	Silver	Non-Standard	Off Exchange	Non-Subsidized	0.686	1.030	\$601.94	\$10.70	\$44.62	\$8.49	\$2.82	\$668.56	\$747.81	\$1,495.62	\$1,443.27	\$2,101.35	9.3%	9.3%	9.3%	9.3%
VT-HMO-SS-001-N II (2024)	HyHMO	Silver	Non-Standard	Off Exchange	Non-Subsidized	0.664	1.030	\$582.98	\$10.38	\$44.62	\$8.24	\$2.82	\$649.04	\$725.98	\$1,451.96	\$1,401.14	\$2,040.00	9.3%	9.3%	9.3%	9.3%
FRVT-HMO-SB-002-S (2024)	HMO	Bronze	Standard	On Exchange	Non-Subsidized	0.594	1.000	\$505.84	\$9.11	\$44.62	\$7.23	\$2.82	\$569.62	\$637.14	\$1,274.28	\$1,229.68	\$1,790.36	10.5%	10.5%	10.5%	10.5%
FRVT-HMOH-SB-003-S (2024)	HDHMO	Bronze	Standard	On Exchange	Non-Subsidized	0.603	1.000	\$514.02	\$9.25	\$44.62	\$7.34	\$2.82	\$578.04	\$646.57	\$1,293.14	\$1,247.88	\$1,816.86	10.3%	10.3%	10.3%	10.3%
FRVT-HMO-SB-004-S (2024)	HMO	Bronze	Standard	On Exchange	Non-Subsidized	0.615	1.000	\$524.42	\$9.42	\$44.62	\$7.48	\$2.82	\$588.75	\$658.54	\$1,317.08	\$1,270.98	\$1,850.50	9.1%	9.1%	9.1%	9.1%
FRVT-HMO-SB-005-N (2024)	HMO	Bronze	Non-Standard	On Exchange	Non-Subsidized	0.600	1.000	\$511.12	\$9.20	\$44.62	\$7.30	\$2.82	\$575.06	\$643.23	\$1,286.46	\$1,241.43	\$1,807.48	10.8%	10.8%	10.8%	10.8%
FRVT-HMO-SB-001-N (2024)	HMO	Bronze	Non-Standard	On Exchange	Non-Subsidized	0.599	1.000	\$510.27	\$9.19	\$44.62	\$7.29	\$2.82	\$574.18	\$642.25	\$1,284.50	\$1,239.54	\$1,804.72	11.6%	11.6%	11.6%	11.6%

<sup>\*\*\*</sup>Child Only Rate = Single Rate per Child

## Please provide Company specific inputs for any cells shaded in blue.

Field Name	Description	Input
Insurance Company Name	Company Name	MVP Health Care
HIOS ID	5 digit HIOS ID (if applicable)	77566
SERFF Filing Number	Filing number assigned by SERFF	MVPH-133660956
Market	Market type: Individual, Small Group, Large Group etc.	Small Group
Product Name	Product name entered in SERFF	VT Small Group 2024
Period Prior to Experience Period Start Date	Beginning date for the 12 month period preceding the base period experience (MM/DD/YYYY)	1/1/2021
Period Prior to Experience Period End Date	End date for the 12 month period preceding the base period experience (MM/DD/YYYY)	12/31/2021
Experience Period Start Date	Beginning date for base period experience (MM/DD/YYYY)	1/1/2022
Experience Period End Date	End date for base period experience (MM/DD/YYYY)	12/31/2022
Projection Period Start Date	Beginning effective date for proposed rates (MM/DD/YYYY)	1/1/2024
Projection Period End Date	Ending effective date for proposed rates (MM/DD/YYYY)	12/31/2024

Insurance Company Name MVP Health Care
HIOS ID 77566
SERFF Filing Number MVPH-133660956
Market Small Group
Product Name VT Small Group 2024

#### Prescription Drug Costs as Percentage of Premium<sup>1</sup>

Enter PMPM drug costs incurred during the below periods for the following prescription drug tiers dispensed only at a pharmacy, network pharmacy, or mailorder pharmacy. Additionally, enter the total premium PMPM and member months for each period.

	Gross of Member	Cost Sharing and	Rebates (Allow	red Basis)				
		Experience	e Period -1	Experien	ice Period	Projecti	on Period	
		01/01/2021-12/31/2021		01/01/2022	-12/31/2022	01/01/2024	-12/31/2024	
		Retail	Mail	Retail	Mail	Retail	Mail	
	Non-Specialty Generic PMPM	\$17.68	\$0.49	\$19.77	\$0.53	\$18.99	\$0.51	
(III)	Non-Specialty Brand PMPM	\$31.80	\$1.20	\$39.97	\$1.63	\$46.41	\$1.89	
	Specialty PMPM	\$58.55	\$0.01	\$68.85	\$0.08	\$86.33	\$0.10	
(B)	Medical Rx PMPM	\$7.	.88	\$6	.02	\$7.10		
	Total (Medical and Rx) Premium PMPM	\$56	7.72	\$57	5.38	\$76	53.30	
	Non-Specialty Generic % of Premium	3.11%	0.09%	3.44%	0.09%	2.49%	0.07%	
(1)	Non-Specialty Brand % of Premium	5.60%	0.21%	6.95%	0.28%	6.08%	0.25%	
	Specialty Total % of Premium	10.31%	0.00%	11.97%	0.01%	11.31%	0.01%	
(B)	Medical Rx PMPM	1.3	9%	1.0	5%	0.9	93%	
	Non-Specialty Generic % of Premium Change vs Prior Period			0.32%	0.01%	-0.95%	-0.03%	
(11)	Non-Specialty Brand % of Premium Change vs Prior Period			1.35%	0.07%	-0.87%	-0.04%	
	Specialty % of Premium Change vs Prior Period			1.65%	0.01%	-0.66%	0.00%	
(B)	Medical Rx % of Premium Change vs Prior Period			-0.	34%	-0.	11%	

	Net of Member Cost Sharing (Paid Amount), Gross of Rebates								
		Experienc	e Period -1	Experience Period		Projection Period			
		01/01/2021-12/31/2021		01/01/2022-12/31/2022		01/01/2024-12/31/2024			
		Retail	Mail	Retail	Mail	Retail	Mail		
	Non-Specialty Generic PMPM	\$10.05	\$0.34	\$11.84	\$0.37	\$10.54	\$0.33		
(III)	Non-Specialty Brand PMPM	\$28.31	\$1.13	\$36.17	\$1.55	\$42.12	\$1.81		
	Specialty PMPM	\$56.97	\$0.00	\$67.21	\$0.08	\$84.29	\$0.10		
(B)	Medical Rx PMPM	\$7	.78	\$5	.94	\$7	.03		
	Total Medical and Rx Premium PMPM	\$56	7.72	\$57	5.38	\$76	3.30		
	Non-Specialty Generic % of Premium	1.77%	0.06%	2.06%	0.06%	1.38%	0.04%		
(1)	Non-Specialty Brand % of Premium	4.99%	0.20%	6.29%	0.27%	5.52%	0.24%		
	Specialty Total % of Premium	10.03%	0.00%	11.68%	0.01%	11.04%	0.01%		
(B)	Medical Rx PMPM	1.3	7%	1.0	03%	0.9	92%		
	Non-Specialty Generic % of Premium Change vs Prior Period			0.29%	0.00%	-0.68%	-0.02%		
(11)	Non-Specialty Brand % of Premium Change vs Prior Period			1.30%	0.07%	-0.77%	-0.03%		
	Specialty % of Premium Change vs Prior Period			1.65%	0.01%	-0.64%	0.00%		
(B)	Medical Rx % of Premium Change vs Prior Period			-0.	34%	-0.	11%		

### <sup>1</sup> Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board:

- (i) for all covered prescription drugs, including generic drugs, brand-name drugs excluding specialty drugs, and specialty drugs dispensed at a pharmacy, network pharmacy, or mail-order pharmacy for outpatient use:
- (i) the percentage of the premium rate attributable to prescription drug costs for the prior year for each category of prescription drugs;
- (II) the year-over-year increase or decrease, expressed as a percentage, in per-member, per-month total health plan spending on each category of prescription drugs; and
- (III) the year-over-year increase or decrease in per-member, per-month costs for prescription drugs compared to other components of the premium rate.
- (B) The insurer shall provide, if available, the percentage of the premium rate attributable to prescription drugs administered by a health care provider in an outpatient setting that are part of the medical benefit as separate from the pharmacy benefit.

Insurance Company Name MVP Health Care
HIOS ID 77566
SERFF Filing Number MVPH-133660956
Market Small Group
Product Name VT Small Group 2024

#### Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board: (ii) the specialty tier formulary list.

#### **Specialty Formulary List**

Provide the specialty formulary information listed below.

Drug Name	Drug Tier	Formulary Name (if multiple formularies are used)
ACTEMRA INJ 162/0.9	Tier 3	MarketPlace
ACTEMRA INJ ACTPEN	Tier 3	MarketPlace
ACTIMMUNE INJ 2MU/0.5	Tier 3	MarketPlace
ADCIRCA TAB 20MG	Tier 3	MarketPlace
ADEFOV DIPIV TAB 10MG	Tier 1	MarketPlace
ADEMPAS TAB 0.5MG	Tier 3	MarketPlace
ADEMPAS TAB 1.5MG	Tier 3	MarketPlace
ADEMPAS TAB 1MG	Tier 3	MarketPlace
ADEMPAS TAB 2.5MG	Tier 3	MarketPlace
ADEMPAS TAB 2MG	Tier 3	MarketPlace
ALYO TAB 20MG	Tier 2	MarketPlace
AMBRISENTAN TAB 10MG	Tier 2	Market Nace
AMBRISENTAN TAB 10MG  AMBRISENTAN TAB 5MG	Tier 2	MarketPlace
AMJEVITA INJ 20/0.4ML	Tier 3	MarketPlace
AMJEVITA INJ 20/0.4ML	Tier 3	MarketPlace
AMJEVITA INJ 40/0.8ML	Tier 3	MarketPlace
AMPYRA TAB 10MG  APOKYN INJ 10MG/ML	Tier 3 Tier 3	MarketPlace  MarketPlace
APONTN INJ 10MG/ML APOMORPHINE INJ 30MG/3ML	Tier 2	MarketPlace
•		1 11 111
AUBAGIO TAB 14MG AUBAGIO TAB 7MG	Tier 3 Tier 3	MarketPlace  MarketPlace
AUSTEDO TAB 12MG	Tier 2	
AUSTEDO TAB 12MG  AUSTEDO TAB 6MG	Tier 2	MarketPlace  MarketPlace
AUSTEDO TAB ONG  AUSTEDO TAB 9MG	Tier 2	MarketPlace
AVONEX PEN KIT 30MCG	Tier 2	MarketPlace
AVONEX PER KIT SOMCG  AVONEX PREFL KIT 30MCG	Tier 2	MarketPlace
BAFIERTAM CAP 95MG	Tier 2	MarketPlace
BARACLUDE SOL	Tier 3	MarketPlace
BARACLUDE TAB 0.5MG	Tier 3	MarketPlace
BARACLUDE TAB 0.5MG  BARACLUDE TAB 1MG	Tier 3	MarketPlace
		1 11 111
BENLYSTA INJ 200MG/ML BENLYSTA INJ 200MG/ML	Tier 3 Tier 3	MarketPlace  MarketPlace
•		
BETASERON INJ 0.3MG	Tier 2 Tier 3	MarketPlace
BETHKIS NEB 300/4ML		MarketPlace
BOSENTAN TAB 125MG BOSENTAN TAB 62.5MG	Tier 2	Market Place
	Tier 2	Market Place
BRONCHITOL CAP 40MG	Tier 3	MarketPlace
BRONCHITOL CAP TOL TEST	Tier 3	MarketPlace
BYNFEZIA PEN INJ 2500MCG	Tier 3	MarketPlace
CARBAGLU TAB 200MG	Tier 3	MarketPlace
CARGLUMIC TAB 200MG	Tier 2	MarketPlace
CAYSTON INH 75MG	Tier 3	MarketPlace
CERDELGA CAP 84MG	Tier 3	MarketPlace
CETRORELIX INJ 0.25MG	Tier 2	MarketPlace

CETROTIDE KIT 0.25MG	Tier 3	MarketPlace
CHOR GONADOT INJ 10000UNT	Tier 3	MarketPlace
CINACALCET TAB 30MG	Tier 2	MarketPlace
CINACALCET TAB 60MG	Tier 2	MarketPlace
CINACALCET TAB 90MG	Tier 2	MarketPlace
CLOVIQUE CAP 250MG	Tier 2	MarketPlace
COPAXONE INJ 20MG/ML	Tier 2	MarketPlace
COPAXONE INJ 40MG/ML	Tier 2	MarketPlace
COSENTYX INJ 150MG/ML	Tier 2	MarketPlace
COSENTYX INJ 300DOSE	Tier 2	MarketPlace
COSENTYX INJ 75MG/0.5	Tier 2	MarketPlace
COSENTYX PEN INJ 150MG/ML	Tier 2	MarketPlace
COSENTYX PEN INJ 300DOSE	Tier 2	MarketPlace
CUPRIMINE CAP 250MG	Tier 3	MarketPlace
CYSTAGON CAP 150MG	Tier 2	MarketPlace
CYSTAGON CAP 50MG	Tier 2	MarketPlace
DALFAMPRIDIN TAB 10MG ER		
	Tier 2	MarketPlace
DEFERASIROX GRA 180MG	Tier 2	MarketPlace
DEFERASIROX GRA 360MG	Tier 2	MarketPlace
DEFERASIROX GRA 90MG	Tier 2	MarketPlace
DEFERASIROX TAB 125MG	Tier 2	MarketPlace
DEFERASIROX TAB 250MG	Tier 2	MarketPlace
DEFERASIROX TAB 500MG	Tier 2	MarketPlace
DEFERIPRONE TAB 1000MG	Tier 2	MarketPlace
DEFERIPRONE TAB 500MG	Tier 2	MarketPlace
DEPEN TITRA TAB 250MG	Tier 3	MarketPlace
DESMOPRESSIN SOL 1.5MG/ML	Tier 2	MarketPlace
DIMETHYL FUM CAP 120MG DR	Tier 2	MarketPlace
DIMETHYL FUM CAP 240MG DR	Tier 2	MarketPlace
DIMETHYL FUM MIS STARTER	Tier 2	MarketPlace
DOJOLVI LIQ 100%	Tier 3	MarketPlace
DOPTELET TAB 20MG	Tier 3	MarketPlace
DROXIDOPA CAP 100MG	Tier 2	MarketPlace
DROXIDOPA CAP 200MG	Tier 2	MarketPlace
DROXIDOPA CAP 300MG	Tier 2	MarketPlace
DUOPA SUS 4.63-20	Tier 3	MarketPlace
DUPIXENT INJ 100/0.67	Tier 2	MarketPlace
DUPIXENT INJ 200/1.14	Tier 2	MarketPlace
DUPIXENT INJ 200MG	Tier 2	MarketPlace
		1 11 111
DUPIXENT INJ 300/2ML	Tier 2	MarketPlace
DUPIXENT INJ 300/2ML	Tier 2	MarketPlace
EGRIFTA SV INJ 2MG	Tier 3	MarketPlace
ENBREL INJ 25/0.5ML	Tier 2	MarketPlace
ENBREL INJ 25MG	Tier 2	MarketPlace
ENBREL INJ 25MG	Tier 2	MarketPlace
ENBREL INJ 50MG/ML	Tier 2	MarketPlace
ENBREL MINI INJ 50MG/ML	Tier 2	MarketPlace
ENBREL SRCLK INJ 50MG/ML	Tier 2	MarketPlace
ENDARI POW 5GM	Tier 3	MarketPlace
ENSPRYNG INJ	Tier 3	MarketPlace
ENTECAVIR TAB 0.5MG	Tier 2	MarketPlace
ENTECAVIR TAB 1MG	Tier 2	MarketPlace
EPCLUSA PAK 150-37.5	Tier 2	MarketPlace
EPCLUSA PAK 200-50MG	Tier 2	MarketPlace
EPCLUSA TAB 200-50MG	Tier 2	MarketPlace
EPCLUSA TAB 400-100	Tier 2	MarketPlace
EPIDIOLEX SOL 100MG/ML	Tier 3	MarketPlace
ESBRIET CAP 267MG	Tier 3	MarketPlace
ESBRIET TAB 267MG	Tier 3	MarketPlace
ESBRIET TAB 801MG	Tier 3	MarketPlace
EXJADE TAB 125MG	Tier 3	MarketPlace
	I IICI J	IVIGINOUS

EXJADE TAB 250MG EXJADE TAB 500MG FASENRA PEN INJ 30MG/ML FERRIPROX TAB 1000MG FERRIPROX TAB 500MG FINGOLIMOD CAP 0.5MG	Tier 3 Tier 3 Tier 2 Tier 3 Tier 3	MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace
FASENRA PEN INJ 30MG/ML FERRIPROX TAB 1000MG FERRIPROX TAB 500MG FINGOLIMOD CAP 0.5MG	Tier 2 Tier 3	MarketPlace
FERRIPROX TAB 1000MG FERRIPROX TAB 500MG FINGOLIMOD CAP 0.5MG	Tier 3	
FERRIPROX TAB 500MG FINGOLIMOD CAP 0.5MG		MarketPlace
FINGOLIMOD CAP 0.5MG	Tior 3	IVIAI KCTI IACC
	1161 3	MarketPlace
	Tier 2	MarketPlace
FIRAZYR INJ 30MG/3ML	Tier 3	MarketPlace
FOLLISTIM AQ INJ 300UNIT	Tier 2	MarketPlace
FOLLISTIM AQ INJ 600UNIT	Tier 2	MarketPlace
FOLLISTIM AQ INJ 900UNIT	Tier 2	MarketPlace
FORTEO INJ 600/2.4	Tier 2	MarketPlace
FYREMADEL SOL 250/0.5	Tier 2	MarketPlace
GANIRELIX AC INJ 250/0.5	Tier 3	MarketPlace
GATTEX KIT 5MG	Tier 3	MarketPlace
GILENYA CAP 0.5MG	Tier 3	MarketPlace
GLATIRAMER INJ 40MG/ML	Tier 2	MarketPlace
GLATIRAMER INJ 20MG/ML	Tier 2	MarketPlace
GLATIRAMER INJ 20MG/ML	Tier 2	MarketPlace
GLATIRAMER INJ 40MG/ML	Tier 2	MarketPlace
GLATINAMEN INJ 40MG/ML	Tier 2	MarketPlace
·		
GLATOPA INJ 20MG/ML	Tier 2	MarketPlace
GLATOPA INJ 40MG/ML	Tier 2	MarketPlace
GLATOPA INJ 40MG/ML	Tier 2	MarketPlace
GONAL-F INJ 1050UNIT	Tier 3	MarketPlace
GONAL-F INJ 450UNIT	Tier 3	MarketPlace
GONAL-F RFF INJ 300/0.5	Tier 3	MarketPlace
GONAL-F RFF INJ 450/0.75	Tier 3	MarketPlace
GONAL-F RFF INJ 75UNIT	Tier 3	MarketPlace
GONAL-F RFF INJ 900/1.5	Tier 3	MarketPlace
HAEGARDA INJ 2000UNIT	Tier 3	MarketPlace
HAEGARDA INJ 3000UNIT	Tier 3	MarketPlace
HARVONI PAK	Tier 2	MarketPlace
HARVONI PAK 45-200MG	Tier 2	MarketPlace
HARVONI TAB 45-200MG	Tier 2	MarketPlace
HARVONI TAB 90-400MG	Tier 2	MarketPlace
HEPAGAM B INJ	Tier 2	MarketPlace
HEPSERA TAB 10MG	Tier 3	MarketPlace
HETLIOZ CAP 20MG	Tier 3	MarketPlace
HUMATROPE INJ 12MG	Tier 3	MarketPlace
HUMATROPE INJ 5MG	Tier 3	MarketPlace
HUMATROPE INJ 24MG	Tier 3	MarketPlace
HUMATROPE INJ 6MG	Tier 3	MarketPlace
HUMIRA INJ 10/0.1ML		
·	Tier 2	Market Place
HUMIRA INJ 20/0.2ML	Tier 2	MarketPlace
HUMIRA KIT 20MG/0.4	Tier 2	MarketPlace
HUMIRA INJ 40/0.4ML	Tier 2	MarketPlace
HUMIRA KIT 40MG/0.8	Tier 2	MarketPlace
HUMIRA PEDIA INJ CROHNS	Tier 2	MarketPlace
HUMIRA PEDIA INJ CROHNS	Tier 2	MarketPlace
HUMIRA PEN INJ 40/0.4ML	Tier 2	MarketPlace
HUMIRA PEN INJ 40MG/0.8	Tier 2	MarketPlace
HUMIRA PEN INJ 80/0.8ML	Tier 2	MarketPlace
HUMIRA PEN INJ CD/UC/HS	Tier 2	MarketPlace
HUMIRA PEN INJ PS/UV	Tier 2	MarketPlace
HUMIRA PEN KIT CD/UC/HS		
	Tier 2	MarketPlace
HUMIRA PEN KIT PED UC	Tier 2	MarketPlace
HUMIRA PEN KIT PS/UV	Tier 2	MarketPlace
HYPERHEP B INJ	Tier 2	MarketPlace
HYPERHEP B INJ	Tier 2	MarketPlace
HYPERHEP B INJ	Tier 2	MarketPlace
ICATIBANT INJ 30MG/3ML	Tier 2	MarketPlace

INGREZZA CAP 40-80MG	Tier 3	MarketPlace
INGREZZA CAP 60MG	Tier 3	MarketPlace
INGREZZA CAP 80MG	Tier 3	MarketPlace
INTRON A INJ 10MU	Tier 3	MarketPlace
INTRON A INJ 18MU	Tier 3	MarketPlace
INTRON A INJ 18MU	Tier 3	MarketPlace
INTRON A INJ 25MU	Tier 3	MarketPlace
INTRON A INJ 50MU	Tier 3	MarketPlace
JADENU TAB 180MG	Tier 3	MarketPlace
JADENU TAB 360MG	Tier 3	MarketPlace
JADENU TAB 90MG	Tier 3	MarketPlace
JADENU SPRKL GRA 180MG	Tier 3	MarketPlace
JADENU SPRKL GRA 180MG  JADENU SPRKL GRA 360MG		1 11 111
	Tier 3	MarketPlace
JADENU SPRKL GRA 90MG	Tier 3	MarketPlace
JAVYGTOR PAK 100MG	Tier 2	MarketPlace
JAVYGTOR POW 500MG	Tier 2	MarketPlace
JAVYGTOR TAB 100MG	Tier 2	MarketPlace
KESIMPTA INJ 20/.4ML	Tier 3	MarketPlace
KITABIS PAK NEB 300/5ML	Tier 3	MarketPlace
KUVAN POW 100MG	Tier 3	MarketPlace
KUVAN POW 500MG	Tier 3	MarketPlace
KUVAN TAB 100MG	Tier 3	MarketPlace
KYNMOBI MIS 10MG	Tier 3	MarketPlace
KYNMOBI MIS 15MG	Tier 3	MarketPlace
KYNMOBI MIS 20MG	Tier 3	MarketPlace
KYNMOBI MIS 25MG	Tier 3	MarketPlace
KYNMOBI MIS 30MG	Tier 3	MarketPlace
LAMIVUDINE TAB 100MG		
	Tier 2	MarketPlace
LANREOTIDE INJ 120/.5ML	Tier 3	MarketPlace
LEDIP-SOFOSB TAB 90-400MG	Tier 2	MarketPlace
LETAIRIS TAB 10MG	Tier 3	MarketPlace
LETAIRIS TAB 5MG	Tier 3	MarketPlace
LEUPROLIDE INJ 14 DAY	Tier 2	MarketPlace
LEUPROLIDE INJ 1MG/0.2	Tier 2	MarketPlace
LEUPROLIDE KIT 14 DAY	Tier 2	MarketPlace
LEUPROLIDE KIT 1MG/0.2	Tier 2	MarketPlace
LUPANETA KIT 11.25-5	Tier 3	MarketPlace
LUPANETA KIT 3.75-5	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(10)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(4)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(5)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(6)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(7)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(8)	Tier 3	MarketPlace
MAVENCLAD PAK 10MG(8)  MAVENCLAD PAK 10MG(9)	Tier 3	MarketPlace
, ,		MarketPlace
	Tier 2	
MAYYENT TAB 100-40MG	Tier 2	MarketPlace
MAYZENT PAK STARTER	Tier 2	MarketPlace
MAYZENT PAK STARTER	Tier 2	MarketPlace
MAYZENT TAB 0.25MG	Tier 2	MarketPlace
MAYZENT TAB 1MG	Tier 2	MarketPlace
MAYZENT TAB 2MG	Tier 2	MarketPlace
MENOPUR INJ 75UNIT	Tier 2	MarketPlace
MIGLUSTAT CAP 100MG	Tier 2	MarketPlace
MIGLUSTAT CAP 100MG	Tier 2	MarketPlace
MOZOBIL INJ	Tier 3	MarketPlace
MULPLETA TAB 3MG	Tier 3	MarketPlace
NABI-HB INJ	Tier 2	MarketPlace
NATPARA INJ 100MCG	Tier 3	MarketPlace
NATPARA INJ 25MCG	Tier 3	MarketPlace
NATPARA INJ 25MCG  NATPARA INJ 50MCG	Tier 3	MarketPlace
	11013	IVIAINCLEIACC

NATPARA INJ 75MCG	Tier 3	MarketPlace
NITISINONE CAP 10MG	Tier 2	MarketPlace
NITISINONE CAP 2MG	Tier 2	MarketPlace
NITISINONE CAP 5MG	Tier 2	MarketPlace
NORDITROPIN INJ 10/1.5ML	Tier 2	MarketPlace
NORDITROPIN INJ 15/1.5ML	Tier 2	MarketPlace
NORDITROPIN INJ 30/3ML	Tier 2	MarketPlace
NORDITROPIN INJ 5/1.5ML	Tier 2	MarketPlace
NORTHERA CAP 100MG	Tier 3	MarketPlace
NORTHERA CAP 200MG	Tier 3	MarketPlace
NORTHERA CAP 300MG	Tier 3	MarketPlace
NOVAREL INJ 10000UNT	Tier 3	MarketPlace
NOVAREL INJ 5000UNIT	Tier 3	MarketPlace
NUCALA INJ 100MG/ML	Tier 2	MarketPlace
NUCALA INJ 100MG/ML	Tier 2	MarketPlace
NUCALA INJ 40MG/0.4	Tier 2	MarketPlace
NUPLAZID CAP 34MG	Tier 3	MarketPlace
NUPLAZID TAB 10MG	Tier 3	MarketPlace
NUTROPIN AQ INJ 10MG/2ML	Tier 2	MarketPlace
NUTROPIN AQ INJ 20MG/2ML	Tier 2	MarketPlace
NUTROPIN AQ INJ NUSPIN 5	Tier 2	MarketPlace
OCALIVA TAB 10MG	Tier 3	MarketPlace
OCALIVA TAB 5MG	Tier 3	MarketPlace
	Tier 3	MarketPlace
OFEV CAP 150MG	Tier 3	MarketPlace
OMNITROPE INJ 10/1.5ML	Tier 3	MarketPlace
OMNITROPE INJ 5.8MG	Tier 3	MarketPlace
OMNITROPE INJ 5/1.5ML	Tier 3	MarketPlace
OPSUMIT TAB 10MG	Tier 3	MarketPlace
ORENITRAM TAB 0.125MG	Tier 3	MarketPlace
ORENITRAM TAB 0.25MG	Tier 3	MarketPlace
ORENITRAM TAB 1MG	Tier 3	MarketPlace
ORENITRAM TAB 2.5MG	Tier 3	MarketPlace
ORENITRAM TAB 5MG	Tier 3	MarketPlace
ORENITRAM TAB MONTH 1	Tier 3	MarketPlace
ORENITRAM TAB MONTH 2	Tier 3	MarketPlace
ORENITRAM TAB MONTH 3	Tier 3	MarketPlace
	Tier 3	
ORFADIN CAP 10MG		MarketPlace
ORFADIN CAP 2MG	Tier 3	MarketPlace
ORFADIN CAP 5MG	Tier 3	MarketPlace
OTEZLA TAB 10/20/30	Tier 2	MarketPlace
OTEZLA TAB 30MG	Tier 2	MarketPlace
OTREXUP INJ 10MG	Tier 3	MarketPlace
OTREXUP INJ 12.5/0.4	Tier 3	MarketPlace
OTREXUP INJ 15MG	Tier 3	MarketPlace
OTREXUP INJ 17.5/0.4	Tier 3	MarketPlace
OTREXUP INJ 20MG	Tier 3	MarketPlace
OTREXUP INJ 22.5/0.4	Tier 3	MarketPlace
OTREXUP INJ 25MG	Tier 3	MarketPlace
OVIDREL INJ	Tier 3	MarketPlace
	Tier 3	
		MarketPlace
OXBRYTA TAB 300MG	Tier 3	MarketPlace
OXBRYTA TAB 500MG	Tier 3	MarketPlace
PALYNZIQ INJ 10/0.5ML	Tier 3	MarketPlace
PALYNZIQ INJ 2.5/0.5	Tier 3	MarketPlace
PALYNZIQ INJ 20MG/ML	Tier 3	MarketPlace
PEGASYS INJ	Tier 2	MarketPlace
PEGASYS INJ 180MCG/M	Tier 2	MarketPlace
PENICILLAMIN CAP 250MG	Tier 2	MarketPlace
	Tier 2	MarketPlace
PENICILLAMIN TAB 250MG PHENYLBUTYRA POW SODIUM	Tier 2	MarketPlace MarketPlace

PIRFENIDONE TAB 267MG  PIRFENIDONE TAB 801MG  PLEGRIDY INJ  PLEGRIDY INJ  PLEGRIDY INJ PEN  PLEGRIDY INJ STARTER  PLEGRIDY PEN INJ STARTER  PONVORY TAB 20MG  PONVORY TAB STARTER  PREGNYL INJ 10000UNT  PROMACTA PAK 25MG  T  PROMACTA POW 12.5MG  T  PROMACTA TAB 12.5MG  T  PROMACTA TAB 12.5MG  T  PROMACTA TAB 25MG  T  PROMACTA TAB 25MG  T  PROMACTA TAB 12.5MG  T  PROMACTA TAB 12.5MG	rier 2 rier 2 rier 2 rier 2 rier 2 rier 2 rier 3	MarketPlace
PIRFENIDONE TAB 801MG  PLEGRIDY INJ  PLEGRIDY INJ T  PLEGRIDY INJ PEN  PLEGRIDY INJ STARTER  PLEGRIDY PEN INJ STARTER  PONVORY TAB 20MG  PONVORY TAB STARTER  PREGNYL INJ 10000UNT  PROMACTA PAK 25MG  PROMACTA POW 12.5MG  PROMACTA TAB 12.5MG  PROMACTA TAB 12.5MG  PROMACTA TAB 25MG  T  PROMACTA TAB 25MG  T  PROMACTA TAB 35MG  T  PROMACTA TAB 35MG  T  PROMACTA TAB 35MG  T  PROMACTA TAB 55MG	rier 2 rier 2 rier 2 rier 2 rier 3	MarketPlace
PLEGRIDY INJ T PLEGRIDY INJ PEN T PLEGRIDY INJ PEN T PLEGRIDY INJ STARTER T PLEGRIDY PEN INJ STARTER T PONVORY TAB 20MG T PONVORY TAB STARTER T PREGNYL INJ 10000UNT T PROMACTA PAK 25MG T PROMACTA TAB 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 35MG T PROMACTA TAB 35MG T PROMACTA TAB 35MG T PROMACTA TAB 50MG T PROMACTA TAB 75MG	rier 2 rier 2 rier 2 rier 2 rier 3	MarketPlace
PLEGRIDY INJ T PLEGRIDY INJ PEN T PLEGRIDY INJ STARTER T PLEGRIDY PEN INJ STARTER T PONVORY TAB 20MG T PONVORY TAB STARTER T PREGNYL INJ 10000UNT T PROMACTA PAK 25MG T PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 35MG T PROMACTA TAB 35MG T PROMACTA TAB 55MG T	rier 2 rier 2 rier 2 rier 3	MarketPlace
PLEGRIDY INJ PEN T PLEGRIDY INJ STARTER T PLEGRIDY PEN INJ STARTER T PONVORY TAB 20MG T PONVORY TAB STARTER T PREGNYL INJ 10000UNT T PROMACTA PAK 25MG T PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 35MG T PROMACTA TAB 55MG T	rier 2 rier 2 rier 3	MarketPlace
PLEGRIDY INJ STARTER T PLEGRIDY PEN INJ STARTER T PONVORY TAB 20MG T PONVORY TAB STARTER T PREGNYL INJ 10000UNT T PROMACTA PAK 25MG T PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 50MG T	rier 2 rier 3	MarketPlace
PLEGRIDY INJ STARTER  PLEGRIDY PEN INJ STARTER  PONVORY TAB 20MG  PONVORY TAB STARTER  PREGNYL INJ 10000UNT  PROMACTA PAK 25MG  PROMACTA POW 12.5MG  PROMACTA TAB 12.5MG  T  PROMACTA TAB 25MG  T  PROMACTA TAB 25MG  T  PROMACTA TAB 35MG  T  PROMACTA TAB 50MG  T  PROMACTA TAB 75MG	rier 2 rier 3	MarketPlace
PLEGRIDY PEN INJ STARTER  PONVORY TAB 20MG  TO PONVORY TAB STARTER  PREGNYL INJ 10000UNT  PROMACTA PAK 25MG  PROMACTA POW 12.5MG  TO PROMACTA TAB 12.5MG  PROMACTA TAB 25MG  TO PROMACTA TAB 25MG  PROMACTA TAB 25MG  TO PROMACTA TAB 50MG  TO PROMACTA TAB 50MG  TO PROMACTA TAB 75MG  TO TAB 75MG  TO TAB 75MG	rier 2 rier 3	MarketPlace
PONVORY TAB 20MG T PONVORY TAB STARTER T PREGNYL INJ 10000UNT T PROMACTA PAK 25MG T PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 50MG T	rier 3	MarketPlace
PONVORY TAB STARTER T PREGNYL INJ 10000UNT T PROMACTA PAK 25MG T PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 75MG T	rier 3	MarketPlace
PREGNYL INJ 10000UNT T PROMACTA PAK 25MG T PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 75MG T	rier 3 rier 3 rier 3 rier 3 rier 3 rier 3 rier 3 rier 3	MarketPlace
PROMACTA PAK 25MG T PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 75MG T	rier 3 rier 3 rier 3 rier 3 rier 3 rier 3 rier 3 rier 3	MarketPlace
PROMACTA POW 12.5MG T PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 50MG T	Tier 3	MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace
PROMACTA TAB 12.5MG T PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 75MG T	Tier 3	MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace
PROMACTA TAB 25MG T PROMACTA TAB 50MG T PROMACTA TAB 75MG T	Tier 3 Tier 3 Tier 3 Tier 3 Tier 3	MarketPlace MarketPlace MarketPlace MarketPlace MarketPlace
PROMACTA TAB 50MG T PROMACTA TAB 75MG T	ier 3 ier 3 ier 3 ier 3 ier 3	MarketPlace MarketPlace MarketPlace
PROMACTA TAB 75MG T	ier 3 ier 3 ier 3 ier 3	MarketPlace MarketPlace
	ier 3 ier 3 ier 3	MarketPlace
	ier 3 ier 3 ier 3	MarketPlace
TOLINIOZITVIE SOE IIVIO/IVIE	ier 3 ier 3	
RADICAVA ORS SUS 105/5ML T	ïer 3	IVIdIKELFIALE
		M4-st-tDl
		MarketPlace
	ier 3	MarketPlace
	ier 3	MarketPlace
RASUVO INJ 15MG T	ier 3	MarketPlace
RASUVO INJ 17.5MG T	ier 3	MarketPlace
RASUVO INJ 20MG T	ier 3	MarketPlace
RASUVO INJ 22.5MG T	ier 3	MarketPlace
RASUVO INJ 25MG T	ier 3	MarketPlace
RASUVO INJ 30MG T	ier 3	MarketPlace
	ier 3	MarketPlace
	ier 3	MarketPlace
	ier 2	MarketPlace
•	ier 2	MarketPlace
	ier 2	MarketPlace
·	ier 2	MarketPlace
	ier 2	MarketPlace
REBIF TITRTN INJ PACK T	ier 2	MarketPlace
REVATIO SUS 10MG/ML T	ier 3	MarketPlace
REVATIO TAB 20MG T	ier 3	MarketPlace
RHOPHYLAC INJ 1500/2ML T	ier 2	MarketPlace
RIBAVIRIN CAP 200MG T	ier 2	MarketPlace
	ier 2	MarketPlace
	ier 2	MarketPlace
-	ier 2	MarketPlace
	ier 2	MarketPlace
	ier 3	MarketPlace
	ier 3	MarketPlace
	ier 3	MarketPlace
SAIZEN INJ 8.8MG T	ier 3	MarketPlace
SAIZENPREP INJ 8.8MG T	ier 3	MarketPlace
SAJAZIR INJ 30MG/3ML T	ier 2	MarketPlace
SAPROPTERIN POW 100MG T	ier 2	MarketPlace
	ier 2	MarketPlace
	ier 2	MarketPlace
	ier 3	MarketPlace
	ier 3	MarketPlace
	ier 3	MarketPlace
	ier 3	MarketPlace
·	ier 2	MarketPlace
SILDENAFIL TAB 20MG T	ier 2	MarketPlace
SKYRIZI INJ 150DOSE T	ier 2	MarketPlace
SKYRIZI INJ 150MG/ML T	ier 2	MarketPlace

SKYRIZI INJ 180/1.2	Tier 2	MarketPlace
SKYRIZI INJ 360/2.4	Tier 2	MarketPlace
SKYRIZI PEN INJ 150MG/ML	Tier 2	MarketPlace
SODIUM PHENY TAB 500MG	Tier 2	MarketPlace
SOFOS/VELPAT TAB 400-100	Tier 2	MarketPlace
SOMATULINE INJ 120/.5ML	Tier 3	MarketPlace
SOMATULINE INJ 60/0.2ML	Tier 3	MarketPlace
SOMATULINE INJ 90/0.3ML	Tier 3	
•		MarketPlace
SOMAVERT INJ 10MG	Tier 3	MarketPlace
SOMAVERT INJ 15MG	Tier 3	MarketPlace
SOMAVERT INJ 20MG	Tier 3	MarketPlace
SOMAVERT INJ 25MG	Tier 3	MarketPlace
SOMAVERT INJ 30MG	Tier 3	MarketPlace
SOVALDI PAK 150MG	Tier 3	MarketPlace
SOVALDI PAK 200MG	Tier 3	MarketPlace
SOVALDI TAB 200MG	Tier 3	MarketPlace
SOVALDI TAB 400MG	Tier 3	MarketPlace
STELARA INJ 45MG/0.5	Tier 2	MarketPlace
STELARA INJ 45MG/0.5	Tier 2	MarketPlace
STELARA INJ 90MG/ML	Tier 2	MarketPlace
STIMATE SOL 1.5MG/ML	Tier 2	MarketPlace
SYPRINE CAP 250MG	Tier 3	MarketPlace
TADALAFIL TAB 20MG	Tier 2	MarketPlace
TAKHZYRO INJ 150MG/ML	Tier 3	MarketPlace
TAKHZYRO INJ 300/2ML	Tier 3	MarketPlace
TAKHZYRO INJ 300/2ML	Tier 3	MarketPlace
TASIMELTEON CAP 20MG	Tier 2	MarketPlace
TERIFLUNOMID TAB 14MG	Tier 1	MarketPlace
TERIFLUNOMID TAB 7MG	Tier 1	MarketPlace
TERIPARATIDE INJ	Tier 2	MarketPlace
TETRABENAZIN TAB 12.5MG	Tier 2	MarketPlace
TETRABENAZIN TAB 25MG	Tier 2	MarketPlace
THIOLA TAB 100MG	Tier 3	MarketPlace
TIOPRONIN TAB 100MG	Tier 2	MarketPlace
TOBI NEB 300/5ML	Tier 3	MarketPlace
TOBI PODHALR CAP 28MG	Tier 3	
		MarketPlace
TOBRAMYCIN NEB 300/4ML	Tier 2	MarketPlace
TOBRAMYCIN NEB 300/5ML	Tier 2	MarketPlace
TRACLEER TAB 125MG	Tier 3	MarketPlace
TRACLEER TAB 32MG	Tier 3	MarketPlace
TRACLEER TAB 62.5MG	Tier 3	MarketPlace
TREMFYA INJ 100MG/ML	Tier 2	MarketPlace
TREMFYA INJ 100MG/ML	Tier 2	MarketPlace
TYMLOS INJ	Tier 2	MarketPlace
TYVASO SOL 0.6MG/ML	Tier 3	MarketPlace
	1	
TYVASO DPI POW 16-32-48	Tier 3	MarketPlace
TYVASO DPI POW 16-32MCG	Tier 3	MarketPlace
TYVASO DPI POW 16MCG	Tier 3	MarketPlace
TYVASO DPI POW 32-48MCG	Tier 3	MarketPlace
TYVASO DPI POW 32MCG	Tier 3	MarketPlace
TYVASO DPI POW 48MCG	Tier 3	MarketPlace
TYVASO DPI POW 64MCG	Tier 3	MarketPlace
TYVASO REFIL SOL 0.6MG/ML	Tier 3	MarketPlace
TYVASO START SOL 0.6MG/ML	Tier 3	MarketPlace
UPTRAVI TAB 1000MCG	Tier 3	MarketPlace
	+	
UPTRAVI TAB 1200MCG	Tier 3	MarketPlace
UPTRAVI TAB 1400MCG	Tier 3	MarketPlace
UPTRAVI TAB 1600MCG	Tier 3	MarketPlace
UPTRAVI TAB 200MCG	Tier 3	MarketPlace
UPTRAVI TAB 400MCG	Tier 3	MarketPlace
UPTRAVI TAB 600MCG	Tier 3	MarketPlace

UPTRAVI TAB 800MCG	Tier 3	MarketPlace
UPTRAVI PACK TAB 200/800	Tier 3	MarketPlace
VEMLIDY TAB 25MG	Tier 3	MarketPlace
VENTAVIS SOL 10MCG/ML	Tier 3	MarketPlace
VENTAVIS SOL 20MCG/ML	Tier 3	MarketPlace
VIGABATRIN PAK 500MG	Tier 2	MarketPlace
VIGABATRIN TAB 500MG	Tier 2	MarketPlace
VIGADRONE POW 500MG	Tier 2	MarketPlace
VIJOICE TAB 125MG	Tier 3	MarketPlace
1111		
	Tier 3	MarketPlace
VIJOICE TAB 50MG	Tier 3	MarketPlace
VOSEVI TAB	Tier 2	MarketPlace
VOXZOGO INJ 0.4MG	Tier 3	MarketPlace
VOXZOGO INJ 0.56MG	Tier 3	MarketPlace
VOXZOGO INJ 1.2MG	Tier 3	MarketPlace
VUMERITY CAP 231MG	Tier 2	MarketPlace
VYNDAMAX CAP 61MG	Tier 3	MarketPlace
VYNDAQEL CAP 20MG	Tier 3	MarketPlace
WINRHO SDF INJ 15000UNT	Tier 2	MarketPlace
WINRHO SDF INJ 1500UNIT	Tier 2	MarketPlace
WINRHO SDF INJ 2500UNIT	Tier 2	MarketPlace
WINRHO SDF INJ 5000UNIT	Tier 2	MarketPlace
XELJANZ SOL 1MG/ML	Tier 2	MarketPlace
XELJANZ TAB 10MG	Tier 2	MarketPlace
XELJANZ TAB 10MG  XELJANZ TAB 5MG	Tier 2	MarketPlace
XELIANZ XR TAB 11MG	Tier 2	MarketPlace
XELJANZ XR TAB 22MG	Tier 2	MarketPlace
XENAZINE TAB 12.5MG	Tier 3	MarketPlace
XENAZINE TAB 25MG	Tier 3	MarketPlace
XOLAIR INJ 150MG/ML	Tier 2	MarketPlace
XOLAIR INJ 75/0.5	Tier 2	MarketPlace
ZEPOSIA CAP .92MG	Tier 3	MarketPlace
ZEPOSIA CAP STR KIT	Tier 3	MarketPlace
ZEPOSIA 7DAY CAP STR PACK	Tier 3	MarketPlace
ZOKINVY CAP 50MG	Tier 3	MarketPlace
ZOKINVY CAP 75MG	Tier 3	MarketPlace
ZORBTIVE INJ 8.8MG	Tier 3	MarketPlace
DEFERASIROX TAB 180MG	Tier 2	MarketPlace
DEFERASIROX TAB 360MG	Tier 2	MarketPlace
DEFERASIROX TAB 90MG	Tier 2	MarketPlace
EGRIFTA SOL 1MG	Tier 3	MarketPlace
INGREZZA CAP 40MG	Tier 3	MarketPlace
JYNARQUE TAB 15MG	Tier 3	MarketPlace
JYNARQUE TAB 30MG	Tier 3	MarketPlace
ONCASPAR INJ 750/ML	Tier 3	
•		Market Place
ONUREG TAB 200MG	Tier 3	MarketPlace
ONUREG TAB 300MG	Tier 3	MarketPlace
PEGASYS INJ PROCLICK	Tier 2	MarketPlace
SAMSCA TAB 15MG	Tier 3	MarketPlace
SAMSCA TAB 30MG	Tier 3	MarketPlace
SEROSTIM INJ 5MG	Tier 3	MarketPlace
SEROSTIM INJ 6MG	Tier 3	MarketPlace
TOLVAPTAN TAB 15MG	Tier 2	MarketPlace
TOLVAPTAN TAB 30MG	Tier 2	MarketPlace
TRIENTINE CAP 250MG	Tier 2	MarketPlace
UPTRAVI TAB 200/800	Tier 3	MarketPlace

Insurance Company Name	MVP Health Care
HIOS ID	77566
SERFF Filing Number	MVPH-133660956
Market	Small Group
Product Name	VT Small Group 2024

## Pharmacy Benefit Manager Information<sup>2</sup>

Please list any pharmacy benefit managers utilized for the following periods. Include additional lines as necessary.

	Experience Period -1	Experience Period	Projection Period
	01/01/2021-12/31/2021	01/01/2022-12/31/2022	1/01/2024-12/31/202
Pharmacy Benefit Manager #1	CVS/Caremark	CVS/Caremark	CVS/Caremark
Pharmacy Benefit Manager #2			
Pharmacy Benefit Manager #3			
Pharmacy Benefit Manager #4			

For each period, enter the PBM, if applicable, administering pharmacy benefits at a pharmacy, network pharmacy, or mail-order pharmacy for each drug tier.

	Experience	e Period -1	Experienc	ce Period	Projection Period	
	01/01/2021-12/31/2021		01/01/2022-12/31/2022		1/01/2024-12/31/202	
	Retail Mail		Retail	Mail	Retail	Mail
Non-Specialty Generic PMPM						
Non-Specialty Brand PMPM						
Specialty PMPM						

For each period, enter the PBM, if applicable, administering drug benefits by a health care provider in an outpatient setting as part of the medical benefit as separate from the pharmacy benefit for each drug tier.

	Experience Period -1 01/01/2021-12/31/2021		Experience Period		Projection Period	
			01/01/2022-12/31/2022		1/01/2024-12/31/202	
	Retail	Mail	Retail	Mail	Retail	Mail
Non-Specialty Generic PMPM						
Non-Specialty Brand PMPM						
Specialty PMPM						

### <sup>2</sup> Vermont Statute 8 V.S.A. § 4062

(2)(A) In conjunction with a rate filing required by subsection (a) of this section, an insurer shall disclose to the Board:
(C) The insurer shall include information on its use of a pharmacy benefit manager, if any, including which components of the prescription drug coverage described in subdivisions (A) and (B) of this subdivision (2) are managed by the pharmacy benefit manager, as well as the name of the pharmacy benefit manager or managers used.

# Certification of Compliance

I hereby certify that I have reviewed the applicable filing requirements for this filing and the filing complies with all applicable statutory and regulatory provisions for the state of Vermont.

Print Name: Karla Austen Title: Chief Financial Officer & Executive Vice President

Signature: M 1 tut Date: 05/09/2023